UNITED STATES SECURITIES AND EXCHANGE

0001376474-14-000313.txt : 20140911 0001376474-14-000313.hdr.sgml : 20140911 20140911122213 ACCESSION NUMBER: 0001376474-14-000313 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20140731 FILED AS OF DATE: 20140911 DATE AS OF CHANGE: 20140911 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARROGENE, INC CENTRAL INDEX KEY: 0001403792 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 208057585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52932 FILM NUMBER: 141097610 BUSINESS ADDRESS: STREET 1: 8560 W. SUNSET BLVD STREET 2: #424 CITY: LOS ANGELES STATE: CA ZIP: 90069 BUSINESS PHONE: 424-274-4791 MAIL ADDRESS: STREET 1: 8560 W. SUNSET BLVD STREET 2: #424 CITY: LOS ANGELES STATE: CA ZIP: 90069 FORMER COMPANY: FORMER CONFORMED NAME: SRKP 16 INC DATE OF NAME CHANGE: 20070620 10-Q 1 aro_10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE

UNITED STATES SECURITIES AND

EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the Quarterly Period Ended July 31, 2014

Commission File Number: 000-52932

ARROGENE, INC.

(Exact name of registrant as Specified in its Charter)


Delaware		20-8057585
(State or Other Jurisdiction of Incorporation or Organization)		(Internal Revenue Service Employer Identification Number)

8560 W. Sunset Blvd., Suite 424 Los Angeles, CA		90069
(Address of Principal Executive Offices)		(Zip Code)

(424) 274-4791

(Issuer’s Telephone Number)

(Former name or former address, if changed since last report.)

2500 Broadway, Bldg. F, Suite F-125

Santa Monica, CA 90404

Securities registered under Section 12(b) of the Exchange Act:

None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $.0001 par value per share

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer o		Accelerated filer o

Non-accelerated filer o		Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes o No x

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court: Yes o No o

APPLICABLE ONLY TO CORPORATE USERS

As of September 10, 2014 the registrant had 21,375,860 shares of its common stock ($.0001 par value) outstanding.

TABLE OF CONTENTS


		Page
	PART I — FINANCIAL INFORMATION

Item 1.	Financial Statements

	Condensed Consolidated Balance Sheets as of July 31, 2014 (unaudited) and October 31, 2013	4

	Condensed Consolidated Statements of Operations for the three and nine months ended July 31, 2014 and July 31, 2013	5

	Condensed Consolidated Statements of Cash Flows for the nine months ended July 31, 2014 and July 31, 2013	6

	Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the nine months ended July 31, 2014 and July 31, 2013	7

	Notes to Unaudited Condensed Consolidated Financial Statements (unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

	Overview	16

	Liquidity and Capital Resources	21

	Results of Operations	23

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25

Item 4.	Controls and Procedures	25

	PART II — OTHER INFORMATION

Item 1	Legal Proceedings	26

Item 1A	Risk Factors	26

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26

Item 3.	Defaults Upon Senior Securities	26

Item 4.	[Removed and Reserved]	26

Item 5.	Other Information	26

Item 6.	Exhibits	26

PART 1. FINANCIAL INFORMATION

Item 1. Financial Statements

ARROGENE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF JULY 31, 2014 (UNAUDITED) AND OCTOBER 31, 2013


	July 31, 2014			October 31, 2013
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	219,035		$	13,822
Prepaid expenses and deposit	20,142			13,709
Debt offering costs	92,968			—
Total current assets	332,145			27,531

Property and equipment, net	928			1,705
Total assets	$	333,073		$	29,236

LIABILITIES AND STOCKHOLDERS’ EQUITY

LIABILITIES:
Current liabilities:
Accrued compensation	$	220,690		$	85,280
Accrued research expenses payable to CSMC	258,091			229,003
Accounts payable and other accrued expenses	438,043			128,368
Bridge notes, less discount of $145,530	554,470			—
Related party payables	49,000			39,000
Convertible notes	10,000			10,000
Total current liabilities	1,530,294			491,651

Total liabilities	1,530,294			491,651

STOCKHOLDERS’ EQUITY:

Preferred stock, $.0001 par value 10,000,000 shares authorized, none issued	—			—
Common stock, $.0001 par value; 100,000,000 shares authorized; 21,375,860 and 21,350,860 shares, respectively, issued and outstanding	2,138			2,135
Additional paid-in capital	4,820,625			4,287,289
Retained deficit	(6,019,984		)	(4,751,839		)
Total stockholders’ equity	(1,197,221)			(462,415		)
Total liabilities and stockholders’ equity	$	333,073		$	29,236

The accompanying notes are an integral part of these financial statements.

ARROGENE, INC.

CONDENSED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED JULY 31, 2014 AND 2013

(Unaudited)


	Three Months Ended July 31 ,					Nine Months Ended July 31,
	2014		2013			2014			2013

REVENUE	$ —			$ —		$	—			$ —	—

OPERATING EXPENSES:
Licensing fees	—		—			—			—
Research and development	82,497		132,592			271,449			317,084
General and administrative	312,827		147,799			876,494			466,813
	395,324		280,391			1,147,943			783,897

Loss from operations	(395,324	)	(280,391		)	(1,147,943		)	(783,897		)

OTHER EXPENSE:
Interest	(94,790	)	(278		)	(120,202		)	(561		)
	(94,790	)	(278)			(120,202		)	(561		)

NET LOSS	$ (490,114	)	$ (280,669		)	$ (1,268,145		)	$ (784,458		)

WEIGHTED AVERAGE SHARES OUTSTANDING:
Basic and diluted	21,375,860		21,350,860			21,370,457			21,289,358
LOSS PER SHARE: Basic and diluted	$ (0.02)		$ (0.01)			$ (0.06)			$ (0.04)

The accompanying notes are an integral part of these financial statements.

ARROGENE, INC.

STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED JULY 31, 2014 AND 2013

(Unaudited)


	2014			2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(1,268,145	)	$	(784,458	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt placement costs and debt discount	96,683			—
Share-based payment expense	344,883			—
Contributed services	90,000			—
Depreciation expense	777			1,174
Increase in prepaid services and deposit	(6,433		)	(7,402)
Increase in other payables and accrued expenses	316,174			204,700
Net cash used in operating activities	(426,061		)	(585,986		)


CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	—			—
Net cash provided by investing activities	—			—


CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of Units at $1.00 per Unit	24,956			227,645
Net proceeds from sale of Bridge Notes	606,318			—
Net cash provided by financing activities	631,274			227,645

Net increase (decrease) in cash	205,213			(358,341)
Cash and cash equivalents at the beginning of period	13,822			539,727
Cash and cash equivalents at the end of period	$	219,035		$	181,386

The accompanying notes are an integral part of these financial statements.

ARROGENE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE NINE MONTHS ENDED JULY 31, 2014

(UNAUDITED)





		Preferred Stock			Common Stock									Retained
		Shares	Amount		Shares	Amount				APIC				Deficit						Total
BALANCES, October 31, 2013		—		$ —	21,350,860			$ 2,135				4,287,289				$ (4,751,839		)				$ (462,415)
Sale of Units at $1.00 per Unit	—			—	25,000				3				24,953				—						24,956
Stock option compensation expense	—			—	—				—				176,883				—						176,883
Bridge Note Warrants	—			—	—				—				205,800				—						205,800
Placement Agent warrants	—			—	—				—				35,700				—						35,700
Contributed services	—			—	—				—				90,000				—						90,000
Net loss	—			—	—				—				—				(1,268,145		)				(1,268,145)
BALANCES, July 31, 2014	—		$	—	21,375,860		$		2,138		$		4,820,625		$		(6,019,984)				$		(1,197,221)

The accompanying notes are an integral part of these financial statements.

ARROGENE, INC.

(a development stage enterprise)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

JULY 31, 2014

(1)

BUSINESS AND OVERVIEW

Arrogene, Inc. (“Arrogene” f/k/a SRKP 16, Inc.), was incorporated under the laws of the State of Delaware on December 7, 2006. On January 11, 2012, we consummated a reverse merger transaction (the “Reverse Merger”) with Arrogene Nanotechnology, Inc. (“ANI”), a company focused on oncology. Hereafter, SRKP 16, Inc., Arrogene and ANI are collectively referred to as the “Company.” Effective September 4, 2012, SRKP 16, Inc. officially changed its name to Arrogene, Inc.

The Company was founded to commercialize both new cancer treatments and imaging targeting technology as well as a proprietary molecular delivery platform that interferes with those targets in order to inhibit and finally eradicate tumor progression. The Company is the exclusive licensee to certain intellectual property rights owned by Cedars Sinai Medical Center (“CSMC”) in Los Angeles, one of the nation’s premiere research institutions (the “License”). CSMC has developed a family of related nano-biopolymers conjugates (collectively referred to here as Polycefin™), believed capable of acting as a drug delivery and targeting platform for cancer therapy and imaging.

We plan on commercializing our products using a licensing and cost sharing strategy, seeking to enter into arrangements with major pharmaceutical companies with existing cancer therapy drugs facing issues relating to patent expirations, market expansion or contraction. It is our goal to only commence later stage clinical trials with a commitment from a licensee to complete Phase II and III clinical trials, predicated on the successful outcome of each phase, and go to market, if approval is received. Further, we are also exploring use of Polycefin as a potential medical diagnostic product(s) for oncology related applications. We also have developed important related intellectual properties surrounding Laminin-411. Pre-clinical investigation is also on-going on methods of inhibiting Laminin-411 as a therapeutic agent, which could be conjugated in various forms of Polycefin in the future.

The majority, of our planned products will require approval or marketing clearance from the United States Food and Drug Administration (the “FDA”). To date we have not filed any applications with the FDA, but we have begun the process of validating our Laboratory Development Test (“LDT”) with applicable regulators.

(2) GOING CONCERN, MANAGEMENT’S PLANS AND BASIS OF PRESENTATION

Going Concern and Management’s Plans

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since our inception in August 2007, we have not generated revenue, incurred operating losses, and as of July 31, 2014, had a retained deficit $6,019,984. Further, as of July 31, 2014, our cash balance was $219,035 and we had a working capital deficit of $1,198,149. These conditions raise substantial doubt about our ability to continue as a going concern.

During the nine months ended July 31, 2014, we sold $700,000 in Bridge Notes (defined below) receiving net proceeds of $606,318 after payment of offering expenses. Management believes that existing cash on hand will be sufficient to fund the Company’s planned activities through at least the end of our fiscal year. This assumes that we continue to defer payment of certain liabilities to our officers but allows for some payments to be made to CSMC for accrued research and development expenses. Additionally, certain key professionals such as legal counsel have also had payments deferred and the proceeds from the Bridge Notes will allow for some partial payments of these deferred balances but not payment in full. While these parties have continued to work with the Company despite this lack of payment, there is no assurance they will continue to do so, and the loss of a key management member, or the loss of CSMC as a research partner, could have a material adverse effect on the Company’s business prospects.

To raise sufficient capital to fund the Company’s business plan, we plan on filing a registration statement with the Securities and Exchange Commission (the “SEC”) for an initial public offering of the Company’s securities. No assurance can be given that this effort will be successful or adequately capitalize the Company.

In the event that we cannot raise sufficient capital within the required timeframe, it will have a material adverse effect on the Company’s liquidity, financial condition and business prospects or force the Company out of business. The accompanying financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from an inability of the Company to continue as a going concern.

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Arrogene and its wholly owned subsidiary ANI. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries), which in the opinion of management, are necessary to present fairly the financial position at July 31, 2014 and the results of operations and cash flows of the Company for the three and nine months ended July 31, 2014 and 2013. Operating results for the nine months ended July 31, 2014, are not necessarily indicative of the results that may be expected for the year ended October 31, 2014.

The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and footnotes thereto for the year ended October 31, 2013 filed on April 2, 2014.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods. Actual results may differ from these estimates.

Adoption of New Accounting Pronouncement

In June 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance (“ASU 2014-10”), which eliminates the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. Additionally, ASU 2014-10 eliminates the separate requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flow and shareholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective for fiscal years beginning after December 15, 2014 and interim periods therein, with early adoption permitted. The Company has adopted ASU 2014-10 effective with the filing of this Quarterly Report on Form 10-Q.

(3)

LICENSE AGREEMENT

On December 23, 2009, we entered into an agreement for the right to an exclusive license agreement with CSMC which provides us with the world-wide rights to U.S Patents No. 7,547,511 “Antisense Inhibition of Laminin-8 Expression to Inhibit Human Gliomas”, No. 7,935,677, “Polymalic Acid-Based Multifunctional Drug Delivery System”, No. 8,309,614 “Poly (Beta Malic Acid) with Pendant Leu-Leu-Leu Tripeptide for Effective Cytoplasmic Drug Delivery”, and No. 8,562,964 along with various Japanese, EU and Asian related patents and applications, related technical information to develop, market and sell human therapeutic and diagnostic products, including new pharmaceutical products and/or non-prescriptive products using the patented technology (the “CSMC Agreement”). The CSMC Agreement has been amended five times; December 8, 2010, June 30, 2011, August 31, 2011, October 28, 2011, and December 30, 2013. The CSMC Agreement also provides us with the rights to several other related, filed, but yet unissued patents. The CSMC Agreement requires royalty payments equal to 3.5% of the gross sales price and other forms of consideration (such as milestone and sublicense payments), as defined in the agreement, on all products using the licensed technology. The CSMC Agreement expires on a country-by-country basis on the date that the last patent covered under the agreement expires (currently 2032).

The CSMC Agreement, as amended, requires us to achieve certain other milestones in order to maintain the agreement. These include the following:

Begin development or enter into a joint venture, licensing or sub-licensing agreement, or other business arrangement with a third party not an affiliate of the Company to cause development of at least one product consistent with sound business practices by December 31, 2012;

Expend at least $500,000 in the aggregate toward the development or promotion of the sale of products based on the licensed patent rights or technical information commencing from the effective date of the agreement and continuing through and including December 31, 2012, and at least $1,000,000 annually thereafter, for further development or promotion of the sale of products through and including December 31, 2013;

Provide to CSMC at least $150,000 (in aggregate) within at least a four year period to fund research and development of the licensed patent rights and technical information;

On or before December 31, 2014, the Company shall have commenced a clinical trial or trials in connection with at least one intended commercial use;

We believe that we have achieved the required milestones for the contractual periods ended December 31, 2013. It is management’s belief that administrative expenses incurred in support of the Company’s business activities meet the

definition of “development and promotion” of the licensed technology. We can, however, provide no assurance that CSMC has concurred with our position and that we will be able to meet any or all of these milestones in the future. In the event that we fail to meet one or more of the milestones required by the CSMC Agreement, there is no assurance that CSMC will agree to amend or waive the requirements and we could lose the License. Additionally, as discussed further in Note 9, we have entered into a research and development agreement with CSMC that satisfies the milestone requirement described above regarding funded research at CSMC. However, in order to extend the Company’s cash on hand, we have been deferring payment to CSMC of our obligations under the agreement. During the second quarter of 2014 we resumed making payments to CSMC but our outstanding balance with them remains delinquent. To date, CSMC has continued to do work under the agreement despite our payment delays but no assurance can be provided that CSMC will continue to do so. As of July 31, 2014, we had an outstanding liability to CSMC of $258,091 which represents amounts owed for services provided by CSMC.

Further, in the event the Company issues or sells shares of common stock, the CSMC Agreement requires that the Company issue to CSMC additional shares of common stock for no additional consideration so as to assure CSMC will own 5% of the total issued and outstanding shares of the Company until December 31, 2015.

(4) BRIDGE NOTES

During the nine months ended July 31, 2014, we sold an aggregate of $700,000 in bridge notes (the “Bridge Notes”), receiving net proceeds of $606,318 after payment of offering costs. The Bridge Notes are due and payable one year after the close of the offering (the “Maturity Date”), bear interest at 10% per annum, and are convertible into shares of our common stock at a conversion price of either (i) 50% of the price per share of our common stock as sold through a qualified initial public offering as defined in the terms of the Bridge Notes, or (ii) in the event a Qualified IPO has not taken place prior to the Maturity Date but there has otherwise developed a public trading market for the Company’s common stock, then the conversion price shall be 50% of the 30 day Volume Weighted Average Price per share as quoted on the over-the-counter market, or (iii) in the event a public trading market has not been established for our common stock prior to the Maturity Date, then the conversion price shall be $1.00 per share. Accrued and unpaid interest on the Bridge Notes will be payable in shares of common stock at the conversion price on the earlier of (i) the date of conversion of the Bridge Notes or (ii) the Maturity Date. Further, for every $1.00 of Bridge Note principal that an investor elects to convert into shares of common stock, the investor will receive one warrant (the “Bridge Note Warrant”). Each warrant shall be exercisable to purchase shares of common stock at a price equal to the conversion price of the Bridge Notes and shall have a life of 5 years from the close of the offering. If the investor elects not to convert their Bridge Notes prior to the Maturity Date, then the note holder will receive one warrant for every $2.00 in Bridge Note principal.

We evaluated the conversion feature of the Bridge Notes within the context of ASC 815 and determined that it did not meet the definition of an embedded derivative due to the Company having no active market for its common stock. We further evaluated the conversion feature of the Bridge Notes within the context of ASC 470-20 and determined that the Bridge Notes did not contain a beneficial conversion feature as the default conversion price of $1.00 per share is greater than the current fair value of the Company’s common stock based on the most recent price paid for the Units.

We evaluated the Bridge Note Warrants using the guidelines established by ASC 815 and determined that it did not meet the definition of a derivative due to the Company having no active market for its common stock. We valued these warrants at $205,800 using the Black-Scholes option pricing model which we recorded as debt discount with a corresponding increase to additional paid in capital using the following assumptions: expected life 5 years, risk free interest rate 1.69% and annualized volatility 78.9%. We are amortizing the debt discount over the life of the Bridge Notes. For the three and nine months ended July 31, 2014, we amortized $49,541 and $60,270, respectively, of debt discount which is included in interest expense on the accompanying condensed consolidated financial statements.

We are also obligated to issue to the placement agents warrants to acquire shares of common stock equal to 10% of the securities underlying the Bridge Notes and Bridge Note Warrants (the “PA Bridge Note Warrants”). The PA Bridge Note Warrants have a life of 5 years and are exercisable at the conversion price of the Bridge Notes and the exercise price of the Bridge Note Warrants, respectively. We evaluated the PA Bridge Note Warrants using the guidelines established by ASC 815 and determined that they did not meet the definition of a derivative due to the Company having no active trading market for its common stock. We valued the PA Bridge Note Warrants at $35,700 using the Black-Scholes pricing model using the

following assumptions: expected life 5 years, risk free interest rate 1.69% and annualized volatility 78.9%. We recorded the PA Bridge Note Warrants as a debt offering cost on the accompanying condensed consolidated balance sheet. We are amortizing the PA Bridge Note Warrants over the life of the Bridge Notes. For the three and nine months ended July 31, 2014, we amortized $8,292 and $10,825, respectively, of PA Bridge Note Warrants which is included in interest expense on the accompanying condensed consolidated financial statements.

The effective rate of the Bridge Notes after taking into account the Bridge Note Warrants and PA Bridge Note Warrants is 44.5%.

(5)

CONVERTIBLE NOTES

Commencing October 2010 through April 2011, we sold in private transactions an aggregate of $726,550 of Convertible Notes. The Convertible Notes were initially convertible into shares of our common stock at $.30 per share (the “Conversion Price”). The Convertible Notes do not bear interest and were originally payable on October 19, 2011. The Convertible Notes are secured by a first lien security interest on all of our tangible and intangible assets. We did not repay the Convertible Notes by the maturity date and the notes were therefore technically in default. During the year ended October 31, 2012, agreed to reduce the conversion price of the Convertible Notes to $.15 per share. $10,000 of Convertible Notes remains outstanding as of July 31, 2014. On an as converted basis, as of July 31, 2014, the estimated value of the Convertible Notes exceeds the principal balance by $27,333.

(6) STOCKHOLDERS’ EQUITY

Common Stock

On August 29, 2013, we entered into an agreement for investor relation services that requires us to issue up to 400,000 shares of common stock as a component of the consideration for the services. The shares are issuable in 100,000 increments for each quarter of service rendered. We valued these shares at $224,000 using the Black-Scholes option-pricing model and are recognizing expense over the 12 months the services are being rendered. For the three months and nine months ended July 31, 2014, we recorded $56,000 and $168,000, respectively, of stock compensation expense which is included in general and administrative expense in the accompanying condensed consolidated statements of operations with a corresponding increase in accounts payable and other accrued expenses on the accompanying condensed consolidated balance sheet.

Units

During the nine months ended July 31, 2014 and 2013, we sold 25,000 and 260,000 units (the “Units”), respectively, for $1.00 per Unit, receiving net proceeds of $24,956 and $227,645, respectively. Each Unit consists of (i) one share of common stock, and (ii) two warrants with one warrant exercisable at $1.50 per share and one warrant exercisable at $2.00 per share. (the “Unit Warrants”). The Unit Warrants expire five years from the date of issuance.

Warrants

In connection with the sale of the Units during nine months ended July 31, 2013, the placement agents earned warrants to acquire 78,000 shares of common stock consisting of 26,000 warrants exercisable at $1.00 per share, 26,000 warrants exercisable at $1.50 per share and 26,000 warrants exercisable at $2.00 per share. Each warrant expires five years from the date of issuance. We valued these warrants at $17,160 using the Black Scholes option-pricing model. We recorded the warrants as a reduction to the net proceeds from the sale of the Units with a corresponding increase to additional paid in capital. The placement agents voluntarily agreed to forgo the earning of warrants in connection with the Unit sale that took place during the nine months ended July 31, 2014.

As of July 31, 2014, we had 6,358,358 warrants outstanding with weighted average remaining lives of 31 months and a weighted average exercise price of $1.44.

Stock Options

On November 1, 2013, we issued a non-statutory stock option to acquire up to 200,000 shares of common stock with an exercise price of $1.00 per share to a consultant for providing certain services as defined in the consulting agreement. The option expires 7 years from the date of grant. The options vest as follows: (i) as to 100,000 options, vesting shall occur 1/3 on each one year anniversary date of the consulting agreement (“Vesting 1”) and (ii) as to 100,000 options, vesting shall occur upon the closing of certain transactions as defined in the agreement at a rate of 2 stock options for each $100 received by the Company in a deal or transaction resulting from the efforts of the consultant (“Vesting 2”). We valued this option at $58,400 using the Black Scholes option-pricing model using the following assumptions: option life 5 years, risk free interest rate 1.37%, and annualized volatility of 78.9% based on a peer group of publicly traded common stocks. Stock options issued to non-employees are remeasured at each reporting date and the cumulative expense is adjusted based on the remeasured grant. We are recognizing expense for this option as the underlying services are provided, ratably over 36 months for Vesting 1, and upon the occurrence of a vesting event for Vesting 2. For the three and nine months ended July 31, 2014, we recognized $2,433 and $7,300, respectively, of expense for this option which is included in general and administrative expense on the accompanying condensed consolidated statements of operations.

In April 2014, we issued stock options to acquire 1,200,000 shares of common stock to certain employees and consultants with an exercise price of $1.00 per share. The options expire 7 years from the date of grant. The options vest under terms ranging from immediately to 1/3 on each anniversary date from the date of grant. We valued these options at $352,800 using the Black Scholes option-pricing model using the following assumptions: option life 5 years, risk free interest rate 1.65%, and annualized volatility of 78.9% based on a peer group of publicly traded stocks. We are recognizing expense for these options over the respective vesting periods. For the three and nine months ended July 31, 2014, we recognized $56,066 and $169,583, respectively, of expense for these options which is included in general and administrative expense on the accompanying condensed consolidated statements of operations.

(7) EARNINGS (LOSS) PER SHARE

Earnings (loss) per share are calculated in accordance with the provisions of ASC 260 “Earnings Per Share” (“ASC 260”). Under ASC 260, basic earnings (loss) per share are computed by dividing the Company’s income (loss) by the weighted average number of common shares outstanding. The impact of any potentially dilutive securities is excluded. Diluted earnings per share are computed by dividing the Company’s income (loss) attributable to common shareholders by the weighted average number of common shares and dilutive potential common shares outstanding during the period. In calculating diluted earnings per share, we utilize the “treasury stock method” for all stock options and warrants and the “if converted method” for all other convertible securities. For all periods presented, the basic and diluted loss per share is the same as the impact of potential dilutive common shares is anti-dilutive.

Warrants and convertible securities excluded from the calculation of diluted loss per share are as follows:


	Three and Nine Months Ended July 31,
	2014	2013

Warrants	6,358,358	5,422,858
Stock options	1,400,000	—
Convertible debt*	766,667	66,667

*Assumes Bridge Note conversion price of $1.00 per share see Note 4 for conversion price calculations.

(8) SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Cash paid during the period for:


	Nine Months Ended July 31,
	2014		2013
Interest	$	435	$	561
Income taxes	—		—

(9) COMMITMENTS, CONTINGENCIES, AND RELATED PARTY TRANSACTIONS

Related Party Transactions

Consulting Agreements

We have an agreement with an entity controlled by our chief executive officer for his part-time personal services as CEO. The agreement is referred to as the Synthetica Agreement. In December 2013, the Synthetica Agreement was amended so that the compensation paid for the services of our CEO is capped at $1 per annum effective January 1, 2014. However, our chief executive may request that his compensation revert back to the original terms of the Synthetica Agreement with 30 days written notice. Under the original terms, there was no monthly retainer or minimum billing amount but the maximum that could be charged to us in any given month was $15,000. During the three and nine months ended July 31, 2014, we were billed $0 and $20,000, respectively, under the Synthetica Agreement. During the three and nine months ended July 31, 2013, we were billed $33,900 and $117,600, respectively, under the Synthetica Agreement. At July 31, 2014 and October 31 2013, $67,600 and $47,600, respectively, is included in accrued compensation on the accompanying condensed consolidated balance sheets resulting from a voluntary deferral of fees due under the agreement, agreed to by Synthetica to allow the Company to optimize its cash flow.

In September 2010, we entered into a business and financial consulting agreement with an entity controlled by our Board chairman for operational consulting services. The agreement was for an initial term of 12 months with an automatic 12 month renewal period unless terminated by either party upon 30 days written notice. The agreement is now on a month-to-month basis. There is no monthly retainer or minimum billing amount but the maximum that can be billed to us in a given month cannot exceed $10,000. Effective January 2014, the fees for this agreement were capped at $1.00 per year. During the three and nine months ended July 31, 2014, we were charged $0 and $10,000, respectively, under this agreement. During the three and nine months ended July 31, 2013, we were charged $20,100 and $75,100, respectively, under this agreement which is included in general and administrative expense on the accompanying condensed consolidated statements of operations. At July 31, 2014 and October 31, 2013, $49,000 and $39,000, respectively, is included in related party payables on the accompanying condensed consolidated balance sheets resulting from a voluntary deferral of fees due under the agreement, agreed to by our Board chairman, to allow the Company to optimize its cash flow.

Contributed Services

As discussed above, effective January 1, 2014, the Company’s chief executive officer and Board chairman began to provide their services for $1 per year. The fair value of those services has been recorded as an expense in the accompanying condensed consolidated financial statements based on the estimated fair value for such services, with a corresponding credit to additional paid in capital. The fair value of the services was estimated based on the terms of the respective agreements prior to January 1, 2014. Contributed services were $45,000 and $90,000, respectively, for the three and nine months ended July 31, 2014.

CSMC

Certain founders and directors of the Company are employees of CSMC. These individuals are also the inventors of the Polycefin technology and are primarily responsible for its development. As described further in Note 3 above, we have an exclusive license agreement with CSMC for this technology.

The License requires royalty payments equal to 3.5% of the gross sales price and other forms of consideration (such as milestone and sublicense payments), as defined in the agreement, on all products using the licensed technology. The License also requires us to achieve certain milestones as described in Note 3.

In December 2012, we entered into an agreement with CSMC to support certain activities within the laboratory necessary to prepare compounds. For the three and nine months ended July 31, 2014, we were charged $38,625 and $142,087, respectively, by CSMC under this agreement which is included in research and development costs on the accompanying condensed consolidated statements of operations. For the three and nine months ended July 31, 2013, we were charged $87,000 and $195,884, respectively, by CSMC under this agreement. As of July 31, 2014, $258,091 is reflected as payable on the accompanying condensed consolidated balance sheets. Work under the agreement concluded during the three months ended July 31, 2014. As discussed in Note 3, we have deferred payments under this agreement in order to extend our cash balance.

Commitments and Contingencies

Litigation

From time to time, we may become party to litigation and other claims in the ordinary course of business. To the extent that such claims and litigation arise, management would provide for them if upon the advice of counsel, losses are determined to be both probable and estimable. We are currently not party to any litigation.

Office Lease

We have a lease agreement for office space with a third party (the “Office Lease”) that expires on May 31, 2015. For the three month periods ended July 31, 2014 and 2013, we recorded $9,434 and $10,950, respectively, of rent expense under the Office Lease which is included in general and administrative expense on the accompanying condensed consolidated statements of operations. For the nine months ended July 31, 2014 and 2013, we recorded $31,880 and $30,392, respectively, of rent expense under the Office Lease.

Commitments under non-cancelable operating leases are as follows as of July 31, 2014:


		Year Ended October 31,
2014	$ 8,100
2015	10,800
	$ 18,900

(10) SUBSEQUENT EVENTS

In August 2014, Dr. Randolphe Swenson, Jr. was elected to serve as a member of the Board of Directors. In consideration of his agreement to serve as a member of the Board of Directors, the Company granted to Dr. Swenson non-qualified options to purchase for five (5) years 50,000 shares of common stock at an exercise price of $1.00 per share, which options are deemed immediately vested.

The Company also entered into a Consultation and Securities Compensation Agreement between the Company, on the one hand and Dr. Swenson, pursuant to which Dr. Swenson was engaged to serve as a consultant to the Company for a term of six (6) months, to oversee and supervise an executive search to recruit a new CEO under the direction and supervision of the Board of Directors.

Pursuant to the Consultation and Securities Compensation Agreement and in consideration of his services as a consultant to conduct a CEO recruitment search, the Company (i) granted to Dr. Swenson non-qualified stock options exercisable for five (5) years to purchase an aggregate of 25,000 shares of common stock at an exercise price of $1.00, and (ii) conditioned on the Company successfully engaging a new CEO on terms acceptable to the Board of Directors during the term of Mr. Swenson’s consultancy, in its sole discretion, agreed to grant to Mr. Swenson additional non-qualified stock options exercisable for five (5) years to purchase an additional 35,000 shares of common stock at an exercise price of $1.00 per share. All of such options will be fully vested and exercisable upon grant.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

OR PLAN OF OPERATION

FORWARD LOOKING STATEMENTS

Our disclosure and analysis in this Quarterly Report on Form 10-Q (this “Form 10-Q”), in other reports that we file with the Securities and Exchange Commission, in our press releases and in public statements of our officers contain forward-looking statements. Forward-looking statements are based on the current expectations of, or forecasts of future events made by, our management. Forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many factors mentioned in this Form 10-Q, for example governmental regulation, general economic and capital market conditions in the United States, and competition in our industry, will be important in determining future results. No forward-looking statement can be guaranteed, and actual results may vary materially from those anticipated in any forward-looking statement.

You can identify forward-looking statements by the fact that they do not relate strictly to historical or current events. They use words such as “anticipate,” “estimate,” “expect” “will,” “may,” “intent,” “plan,” “believe,” and similar expressions in connection with discussion of future operating or financial performance. These include statements relating to future actions, prospective products or product approvals, future performance or results of anticipated products, expenses, financial results or contingencies.

Although we believe that our plans, intentions and expectations reflected in these forward-looking statements are reasonable, we may not achieve these plans or expectations. Forward-looking statements in this Form 10-Q will be affected by several factors, including the following: the ability of the Company to raise sufficient capital to finance its planned activities including completing development of its Polycefin technology; the ability of the Company to meet its obligations under the License including meeting the required milestones and making required payments; receiving the necessary marketing clearance approvals from the United States Food and Drug Administration; successful clinical trials of the Company’s planned products including the ability to enroll the studies in a timely manner, patient compliance with the study protocol, and a sufficient number of patients completing the studies; the ability of the Company to commercialize its planned products; the ability of the Company to successfully manufacture its products in commercial quantities (through contract manufacturers); market acceptance of the Company’s planned products, the Company’s ability to successfully develop its licensed compounds, alone or in cooperation with others, into commercial products, the ability of the Company to successfully prosecute and protect its intellectual property, the Company’s limited operating history; the Company’s lack of profitability; and the Company’s ability to hire, manage and retain qualified personnel. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained in this Form 10-Q. In particular, this Form 10-Q sets forth important factors that could cause actual results to differ materially from our forward-looking statements. These and other factors, including general economic factors, business strategies, the state of capital markets, regulatory conditions, and other factors not currently known to us, may be significant, now or in the future, and the factors set forth in this Form 10-Q may affect us to a greater extent than indicated. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in this Form 10-Q and in other documents that we file from time to time with the Securities and Exchange Commission including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K to be filed in 2014. Except as required by law, we do not undertake any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis of financial condition and results of operations should be read in conjunction with the Company’s financial statements and the related notes, and the other financial information included in this Quarterly Report.

Overview

The Company was founded to commercialize both a new cancer treatment and imaging targeting technology as well as a proprietary molecular delivery platform that interferes with those targets in order to inhibit and finally eradicate tumor progression. The Company is the exclusive licensee to certain intellectual property rights owned or co-owned by CSMC in Los Angeles, one of the nation’s premiere research institutions (the “License”). CSMC has developed a family of related nano-biopolymers conjugates (collectively referred to here as Polycefin™), believed capable of acting as a drug delivery and targeting platform for cancer therapy and imaging. The founders of Arrogene were principally involved in all research and development behind all critical discoveries and science at CSMC related to Polycefin and authored all the patents underlying the technologies behind Polycefin (the “Technology”) and include internationally acclaimed brain surgeon and scientist Dr. Keith Black, Dr. Julia Ljubimova, Dr. Eggehard Holler, Dr. Alex Ljubimov. Work on Polycefin involved seven years of development and over $7,500,000 of grants funded mainly from the NIH.

We also have developed important related intellectual properties surrounding Laminin-411. Laminins are the major components of basement membranes that are orderly sheet-like structures secreted by cells to separate several cell types from one another. Laminins play key roles in cell adhesion, polarity, movement, and differentiation. They form a family of related but distinct proteins. Like all laminins, Laminin-411 is comprised of three chains, a4, b1, and g1 (hence the name). In normal tissues, Laminin-411 expression is almost negligible in blood vessels. At the same time, vessels in some organs, like breast and brain, predominantly contain another, closely related, isoform, Laminin-421 (a4b2g1). Our scientists were the first to demonstrate that during tumor development, Laminin-411 (formerly, laminin-8) is produced in excessive amounts, while the normal Laminin-421 gets suppressed, causing a shift from “normal” to “tumor” laminin (Ljubimova et al., Cancer Res, 2001; Fujita et al., Breast Cancer Res, 2005). Laminin-411 has been implicated in cell migration and increased production of some cancer stem cell proteins. In general, abnormal interactions between tumor cells and laminins are among major traits of various cancers. Taken together, the data presented above suggest that by blocking the production of Laminin-411, one may expect to slow down or arrest tumor growth and inhibit cancer cell spread, as well as possibly suppress cancer stem cells thereby diminishing chances of disease relapse.

Using clinical material from 65 patients with brain gliomas, we found an inverse correlation between Laminin-411 overproduction, patients’ survival and time of recurrent development (Ljubimova et al., Cancer, 2004). In 2007, our founders, in their capacity as researchers at CSMC, started a clinical trial to examine a possible clinicopathological use of Laminin-411 as a diagnostic tool for advanced brain glioma and as a prognostic indicator that could predict disease recurrence. The study of the expression of Laminin-411 and Laminin-421 was performed this time with the paraffin-embedded archival material routinely used in all pathological laboratories. Currently, this trial is nearing completion, with more than 300 cases of human tumors analyzed. The data show that this protein is overproduced in more than (85%) of grade IV gliomas. Its production is correlated with poor patient survival, as compared to patients whose tumors predominantly contain a normal isoform, Laminin-421. This data is currently being prepared for publication. As a result, we are in the process of commercializing this new test as a Laboratory Developed Test and we are currently nearing the end of a negotiation with a partner for delivery of this test into clinical practice. With this potential partner, we have conducted protocol development and have furthered our clinical trial to measure the range of application for Laminin 411. Conclusions of that clinical trial indicate that Laminin 411 is over-expressed in many tumors beyond the initial indications and we are working on incorporating those findings in both published results and the market strategy for the LDT.

Beyond diagnostic and prognostic applications, we believe that our discovery of Lamin 411’s role in tumor growth can be exploited together with our Polycefin technology towards novel tumor inhibiting treatments. We are currently working on the technology allowing us to combine antisense oligonucleotides against two Laminin-411 chains on one nanopolymer (Polycefin) molecule and target them specifically to tumor cells. As a result, we were able to stop brain glioma and HER2/neu breast cancer growth in mice without harming other unaffected organs (Ding et al., Proc Natl AScad Sci USA, 2010, J Control Release, 2013). This appears to be a superior approach to using antibody blocking because, due to being buried in basement membranes, laminins may not be accessible enough to the antibodies in real-life tumors to obtain a therapeutic effect. We plan to use our nanopolymer Polycefin to block Laminin-411 production in primary and metastatic brain and breast tumors. Importantly, due to special chemical groups on the polymer backbone, it can deliver the antisense drugs to the tumor cells specifically, largely avoiding non-cancer cells. Our published results to date show the feasibility of this approach.

Antisense drugs and other therapeutics like siRNA have significant problems in delivery to tumor cells. Besides rapid clearance from blood, they cannot specifically get inside tumor cells causing potential problems for the healthy cells and induce immunotoxicity. Our nanopolymer platform has special antibodies that guide the drug complex to the tumor cells. Once in these cells, another special module on the delivery vehicle helps release the drugs inside the cell, where they get detached from the polymer by natural mechanisms and exert their blocking function. As a result, the drug has much lower clearance when injected into the bloodstream, and the possibility of it getting into normal cells is minimized. We have shown that such a nanopolymeric delivery system targeting Laminin-411 can efficiently suppress growth of brain cancers by reducing tumor vasculature and causing tumor cell death (Fujita et al., Angiogenesis, 2006; Ljubimova et al., Front Biosci, 2006; Ding et al., Proc Natl Acad Sci USA, 2010, J Drug Target 2013, J Control Release 2013). Therefore, we believe that this delivery system is currently most promising for specific treatment of tumors targeting their blood supply. However at this time, these findings are based on pre-clinical research and there can be no assurances that they can be successfully translated into successful therapies in the future.

In vivo studies show evidence that when attached to the platform, drugs for cancer therapy could have increased treatment efficacy and reduced side effects. In vivo and in vitro studies, many of which have been published, have shown that tumor size was reduced and animal survival increased using the targeting platform in conjunction with therapeutics as compared to using those same therapeutics in conventional therapies. ¹ ²

We believe that Polycefin has the ability to harbor various drugs at the same time making it a potential master delivery vehicle that can be customized for a particular tumor and even for an individual patient.³ Additionally, in vivo treatment has shown effectiveness against more than one, widely different, type of cancers: HER2/neu positive breast cancer, EGFR positive Triple Negative Breast Cancer (TNBC) and Glioblastoma, suggesting that Polycefin’s application might be flexible and appropriate to a wide range of cancer types and therapeutics (Inoue et al, Cancer Research 2011, Inoue et al, PlosOne 2012, Ding et al, J Control Release 2013).

We also have presented evidence that the PMLA nanoplatform was well tolerated in vivo and in vitro in extreme dosages without toxicity and immune reactions. PMLA and the nanoconjugates purified free of endotoxin activated neither complement nor macrophages. They also did not show appreciable toxicity for cultured liver HepG2 and kidney LLC-PK1 human cells even at in vitro dosages as high as 1 mg/ml. Analysis of blood biochemistry, metabolic assays, CBC panel, and immunotoxicity did not reveal any abnormalities compatible with toxicity in vitro or in vivo even after 12 repeated systemic nanodrug injections. In particular, hemolysis was not observed, and only minimum complement activation was noticed at very high dosage of nanoconjugates (1.0 mg/kg), which is 37 times higher than

¹ Inoue S., Ding H., Portilla-Arias J., et al (2011) Polymalic Acid-Based Nanobiopolymer Provedes Efficient Systemic Breast Cancer Treatment by Inhibiting both Her2/neu Receptor Snthetsis and Activity. Cancer Res; 71(4) February 15, 2011

² Inoue S, Patil R, Portilla-Arias J, Ding H, Konda B, et al. (2012) Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative

Breast Cancer. PLoS ONE 7(2): e31070. doi:10.1371/journal.pone.0031070

³ Ding H., Portilla-Arias J., Patil R., et al. (2011).

H. Ding, J. Portilla-Arias, R. Patil, K.L. Black, LJubimova JY, E. Holler. (2013) The optimization of polymalic acid peptide copolymers for endosomolytic drug delivery. Biomaterials 32 (2011) 5269-5278

J Control Release 2013

nanodrug therapeutic concentration. The degree of activation was far less than that observed with FDA-approved Doxil. The nanoconjugates did not induce significant platelet aggregation, and did not affect coagulation pathways. Special tests excluded the presence of pyrogenic material in the nanoconjugate preparations.

Under conditions of advanced cancer, continuous treatment could be necessary until the tumor regresses. In clinics, however, in many cases the chemotherapy must be discontinued due to life threatening side effects such as liver, kidney, cardio- or neurotoxicity. The significant side effects, in particular thrombocytopenia and leukopenia, induction of thrombosis and suppression of immune system (immunotoxicity) are the major indications for treatment interruption. This situation with prolonged treatment was tested by conducting 12 consecutive nanodrug systemic administrations against growing TNBC over the period of 8 weeks. As a result, the tumor growth was significantly inhibited, and the treatment was well tolerated without noticeable abnormalities in blood cell counts, multiple biochemistry parameters, and with no immunostimulatory or immunosuppressive response. Thus, PMLA-based nanodrugs of the Polycefin^TM family passed multiple toxicity and efficacy tests in vitro and in vivo on preclinical level and may prove to be efficacious for the treatment of cancer patients in the future (Ljubimova JY, et, al (2013). J Drug Target, 21:956-967).

As survival rates for primary cancers improve, increasingly significant percentiles of the patient population are developing metastatic forms of these cancers, which are often found late stage and have few or no treatment options. Arrogene estimates that 30% of breast and 75% of lung primary cancers metastasize to the brain, based on published studies. Polycefin’s ability to pass through the tumor’s Brain Tumor Barrier (BTB), which is the part of brain blood barrier (BBB) could make it ideally suited for use as a diagnostic and/or therapeutic to treat such metastatic cancers, and these might present early market opportunities.

It is estimated that approximately 207,000 new cases of breast cancer are diagnosed every year in the U.S. Approximately 204,000 cases of lung cancer are diagnosed annually. Additionally there are between 120,000 and 140,000 annual cases of secondary brain cancers, according to various published sources. Based on these patient populations, and certain price and usage assumptions, we have estimated that the total market potential for Polycefin based therapeutics products could exceed $30 billion annually.

Our first therapeutic drug candidate is AG 101 which will target certain brain cancer. We need to commission final Phase 0 toxicology studies at an external laboratory for AG101 drug candidate preparation of an IND for submission to the FDA to receive clearance to begin human clinical trial work. We then plan to commence a Phase I clinical trial. We have estimated the cost related to an IND submission and a Phase 1 clinical trial to be $4,000,000 - $5,000,000 which will require additional funding.

We plan to bring our products to market using a licensing and cost sharing strategy. We will seek to joint venture with pharmaceutical companies with existing cancer therapy drugs or active diagnostic imaging agents.

Over the following twelve months we are targeting a number of objectives and milestones that we plan to pursue utilizing cash on hand and proceeds from capital raising efforts. We may or may not be successful in consummating such capital raises and this remains a significant risk to our ability to meet our objectives. These objectives and milestones are the commissioning of final Phase 0 toxicology studies for our first Polycefin drug candidate; prepare an IND for submission to the FDA to receive clearance to begin human clinical trial work; and begin human clinical studies once such IND clearance can be obtained. There are various factors that can influence the timing of starting and completing these objectives and milestones as well as the total costs. Such factors include, but are not limited to, the pace and success of scientific developments, the availability of financial and human resources, competing demands of our scientific team, and changes in regulatory requirements. Due to the inherent uncertainty and variability related to these activities, we cannot accurately predict start dates, completion dates and total costs. We will also need to raise additional capital in order to complete our planned activities.

In addition, we are expanding our production of the key ingredients for the production of Polycefin, according to a proprietary production and purification process, in preparation to support both pre-clinical and clinical phases of

upcoming clinical trials. We are also taking steps to negotiate outside supplies agreements to create industrial partnerships relating to the production under license of these compounds.

General Factors

Our profitability will be affected by costs associated with our efforts to develop Polycefin into a commercial product including regulatory approvals, the expansion of our general and administrative capabilities, and the expenses that we incur as a public reporting company. These costs include costs associated with, among other things, financial reporting, information technology, complying with federal securities laws (including compliance with the Sarbanes-Oxley Act of 2002), tax administration and human resources related functions.

LIQUIDITY AND CAPITAL RESOURCES

As of July 31, 2014, the Company’s cash balance was $219,035 compared to $13,822 at October 31, 2013.

The following is a summary of the Company's cash flows provided by (used in) operating, investing, and financing activities for the nine months ended July 31, 2014 and 2013.


	Nine Mos. Ended July 31, 2014	Nine Mos. Ended July 31, 2013
Net Cash Used in Operating Activities	$ (426,061)	$ (585,986)
Net Cash Provided by Investing Activities	—	—
Net Cash Provided by Financing Activities	631,274	227,645
Net Increase (Decrease) in Cash and Cash Equivalents	205,213	(358,341)

Operating Activities

During the nine months ended July 31, 2014, $426,061 of cash was used in operating activities which primarily represents cash operating expenses. As discussed elsewhere in this Quarterly Report, we have been deferring payments to our officers, certain professionals and CSMC to minimize cash used in operating activities in order to extend our cash on hand until such time that we can raise additional capital.

Investing Activities

During the nine months ended July 31, 2014, no cash was provided by or used in investing activities. As of July 31, 2014, we had no material commitments for capital expenditures.

Financing Activities

During the nine months ended July 31, 2014, $631,274 of cash was provided by financing activities, consisting primarily of net proceeds from the sale of Bridge Notes.

Management’s Outlook

As of July 31, 2014, our cash balance was $219,035. Management believes that existing cash on hand will be sufficient to fund the Company’s planned activities through at least the end of the fiscal year. This assumes that we continue to defer payment of certain liabilities to our officers but allows for some payments to be made to CSMC for accrued research and development expenses. Additionally, certain key professionals such as legal counsel have also had payments deferred and the proceeds from the Bridge Notes will allow for some partial payments of these deferred balances but not payment in full. While these parties have continued to work with the Company despite this lack of

payment, there is no assurance they will continue to do so, and the loss of a key management member, or the loss of CSMC as a research partner, could have a material adverse effect on the Company’s business prospects.

The success of our business will depend in great part on our ability to conduct research and development on the technology covered by the License. Our ability to conduct research and development activities is greatly dependent upon our financial resources. No assurance can be given that the necessary financing will be available on terms acceptable to us, if at all. If adequate additional funds are not available when required, we may have to delay, scale-back, or eliminate certain aspects of our research, testing and/or development activities.

In the event that we cannot raise sufficient capital within the required timeframes, it will have a material adverse effect on the Company’s liquidity, financial condition and business prospects or could force the Company out of business.

RESULTS OF OPERATIONS

THREE MONTHS ENDED JULY 31, 2014 COMPARED TO THREE MONTHS ENDED JULY 31, 2013

Research and Development

During the three months ended July 31, 2014, research and development expense decreased by $50,095 or 38% compared to the prior year period. The decrease in research and development expense is the result of reduced activity under the CSMC research agreement which concluded during the three months ended July 31, 2014.

General and Administrative

General and administrative expense increased by $165,028 or approximately 112% for the three months ended July 31, 2014 compared to the prior year period. The increase in expense is primarily the result of an increase in share-based compensation expense related to stock options and investor relations.

Loss from Operations

As a result of the factors described above, the loss from operations for the three months ended July 31, 2014, increased by $114,933 compared to the prior year period.

Other Expense

For the three months ended July 31, 2014, other expense increased by $94,791 compared to the prior year period. The increase in other expense is the result of interest expense related to the Bridge Notes sold during 2014.

Net Loss

As a result of the factors described above, we recorded $490,114 of net loss for the three months ended July 31, 2014 compared to a $280,669 net loss for the prior year period.

NINE MONTHS ENDED JULY 31, 2014 COMPARED TO NINE MONTHS ENDED JULY 31, 2013

Research and Development

During the nine months ended July 31, 2014, research and development expense decreased by $45,635 or 14% compared to the prior year period. The decrease in research and development expense is the result of reduced activity under the CSMC research agreement which concluded during the three months ended July 31, 2014.

General and Administrative

General and administrative expense increased by $409,681 or approximately 88% for the nine months ended July 31, 2014, compared to the prior year period. The increase in expense is primarily the result of an increase in share-based compensation expense related to stock options and investor relations.

Loss from Operations

As a result of the factors described above, the loss from operations for the nine months ended July 31, 2014, increased by $364,046 compared to the prior year period.

Other Expense

For the nine months ended July 31, 2014, we recorded other expense of $120,202 compared to $561 for the prior year period. The increase in other expense is the result of interest expense related to the Bridge Notes sold during 2014.

Net Loss

As a result of the factors described above, we recorded $1,268,145 of net loss for the nine months ended July 31, 2014 compared to a net loss of $784,458 in the prior year period.

Critical Accounting Policies and Estimates

Please refer to our Annual Report on Form 10-K for the year ended October 31, 2013 for accounting policies that management believes are critical to understanding the Company’s financial statements.

Recently Issued Accounting Pronouncements

Please refer to our Annual Report on Form 10-K for the year ended October 31, 2013 for management’s view on the impact of recently issued accounting pronouncements.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Contractual Obligations

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

Subsequent Events

for a term of six (6) months, to oversee and supervise an executive search to recruit a new CEO under the direction and supervision of the Board of Directors.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules, regulations and related forms, and that such information is accumulated and communicated to our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

As of July 31, 2014, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and our principal financial officer of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting during the quarter ended July 31, 2014 that have materially affected or are reasonably likely to materially affect our internal controls.


PART II.	OTHER INFORMATION

	Item 1.	Legal Proceedings
		None.

	Item 1A.	Risk Factors As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

	Item 2	Unregistered Sales of Equity Securities and Use of Proceeds
		None.

	Item 3.	Defaults Upon Senior Securities

		None

	Item 4.	Mine Safety Disclosures

		NA

	Item 5.	Other Information

		None.

	Item 6.	Exhibits and Reports on Form 8-K
			Exhibits

	*		31.1	Certification of Chief Executive Officer
	*		31.2	Certification of Chief Financial Officer
	*		32	Certification pursuant to USC Section 1350
	**		101.INS	XBRL Instance Document
	**		101.SCH	XBRL Schema Document
	**		101.CAL	XBRL Calculation Linkbase Document
	**		101.LAB	XBRL Label Linkbase Document
	**		101.PRE	XBRL Presentation Linkbase Document
	**		101.DEF	XBRL Definition Linkbase Document

	*			Filed herewith
	**			Furnished, not filed.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.


		ARROGENE, INC

Date:	September 11, 2014	By:	/s/ Maurizio Vecchione
			Maurizio Vecchione, Principal Executive Officer

Date:	September 11, 2014	By:	/s/ Jeffrey S. Sperber
			Jeffrey S. Sperber, Principal Financial and Accounting Officer

EX-31.1 2 aro_ex31z1.htm CERTIFICATION Converted by EDGARwiz

Exhibit 31.1

CERTIFICATIONS

I, Maurizio Vecchione, Chief Executive Officer of ARROGENE, INC., Inc. certify that:

I have reviewed this quarterly report on Form 10-Q of ARROGENE, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: September 11, 2014	By:	/s/ Maurizio Vecchione
			Maurizio Vecchione
			Chief Executive Officer
			(Principal Executive Officer)

EX-31.2 3 aro_ex31z2.htm CERTIFICATION Converted by EDGARwiz

Exhibit 31.2

CERTIFICATIONS

I, Jeffrey S. Sperber, Chief Financial Officer of ARROGENE, Inc., certify that:

I have reviewed this quarterly report on Form 10-Q of ARROGENE, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: September 11, 2014	By:	___/s/ Jeffrey S. Sperber
			Jeffrey S. Sperber
			Chief Financial Officer
			(Principal Financial Officer)

EX-32 4 aro_ex32.htm CERTIFICATION Converted by EDGARwiz

Exhibit 32

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18
U.S.C. 1350

The undersigned, the Chief Executive Officer and the Chief Financial Officer of ARROGENE, Inc. (the “Company”), each hereby certifies that, to his knowledge on the date hereof:

(a)

the Form 10-Q of the Company for the quarter ended July 31, 2014, filed on the date hereof with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

(b)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: September 11, 2014	By:	__/s/ Maurizio Vecchione
		Maurizio Vecchione
		Chief Executive Officer


	By:	__/s/ Jeffrey S. Sperber
		Jeffrey S. Sperber
Date: September 11, 2014		Chief Financial Officer

EX-101.CAL 5 skrp-20140731_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 skrp-20140731_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.INS 7 skrp-20140731.xml XBRL INSTANCE DOCUMENT 10-Q 2014-07-31 false ARROGENE, INC 0001403792 --10-31 21375860 Smaller Reporting Company Yes No No 2014 Q3

20142

13709

92968

332145

27531

928

1705

333073

29236

220690

85280

258091 229003

438043

128368

554470

49000

39000

10000

1530294

491651

1530294

491651

2138

2135

4820625

4287289

-6019984

-4751839

-1197221

-462415

333073

29236

0.0001

10000000

0.0001

100000000

21375860

21350860

82497

132592

271449

317084

312827

147799

876494

466813

395324

280391

1147943

783897

-395324

-280391

-1147943

-783897

94790

278

120202

561

-94790

-278

-120202

-561

-490114

-280669

21375860 21350860 21370457 21289358

-0.02

-0.01

-0.06

-0.04

-784458

96683

344883

777

1174

-6433

-7402

316174

204700

-426061

-585986

24956

227645

606318

631274

227645

205213

-358341

13822

539727

181386

2135

4287289

-4751839

-462415

21350860

3 24953 24956 25000

176883

205800 205800 35700 35700

90000

-1268145

2138

4820625

-6019984

-1197221

21375860

(1)   BUSINESS AND OVERVIEW   Arrogene, Inc. (Arrogene f/k/a SRKP 16, Inc.), was incorporated under the laws of the State of Delaware on December 7, 2006.  On January 11, 2012, we consummated a reverse merger transaction (the Reverse Merger) with Arrogene Nanotechnology, Inc. (ANI), a company focused on oncology.  Hereafter, SRKP 16, Inc., Arrogene and ANI are collectively referred to as the Company.  Effective September 4, 2012, SRKP 16, Inc. officially changed its name to Arrogene, Inc.   The Company was founded to commercialize both new cancer treatments and imaging targeting technology as well as a proprietary molecular delivery platform that interferes with those targets in order to inhibit and finally eradicate tumor progression.  The Company is the exclusive licensee to certain intellectual property rights owned by Cedars Sinai Medical Center (CSMC) in Los Angeles, one of the nations premiere research institutions (the License).  CSMC has developed a family of related nano-biopolymers conjugates (collectively referred to here as Polycefin ), believed capable of acting as a drug delivery and targeting platform for cancer therapy and imaging.   We plan on commercializing our products using a licensing and cost sharing strategy, seeking to enter into arrangements with major pharmaceutical companies with existing cancer therapy drugs facing issues relating to patent expirations, market expansion or contraction.   It is our goal to only commence later stage clinical trials with a commitment from a licensee to complete Phase II and III clinical trials, predicated on the successful outcome of each phase, and go to market, if approval is received.  Further, we are also exploring use of Polycefin as a potential medical diagnostic product(s) for oncology related applications.  We also have developed important related intellectual properties surrounding Laminin-411. Pre-clinical investigation is also on-going on methods of inhibiting Laminin-411 as a therapeutic agent, which could be conjugated in various forms of Polycefin in the future.   The majority, of our planned products will require approval or marketing clearance from the United States Food and Drug Administration (the FDA).  To date we have not filed any applications with the FDA, but we have begun the process of validating our Laboratory Development Test (LDT) with applicable regulators.

(2) GOING CONCERN, MANAGEMENTS PLANS AND BASIS OF PRESENTATION   Going Concern and Managements Plans   The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since our inception in August 2007, we have not generated revenue, incurred operating losses, and as of July 31, 2014, had a retained deficit $6,019,984.   Further, as of July 31, 2014, our cash balance was $219,035 and we had a working capital deficit of $1,198,149. These conditions raise substantial doubt about our ability to continue as a going concern.   During the nine months ended July 31, 2014, we sold $700,000 in Bridge Notes (defined below) receiving net proceeds of $606,318 after payment of offering expenses. Management believes that existing cash on hand will be sufficient to fund the Companys planned activities through at least the end of our fiscal year.  This assumes that we continue to defer payment of certain liabilities to our officers but allows for some payments to be made to CSMC for accrued research and development expenses.  Additionally, certain key professionals such as legal counsel have also had payments deferred and the proceeds from the Bridge Notes will allow for some partial payments of these deferred balances but not payment in full.  While these parties have continued to work with the Company despite this lack of payment, there is no assurance they will continue to do so, and the loss of a key management member, or the loss of CSMC as a research partner, could have a material adverse effect on the Companys business prospects.   To raise sufficient capital to fund the Companys business plan, we plan on filing a registration statement with the Securities and Exchange Commission (the SEC) for an initial public offering of the Companys securities. No assurance can be given that this effort will be successful or adequately capitalize the Company.   In the event that we cannot raise sufficient capital within the required timeframe, it will have a material adverse effect on the Companys liquidity, financial condition and business prospects or force the Company out of business.  The accompanying financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from an inability of the Company to continue as a going concern.   Basis of Presentation   The accompanying condensed consolidated financial statements include the accounts of Arrogene and its wholly owned subsidiary ANI.  All intercompany transactions have been eliminated in consolidation.  The condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the SEC.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations.  The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries), which in the opinion of management, are necessary to present fairly the financial position at July 31, 2014 and the results of operations and cash flows of the Company for the three and nine months ended July 31, 2014 and 2013.  Operating results for the nine months ended July 31, 2014, are not necessarily indicative of the results that may be expected for the year ended October 31, 2014.   The unaudited condensed consolidated financial statements should be read in conjunction with the Companys audited financial statements and footnotes thereto for the year ended October 31, 2013 filed on April 2, 2014.   Use of Estimates and Assumptions   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods.  Actual results may differ from these estimates.   Adoption of New Accounting Pronouncement   In June 2014, the Financial Accounting Standards Board (FASB) issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance (ASU 2014-10), which eliminates the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. Additionally, ASU 2014-10 eliminates the separate requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flow and shareholders equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.  ASU 2014-10 is effective for fiscal years beginning after December 15, 2014 and interim periods therein, with early adoption permitted.  The Company has adopted ASU 2014-10 effective with the filing of this Quarterly Report on Form 10-Q.

(3)  LICENSE AGREEMENT   On December 23, 2009, we entered into an agreement for the right to an exclusive license agreement with CSMC which provides us with the world-wide rights to U.S Patents No. 7,547,511 Antisense Inhibition of Laminin-8 Expression to Inhibit Human Gliomas, No. 7,935,677, Polymalic Acid-Based Multifunctional Drug Delivery System, No. 8,309,614 Poly (Beta Malic Acid) with Pendant Leu-Leu-Leu Tripeptide for Effective Cytoplasmic Drug Delivery, and  No. 8,562,964 along with various Japanese, EU and Asian related patents and applications, related technical information to develop, market and sell human therapeutic and diagnostic products, including new pharmaceutical products and/or non-prescriptive products using the patented technology (the CSMC Agreement).  The CSMC Agreement has been amended five times; December 8, 2010, June 30, 2011, August 31, 2011, October 28, 2011, and December 30, 2013. The CSMC Agreement also provides us with the rights to several other related, filed, but yet unissued patents.  The CSMC Agreement requires royalty payments equal to 3.5% of the gross sales price and other forms of consideration (such as milestone and sublicense payments), as defined in the agreement, on all products using the licensed technology.  The CSMC Agreement expires on a country-by-country basis on the date that the last patent covered under the agreement expires (currently 2032).   The CSMC Agreement, as amended, requires us to achieve certain other milestones in order to maintain the agreement.  These include the following:   ·         Begin development or enter into a joint venture, licensing or sub-licensing agreement, or other business arrangement with a third party not an affiliate of the Company to cause development of at least one product consistent with sound business practices by December 31, 2012; ·         Expend at least $500,000 in the aggregate toward the development or promotion of the sale of products based on the licensed patent rights or technical information commencing from the effective date of the agreement and continuing through and including December 31, 2012, and at least $1,000,000 annually thereafter, for further development or promotion of the sale of products through and including December 31, 2013; ·         Provide to CSMC at least $150,000 (in aggregate) within at least a four year period to fund research and development of the licensed patent rights and technical information; ·         On or before December 31, 2014, the Company shall have commenced a clinical trial or trials in connection with at least one intended commercial use;   We believe that we have achieved the required milestones for the contractual periods ended December 31, 2013.  It is managements belief that administrative expenses incurred in support of the Companys business activities meet the definition of development and promotion of the licensed technology. We can, however, provide no assurance that CSMC has concurred with our position and that we will be able to meet any or all of these milestones in the future.  In the event that we fail to meet one or more of the milestones required by the CSMC Agreement, there is no assurance that CSMC will agree to amend or waive the requirements and we could lose the License.  Additionally, as discussed further in Note 9, we have entered into a research and development agreement with CSMC that satisfies the milestone requirement described above regarding funded research at CSMC.  However, in order to extend the Companys cash on hand, we have been deferring payment to CSMC of our obligations under the agreement.  During the second quarter of 2014 we resumed making payments to CSMC but our outstanding balance with them remains delinquent.  To date, CSMC has continued to do work under the agreement despite our payment delays but no assurance can be provided that CSMC will continue to do so.  As of July 31, 2014, we had an outstanding liability to CSMC of $258,091 which represents amounts owed for services provided by CSMC.   Further, in the event the Company issues or sells shares of common stock, the CSMC Agreement requires that the Company issue to CSMC additional shares of common stock for no additional consideration so as to assure CSMC will own 5% of the total issued and outstanding shares of the Company until December 31, 2015. (4)  BRIDGE NOTES   During the nine months ended July 31, 2014, we sold an aggregate of $700,000 in bridge notes (the Bridge Notes), receiving net proceeds of $606,318 after payment of offering costs.  The Bridge Notes are due and payable one year after the close of the offering (the Maturity Date), bear interest at 10% per annum, and are convertible into shares of our common stock at a conversion price of either (i) 50% of the price per share of our common stock as sold through a qualified initial public offering as defined in the terms of the Bridge Notes, or (ii) in the event a Qualified IPO has not taken place prior to the Maturity Date but there has otherwise developed a public trading market for the Companys common stock, then the conversion price shall be 50% of the 30 day Volume Weighted Average Price per share as quoted on the over-the-counter market, or (iii) in the event a public trading market has not been established for our common stock prior to the Maturity Date, then the conversion price shall be $1.00 per share.   Accrued and unpaid interest on the Bridge Notes will be payable in shares of common stock at the conversion price on the earlier of (i) the date of conversion of the Bridge Notes or (ii) the Maturity Date. Further, for every $1.00 of Bridge Note principal that an investor elects to convert into shares of common stock, the investor will receive one warrant (the Bridge Note Warrant).  Each warrant shall be exercisable to purchase shares of common stock at a price equal to the conversion price of the Bridge Notes and shall have a life of 5 years from the close of the offering.  If the investor elects not to convert their Bridge Notes prior to the Maturity Date, then the note holder will receive one warrant for every $2.00 in Bridge Note principal.   We evaluated the conversion feature of the Bridge Notes within the context of ASC 815 and determined that it did not meet the definition of an embedded derivative due to the Company having no active market for its common stock.   We further evaluated the conversion feature of the Bridge Notes within the context of ASC 470-20 and determined that the Bridge Notes did not contain a beneficial conversion feature as the default conversion price of $1.00 per share is greater than the current fair value of the Companys common stock based on the most recent price paid for the Units.   We evaluated the Bridge Note Warrants using the guidelines established by ASC 815 and determined that it did not meet the definition of a derivative due to the Company having no active market for its common stock.  We valued these warrants at $205,800 using the Black-Scholes option pricing model which we recorded as debt discount with a corresponding increase to additional paid in capital using the following assumptions: expected life 5 years, risk free interest rate 1.69% and annualized volatility 78.9%. We are amortizing the debt discount over the life of the Bridge Notes.  For the three and nine months ended July 31, 2014, we amortized $49,541 and $60,270, respectively, of debt discount which is included in interest expense on the accompanying condensed consolidated financial statements. We are also obligated to issue to the placement agents warrants to acquire shares of common stock equal to 10% of the securities underlying the Bridge Notes and Bridge Note Warrants (the PA Bridge Note Warrants).  The PA Bridge Note Warrants have a life of 5 years and are exercisable at the conversion price of the Bridge Notes and the exercise price of the Bridge Note Warrants, respectively.  We evaluated the PA Bridge Note Warrants using the guidelines established by ASC 815 and determined that they did not meet the definition of a derivative due to the Company having no active trading market for its common stock.  We valued the PA Bridge Note Warrants at $35,700 using the Black-Scholes pricing model using the following assumptions: expected life 5 years, risk free interest rate 1.69% and annualized volatility 78.9%.  We recorded the PA Bridge Note Warrants as a debt offering cost on the accompanying condensed consolidated balance sheet.  We are amortizing the PA Bridge Note Warrants over the life of the Bridge Notes.  For the three and nine months ended July 31, 2014, we amortized $8,292 and $10,825, respectively, of PA Bridge Note Warrants which is included in interest expense on the accompanying condensed consolidated financial statements. The effective rate of the Bridge Notes after taking into account the Bridge Note Warrants and PA Bridge Note Warrants is 44.5%.

(5)  CONVERTIBLE NOTES   Commencing October 2010 through April 2011, we sold in private transactions an aggregate of $726,550 of Convertible Notes.  The Convertible Notes were initially convertible into shares of our common stock at $.30 per share (the Conversion Price). The Convertible Notes do not bear interest and were originally payable on October 19, 2011. The Convertible Notes are secured by a first lien security interest on all of our tangible and intangible assets.  We did not repay the Convertible Notes by the maturity date and the notes were therefore technically in default.  During the year ended October 31, 2012, agreed to reduce the conversion price of the Convertible Notes to $.15 per share. $10,000 of Convertible Notes remains outstanding as of July 31, 2014.  On an as converted basis, as of July 31, 2014, the estimated value of the Convertible Notes exceeds the principal balance by $27,333.

(6)  STOCKHOLDERS EQUITY   Common Stock   On August 29, 2013, we entered into an agreement for investor relation services that requires us to issue up to 400,000 shares of common stock as a component of the consideration for the services.  The shares are issuable in 100,000 increments for each quarter of service rendered.  We valued these shares at $224,000 using the Black-Scholes option-pricing model and are recognizing expense over the 12 months the services are being rendered.  For the three months and nine months ended July 31, 2014, we recorded $56,000 and $168,000, respectively, of stock compensation expense which is included in general and administrative expense in the accompanying condensed consolidated statements of operations with a corresponding increase in accounts payable and other accrued expenses on the accompanying condensed consolidated balance sheet.   Units   During the nine months ended July 31, 2014 and 2013, we sold 25,000 and 260,000 units (the Units), respectively, for $1.00 per Unit, receiving net proceeds of $24,956 and $227,645, respectively.  Each Unit consists of  (i) one share of common stock, and (ii) two warrants with one warrant exercisable at $1.50 per share and one warrant exercisable at $2.00 per share.  (the Unit Warrants).  The Unit Warrants expire five years from the date of issuance.   Warrants   In connection with the sale of the Units during nine months ended July 31, 2013, the placement agents earned warrants to acquire 78,000 shares of common stock consisting of 26,000 warrants exercisable at $1.00 per share, 26,000 warrants exercisable at $1.50 per share and 26,000 warrants exercisable at $2.00 per share.  Each warrant expires five years from the date of issuance.   We valued these warrants at $17,160 using the Black Scholes option-pricing model.   We recorded the warrants as a reduction to the net proceeds from the sale of the Units with a corresponding increase to additional paid in capital.   The placement agents voluntarily agreed to forgo the earning of warrants in connection with the Unit sale that took place during the nine months ended July 31, 2014.   As of July 31, 2014, we had 6,358,358 warrants outstanding with weighted average remaining lives of 31 months and a weighted average exercise price of $1.44.   Stock Options   On November 1, 2013, we issued a non-statutory stock option to acquire up to 200,000 shares of common stock with an exercise price of $1.00 per share to a consultant for providing certain services as defined in the consulting agreement.  The option expires 7 years from the date of grant. The options vest as follows: (i) as to 100,000 options, vesting shall occur 1/3 on each one year anniversary date of the consulting agreement  (Vesting 1) and (ii) as to 100,000 options, vesting shall occur upon the closing of certain transactions as defined in the agreement at a rate of 2 stock options for each $100 received by the Company in a deal or transaction resulting from the efforts of the consultant (Vesting 2).  We valued this option at $58,400 using the Black Scholes option-pricing model using the following assumptions: option life 5 years, risk free interest rate 1.37%, and annualized volatility of 78.9% based on a peer group of publicly traded common stocks.  Stock options issued to non-employees are remeasured at each reporting date and the cumulative expense is adjusted based on the remeasured grant. We are recognizing expense for this option as the underlying services are provided, ratably over 36 months for Vesting 1, and upon the occurrence of a vesting event for Vesting 2.  For the three and nine months ended July 31, 2014, we recognized $2,433 and $7,300, respectively, of expense for this option which is included in general and administrative expense on the accompanying condensed consolidated statements of operations.   In April 2014, we issued stock options to acquire 1,200,000 shares of common stock to certain employees and consultants with an exercise price of $1.00 per share.  The options expire 7 years from the date of grant. The options vest under terms ranging from immediately to 1/3 on each anniversary date from the date of grant.  We valued these options at $352,800 using the Black Scholes option-pricing model using the following assumptions:  option life 5 years, risk free interest rate 1.65%, and annualized volatility of 78.9% based on a peer group of publicly traded stocks.  We are recognizing expense for these options over the respective vesting periods.  For the three and nine months ended July 31, 2014, we recognized $56,066 and $169,583, respectively, of expense for these options which is included in general and administrative expense on the accompanying condensed consolidated statements of operations.

(7)  EARNINGS (LOSS) PER SHARE   Earnings (loss) per share are calculated in accordance with the provisions of ASC 260 Earnings Per Share (ASC 260). Under ASC 260, basic earnings (loss) per share are computed by dividing the Companys income (loss) by the weighted average number of common shares outstanding. The impact of any potentially dilutive securities is excluded. Diluted earnings per share are computed by dividing the Companys income (loss) attributable to common shareholders by the weighted average number of common shares and dilutive potential common shares outstanding during the period. In calculating diluted earnings per share, we utilize the treasury stock method for all stock options and warrants and the if converted method for all other convertible securities. For all periods presented, the basic and diluted loss per share is the same as the impact of potential dilutive common shares is anti-dilutive.   Warrants and convertible securities excluded from the calculation of diluted loss per share are as follows:   <table border="0" cellspacing="0" cellpadding="0" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="42%" valign="bottom" style='width:42.78%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="45%" colspan="3" valign="bottom" style='width:45.16%;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Three and Nine Months Ended July 31, </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr align="left"> <td width="42%" valign="bottom" style='width:42.78%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 2014 </td> <td width="5%" valign="bottom" style='width:5.02%;border:none;border-top:solid windowtext 1.0pt;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> 2013 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr align="left"> <td width="42%" valign="top" style='width:42.78%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;border:none;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;border:none;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr align="left"> <td width="42%" valign="top" style='width:42.78%;padding:0'> Warrants </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;padding:0'> 6,358,358 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;padding:0'> 5,422,858 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr align="left"> <td width="42%" valign="top" style='width:42.78%;padding:0'> Stock options </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;padding:0'> 1,400,000 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;padding:0'> </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr align="left"> <td width="42%" valign="top" style='width:42.78%;padding:0'> Convertible debt* </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;padding:0'> 766,667 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;padding:0'> 66,667 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> </table>   <table border="0" cellspacing="0" cellpadding="0" style='margin-left:.5in;border-collapse:collapse;display:none'> <tr style='display:none'> <td width="42%" valign="bottom" style='width:42.78%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="45%" colspan="3" valign="bottom" style='width:45.16%;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Three and Nine Months Ended July 31, </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr style='display:none'> <td width="42%" valign="bottom" style='width:42.78%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 2014 </td> <td width="5%" valign="bottom" style='width:5.02%;border:none;border-top:solid windowtext 1.0pt;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> 2013 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr style='display:none'> <td width="42%" valign="top" style='width:42.78%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;border:none;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;border:none;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr style='display:none'> <td width="42%" valign="top" style='width:42.78%;padding:0'> Warrants </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;padding:0'> 6,358,358 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;padding:0'> 5,422,858 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr style='display:none'> <td width="42%" valign="top" style='width:42.78%;padding:0'> Stock options </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;padding:0'> 1,400,000 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;padding:0'> </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr style='display:none'> <td width="42%" valign="top" style='width:42.78%;padding:0'> Convertible debt* </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;padding:0'> 766,667 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;padding:0'> 66,667 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> </table>       *Assumes Bridge Note conversion price of $1.00 per share see Note 4 for conversion price calculations.

(8)  SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION   Cash paid during the period for:   <table border="0" cellspacing="0" cellpadding="0" style='margin-left:.75in;border-collapse:collapse'> <tr align="left"> <td width="45%" valign="bottom" style='width:45.48%;padding:0'>   </td> <td width="13%" valign="bottom" style='width:13.3%;padding:0'>   </td> <td width="40%" colspan="5" valign="bottom" style='width:40.04%;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Nine Months Ended July 31, </td> <td width="1%" valign="bottom" style='width:1.18%;padding:0'>   </td> </tr> <tr align="left"> <td width="45%" valign="bottom" style='width:45.48%;padding:0'>   </td> <td width="13%" valign="bottom" style='width:13.3%;padding:0'>   </td> <td width="15%" colspan="2" valign="bottom" style='width:15.98%;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 2014 </td> <td width="2%" valign="bottom" style='width:2.46%;padding:0'>   </td> <td width="21%" colspan="2" valign="bottom" style='width:21.6%;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> 2013 </td> <td width="1%" valign="bottom" style='width:1.18%;padding:0'>   </td> </tr> <tr align="left"> <td width="45%" valign="bottom" style='width:45.48%;padding:0'> Interest </td> <td width="13%" valign="bottom" style='width:13.3%;padding:0'>   </td> <td width="3%" valign="bottom" style='width:3.62%;border:none;padding:0'> $ </td> <td width="12%" valign="bottom" style='width:12.36%;border:none;border-top:solid windowtext 1.0pt;padding:0'> 435 </td> <td width="2%" valign="bottom" style='width:2.46%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.18%;border:none;padding:0'> $ </td> <td width="16%" valign="bottom" style='width:16.42%;border:none;border-top:solid windowtext 1.0pt;padding:0'> 561 </td> <td width="1%" valign="bottom" style='width:1.18%;padding:0'>   </td> </tr> <tr align="left"> <td width="45%" valign="bottom" style='width:45.48%;padding:0'> Income taxes </td> <td width="13%" valign="bottom" style='width:13.3%;padding:0'>   </td> <td width="15%" colspan="2" valign="bottom" style='width:15.98%;padding:0'> </td> <td width="2%" valign="bottom" style='width:2.46%;padding:0'>   </td> <td width="21%" colspan="2" valign="bottom" style='width:21.6%;padding:0'> </td> <td width="1%" valign="bottom" style='width:1.18%;padding:0'>   </td> </tr> <tr align="left"> <td width="247" style='border:none'></td> <td width="72" style='border:none'></td> <td width="20" style='border:none'></td> <td width="67" style='border:none'></td> <td width="13" style='border:none'></td> <td width="28" style='border:none'></td> <td width="89" style='border:none'></td> <td width="6" style='border:none'></td> </tr> </table>

Related Party Transactions   Consulting Agreements   We have an agreement with an entity controlled by our chief executive officer for his part-time personal services as CEO. The agreement is referred to as the Synthetica Agreement.  In December 2013, the Synthetica Agreement was amended so that the compensation paid for the services of our CEO is capped at $1 per annum effective January 1, 2014.  However, our chief executive may request that his compensation revert back to the original terms of the Synthetica Agreement with 30 days written notice.  Under the original terms, there was no monthly retainer or minimum billing amount but the maximum that could be charged to us in any given month was $15,000. During the three and nine months ended July 31, 2014, we were billed $0 and $20,000, respectively, under the Synthetica Agreement.  During the three and nine months ended July 31, 2013, we were billed $33,900 and $117,600, respectively, under the Synthetica Agreement. At July 31, 2014 and October 31 2013, $67,600 and $47,600, respectively, is included in accrued compensation on the accompanying condensed consolidated balance sheets resulting from a voluntary deferral of fees due under the agreement, agreed to by Synthetica to allow the Company to optimize its cash flow.   In September 2010, we entered into a business and financial consulting agreement with an entity controlled by our Board chairman for operational consulting services.   The agreement was for an initial term of 12 months with an automatic 12 month renewal period unless terminated by either party upon 30 days written notice.  The agreement is now on a month-to-month basis. There is no monthly retainer or minimum billing amount but the maximum that can be billed to us in a given month cannot exceed $10,000.   Effective January 2014, the fees for this agreement were capped at $1.00 per year. During the three and nine months ended July 31, 2014, we were charged $0 and $10,000, respectively, under this agreement.  During the three and nine months ended July 31, 2013, we were charged $20,100 and $75,100, respectively, under this agreement which is included in general and administrative expense on the accompanying condensed consolidated statements of operations.  At July 31, 2014 and October 31, 2013, $49,000 and $39,000, respectively, is included in related party payables on the accompanying condensed consolidated balance sheets resulting from a voluntary deferral of fees due under the agreement, agreed to by our Board chairman, to allow the Company to optimize its cash flow.   Contributed Services   As discussed above, effective January 1, 2014, the Companys chief executive officer and Board chairman began to provide their services for $1 per year.  The fair value of those services has been recorded as an expense in the accompanying condensed consolidated financial statements based on the estimated fair value for such services, with a corresponding credit to additional paid in capital. The fair value of the services was estimated based on the terms of the respective agreements prior to January 1, 2014. Contributed services were $45,000 and $90,000, respectively, for the three and nine months ended July 31, 2014.   CSMC   Certain founders and directors of the Company are employees of CSMC.  These individuals are also the inventors of the Polycefin technology and are primarily responsible for its development.  As described further in Note 3 above, we have an exclusive license agreement with CSMC for this technology.   The License requires royalty payments equal to 3.5% of the gross sales price and other forms of consideration (such as milestone and sublicense payments), as defined in the agreement, on all products using the licensed technology.   The License also requires us to achieve certain milestones as described in Note 3.   In December 2012, we entered into an agreement with CSMC to support certain activities within the laboratory necessary to prepare compounds.  For the three and nine months ended July 31, 2014, we were charged $38,625 and $142,087, respectively, by CSMC under this agreement which is included in research and development costs on the accompanying condensed consolidated statements of operations. For the three and nine months ended July 31, 2013, we were charged $87,000 and $195,884, respectively, by CSMC under this agreement.  As of July 31, 2014, $258,091 is reflected as payable on the accompanying condensed consolidated balance sheets.  Work under the agreement concluded during the three months ended July 31, 2014.  As discussed in Note 3, we have deferred payments under this agreement in order to extend our cash balance.

Commitments and Contingencies   Litigation   From time to time, we may become party to litigation and other claims in the ordinary course of business.  To the extent that such claims and litigation arise, management would provide for them if upon the advice of counsel, losses are determined to be both probable and estimable.  We are currently not party to any litigation.   Office Lease   We have a lease agreement for office space with a third party (the Office Lease) that expires on May 31, 2015.  For the three month periods ended July 31, 2014 and 2013, we recorded $9,434 and $10,950, respectively, of rent expense under the Office Lease which is included in general and administrative expense on the accompanying condensed consolidated statements of operations.  For the nine months ended July 31, 2014 and 2013, we recorded $31,880 and $30,392, respectively, of rent expense under the Office Lease.   Commitments under non-cancelable operating leases are as follows as of July 31, 2014:   <table border="0" cellspacing="0" cellpadding="0" style='margin-left:130.5pt;border-collapse:collapse'> <tr align="left"> <td width="54" valign="bottom" style='width:40.55pt;padding:0'>   </td> <td width="7" colspan="2" valign="bottom" style='width:5.2pt;padding:0'>   </td> <td width="149" valign="bottom" style='width:111.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Year Ended October 31, </td> </tr> <tr align="left"> <td width="54" valign="bottom" style='width:40.55pt;padding:0'> 2014 </td> <td width="1" valign="bottom" style='width:1.0pt;padding:0'>   </td> <td width="155" colspan="2" valign="bottom" style='width:115.95pt;border:none;border-top:solid windowtext 1.0pt;padding:0'> $              8,100 </td> </tr> <tr align="left"> <td width="54" valign="bottom" style='width:40.55pt;padding:0'> 2015 </td> <td width="1" valign="bottom" style='width:1.0pt;padding:0'>   </td> <td width="155" colspan="2" valign="bottom" style='width:115.95pt;padding:0'> 10,800 </td> </tr> <tr align="left"> <td width="54" valign="bottom" style='width:40.55pt;padding:0'>   </td> <td width="1" valign="bottom" style='width:1.0pt;padding:0'>   </td> <td width="155" colspan="2" valign="bottom" style='width:115.95pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 2.25pt;border-right:none;padding:0'> $            18,900 </td> </tr> <tr align="left"> <td width="55" style='border:none'></td> <td width="2" style='border:none'></td> <td width="6" style='border:none'></td> <td width="150" style='border:none'></td> </tr> </table>

(10)  SUBSEQUENT EVENTS   In August 2014, Dr. Randolphe Swenson, Jr. was elected to serve as a member of the Board of Directors. In consideration of his agreement to serve as a member of the Board of Directors, the Company granted to Dr. Swenson non-qualified options to purchase for five (5) years 50,000 shares of common stock at an exercise price of $1.00 per share, which options are deemed immediately vested.   The Company also entered into a Consultation and Securities Compensation Agreement between the Company, on the one hand and Dr. Swenson, pursuant to which Dr. Swenson was engaged to serve as a consultant to the Company for a term of six (6) months, to oversee and supervise an executive search to recruit a new CEO under the direction and supervision of the Board of Directors.   Pursuant to the Consultation and Securities Compensation Agreement and in consideration of his services as a consultant to conduct a CEO recruitment search, the Company (i) granted to Dr. Swenson non-qualified stock options exercisable for five (5) years to purchase an aggregate of 25,000 shares of common stock at an exercise price of $1.00, and (ii) conditioned on the Company successfully engaging a new CEO on terms acceptable to the Board of Directors during the term of Mr. Swensons consultancy, in its sole discretion, agreed to grant to Mr. Swenson additional non-qualified stock options exercisable for five (5) years to purchase an additional 35,000 shares of common stock at an exercise price of $1.00 per share.  All of such options will be fully vested and exercisable upon grant.

Going Concern and Managements Plans   The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since our inception in August 2007, we have not generated revenue, incurred operating losses, and as of July 31, 2014, had a retained deficit $6,019,984.   Further, as of July 31, 2014, our cash balance was $219,035 and we had a working capital deficit of $1,198,149. These conditions raise substantial doubt about our ability to continue as a going concern.   During the nine months ended July 31, 2014, we sold $700,000 in Bridge Notes (defined below) receiving net proceeds of $606,318 after payment of offering expenses. Management believes that existing cash on hand will be sufficient to fund the Companys planned activities through at least the end of our fiscal year.  This assumes that we continue to defer payment of certain liabilities to our officers but allows for some payments to be made to CSMC for accrued research and development expenses.  Additionally, certain key professionals such as legal counsel have also had payments deferred and the proceeds from the Bridge Notes will allow for some partial payments of these deferred balances but not payment in full.  While these parties have continued to work with the Company despite this lack of payment, there is no assurance they will continue to do so, and the loss of a key management member, or the loss of CSMC as a research partner, could have a material adverse effect on the Companys business prospects.   To raise sufficient capital to fund the Companys business plan, we plan on filing a registration statement with the Securities and Exchange Commission (the SEC) for an initial public offering of the Companys securities. No assurance can be given that this effort will be successful or adequately capitalize the Company.   In the event that we cannot raise sufficient capital within the required timeframe, it will have a material adverse effect on the Companys liquidity, financial condition and business prospects or force the Company out of business.  The accompanying financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from an inability of the Company to continue as a going concern.

Basis of Presentation   The accompanying condensed consolidated financial statements include the accounts of Arrogene and its wholly owned subsidiary ANI.  All intercompany transactions have been eliminated in consolidation.  The condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the SEC.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations.  The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries), which in the opinion of management, are necessary to present fairly the financial position at July 31, 2014 and the results of operations and cash flows of the Company for the three and nine months ended July 31, 2014 and 2013.  Operating results for the nine months ended July 31, 2014, are not necessarily indicative of the results that may be expected for the year ended October 31, 2014.   The unaudited condensed consolidated financial statements should be read in conjunction with the Companys audited financial statements and footnotes thereto for the year ended October 31, 2013 filed on April 2, 2014.

<table border="0" cellspacing="0" cellpadding="0" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="42%" valign="bottom" style='width:42.78%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="45%" colspan="3" valign="bottom" style='width:45.16%;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Three and Nine Months Ended July 31, </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr align="left"> <td width="42%" valign="bottom" style='width:42.78%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 2014 </td> <td width="5%" valign="bottom" style='width:5.02%;border:none;border-top:solid windowtext 1.0pt;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> 2013 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr align="left"> <td width="42%" valign="top" style='width:42.78%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;border:none;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;border:none;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr align="left"> <td width="42%" valign="top" style='width:42.78%;padding:0'> Warrants </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;padding:0'> 6,358,358 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;padding:0'> 5,422,858 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr align="left"> <td width="42%" valign="top" style='width:42.78%;padding:0'> Stock options </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;padding:0'> 1,400,000 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;padding:0'> </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr align="left"> <td width="42%" valign="top" style='width:42.78%;padding:0'> Convertible debt* </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;padding:0'> 766,667 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;padding:0'> 66,667 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> </table>   <table border="0" cellspacing="0" cellpadding="0" style='margin-left:.5in;border-collapse:collapse;display:none'> <tr style='display:none'> <td width="42%" valign="bottom" style='width:42.78%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="45%" colspan="3" valign="bottom" style='width:45.16%;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Three and Nine Months Ended July 31, </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr style='display:none'> <td width="42%" valign="bottom" style='width:42.78%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 2014 </td> <td width="5%" valign="bottom" style='width:5.02%;border:none;border-top:solid windowtext 1.0pt;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> 2013 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr style='display:none'> <td width="42%" valign="top" style='width:42.78%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;border:none;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;border:none;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr style='display:none'> <td width="42%" valign="top" style='width:42.78%;padding:0'> Warrants </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;padding:0'> 6,358,358 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;padding:0'> 5,422,858 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr style='display:none'> <td width="42%" valign="top" style='width:42.78%;padding:0'> Stock options </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;padding:0'> 1,400,000 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;padding:0'> </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> <tr style='display:none'> <td width="42%" valign="top" style='width:42.78%;padding:0'> Convertible debt* </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.06%;padding:0'> 766,667 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="20%" valign="bottom" style='width:20.08%;padding:0'> 66,667 </td> <td width="5%" valign="bottom" style='width:5.02%;padding:0'>   </td> <td width="2%" valign="bottom" style='width:2.0%;padding:0'>   </td> </tr> </table>

<table border="0" cellspacing="0" cellpadding="0" style='margin-left:.75in;border-collapse:collapse'> <tr align="left"> <td width="45%" valign="bottom" style='width:45.48%;padding:0'>   </td> <td width="13%" valign="bottom" style='width:13.3%;padding:0'>   </td> <td width="40%" colspan="5" valign="bottom" style='width:40.04%;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Nine Months Ended July 31, </td> <td width="1%" valign="bottom" style='width:1.18%;padding:0'>   </td> </tr> <tr align="left"> <td width="45%" valign="bottom" style='width:45.48%;padding:0'>   </td> <td width="13%" valign="bottom" style='width:13.3%;padding:0'>   </td> <td width="15%" colspan="2" valign="bottom" style='width:15.98%;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 2014 </td> <td width="2%" valign="bottom" style='width:2.46%;padding:0'>   </td> <td width="21%" colspan="2" valign="bottom" style='width:21.6%;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> 2013 </td> <td width="1%" valign="bottom" style='width:1.18%;padding:0'>   </td> </tr> <tr align="left"> <td width="45%" valign="bottom" style='width:45.48%;padding:0'> Interest </td> <td width="13%" valign="bottom" style='width:13.3%;padding:0'>   </td> <td width="3%" valign="bottom" style='width:3.62%;border:none;padding:0'> $ </td> <td width="12%" valign="bottom" style='width:12.36%;border:none;border-top:solid windowtext 1.0pt;padding:0'> 435 </td> <td width="2%" valign="bottom" style='width:2.46%;padding:0'>   </td> <td width="5%" valign="bottom" style='width:5.18%;border:none;padding:0'> $ </td> <td width="16%" valign="bottom" style='width:16.42%;border:none;border-top:solid windowtext 1.0pt;padding:0'> 561 </td> <td width="1%" valign="bottom" style='width:1.18%;padding:0'>   </td> </tr> <tr align="left"> <td width="45%" valign="bottom" style='width:45.48%;padding:0'> Income taxes </td> <td width="13%" valign="bottom" style='width:13.3%;padding:0'>   </td> <td width="15%" colspan="2" valign="bottom" style='width:15.98%;padding:0'> </td> <td width="2%" valign="bottom" style='width:2.46%;padding:0'>   </td> <td width="21%" colspan="2" valign="bottom" style='width:21.6%;padding:0'> </td> <td width="1%" valign="bottom" style='width:1.18%;padding:0'>   </td> </tr> <tr align="left"> <td width="247" style='border:none'></td> <td width="72" style='border:none'></td> <td width="20" style='border:none'></td> <td width="67" style='border:none'></td> <td width="13" style='border:none'></td> <td width="28" style='border:none'></td> <td width="89" style='border:none'></td> <td width="6" style='border:none'></td> </tr> </table>

<table border="0" cellspacing="0" cellpadding="0" style='margin-left:130.5pt;border-collapse:collapse'> <tr align="left"> <td width="54" valign="bottom" style='width:40.55pt;padding:0'>   </td> <td width="7" colspan="2" valign="bottom" style='width:5.2pt;padding:0'>   </td> <td width="149" valign="bottom" style='width:111.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Year Ended October 31, </td> </tr> <tr align="left"> <td width="54" valign="bottom" style='width:40.55pt;padding:0'> 2014 </td> <td width="1" valign="bottom" style='width:1.0pt;padding:0'>   </td> <td width="155" colspan="2" valign="bottom" style='width:115.95pt;border:none;border-top:solid windowtext 1.0pt;padding:0'> $              8,100 </td> </tr> <tr align="left"> <td width="54" valign="bottom" style='width:40.55pt;padding:0'> 2015 </td> <td width="1" valign="bottom" style='width:1.0pt;padding:0'>   </td> <td width="155" colspan="2" valign="bottom" style='width:115.95pt;padding:0'> 10,800 </td> </tr> <tr align="left"> <td width="54" valign="bottom" style='width:40.55pt;padding:0'>   </td> <td width="1" valign="bottom" style='width:1.0pt;padding:0'>   </td> <td width="155" colspan="2" valign="bottom" style='width:115.95pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 2.25pt;border-right:none;padding:0'> $            18,900 </td> </tr> <tr align="left"> <td width="55" style='border:none'></td> <td width="2" style='border:none'></td> <td width="6" style='border:none'></td> <td width="150" style='border:none'></td> </tr> </table>

2006-12-07

January 11, 2012

Arrogene Nanotechnology, Inc. (ANI)

a company focused on oncology

0 6019984

219035

700000 606318

205800

Black-Scholes option pricing model

P5Y

0.0169

0.7890

49541 60270

35700

Black-Scholes pricing model

P5Y

0.0169

0.7890

8292 10825

726550

The Convertible Notes were initially convertible into shares of our common stock at $.30 per share (the Conversion Price).

shares of our common stock

Convertible Notes do not bear interest

originally payable on October 19, 2011

10000

224000

56000

168000

25000 260000 1.00 1.00 24956 227645

17160

58400

P5Y

0.0137

0.7890

2433

7300

6358358

5422858

1400000

766667

66667

6358358

5422858

1400000

766667

66667

435

561

67600 47600

In September 2010, we entered into a business and financial consulting agreement with an entity controlled by our Board chairman for operational consulting services.

49000

39000

38625

142087

87000

195884

258091

9434

10950

31880

30392

8100 10800 18900

Dr. Randolphe Swenson, Jr. was elected to serve as a member of the Board of Directors

0001403792 2012-10-31 0001403792 us-gaap:CommonStockMember 2013-10-31 0001403792 fil:APICMember 2013-10-31 0001403792 us-gaap:RetainedEarningsMember 2013-10-31 0001403792 2013-10-31 0001403792 fil:SyntheticaLtdMember 2013-10-31 0001403792 fil:EntityControlledByBoardChairmanMember 2013-10-31 0001403792 2013-11-01 2014-07-31 0001403792 2014-09-10 0001403792 2014-07-31 0001403792 2014-05-01 2014-07-31 0001403792 2013-05-01 2013-07-31 0001403792 2012-11-01 2013-07-31 0001403792 2007-08-07 2014-07-31 0001403792 2013-07-31 0001403792 us-gaap:CommonStockMember 2013-11-01 2014-07-31 0001403792 fil:APICMember 2013-11-01 2014-07-31 0001403792 us-gaap:RetainedEarningsMember 2013-11-01 2014-07-31 0001403792 us-gaap:CommonStockMember 2014-07-31 0001403792 fil:APICMember 2014-07-31 0001403792 us-gaap:RetainedEarningsMember 2014-07-31 0001403792 fil:ArrogeneNanotechnologyIncMember 2013-11-01 2014-07-31 0001403792 fil:BridgeNoteWarrantsMember 2014-07-31 0001403792 fil:BridgeNoteWarrantsMember 2013-11-01 2014-07-31 0001403792 fil:PaBridgeNoteWarrantsMember 2014-07-31 0001403792 fil:PaBridgeNoteWarrantsMember 2013-11-01 2014-07-31 0001403792 fil:October2010ThroughApril2011Memberfil:ConvertibleDebt1Member 2013-11-01 2014-07-31 0001403792 fil:ConvertibleDebt1Member 2014-07-31 0001403792 fil:CommonStock1Member 2013-11-01 2014-07-31 0001403792 fil:CommonStock1Member 2014-05-01 2014-07-31 0001403792 fil:CommonStockPurchaseWarrantsMember 2013-11-01 2014-07-31 0001403792 fil:StockOptions1Member 2013-11-01 2014-07-31 0001403792 fil:StockOptions1Member 2014-05-01 2014-07-31 0001403792 fil:Warrants1Member 2013-11-01 2014-07-31 0001403792 fil:Warrants1Member 2014-05-01 2014-07-31 0001403792 fil:Warrants1Member 2013-05-01 2013-07-31 0001403792 fil:StockOptions1Member 2013-11-01 2014-07-31 0001403792 fil:StockOptions1Member 2014-05-01 2014-07-31 0001403792 fil:ConvertibleDebt1Member 2013-11-01 2014-07-31 0001403792 fil:ConvertibleDebt1Member 2014-05-01 2014-07-31 0001403792 fil:ConvertibleDebt1Member 2013-05-01 2013-07-31 0001403792 fil:Warrants1Member 2012-11-01 2013-07-31 0001403792 fil:ConvertibleDebt1Member 2012-11-01 2013-07-31 0001403792 fil:SyntheticaLtdMember 2014-07-31 0001403792 fil:September2010Memberfil:EntityControlledByBoardChairmanMember 2013-11-01 2014-07-31 0001403792 fil:EntityControlledByBoardChairmanMember 2014-07-31 0001403792 fil:CSMCMember 2014-05-01 2014-07-31 0001403792 fil:CSMCMember 2013-11-01 2014-07-31 0001403792 fil:CSMCMember 2013-05-01 2013-07-31 0001403792 fil:CSMCMember 2012-11-01 2013-07-31 0001403792 fil:CSMCMember 2014-07-31 0001403792 fil:YearEndingOctober312014Member 2014-07-31 0001403792 fil:YearEndingOctober312015Member 2014-07-31 pure iso4217:USD shares iso4217:USD shares Less discount of $145,530 Preferred stock, $.0001 par value 10,000,000 shares authorized, none issued. Common stock, $.0001 par value; 100,000,000 shares authorized; 21,375,860 shares issued and outstanding. Common stock, $.0001 par value; 100,000,000 shares authorized; 21,350,860 shares issued and outstanding. At $1.00 per Unit Assumes Bridge Note conversion price of $1.00 per share see Note 4 for conversion price calculations.

EX-101.LAB 8 skrp-20140731_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Convertible Debt {1} Convertible Debt Bridge Notes, Aggregate sold The aggregate amount of Bridge Notes sold during the indicated period. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Amortization of debt placement costs and debt discount Deficit Accumulated in Development Stage General and administrative Common stock Entity Well-known Seasoned Issuer Entity Central Index Key Year ending October 31, 2015 Sale of Units, Value Convertible Debt Outstanding Fair Value Assumptions, Risk Free Interest Rate Bridge Note Warrants {1} Bridge Note Warrants The amount of debt discount related to PA bridge note warrantss amortized during the indicated period. Going Concern and Management's Plans Supplemental Disclosure of Cash Flow Information Adjustments to reconcile Net Income (Loss) to net cash used in operating activities: Equity Component Type of Security Net cash provided by financing activities Net cash provided by financing activities Shares issued for License Research and development Total liabilities and stockholders' equity (deficit) Total liabilities and stockholders' equity (deficit) Additional paid-in capital Property and equipment, net CONDENSED CONSOLIDATED BALANCE SHEETS Document Type Entity Registrant Name Accounts Payable, Related Parties, Current Sale of Units, price per unit Commitments and Contingencies {1} Commitments and Contingencies Cash acquired in business acquisition Net cash used in operating activities Net cash used in operating activities (Increase) decrease in prepaid services and deposit Non-cash charge for reduction in conversion price of Convertible Notes OTHER INCOME (EXPENSE): Accrued compensation Document Fiscal Period Focus Business Acquisition, Description of Acquired Entity Advances from related parties Capital expenditures Capital expenditures STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Common Stock, Par Value Total assets Total assets Entity Filer Category Class of Stock Time Reference {1} Time Reference Deficit accumulated during development stage Details Schedule of Commitments under non-cancelable operating leases Basis of Presentation Going Concern, Management's Plans and Basis of Presentation Business and Overview Year ending October 31, 2014 Operating Leases, Rent Expense Allocated Share-based Compensation Expense Revenue since inception Related Party Transactions Net increase (decrease) in cash Proceeds from sale of Series A Preferred Stock Common Stock, Shares Outstanding Preferred stock Debt offering costs Current Fiscal Year End Date Entity controlled by Board chairman Synthetica, Ltd Related Party Transactions, by Related Party Income Taxes Paid, Net Interest Paid Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Class of Stock {1} Class of Stock Fair Value Assumptions, Expected Term Bridge Notes {1} Bridge Notes The amount of debt discount related to PA bridge note warrantss amortized during the indicated period. Earnings (loss) Per Share Notes Proceeds received from Promissory Notes Sale of Units at $1.00 per Unit, Value Statement, Equity Components Weighted Average Shares Outstanding, Basic and diluted Other Income (expense) Other Income (expense) Entity Voluntary Filers Commitments under non-cancelable operating leases September 2010 Warrants Business Acquisition, Effective Date of Acquisition {1} Business Acquisition, Effective Date of Acquisition Schedule of Cash Flow, Supplemental Disclosures License Agreement Net proceeds from sale of Convertible Notes STATEMENTS OF CASH FLOWS Document Fiscal Year Focus Entity Current Reporting Status Document and Entity Information: Related Party Sale of Units, Shares Debt Instrument, Payment Terms Debt Instrument, Interest Rate Terms PA Bridge Note Warrants, Debt Discount Amortized The amount of debt discount related to PA bridge note warrantss amortized during the indicated period. Business Acquisition, Acquiree Convertible Notes Interest Interest OPERATING EXPENSES: Preferred Stock, Shares Issued Preferred Stock, Shares Authorized Convertible notes Accounts Payable and accrued expenses Entity Incorporation, Date of Incorporation Related Party Transaction, Description of Transaction Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Common Stock Purchase Warrants Time Reference Use of Estimates and Assumptions Depreciation expense Share-based payment expense Loss Per Share, Basic and diluted STOCKHOLDERS' EQUITY (DEFICIT): Total liabilities Total liabilities Common Stock {1} Common Stock October 2010 through April 2011 Assets, Fair Value Disclosure Bridge Notes {2} Bridge Notes The amount of debt discount related to PA bridge note warrantss amortized during the indicated period. Net proceeds from sale of Units Net proceeds from sale of Units CASH FLOWS FROM FINANCING ACTIVITIES: Balances, Value Balances, Value Balances, Value Operating Expenses Operating Expenses Cash and cash equivalents Cash and cash equivalents at the beginning of period Cash and cash equivalents at the end of period Amendment Flag Document Period End Date CSMC PA Bridge Note Warrants The amount of debt discount related to PA bridge note warrantss amortized during the indicated period. Bridge Notes, Debt Discount Amortized The amount of debt discount related to bridge notes amortized during the indicated period. Fair Value Measurements, Valuation Techniques Bridge Notes The full disclosure covering Bridge Notes. CASH FLOWS FROM INVESTING ACTIVITIES: CASH FLOWS FROM OPERATING ACTIVITIES: Placement Agent warrants Monetary amount representing expense for Bridge Note Warrants, during the indicated time period. Bridge Note Warrants Sale of Units at $1.00 per Unit, Shares Balances, Shares Balances, Shares Balances, Shares Common Stock, Shares Issued Preferred Stock, Par Value LIABILITIES: Total current assets Total current assets Current assets: Fair Value Assumptions, Expected Volatility Rate Bridge Notes, Net Proceeds The net proceeds from Bridge Notes sold during the indicated period, after payment of offering costs. Business Acquisition, Name of Acquired Entity Policies Repayments of Promissory Notes Repayments of Promissory Notes Preferred Stock Net Income (Loss) Income (Loss) from operations CONDENSED STATEMENTS OF OPERATIONS Total stockholders' equity (deficit) Total stockholders' equity (deficit) Retained Deficit Bridge notes Prepaid expenses and deposit Subsequent Event, Description Arrogene Nanotechnology, Inc. Tables/Schedules Subsequent Events Repayment of related party advances Repayment of related party advances Increase (decrease) in other payables and accrued expenses Contributed services Stock option compensation expense APIC Related party payables Current liabilities: AccruedCompensation Type of Security {1} Type of Security Business Acquisition Stockholders' Equity Common Stock, Shares Authorized Total current liabilities Total current liabilities LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) ASSETS Stock options Debt Conversion, Converted Instrument, Type Debt Instrument, Convertible, Terms of Conversion Feature Net proceeds from sale of Bridge Notes Net cash provided by (used in) investing activities Net cash provided by (used in) investing activities Statement {1} Statement Common Stock Statement Accrued research expenses payable to CSMC Entity Common Stock, Shares Outstanding EX-101.PRE 9 skrp-20140731_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 10 skrp-20140731.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000270 - Disclosure - Bridge Notes: Bridge Note Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 000320 - Disclosure - Supplemental Disclosure of Cash Flow Information: Schedule of Cash Flow, Supplemental Disclosures (Details) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Bridge Notes link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Supplemental Disclosure of Cash Flow Information: Schedule of Cash Flow, Supplemental Disclosures (Tables) link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - Condensed Statements of Operations (unaudited) link:presentationLink link:definitionLink link:calculationLink 000330 - Disclosure - Related Party Transactions: Consulting Agreements (Details) link:presentationLink link:definitionLink link:calculationLink 000300 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 000310 - Disclosure - Earnings (loss) Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Convertible Notes link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Condensed Consolidated Balance Sheets - Parenthetical (July 31, 2014 unaudited) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - License Agreement link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Going Concern, Management's Plans and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 000290 - Disclosure - Convertible Notes (Details) link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Going Concern, Management's Plans and Basis of Presentation: Use of Estimates and Assumptions (Policies) link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Business and Overview link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Earnings (loss) Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 000280 - Disclosure - Bridge Notes: PA Bridge Note Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Going Concern, Management's Plans and Basis of Presentation: Going Concern and Management's Plans (Policies) link:presentationLink link:definitionLink link:calculationLink 000350 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Going Concern, Management's Plans and Basis of Presentation: Basis of Presentation (Policies) link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - Commitments and Contingencies: Schedule of Commitments under non-cancelable operating leases (Tables) link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Earnings (loss) Per Share link:presentationLink link:definitionLink link:calculationLink 000340 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - Business and Overview (Details) link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - Condensed Statements of Cash Flows (unaudited) link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Condensed Consolidated Balance Sheets (July 31, 2014 unaudited) link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 000260 - Disclosure - Bridge Notes (Details) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) - (Unaudited) link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 000360 - Disclosure - Commitments and Contingencies: Schedule of Commitments under non-cancelable operating leases (Details) link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - Supplemental Disclosure of Cash Flow Information link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Condensed Consolidated Balance Sheets (January 31, 2014 unaudited) link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - Going Concern, Management's Plans and Basis of Presentation: Going Concern and Management's Plans (Details) link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 000370 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0"I^C`/Y@$``,P7```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-%JVS`8A>\+>P>CVQ$K MDM:N&W%ZL767;:'=`VC6G]C$EH2DMLG;5W;:4DJ6$A;8N8E)+/WGB\`?^,PN MUGU7/%"(K;,5$^64%61K9UJ[K-CONU^3^[MM8ID_(':]ZE3)X3RKQS7!.; MUL?/&8/QG0G#G;\'/.^[SD<36D/%C0[I2O<9@Z\[_NC"ZH]SJW+_D!V4;K%H M:S*NON_S"931!](F-D2I[\KQ6O:ZM2_<>_+'Q9&/%W%DD.'_C8,/Y)`@'`J$ MXPL(QRD(QQD(QU<0CG,0CF\@'&**`H)B5(&B5('B5($B58%B58&B58'B58$B M5H%B5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEB5H5B5H5B5H5B5H5B M5H5B5H5B5H5B5O6_S)IR5TI\_/SW!W<<\T%9%].FHWCD%^SMT(^2&QW(W*:0 M6^6C`[R=O8\C=ZXWP?F8V^=`AY_"2[T\[)[X/(A":NFU8-Y5U+XFYN;Z\,!W M33$-W;@ALR.;CUW\_`D``/__`P!02P,$%``&``@````A`+55,"/U````3`(` M``L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24 MFV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A M363X8<'%#U1?````__\#`%!+`P04``8`"````"$`\*#N9/0!``#)%@``&@`( M`7AL+U]R96QS+W=O_4G9E2_HBT%[12 MKRP\@)6X346;1+9AZ=MC%384B?UV#]%<(ME1QI\^C^?YU>FB,FUM=MUK2_-P4>S7)S]N+WW.Y?R1['9]K'( M4=I8FB:E_L;:6#5^[^*DZWV;WZR[L'3J=VW`:PRR^Q"Q6 M=6G"JB8QQ<.ASTO_.WBW7F\K?]=5SWO?IF_6L+^[\!0;[U,.ZL+&I](,4]$> MWY!,LF9C_R(G^Z$KYPK)X;FR')XC.7(]IIR8#KN<;L-.O8_1^DQCKC]DQJ>$ M8>HC69B0')DIRY$9DG.IK.82B2%65D,,Y6B;0]`=OE!VAR^0.Z)=A`4681FU M"*<,*Y_M_N#!<6B/3WBXM?,7IZ\V!PAR@',;H4I)GJ+TY5&Q-##@,V>&J3]8 MN$9RM"$%TU@[<6#>D+HUT!O6YC=#?HMVR1%8"53K0KLN"2/.JQ^@]W M"**0'+[Y0?TX@T``/__`P!02P,$%``&``@````A`,GL4F2. M`P``U0L```\```!X;"]W;W)K8F]O:RYX;6R4EE%3FT`0Q]\[T^_`\%X)D%AU MC([1V#K3:J:Q^GASPB7<>-SAW6'TVWF M#5=RZH<[(]]C,E$IE^NI__?Z_-N>[QE+94J%DFSJ/S/C'Q]]_7*X4?K^3JE[ M#P2DF?J9M<5!$)@D8SDU.ZI@$NZLE,ZIA5"O`U-H1E.3,69S$42CT6Z04R[] MK<*!_HB&6JUXPLY44N9,VJV(9H):2-]DO##^T>&*"W:SK MH,;.4VY9.O4G$*H-:UW093$KN8"[^_$H]H.CILB%]E*VHJ6PUU#>JSKX%8VC M:+?Z967%#6<;\W:H"KVG6RY3M:E^"M8^-U$,"6SJ6[<\M1G<'XU&S;6?C*\S M^WH1Y`.D7SL(_U-_>K(N[]41`ITB8"5S0K M#9?,F+I)5S!TCT`(.AS#K#4Y?._F\$/!3%:-29B6Y#>5=/UBR@+:@V7VD M5^87S`^TF)RL-:O/HY-C0+1)8+][0&G5/0<)0J>5W MHNB$#H%_JO4$4[2@&H;R6E-I:%+O M*ZR!P0E[^,MS;K<`88 MOO"3].&A'F/\0H>_88P!B&8[3#"-H8/CL!#`\2:$"84UW-EZ[Y!"EDG&TA+K M8%PC%]=!8+!%$XQNY*![J@:Z37!"F.#((;AWWY`S9BD7N/512\8!>-AH.-L8 M'>%)@*!C-%X@?6G@&=@^56OEET="(B!V1GL?65A&H>@TY[AA8T`/"S4700``&(/```8````>&PO=V]R:W-H965T&UL ME)=OCZHX%,;?;[+?@?!>H?PK&/5F$&;W)G>3S6;OW=>(5J--Y(PPI:KTPTMTV#U#G=%?5A9?[\]WD6F@9K MLWJ7E;0F*_.#,//;^O??EF?:O+`C(:T!"C5;F<>V/2TLB^5'4F5L3D^DAE_V MM*FR%BZ;@\5.#)0*>>(RNR0&F]W!7@@*?=:,A^93ZA18I1$)9#1D%F[OA<*:2OK*75?P)"O900<7H1%Z+O?T=SS_%Q^!45 MKU>!SU'EJZ%`T)T?^!Q%'@W%$LGI-O1L0`.#?7;*^'1`"U"^)%FD M9$C[9UF'='.1)ZZR,K%I0$(9M,K;&KM+ZPVJF_=(?`7Q5&1S07@MN6QRN3'* M(O61]$+P1@)'@RVHFVSK>L]P()NT8,'2_2?M_(OR/7\2.M,HD,.!AY7J2.D,J`B[`=CKVL.(,I];@S M#FO.0G7<6"!!YPP6LM#1KFN1[SI:8!L9<$+;C;3%()$!!.8C;PQ=>),)'+JAU!F*-UC) M'B\;AU5OH:V532#"V\R]9DXAKKI3B.OV%.26/[Y'DE;]V\LCA]7U)-0R'PL$ M)L4P)_7UY"Z1W"726X12ON@K]CBLE4];#F*!].6+H+&T^FX$X'73%/;9!4$?"#,;^*+P2;J,?KUM&:,VU"Q#USPUI/?.I-5;AJ3I7XW!U_ MF3_&^39`,GS'J-@T*$;UW0N<.OB4A1CX3G-FS_7IM)D2 MXXSJMY83#6T4?K;11AE[1U14'%W$=KHBS8%L2%DR(Z>O_%CB0G3#W>'(].3P M;:9V/T8+V/Q.[R?\B,7O6\,#<,(Y90?R5]8T"Q$#%'?JWI6SLD:;$/3C%S=NF M>1!:-8A8RTJZ?0NE1(GI:U%KP]<5QKV+!UPWB!J^D,-KJW$6(8\'H;_9,;*FWGXS,OL@:,-E8)E^` MM=9O7OJ:^2T\S&Y.O[0%^&9(!CG?5.Z[WGX&690.JSW$@'Q M,?)SCW_/^M&*%WLKO@K>VS)L(/OD[>K>6\69^0LGF*'[G7@Q5OK\XG[_\NIE MT`S.-%=I6_U/<>$-(?=[\^*48N"GI(Q'5]Z"9M*6<]"_]G7^=C@ZE3)X"J,4 M.DV!*6`%566)T!L_)@DRN]UN@A>)+]K5_A(GNYT#UKW`R6IX`5^Y*61M204Y M(GO1&-O6A-D,"Z>;MK_7VN%,M8\E?D(!FZ(7H3C7VAT7ON6ZC_+\#P```/__ M`P!02P,$%``&``@````A`&8;3(*%!```T1```!D```!X;"]W;W)K&ULE%C;;J,Z%'T?Z?P#XGU"(!<:E&34A*LT(QT=GJZF9UK;7MQ79B=_WC(TV4=Y*SF&8;59],585D$3W& MV7FC_O.W^_U%55@19L)F?-7;-27@L16FB&=/I4DO#.%.%@Y4_XT%/IS@B M-HUN*/"^F-%26 MZGK(0%-?!H(&H$$L=3;0IW(V?,^(!GPZ&^["L\'Z.P0>4S:D')"!$AN!A\1< MM#4.4E#C(O#02&4\9*#$1^`AD:."5=TN^G+9 M7L].<&`GUQQIQ7MDX/1M!`8E#C)0XB(P*/&0@1(?@4%)@`PY(UA,,R/<:^-9 M<5$[*\.4'N1.<);EQEO.%B_PW4YS+QCSN@GMIF0Q-XP76>+($KFM$C0DK7Z"?=;,:CPC3FYGI)MF.X&=X$"YP7Y"!CYI&X%!B8,,E+@(#$H\ M9*#$1V!0$B!#[B?X%&IF]%P_<5$[JVX_"8[H)WT^Y5_M-/>"T>@G!`97X2`# M%^Y^6<63)3X"@U4"9,A9P6=3,ZOQ?N)D.:-9.X&=X(SU$S)PP38"@[-WD($2 M%X%!B8<,E/@(#$H"9,@9\<-^SUE@/"LNDK.2WY\$1_23N80O:7/N!0'.'_7F MG$MG`[OIT6/A?&WA-BWZIN%][>$W/7JF$8Q:M-[A8+7-M,=3YF0XHI6'_/)H MM.L@^PYB=Q"G@[@=Q.L@?@<)FDAK53#%UK+PHO$_#TVE3;NMY([851P=CF]U MVQC=,R6?$$0GKB+B5-F!G(<7[B.W"WE=R.]"_![WJ"C"$?Y(D M3(GHC=^Y5O#!7:/5?7!E0<8P%PF'1>-%4?H+W"!?C5Z%!:?FKI/+;YP]^,ZP M]GT^MF'!&;/'Q[#@(-G%?<."PR+@6CU1N%!>PS/Y%>;G.&-*0DZP^.G$A,^W M7%Q)Q8N"7LN+R8$6<)4L?[W`OPX(W`BF$R"?*"WP!2]0_S-B^QL``/__`P!0 M2P,$%``&``@````A``@?.;2!!```PA(``!D```!X;"]W;W)K&ULE)A;;Z,X&(;O5]K_@+@OA#-!248EG$::E5:KG=EK0IP$%7`$ MM&G__7[&0+"9XK07H=B/7]OOYR.;;^]E(;VANLEQM94U925+J,KP,:_.6_GG MO]&3*TM-FU;'M,`5VLH?J)&_[?[\8W/#]4MS0:B50*%JMO*E;:^>JC;9!95I MH^`KJB#GA.LR;>&U/JO-M4;IL2M4%JJ^6MEJF>:53!6\^A$-?#KE&0IP]EJB MJJ4B-2K2%MK?7/)K,ZB5V2-R95J_O%Z?,EQ>0>*0%WG[T8G*4IEYW\\5KM-# M`?U^U\PT&[2[EYE\F6:"[[%=7[\D5<(W(8XD0@<,'XAZ/_X$:`F`T=!1M$MHI3A`AH`OU*9DZ$! MCJ3OW?.6']O+5C9LQ7)6A@:X=$!-&^5$4I:RUZ;%Y7\4ZGHTBNB]B`&M[_,U MQ=0MQ_V*BMFKP'-0L;ZN`JWN.@3/0<54=-?2+/L+/;)[%7CV*H:FN)9EVJ[S MN"].KP*3;6C+XSU2::2ZP`=IF^XV-;Y),)L@%LTU)7-3\T!YB#B-SS@&/AL" M$'LB\DQ4MC*T$*+;P+A]V^FVN5'?8*QE/>//&8TE]@-!!A:1#6@"_(ZR#J<: M#F7N"*<:#<2@&HM5DSER5U7!N=$^&*Q3^WX_40:7"$Q<&EKB#PGWQNN<)7/" ML5@DH`BT>#2)$PF%1"0D8B&1+!&,9S"Q'_>,P(QG?,*>3PAHPM00UV4]"\5( M-$=TF[,^GC.:X[!5),S$V&WFIJX/`H)S)O'33J?,K3CNC7KUY[))\;>$1"0D8B&1+!&,<^1& M,3F6+`\^`G/..=S8\2G3+T[FVN*6R#V3KSNVR:V0`066+!02D9"(A42R1#`6 MKED+R6XB7@1)(,=;?-:8KAA$_W8RGK*SEL3^;Z M@[[2(SIS[C'Y[1KNRF0X+_HJ1`*Q2BA&(C$2BQ%R^R<]ZGU=*8Z[)AOE^'?? MZJG']*I/;WPEJL]HCXJBD3+\2J[Q%D1G3!T_,3P;Y(;"I?N:!_>S>7JH>7## MFJ?[NN?_3F>O>W!B!UX=*X`O"-?TC/Y*ZW->-5*!3M`TZ!H<4VKZ#8*^M/C: MW5$CA3112-6NZC9IDZ9I'\^.,6`58V0[3?OO=\U= MG)"L7<,#PG!\SKG']F5Y_:1:\BB,E;HK:#*)*1$=UZ7LZH+^_'%_<46)=:PK M6:L[4=!G8>GUZOV[Y5:;!]L(X0@P=+:@C7/](HHL;X1B=J)[T<&72AO%'`Q- M'=G>"%8.DU0;I7&<1XK)CB+#PKR%0U>5Y.).\XT2G4,2(UKFP+]M9&]W;(J_ MA4XQ\[#I+[A6/5"L92O=\T!*B>*+SW6G#5NW4/=3`=-J64JHP,=.C*@*>I,L;NOO1R/*+ M[`2$#-@M3,HR->U M*)_OA.40*-!,TLPS<=V"`;@3)?W.@$#84T%3$):E:PHZS2?9+)XF`"=K8=V] M])24\(UU6OU&4#*80J[!VAUS;+4T>DM@N0%M>^8W3[(`XITG9`@N7S()[CS) MC6G;('>V4? ME[=RBR\.9?9&1C+3$@^F$^S:;"/RHBY&LI/8KC"]Y'NY3FZ'GRL>QEX M41LH`8*<,N.0S6K_44=O'K`?M)QP[V_.@`,5CY+,VS[(72\U,#^7\- M^$G'!O)0(!I`S&$$:38+F%$(L$G/#\%/.O9P%?C1`V+&'N8!,_+@&_K!H7M] M`3SX2#O?YXO:B!EIYR^&PO=V]R:W-H965TKVI2S0,Q62\2K&KN5@1*N$IZS:Q_C']X>;$".I2)62@EK(Q=/,J=4(7"H9(QSI>JE;+ZY/DI-W-?G\9/0H>[^1S/GQHV#I9U91 M"!O*I`NPX_Q)2Q]3?0D&VQ>C'YH"?!4HI1DY%.H;/WZB;)\KJ'8`$]+S6J:O M]U0F$"C86%Z@G1)>```<4I>/G+B-S6RIAXK0E\MR9N8/E>L`C_Q676NL!WZ^)=C6*;:34IW1-%UBO! MCPA6'H#+FNAU["[!^!2/F4P7V%MY05#:Y$Z[Q'B!$40AH<;/:\\/5_8S%"9I M-1NC@6.G6?A#R?92XG8*&X`[:@BR3_WG8I[@M%C#Z>)JVHVYT"?QNL'PT)-D83-EF&7C0&[-]VG=`+NN$#/'^( M-XVEQ2.LP.E\371&`\<._?QD$]V48L`&VZM=1ZD%CRM$>W!C- M%.6EPO//JV!`J9OHZ.WR]^VA!XTIYZ-U:#13E$8QBYH=Y%KS,.I_P@\WY_(, MD*/_0=:#QLB+$;+13"$;18OL6(LPTRV[&]#J:K*G7XC8LTJB@F8P%!X->T689FE.%*^;7K'C"II< M\S.'_S047J>.!>*,VX^Y>T_@T``/__`P!02P,$%``&``@````A`"A" M6R(8`P``7`D``!D```!X;"]W;W)K&ULG)9;;YLP M&(;O)^T_6+XOIT"`**1JTG6KM$G3M,.U`P:L`D:VT[3_?I]Q0@+96#HN.+Y^ M>?S:YF-Y^U)7Z)D*R7B38-=R,*)-RC/6%`G^\?WA)L)(*M)DI.(-3?`KE?AV M]?[=/`\9RF]Y^FNIHTR)H)61`&_+%DKCVYU>HU=3<33KKU) M>=V"Q9953+UVIAC5Z>*Q:+@@VPKZ_>+Z)#UZ=Q<7]C5+!9<\5Q;8V0;TLL^Q M'=O@M%IF#'J@8T>"Y@F^;&-NK99?/3T;W\NP\_45:4"D8[@`[I?BVRUWLJ4P@4 M;"POT$XIKP``]JAF>F9`(.2E.^Y9ILH$S^96$#HS%^1H2Z5Z8-H2HW0G%:]_ M&9%[L#(FWL$$C@<3-[!\+PBCM[C,#BYP/*+`Z32";;K3I7-/%%DM!=\CF'$` M+%NBYZ^[`)=C+*83?5!_RPD"TB9WVB7!(480@82Q?5YYLWAI/\.`I`?-VFA@ MWVM"?RC97$K<7F$#<$\-`9Y3_WD0CW!:K.'TH&K:M;EQ3N+UK^D4FRG%``0B MNQY$BQ,,WGT"GN\,W[PVFJC+T(\#_Q2`(3M_/G>\\-1^P.6_A4N+AUQQ.,(R M$MCWZ,%0L9E2#-!@N5P?F18/T;QQ)&NC,9%Y3A`YITQ,9A."`=E\2*;7P@P^ M--.S2S<:$XZFT]IHIM*[5'C^K$]X0`FK[#R_ZRAUHS'E:/6MC6:*\E+A^:=Y M,*#497/T7?EWEKK1F'+>IV`6K]%,41K%+.[6D&O-H_A\BS[+QZCF4(VB@.R8X51[)QOXYE@JISYCM=4%'1#JTJBE.]T!7.AX_W=OKC> M>5U][!]`<6M)0;\04;!&HHKFT!1>#8M%F/)H+A1ONRJQY0K*6G=:PE\,A0^I M8X$XYUP=+W0![O^+5K\!``#__P,`4$L#!!0`!@`(````(0!N!1M79P(``*@% M```9````>&PO=V]R:W-H965TF9K8WP,LA2+4L3],)4UQV-##, MS34*=:RE>YE(*5$ MB?ESW6G#URWF?B6%T597+D$Z%HQ>YGS'[A@R+1>EQ`Q\V8F! MJJ"K;/XPIFRY&.KS4\+>GCT3V^C]1R/+S[(#+#8>DS^`M=8;#WTN_2L,9A?1 M3\,!?#6DA(IO6_=-[S^!K!N'ISW&A'Q>\_+E$:S`@B)-D@\VA&[1`*Y$2=\9 M6!!^&.Y[6;JFH#EVQAJL>Y*>BA*QM4ZK7^%CYLW$X/P8C/=C<#9.;O/Q=):A MV#]86'`R)/;('5\NC-X3;!;4M#WWK9?-D?GM3-"%QZX\N*!32M"LQ>KOEOEH MLF`[+)DX8AX"!M>(R2*"H6A41K7KE3W8*_N">"L/X<6Y3/ZVS.A_9#RXH+A& M\_EH%'F#:C:>0-R@$S&PH_3?T5`:^$L1NN M%_;@OX5GD3<(!TP0GJ234?8'$(3#Q(3&4F!J^`!M:XG06S\-&3J.;^.@KO)A MUN('')2>U_"%FUIVEK1086B:3%'S^_<=X\`&:)/L"\;VF<.&U*,RGCY M):NX(/L"=+^X$Q*WW,UD1%^R6'#)4V4!G6T<'6M>V`L;F-:KA($"'78D:!KB M!W>YFV)[O6KB\YO1HSQ[1S+GQT^")5]912'8D":=@#WG3QKZ)=%+8&R/K!^; M!'P7**$I.13J!S]^IBS+%60[`$%:US)YC:B,(:!`8WF!9HIY`0[`$Y5,5P8$ MA+PTXY$E*@^Q/[6"F>.[`$=[*M4CTY08Q0>I>/G'@-P3E2'Q3B0PGDCJ";2+:)"@BBJQ7@A\1 M%#W$3-9$'R%W"80Z,Q,831R[7/TO59`C3?*@64(\PPC,)937\]KSW97]##41 MGS`;@X%GAQD@MBU"%X"FC88+N[,%&P1T*D#_N8I_UU7KK`9K9]O/;,S"N6=> MW_?M&#&4%XTALZ#/LAM#//_M2SU!4%ZW"])@.!)GD?5\O__MC<%`X771'WBW MO8J(KB)VEQ`]?>#([?HT.,00O+^2`&6X.XI/,J8G<)T=,Y M[>N\K$^#^_I&!6H@)H&>NW#\@?[M.<#UY][;R3&716]_#HAIOPR@P6DGS!<" M?S'S9AW`*#/]RUR/)149W=*BD"CF!]V;7(A\M]JUS0>OZ7S=!K2MFF3T&Q$9 MJR0J:`JFCC6#N`K3^,Q$\;JY?/=<0<-J7G/X/Z%P[3D6@%/.53O1K;7[XUG_ M!0``__\#`%!+`P04``8`"````"$`-B1EZV$#``"<"P``&0```'AL+W=O M)CA#W*`%SF$DIBQ#`G[9WN0%PR@J)V6I.;"LD9DADNN*P6-].&@*A.$4"?"?)Z3@)[8L[$.7(?9Z*)Y"FA5`L2,I$1\EJ:YEH?=MGU.&=BG$ M_6Z[*#QQES\M^HR$C'(:"P/H3.5H.^:I.36!:3&+"$0@9=<8CN?ZB^UM1[JY MF)7Z_"7XR*^^-9[0XX:1Z#O),8@-:9()V%'Z*J'?(FF"R69K=E`FX"?3(ARC M0RI^T>,6DWTB(-M#"$C&Y44?/N8A"`HTQF`HF4*:@@/PU#(B*P,$0>_E^T@B MD3S[`X M%0N\3RQ`V-,%MYH,3I\FNX;M6J-/A#&J.,9G#L?Y+`=LJU)/>%=^]-?35+DI M4^TC@18S1H\:;!]0GQ=(;D;;`^+;N86D2NR+!,]UB`'2QJ$>WQ:#\7AFOD$1 MA15F>0-31ZS:",>N0WP%@>=EH3IBW48T28(V9%`GV;0139)M&W(A,4'#LY!0 M3_V%E&`II-PT4MEET[!J&GQE`'#SI7V'0BMH\0M6J` M8_1:07FKC._>*J>31TYJ*MDX-)8*`W[<5;(3X7?C$UR"ZSJZHWJY+15$%9,[M9K%M+H>=]KCOAI_D(9U)R*X7N.&#YOK M\1L^0%G'D@=VP+VUO M>&PO=V]R:W-H965T\(%976,'--&!JE3EM'Z&*,_OV^O0F0(B>L,EZPF,7HD`EUO/G]: MGQF_$P4AT@"&6L2HD+)9699("U)A8;*&U#"2,UYA"4U^M$3#"<[:255IN;:] MM"I,:Z095OP]'"S/:4H2EIXJ4DM-PDF))<0O"MJ(CJU*WT-787YW:JY25C5` M<:`EE8\M*3*J=/7M6#..#R7H?G!\G';<;6-&7]&4,\%R:0*=I0.=:XZLR`*F MS3JCH$"EW>`DC]&-L]HOD;59M_GY2\E9#+X-4;#S%TZS[[0FD&RP21EP8.Q. M0;]EJ@LF6[/9MZT!/[F1D1R?2OF+G;\2>BPDN+T`04K7*GM,B$@AH4!CN@O% ME+(2`H"G45&U,R`A^*%]GVDFBQAY2W,1V)X#<.-`A+REBA(9Z4E(5OW3(.=" MI4G<"PG,N)`XCNF[BR!\!XNE(VH%)ECBS9JSLP&;!M84#59;T%D!^XW;NBMK7O(:7K!;.>8P!]#=AU$95#Q)EW'$Z\S MGK+O$,H^D-3K@FP-=3WO5!>^`JOPNW6WN@.XG_2,U]W-$<%B#$GF$'>,V,\1 M`Y*1'.\C1Q\$XY6W&A*V5H6N'TW&=\-QQW,7T23T9`AP`\?WH_$* M^R'`1"1O(O:O(4;ZX%"]?R,J M\%C?S#D-6;;.>>'2G8H;CH>!;=MC7Y+AN..[=CBQ?C\"1(OP)>.68V&J<3AYBP(N"Q7'\Q3:/GT9Z%I9 M$7XD.U*6PDC9215Z#_+?]_9WT(VK2LBD?^NLH+#-^Q.XL]I^JY\`=T:#C^0' MYD=:"Z,D.2QEFP%8PO6MHQN2-6WE/C`)MT7[6<#/`8&2:9L`SAF374,5QOYW M8_,?``#__P,`4$L#!!0`!@`(````(0`*D^[EM`(``/$&```9````>&PO=V]R M:W-H965T/SGF.?+.Y>JQ*],*FXJ!/L.QY& MK*8BX_4NP3^^/]Q$&"E-ZHR4HF8)?F,*WRT_?E@N:B0C6;NH*MW`\V[=BO`:6T(LKV&(/.>4I8+N M*U9K"Y&L)!KB5P5O5$>KZ#6XBLCG?7-#1=4`8LM+KM]:*$85C1]WM9!D6X+O M5W]":,=N!R-\Q:D42N3:`9QK`QU[GKMS%TC+1<;!@4D[DBQ/\+T?;R;872[: M_/SD[*!ZST@5XO!)\NR)UPR2#64R!=@*\6RDCYF9@L7N:/5#6X"O$F4L)_M2 M?Q.'SXSO"@W5GH(AXRO.WE*F*"04,$XP-20J2@@`?E'%S4!,\P`A<*RO.R#*+I MPGV!G-*C9C76S"9#R;J3F`P:;MI-G+G^<,FF4YCR@:63+\A6W]>?*]6%;\0F M_&[?E9T`]MG/<-_U6#&[,)R.)<$0LADK>I"!G?!_[!@Q'+%^]&$XW'IE-9.> MYB+\];N*]%W%YE^*@3$Y/IR&7&"(7GGZD2W%_ZL)FK/XGP27IZT_FO?FT^] MX?*T_S[TH^CB/30;$X+%AUXX/U?6VK*MQ-ZTBLD=6[.R5(B*O6D3(81UFCUU ML/O`',"+^94?P[48SZ?0\=IY][0`.DY#=NP+D3M>*U2R'+;RG!E<:VE[EAUH MT;3W?BLT])KVL8!/"X,+YSD@SH70W&PO=V]R:W-H965T&UL MG%G;CIM($'U?:?\!\3XVW=RM\40!D]U(66FUVLLS@[&-8HP%3";Y^ZVFNG%W MX;&9O(S'S:GR.57550T\?OA>'ZUO9=M5S6EMLX5C6^6I:+;5:;^V__G[TT-D M6UV?G[;YL3F5:_M'V=D?GG[]Y?&U:;]VA[+L+?!PZM;VH>_/J^6R*PYEG7>+ MYER>X,JN:>N\AZ_M?MF=VS+?#D;U<76RT<.JG>.CV>VJHMPTQ4M= MGGITTI;'O`?^W:$Z=\I;7Z62'2J.5[&2_#T]+BM0($(N]66N[7] MD:TR'MO+I\?V]K/:''M+M@R(A;+7]L2F[`B(*;A;<%YZ*Y@@$ MX*]55Z(T("+Y]^'SM=KVA[7M!@L_=%P&<.NY[/I/E7!I6\5+US?U?PABTA4Z MX=()?"HGSL+C?A@-7FY8NM(2/J5EN(A\WPNB$'[^AJ$G#>'SG3$?@?%\#GK M)Y<8L2$!F[S/GQ[;YM6"JH:8=.=<[!&V`F0%>&V#JY&9 MZYK4$H1$0UXXBQV7`-VR'(?*Z!7,C3L*1:09&V"%`\YD+,&'N$>8("9"Y MPSS"(\7K&G'=@+FA$YL.,\W`(`ZE/Y^X`!/B)*()0I!XS.,@,GFD>%TCKA8N M:20N,X6@U1*\A[H`$^J!22U!"%)W78TY.KJN$%Q`86RT"$R,PUOL!:'#JUCWFXM`DQ8$UX)0E2\ M72KJ!-Y/.(F&2ZB1%\ M)D:55C=BTKK`X';]#%9$!YF!B<1('7[DQ`212H2N`P>GTAX[#JFZ3+<(0@Z0\-W(\0BJ5"%V(;L-XY-)6F^DVIA`QQ8@0%HH3YKVD MX/@SM!"F"4,,:H&SH!>22DDE`NI]W#X>F7\;B=&W&&W'V6T_IF(Q_C3%=VH/ MAZ4AD[2:A"%&I@S*:*(2`7K&=!-W:I))GX.)25^,P/GT<6`:].G$$#<98PM@ MP'Y"'P$Z_3LFF?1YA;Z8@_/IX]0TZ-/1P?3)RWS7X3&IH%1"=`&ZD1>SP"?M M(M-MS`2(F3A?`4Y00P$=(=RB M/JF0A*EIJV',G35BTQ%VTV:XR`WDDJ;M,3()AW!28=??GO84JF$:&W"-.)1 MR".R>3/=R)0`=/02O2-!H$F.:*/FB$$)#X'#XC@B.4@E1M=@6'FASR)W(@(Q MTW;-R?'@CHCIF<`GA90,'M6!\X&Q..2<]-Y48G01^DGBP0NXQTCV,MW(3(28 MM:17W#]TG#T&L5#ID/"$6/JF>R$$731,UG*+J[HG.1D MU`L]HO;?^6AS<$.ZTR0_>`8P]1#1J70$H(N>T4XM90;*S(\8S20_/Z,')[R1 M'])/$GC6/^P6H][(V$PO($5^,UT2KPVDJS$_^!H`GT+79;LOT_)X[*RB>1&/ M^$-X?#.NXNL'X*/>/]`K;`6/C<$S6=_`"XMKZQ^Y#YZ&5PC$`O887`FN^()J MA2OAU2L17(G$E>7H#MY+G/-]^4?>[JM39QW+'8AR%N)-0(MO-O!+WYR')^;/ M30]O)(9_#_`&JH0'W\X"P+NFZ=47\0/C.ZVG_P$``/__`P!02P,$%``&``@` M```A``AE6*W4`@``WP@``!@```!X;"]W;W)K)-@W_$PHDW&<]:L$_SG]]/=!".I2).3BC]4XOO%YT_S+1Y?QNH6(%:N8>N]",:JSV?.ZX8*L*ACWFS\FV3Z[NSF+KUDFN.2%2%O.YBWM7G+Z-;>?(9R9)OOPJ6?V<- MA6+#-.D)6''^HM'G7'\%G=VSWD_=!/P4**<%V53J%]]^HVQ=*ICM$`:DQS7+ MWQ^IS*"@$.,$H4[*>`4"\(YJIE<&%(2\==OWZ,PC491E?+`O40_=YT)VZKD!+F,K7132>NZ]0_FR'+,^1 MH$^DY\3(/R`NZ!T<872VXP@6P,=3MW?4G6"2,#HZAH?X;AA+@XQ/$(M(AXB> M(CSG5'%83<,)ANRC6F2I&<0/NN+Z7^ZL\J:7VWM:,+;KM31L:<66ED$B8^69 M5Q])!Y&>'"RSZ^4T;,E-^D]>&F3U8JL22X/TI]!BTF&FIZ>/QY/]8WCA:]C2._[DS6_2($8O\$=Q M.(ELNT&D)S>]14[#EIRU92T-&Q2K,"65N%&^[W7;%%9PLW<<2_DA0V(H]!^""<[6_T6?@X:_)XC\```#_ M_P,`4$L#!!0`!@`(````(0"O\V,+V3@``&&P```4````>&POZY^\'F')(5 M\]YDT!M-)_E73^[RXLF_?OU?_\N713'/>'=2?/7DPWQ^^\7SYT7_0S[N%9O3 MVWS"7ZZGLW%OSK_.;IX7M[.\-R@^Y/E\/'J^L[7UXOFX-YP\R?K3Q63^U9.7 M>_M/LL5D^+=%?NA^V7FU]^3K+XOAUU_.OSZ:]A?C?#+/6$;6F5S/>H>?Y6]G4[F'PH>'>2#^E__L!AM9KO;K6QG:WNO_L=N?KN9 M;6\M_^,]R_BB/MC3^@]^Z1?YS;"8SWILZ+0WSNM//6U?7)Q]TSGMM+*3T\/Z M7^,B+N]NFZ]N;VW\:>4;Y_EL.!4!!]E1;]YXN0V)!T;FXU'OIC[*T^O>J&B\ MXW=T"'-FO1%,&>2?LC_F=XVWM[:@]M;NRU<[]3\=+F8S7L^.AT6?(?Z<]V8K ME_AT8X,=[F[7QPC+F(['TTG6G4_[W[>R[H?>+"^RL\7!7O':\7"4S[)# M2'(SG367WAWW1GK@(K^=SN8,DQU.Q[>]2>/)L`J_H?+Y[KPW7Q3UV9_^.6_\ MYH?X;CI:3.:]V1U48>K&8T]/I_71_)OO\]%HX_O)]"-DR'L%*CO(3HIBD<_J M+T1!2@E_C*8U9UNF*?77O7`M'^!/N_79_7)/@)H99.W-T>.6B64VO4:.DI_K MKQY.D;))P<;XIV(Z&@[@W"![W1OU)OTHO!D.>>9>OO MND?9VK/ZL&?]><2%QG*#D/:*@L$;FG[8*SX8./7U#_G?%L,?>J-\,F^0\GR6 MW_:&@RS_!$862*<0;8!@%<-Y?4%'^=4<8ERCMU6.M[*)GEC1C?<\F$"!4;#WM5P-)P/\R89VOW^;`$K^N@' MVS.FUI<3GD$UT?0^U`JDN.W=]:Y&>3:?9H?=MX=+7I1E*+)S_YSVT_,SAD'J M+[V>#03:9SINZ]I?M_UY__.E//_[T8_W'BWQD`G;;$Q7]*AN<11:QHO.A M=K!TNBJO$C+6YW,/?N:![N79X1^_/7MSU+GH/LTZ?WIW'+Y MK"&]QD_M`-X23K M]VZ'2&M]^HM\CB/`XH[RZV&_J06.&K:4#]/1`#!\:E(,*]8'[I6&*CY$61#;!)$CIATMKVWGYK?W>KOH$:>5O9VJ:,'?N>9:#`(I<_P2_Z3U8X MF]1;S#],9\._YP/T$(S.AH+HP69][)01S8%_S\B?&?KWV MG!RU+_F7U^TW[=/#3M;]MM.Y[-9Y4?*YZ_P+%I%])P;?^Z3W1-J1ZP]]PRQW MPX/U4G'?,JJ/W;N&I8\_9`'W^UFEQ98GE,O^%%*I,PR3&0G,]?T&>O?!;OUN MG;YGYYV+]N7)Z3=9Y[^=B_/=!DI>!'OD+/(/^6AJAK(^U#?YA$6/3(5Z@_%P M8J[\?/A#0PS\[K#='6_BZF/)S1GGV?J;:5$\RZYGTW$F6^U(4G_X[/+;SH4B M@K.WG6S=[Z.)]B>3>8YM;=CV,]1E9HZ59O3VLH&*&4H(K/5Q4G4XAH)#JX M.C(2WJX\RS;P_.[U`E,MJ*^Z?7[2\$K\Z!ENS6*\<(X"QNXHCP)$.`*=ZF.9 MB:K_Z%W8HN5P)>O-L\]ZI>7SG@OWO=#%*Y7BO9L,T4">7B/@W\J0.?O)SUM? MUKUON=D;KPDF$6CY`167,+A\]1>\LW:*LY:][\T4(#?O>J/'N6W;&3H)ESQS#J82RJJ MR)^Q'O=/VA`O6EP61,6O:VE<%D:0_QG&$DT,8$-XX.S#/=&)B'TO7>N[K//[ M^.04KT6V[3/\UDRWLVD_SP>%,S1%"@7U.58_GNAH0S?C=ICIA^$`AEW=9=?# M"6&Y(MA25)9--_1\J5%5Y*D_;NHC,VVT2Z)M:3!CUZ M#')AJ]]NUY&S/OSK14%0@Y'3,L\PE3\,\X_UATZ71:7KV\\4A&:OWW5/3CO= M;M8^/5\?H3V;38'!G$SAI+^9K?_S'_\S_/3/?_RO[/KY]\][ M6??BC^?9]@OWS+,6D%D@\B'!`I<6.-TS(]RH!R1!,Q'1($O_C;)_M";+)2MVG9IU1TFR8'\2;$8DP)FBAX0`Q6*/!OG MLQO-!KH7D@@&7==T+/W"/_+6'F$#S[*/P_F'+&R);.D$DO4_3*:CZ8AX\JEMR<]FU,EG,S/A`F[V@Q7Z+<]2[QD4B/YC2I57.(I:U3T\R;9D7 M1[D@+B>9%.-H(!$:^E7C,6C"31;`^!WR-?8\Z;=;7%W1:L_2R1"E,B.D5$Z9*XW@1"D!DC4R`F5V! M2P#X1Y2%[)@(G_<\\&NCPW$/7;G)2#;>$$[IGR*!M)8#(CO<@/D"(Z*I;QA*)0KQ,-W[T/$A_]0?H7(_Y-D(2T]F MS4C(?I5+.+^4=D'D.HP'_1F1=9E$92VAZ:_DWII%B"K'%]\%L<5.R M63)3RDID.IR/`L8LO5N7;O32U<@OO,\E+]+,BK0:8B^,WX-%']X(15F&9ZK] M,_/+<[!,BGY0(87$/6@`T[_7+ZB`8QI"B*+*C[SQ,:?!R;CW5\D4F9@QOB3L M$)\=;)#4=/*:?R*LTV!!:_RF1`P,:,\,FB53"L<3/_$M:\$KQ?D8^C"NE8U[ ML^\QO_P&Y`GO1"NYIP[^X#I\/T%GD$4V?S-E.2Q\.A$P2)>5U59D,5,ACI"K M/R+JU*+Q<"G*N!4;\HV'IMK.P@>R>5T`ID8Y*G6.=.79"?@&*4_XW]IP+4FN M4S]#3\EIL>CC/Q?7BQ%+G+,H$_B\1_H6.A;8'PUV,]6ZW79;V1`QNI4GP$+9 M&IY9CGX.).3'BQFC`L%8":$LFX!GGVY'Y,2@.;@M62^EU.$/T$_IC]'&7C<' MP][-!%D@UF0>2D%&JVG"L$H\*S,[G^4;D:)#M\*,I;7T)2*.AG%'(LB.YY2BY38'`E@VDDJ!;($=#P^ M:@=DO)QF*O1(9HQKN`(XER,!).8^97`P.7G&ZP#<@C#1OX1GN'#[9R\2:6T1 M"54-R3B"`K[I7:D@12FP$L9?PDFS`V^.+LT,&)CX>97UGS$V:CJ=%0VJ?F/L M/D0L\QEEKK>]"4Q4*/,4,(:XSD]4VL0Q2R:#^I^DIF[XUW?P#[\YD[]/\O*P M.W3]C>=MYU3%O9OW>R<-*;S&U^WNR?=[.PX.[_H=/DS.;"ST_J(E<49 M1\KUF26S%=;?DJ!0?7'.CS$\EN7D^,6RG/?_45O`*^3^C(%7>>X#+]4FJ#HM M4"/@6_Z#Q.70>W(F;`+,X81DNF&!4Q]^$STW9;*!2(&G_L$E'!#S]N*&(/>G M'W%4<5>#"$ANY#/+;`Q@V@\YPP)7$RNC`7D$#$X81F2I9-\EI$R+I%1JBBWD MD#\PA*]@^')$MO:BM;7]JO7J8,]A>X2[I8-HV1;(7/D"IOSSM1T&V-K=M[EM MY9KIXW1F%LZ74@`N*YEH96O;K>U7!ZWMO5>;\H]`4*CC:C!@;V_(#\7B"A8X M"!U,%\3<"#JZH06XFMZ=52 M'_X7FXFR!5='+B,REMAX4AN`#D[XP$$;>%HLS#U'#464:Z`^%4KGX7E8+`-; M'L$JW%`+GF?@'X`ATD`.L4ATOG9-#G=@H\S0Y0?9!$D^)L46!96BJ#,O',[Q M57S>@T&"2YN4!\U98&R+)^0+"O#PHY5>DC$L9*[]$,PRE;48]P;F(9N[J8=" M(34ZJZ*%-XQIS@6"_O1C6=T;823"DK[/B0)FTVOGJ,LQP6V`%`6DN$'_54DK M\I%#;V]]8TY'#B];-23PI#:$COD*$;(B+@8+MLUTEV2$O55P;?("NP!EF8FC:6IB:@U2`OJ'/J;5A+ MLHL,*#D(Q\"6QL1B\I>)0DB<"+.0_'KG!"],H/$'4UCGT(<',J&1QNIE(O0X MFA!<"$69&&L?P_OGC+407P#E`Q#M!>"#9>8UV)9Z#(5K*:KU!D1RT"JW&%8: MH7G]QDSBKT):`]X4MP2Z35-W23;1PTU4H(!7;&JI(I7#HE&&U/(XM``,O`!` M>W`]4^9(14M2DK]+/#JS/*1!9N>3"ZFU^C%^NMROX%-T.RZ,,[%7<,AKDIG% M%2ZBM`AJ,*<3GOBN-*UQ/*-[P(DX<0V2Q!"S,(K3`-4.*5])<7@JBK7&]PX;P#L?Y]8P\ M`V;/+^_QLC"B66^(A0$!2AL?C8YQH>1K$!<)*33I5S8*,F*%KL$MPCW0PR%C MS;THYXCVA^1P%2XZO#4S?"#',=+).!G.VR!PEJD!K&=0Y*0I#)V*WOU MD?J;4A665)''@8@H8T1"36QM$S=8;JCOG;LD#^@QUMQ"N-Z.ITCEA@=K#VP39PEP.<1D<:3TL*TI8N] M52U"AI"=B]:S@1D)%VXXV@N?2,:15R>F+[P[J\%Y7FE'>UB$(!=GECVNC MH!UYQ^)9"'D]FDUO06XHSGNE,<1<8E\G>(Y%(;&#G9!3P11)F^$,"HDJ)=FM MP&-\L]I?TC`H1IHDF,H:Z\O:O-'$G/9K<[-8@YX-/H`LB_X=;Y#DBT:ZQSNV M9^BRW!5QSV(`XN#">7$:[YY1_.8!Q$``90V'A`'",!(=?IEA6#,A@B5,E_SE MOH0@K%TNJCQ7?J(&/<7#^.G'T#7=L$R7+"XV<$@?'ZR9!4KH$AAJ$)?(\_9? M%Y.^:9/)?$)9`0+71K%%& MNEYMKXVMOL-!@HX=A%:.DU./MEQXBSL;13&1QFETM".E^"4+=SL7D*AKX5=0 M=A9)1_<,WEO6XMUF=S/[IMT^M]R%=P6*1'6D*^/>]XA"96OR4OW6D&?L6,]Y MA^(*0(5_`]6"+61.;R3%A]0$ZM]+.!0%X;-2+E+-5>\XTVU9'U[0C$M)I[%7 M+CW9^K4A#T1"HR&,HO=):;U^0E!S(U1*0] M\$T/+/J4RDN[!.WSV72"\70M#%4S/M-)AQ-J:0L":8F>10LT@%O]E.4DPW2) MXRE6D#=\/>5_C,''[>YKXZVEI2EA==_9,'3,MT)3*W/H_\_YK^%SCDO\7;DO M3GUL/^'?*!LX-1ESS,-^F1W#(_?((3FRJ]E0S_EJA+VYHQ_LW$?NGL-J3V?Z M\;G-PMD-5\>P&))EW^3N`(="JO5+,+R?O=K>?_9%UO$6WT-ZL*WE]B]B^_V% M2SQJR,*J8SA_8B<>%1+OSS`@S=^1!+6*QHGOB2JG_@;7559U"6%^"Z)8H;;D MC]@6K%OT?`R]$H%WRJ9]HD=H3M\0\BJ??U0>+0W5017(#'7*>,@U)Y1#Q#^: M*QJQ89,\K$L:R56A)EJN,:LMK)"3`@"B)98&-FX8T'YF*3"%^G8TR6S"9>LV MYM,-4_-A>:I'MD`*FF`D^L0KI#.(8-6.(N-KIK-06ZWO_,)&^`;A5D:RE!B< M"M=GP$-T5G&2P2EV)=*:D!%2K._2,>+\.4PZ#Q;]V="E&CTV-=]-$D-LQB7L MM26C/I:9"'%R`Z_H`A:&K>\E4_C=7P]G9)',;JT8@DP")[-44U^]?+8(>6P#1_V\_6V(+\D50(7%"+IR!W0E8U26B14HE]%RXQ%[L%MO>= M-;5MFO\_'/O&#&^DAXK[5>QG:?)C`X2"RLX[#6YG\+%4([6G,#_I"EWR0LN+ MSH-/(AB;V,"?%J1!X&84=)KD3[Z&:XW%7`FI?P/`?W-RJ`[;K/W- M1<=J$G$E"47/DE:2G5T)Q]8K2_Q`7#)D<@3!"@"]%T@>?3@KV\M9X:^-LG_R MO+'?DF!.\4A9J2E)1>52-,BHCP8;'_D]\^T`#`P37I?]/?ZS MO:TFE3:P2CP!8)RXS@5OL$(1\$#=OC#"4DX,YI_*OET0I63?C(93CD@"^"T_ M]*O=_=:+E]0G&%M%.H)$;&*[SZ$)PGHH\9:,P9"TF>$];H"5R^C)0<0)<+IW M!465.-Y!:Q="OMC>"\-EZZ\I3Y`$#Z/ZGIIS[*3BW3?Y8L/_)[L$T(3'$$.J MW3%'3YIT>#>?DI$KQJRL,KW-"W0A;R+406O_Q4[KU8L]TL]`DB-S*$7^@?8" MLCM@=^>=X4"[&$*14&AUE7/GIZ7%O%9\PAI3<&>509"?[/QI2.Q1*U;:A:4D MFLDT&\U!W+)V:FYHO6R,%X%=\5Z$>F5NJ\T!B([K1V#DYU"&(QL;XK&S`!`H M/N`:%H3Q;C_P+^FG"1E(D\H()K+^$=W4_A'_`CX+5#'OY.HL%+L6.Y2^*WY? M]F(=&+AR:-5I5.+%?_"A$./_A`+MMQ;_"+2!51VK^Y:Q4DUXE2+L42 M]DMUJ%2<`NLY@S_!VU#3`K;-(BM7A[VCDL,Q7V(**.-9OF+O,4293>]Z(W?R MRCD9RIMBT:?9[N;^[T)0>T.*L<@*NAK5>D-3C>W-K4328A&\I1L&K-%\I_50 MGZ"[!F]>;3PF.I8(-A4/=02\,SBA"F42IK/9U@*'^@# M40M1K`0YJD>J5AN^=.[;NK*T\K@V3Q1@U6FB2Q!?DTR91U&/B;9+C6PE8J,9A-![OS>F=[R9/P2 MJF&M@)9R\K7]LCSK.`0IU%B&PM$%ZB+MRLJM7VL\-97R6Y4::MM1(1!>9-(+ M;]0)+[*A$0]Q5>]A`^+Q^&&GM5S%7I+2S4O3`U&<3)%=AF$A?L:Z+%LMH;Y! M,`>(D1$4U=B2=A_"PW/GV@@27=4O M2-+:-L?P=.YP'=T!8T5OKN, MS`IFZNFEW'S(?LZL1^XJA[YY0ZI]7B1H$Z&?++WZN+R<(&@`:*5'SFHVKEF. M;2,7)$C+!&,D@YW$!##,U-IHUD:KAK3&LM^KS=PZ)Q$)1OCH.XP\%H:,E.'D M($NP4$(CQ9)TJ@50MLSGGD`KY5OK8FE98=<@6&:Z73U6*Q`?6$#U,)HE=/%2 MK=5;:&]FJUC<*F-70Z1J:3<)6L>UFN4CFX`"H]5XJJD@B-4HND,`G)DP M>I0,DP/7@:W&.RJ6M,Y,/\I9:.E-N>6@IM*`BU`09T,FRO*`H)09K(�$EJ MF;>7G'GZ6T<`N>QPBMR6K^8P*"XA<>`$\";<0!S$#-\-AQ][XGY@<4!N&)G: M@3D<-J*U^]+J)N'T>)<,Z$VC=11KY+H9-?Q8T@$0-NS:&F1^I()F<;7^CSWS M_!BPDF\1[9$\?`22Z)2:G-E\XYP.V=1J/D=.##F,!85,,OT>N2#!J:I5+@`S M33*K:2*C-3#E"@PH\;:,MHQF!1Y6<:TDGV@0R9,N'C"1`WW%-/0AH;XR,S-+ MY`EX^+F3**-O;O"*ZM7-Q+K:F>>F+*8F=N9N M-SO`K&,.SB6[#54"*];9L)!O;6?_H+7U:MLGS4A<2ABLW.[+[LB!*U8IY6$> M4%P@KI#&:7BUL0_/*WW0\;)PYSNZT3?%CX03[K@^"Y(U0)2($G2U3%.Q89%W MB4W^[0%?XK9!(\-[,<&Z8G2+O86&Y8,(%W7T$+;0*XT>0VW#2X\PQ@K=^K(? M(Z*Y70[B8RT!14KUZM:*)"UC4HASKX+]*OM(N0ND2\Y"-V^:1+5(2MH.47]!/: M:453.O`L'=L*S@,UID)AU-L=H<"#-V?*Y4%%8C4"1'L1FXQ"1N`M%P31OH0/ MCZ?MEGN%VZ7`!7>3Z`[SL+WU.SNI*U=T[#U53!#"@2%U%X]8G%.R5MJ="JY& M46RI%RP_Y0)ER)F3>@6XUH?/LGVFX1>MV?T9Y\2)JGYN#HF6J*TSNK-"P1%] M,ZCGJM:J9BS-+EV$KFE3\EK\M3YD716E[2F+ZV2?7#X:/9C;)G^((WEO%SM2Q MP;D0#3H[5_4J3TF\NT4L?Y?IPB>Z-!NGZ\\MDU%R@-7^;8&QCK&4HOT-UN_2 M!'`J'+]@ZY"M2;?EVQ(91#]+-B%O2/&0V]HJ)3.,A]>/6$Z M,J*WU#%C..^6,1<8T!+Z&9,4WS7B^!,W1-VX$I:SX/R"UHK_GJ[AO?M;2$-V M=*HG/!]%-O^D(X5%<*UI%>HC,X#STN4XH&%SJ&',UBUG@D.:9#TN!>PF-H=- MYYBN#3KW?>4J9@&6@JI0^L0-&PGBB6D08;UU@DSQ>CA+^6&I0VB_##02T688 MD,-N(W)RN(S4">=W=,D"`IKLLN1\P[B^AV84U]4;*EBM2.XUAS?)706`3@9T M10T/DDC,'*=8C[6[A]G!]KZ9IP'GORBG*8=IXD8%<,!E9*+*BE`/LZONXH'< M<1P0KC6SRI_LG:>1!T)%X'*GY;BXZF`"F&H,3%72:3S[#"'(K[S?O9=;&SM; M2[E:H%@@@DN%C`_Q7'`YQ)W-3S`B4!R@U!@%$3ZV<"40X<8?D-7Q3L$<\ M!SL5^$-1XZG+P%I7FCHG(*B'F%6610E@N.!1:ZPSD!([HE0WL4%F,$]VP]L M<0,6^E>69EZK+7^CVT>#V9GOU1$1)<#C*5OV80?.)R16F(E#H.B+,S.*GY6< M=[D(>5,D5XI;';;A;=`<3K,$M"-QX+TY(_5!U`78EVN)&6[SYGVCU1=E.YY! MG\<]7-AA\3T]2.0&HFVT'HSMS1>O?F?R[O*4NEDL^V%*_457]=UE+P\V7_UN MTTX]`AYT:^EB#JW7B7*Z+3D4]G,`73V2R(DU2!T+(_G]P0V.%G[[>5G:VMXK M:JK;MF(.\[1V7E*T$AE=9X%:3]"&&KWMO".ZY`L$EM"*9*"T814;KQ[TP?ZL MDVG+5$8=I>[X\! MY4$#EWP8W05FI9PP\B4_E"HV>7>'G7^ M!C(?)GF/4QSR6N7MKGIN>7=9'BD MH?X:CP*0W]Z2^;?3KKYC?DO7_^`S63X(5QKD(5[`2Z"HX^_ZD0&H)_)V7K3V M][=D^AHLW5S>QO9;]2[_!W4'2]$:I("PF%V?4:,.[:SM@]-^:YMDFLH\4G`0 MW#26"SQ7M&Z>@;]@ITPKFGJ%PW:UO"3^@*V,JSMHO[`2>4C)`-FAXXC3["J) M<#_&\LT)GLWIP;DBO*`>;7VO)&9(Z[A3ESK)`K(H&A[_@Q6GDD"Z34C4I#`3ZP\TEKED2S>5X6\W0ZO?F MDD'7M4VB^\C93:)/5_)?ID^8&%=(2DL!6%R>K=1JM(,SB,S_6_E5V1)Q1BU( MU@E4?\&51."-'8HA]JA&M'51HF_3;J+3ID`)GP(+=AL^K.V\;.WN[GK03V%J M_G57-1C?[,WUUSC7\[LO:Y^`6'^A(D1Z4;;:PMU5V?5GV:COE-MQ4KIK*(8? M#YM-HO#AA5K$7>;C*\B.F27K7U1A/-:A++42RT$+2^&Y:&%QJ\AAKWH7-*1, M[JJ<>6H<9%%CO[%EO2>E25AU/%UC3*)D&UB%^D"]X M,W%!:(S=0NBYO1-NDM#6PR8M[KC*Y5:D*ZS&HOX&"DWSD-I2=$G7]KFT`R]: M+ZYMOZ#X")>:'IG5_XP[1)NNBS"L?JE3YBX:&=FPRQLTA!O:Y4,BUNI1B.0X MHE7?5^8BF$&C+\3W@,W:IVMKXT]V:;_?!V#P\`4%C76>=EVQ+`E5_S$!QGL8 M9$3#:#AU-*<"+SDP:8>T@?Z9;E*V%>R93>GJ9U5O6AI3YN7TF+B[LB"(:+_: M?^&D80L'=[Q5I4`.`9<<'Q=`I#2*T76:"K"MO`\+0AYTNY-U M'+L#(S'M'NHCAC%T*C1\\S!(G?DGS>8KTW#?+JA_-@Z&`WJ?EQ`$0V\TDB]4 M=)3BCJ1-YQL,O.^5)A,K MU1G'(L!(Y<(5F,&H%4'"E' ME2TSQ\9ZQV"$_ERYSB<*5>@9+87@\Z@FKI8M$K4,JUO7Y3+I("T*$G(T$)^M M]+[`!UU?QPN2'B\!<1\@*"I>:1H,R[26ZAW>:Z3GPASB\KM#FBW%B7>RM!>#SKW&L3DFFV!VHKB/90;DY0RJQZQR% M;-K"+EMSMM6GXQ.==5X3)X1,';T#4E==)RLZ$61URB2O6**^PV.-;)I.^48G M8&097.N02-3'TU49J'0Z&GW_`GN=R>'IZ!/*'$C:_.J#8KY\LSLZJ8OS(SP[ZPW^&]N]*)ESVI^=J2^1NZ>GV7;SW=ENLVIDV%P M_2=<@XP8V%T(`;4EN?&,O2W38&;&C-4C5K+`=3554GE60XE9 MGJ[57$"#MI&@KH($52UH__ MT&+0[LO?.3=C>34(=EA!J*PHTNV2D[3C#`W*QI]=DXBZW>E^@;"I`V,%(*?W M7AY=+<2"6&ETSD6CT[LD\[R&+*)I"#(:.X^H"!;YGU1 M54[=G3YB;EK^3$;UJ@1'W'3-N$(:;M=Q!3:Y$J[U1;K*2JGMK#CT$>+P]=0( M0_^P`I/=%P$S-5[4$D?H*/*FBX0G1/+0L1XZ1Y60>6G0$JA9I\//C5@>$2"LBE@:A@3/,&81Z?#_ MZ`)8-IA:!0/#4$[;;MUC$@#.@#J)2$)B#WXHMW>[B>[OM1OB5@K7#N*S1R.\ M[\:U?C<@R2[?-A0:DF3EKJ2Y+@03YB=PCAI743S"5L!TIP3.%:N4PH.*"IIV M]W>65<(_Z^#=BTW,^4AT>K'_*Z.3B8C!TKT@0!-Q-"*QSE-&BE%=<>OY:,`O MJ'6G*JK4P@L?3&Z_H/)]@!]43NJKW54M31?ZGTE/.\X[)N+&MG/;\CG(V%4/ M6-TS7'^I#%RG?7'*5;5=OG%TUNWR.)\PZG[;ONC4'Z^/&^,J0W4._?9UMRYX M(*-.,B.]%$O&PT!;&5,SX6I/(4&@3K"B4FL`T5H.7>N!G4$@Y6:?>'+4\@Y*P]VFH5S(?8JIW-0OWDUOSL5<'&`(38'IVGU^-KAD#]ZQ3&#<2MS?:K*$3(')@"GM MIH[P!(&1]VG#(3D^L",'!JDM%C`[PP7P]J$$C8"\Z/L(N"MWWO"X^[DE,K*> M\K:K!DGKC6%B\&08AMO/,3/X#9+9YB`N]>:?L.)%R3:Z1_U4+%0HA'#;X0>= MI=8JE8;OF\D/6Y-TE=N2VZ3G"DX/*:+0/Y>"4Q(UTCEE'/TU.%U(U4;X<\-6 MOP\I(NUW^1ZBW,4;DTJ6X#X@Z"N6+A^.)8<@J`X3E]%/.J4M+7M+T]X'[NGK M6'4EE##J+U6"FU6Q'B&K1IAY[ MZKL4IVH>W3-Q:KP2Q18<:Y"]R^&]D:7OB6B.XM6"(N:A;L/1!Z60?>24"A9( M6%_U^H'51-Z=G[^Q>SG:;[*CD^XAP/SNHJ-+PN.7A?C*W/'9Q=NEMX7;5)9M M27(<3E"UI\9![2:??OIQ%:/6ZDL^<>@Y[WVJE_?G7U_X3V&(]]JAB--X"-?!M3REE9Z854`?:*.#7_.9O@ACH::UQ7/PG=,3GRA1^AOV MZ!P%7@06N@#XEL5MZ+X&:6=AWT,M8XTB.^R<.5POXUY>6O*=F>Y=^-QE>3N$ M/%*@+I[6<:ER*?NRIT$I])KBC^(YCA"YC!4/H_QJG7/%C$H3:5PI$J;-LEJ! M`TV,MXPACY*OG+)9.Y"2M(;$KP%9S5>7H)?']I81S=V,RK$V$B"V+%&NLBS[ M>-`]8ZTY;$$]?KP89]SBZNXIML-IX7@)E>1/]F?;E#NC>07! ML>WZV`\;H3@H?P93[JX.MCEL0DYN*]V%V2XSB8\+$JU4K84QU9HO;.U8#JWN M?"[,]UDE."+1SU@$+BY!7&41N[NM5Z1&9#76MK>+LP"C\RJ7:7%TR(6=QZPGE4W9$-`(:-Q87Z1FA"Z%4@ MZ>XH1.R'6";N]$9Q8NVR.FA`'&0.J;MD?\DTYA8(;>",+-/DSG;=5B0O,WOA%#^(N&H;(_!B?4OLLLI[,:-JJK0YXF ML`3?A@O5Y97H2CNGSM8U83`/F-ASOQQ+(`)(XK6[!)(*C/B;P5VO!1IGNJ]$ M-?Y2;.,+6(T@D':11)E0BD>6,DOHCWQ4L#]\.52)YE^*4P$3`U"YQ:X"*H@8 MU_7+X2G.#3HJG6SXQ&>SE767)B=-Z4%/TP7XLP+\E`+*`PK_OT8:#6[>`XEF M@W?!1%KN0^U\;=?^N;Z[VA;*F[G2[][_IT)%>1-5=$&&?QD\XBRZJ!;H[:[X M<&P;U([7*-CE!:W5[H_3*H_3[EZ"%4ZC!*^Z&Y3\!E5G2SXI+0WER%K`2<-2 M[X69&GK4U%W7:0^6CA['=W36\TJ7BL6:+3\P2TA`X9$(!Q[2D%):AB316TG4 MERUAR9J$+G;W5E@3)D@^6KV#A6XE;B,UCJZN])J92`;''FCY86CSILI55!97 M<1U+32_!1:&W/T0<@-(5,O^R.8^!LD5GY*H`5TI MQ3%KQN%1.P*C]]7ZQDG4EZR,W]O"BOU=SG\ M/WCUG$>(L%7C:MPO\8C@LW:=6[R^!4%(&109TR`F/F8:EM+GVG`Q&V&V7?W! M[.&.HKX7YN0^(H&$1R=N]0T?:0N7W5O9Y%8-OHB=PD==E?8+4O@6NT3G8/>@ M]6)GWSD'VWL[K:T#[NPL,4-)?!Q(V\3#O03>QWG21Y*DJ-0(1]-;:S%U'\?^ M53R$8W/E'@XU^`HA<(N;9Z\1T+9?<9[R`&?QX9OWJ@W$A,R/W8^#4Q*N><'U M\-^(P.PB9*%-\1$4J/0BNFH0GTM;%EHIC/&A7Y+#RZEUF!866U`9^B MX8_B7R*2"^YXD_6[/MNELL";];N++"^BF,UOHZ%2H+;_NJ>#=9D?LMNZ%Z^9 M&WM#?.1N+ZJ;B&-]>L824JB:_M<6[SX"@ M<,8'MG2K5?!\O,DES5]@0'?^M4YV! MPWE*.QTVG MJOHN&G7A[U()-XZX#`H($+W#M5>T&.QYY-NB+[81%D%^HFM;"IG$-)V1+OD_ M-%!*J'%/A\4J*G!FX^#`1X?Y\,MSXL MZI,EE++T34$OVX"D+Y((+YFZ`E:--/R?L3-\_D"H5J;+6G4Y75-RH/Y_Q)CZ M/SXNN;7UH!>@]?:!4GWUI[M\#PK72J+2D0_92,*O;V^Y&L7K+F+&=3\BA=,)]R'SL[*W=OL'.Y=WH0O213'2 M-"X%!NGDU;K`BW\Y"OZR*R3*8QV$J[?XLWVQ,501'CEB)12DVXHRFUN5UN]7 M;4V1Y15*H7^#I<<[5X2$UO++\4;?8.BO^2Q6W\;R@!873(&=L0]S.@BEXD2* M-&E.4:,B!>4Z3^1`(\JW@DGS*F%PFE+$8"EWZ.H,@MYN_)J>O1=K$.U(W?!Q M"_''#\W%`"X\58NC?;!30R7TXT9);%'XEI?;4/)G)P_NJPLU[N$5V`)EJYSE M"ML1P;GCUV<;B^&GC/-%OAO,$@YJ)5%M3VO!?U7:`!BTF#I4AKRCQ\@`ZXPS M2XRHJ\955`E.`A;+A$_'B=*A].^KQ;3.B/-D_XYRCR:\)L?&BR(-X8^QKBE1 ME6C\FRY*9VO:EM^H.;1N^U4%T#F)!RE!M>3N6[4,&I>H`A2.F@('*K?&^?,C M/T=-DG,;VJ5=AHIB>&D,DH)_PV7,^E`Z`:]]W$,=""6G];C5J\BND(0/G1/+ M`2CM;0C"][9$"I=+"D+;)P"!90JJ.2HC2>)VS5QUX+228.26>"?CI&WTLCPE M^/PBNI<9&RXH4/3PP[C]W' M:W>W_+6^7J]K-AU(KUYX98&/G>P=T`@7._ZPJ`L$K*/"'2/(5L_;6=5]]H6: M&#E`ZZX=;Q,:A>Z5U,QT/OFPSZIRTEF:E^QDBM83QCZGI-V5(>4#55+0)M_< MS\_#E`TW)OQ!V_R5UE)G]V.;0:H$BOTBK6S%0/2\K=A\NKD'C%-?.%1?'/K1_H,_*@I+.W9;*IJ4';: MFY#&Y()[NPK;/ES6<*+BV&U=&E28E>&#*;%<=Z3[%"15Y9_KRWL:,]7^*P#U M!Y;/<:IFL3"RNO4[5LZMO_STL]MQ?96G)XI.ZV\NG_8H?$7%N3BVK\_,[DY& MR\6\GG*-M3/`9'.,I/49?Q%*55Y>">V!Z=GZN^Y1MM;8-+'69O@`RTY]??[E M^L\7.BM`4P!21CY!_V6X6'_LR"ZIP]?B],_8-\?Z=%::2:0P<]/(1R1]:RCZ M?9M(G^:K,O$:7AW)K:^J^NPI]\>?SZ9VV/]S3WY1Z:2+_86/7-F1;@U28YS= MS]9VM_WDC25B:G)]./!81;+O[**"LINNOLKDH;?6&&H->+RM%YWMN+2/5JA] MJ?[RTV4'XE41*6^:J[^2S)>81"`@?)_U$O>Q_M)3?T%<_?=5@UWH&KECG3@Y ML1B-OJL+@.6AK\>U?%?>,+?L_506OEAYX=.]3%YQ,U"+$L.#^+WB_?IN:\SZ M+)<.DP[14T"]HD3I'[7$5K8<&^K/96=EMW=]<2%GHWX=TA7U:W?JCTOO2'.Z M2S;,V0FG:]-);>7U5XVH)Y-B/J/#=<+BDS=:F:3/LDWN5^MV/79WDM8'>NH2 M`O6K/ZRJ\IM<8U-?D.VL7'?<&48DW>_EW6U#$YZ6L8LEZG$AL%<6'BV=)1VO MHF*.@/5WGB8TMEHG53;W9?O*93OUUQJL.O25(5KBA MI_Y:=\EM*_>;#'EY4,A>SDA(]&DZX'IKWSC>F$/>]H8KS6U`27 M/!?VVJ;[?@`^VC4P"2.+[(RH6EU,)`'.7&0!:EON2H$R7CZ]]:D5J*^J39,= M'\Y&/-)Y*^L3$I+PKK_9]?<9V%T&N-B6E;OG(>&-=0G;C1;W/&Q6J_Y,#&#J M1W.J7O6O%)"4,E!?QZ\T`9Z&==/6AT]U11I0__O_%;WY598\((PJR;W*U8PX M<]X;-GR>U6#__PML/55K]SZ`WC5#M?_@)I*:;2R M=#124QA#5_2LSRH@'\Y=+5OQ+L)2EIWO%\HS1`K2[*/!;-+L'- MSTY64YED70_,#=P7YJ2S/VC(.JVLQI:[BZ"#6?4WO>T]XMG]^K.-LEE)]_L> MK:A%_>&G_RYELW*6YT4Q__K_"````/__`P!02P,$%``&``@````A`*\`HA>E M"@``;EH```T```!X;"]S='EL97,N>&ULW%QMC^+($?X>*?_!\B913LH,8,P` M<\!I8<;)2IO-*3M1(N6BR!@SXQN_<+;9@XORWU/5?JL&C-N#<5_NT.U@XZYZ MJI[JZNINVY-O=IZK?+'#R`G\J=J[[:J*[5O!RO&?I^K?GHR;D:I$L>FO3#?P M[:FZMR/UF]FO?S6)XKUK?WZQ[5@!$7XT55_B>'/?Z436B^V9T6VPL7WX91V$ MGAG#8?CMXIN.KB81[SQ(1XIGAZW9S8P7>QHR=I>,Z M\9[)4A7/NO_P[`>AN70!ZJZGFU8FFQT]4)3%Y$:P`Q.]^V`;QU[])_KS[ MP[MWW7]_]?4__VJO_O7=[X]_^^XKM9.I(3*!@_,R;[MGQ<+/B>1.:L%LL@Y\ M8H@&;D)OW;_ZP8^^@;]!,(!Y>-EL$OVD?#%=.--#>%;@!J$2`\M@'SOCFYZ= M7+$P76<9.GC9VO0<=Y^6"2B2?/VV1^?$F3M>@6M\'DY50T# M,P;*NP;3;JR0J'Q?OC0 MFCN;5U9F79J&V^H!V.&:]:(#7?=,_QX:^&DC3EH>T!IE#`JX^+WK//O)O;MN)+5A%%4&LXKIN7FOT^%F-P9C:! MJC>V0]^``R7]_K3?0"GF0X&.='>2ZRJN?@[-?4]C!8E8@RAPG16B>%ZP`C`= M@!=WC\;BD>DER$11E`@UC,7P"D(?Y^-%\T@7XW'30C4#/@T+?3_`3\-"#?AO MT9A/TT2A-P4REZ?$#D[8NK?#\7@\ZMV-1J.QWN_I.G/R,HUHQU_9.QOG<(VY MZ1C!`!",^Z/QG09`NOJ(J6H501\`#`>#T:`WUG3XGQ5GUT?0M$\'JFQ6"0)) MK!($DEAE:@92R;G9Q+77,"DQDY47$M#GAUTK+KUH=X=Z@/M+IG8-*3:LU?. MUCNV+M=]DC]P(_JVVG#B0S]7DLY\BZ6I#K*0TB?8@E'-F!9L`#&1A81@BR9L M+)9I16TD+<1L)`T$;20M1&V$KG.J7`5;V#($-@P1MTNFQW5CI?3`@GP M$Q%3V>;8GY5-3GBTLHVH3S/G07XYZAMS#3^LBCQA:46+8SLK&IRPLJ*%J(U\ MW)RT.)_B8WH^@>3`W]SE;X,!BI*&&9Z#)%BL8UR2Y06%$XL!5[VAJKX*P19O M\ZN@<&)QUN*`XSH$I",Z%`B6[;J?<HE^\).P/R[1#TLX M)_D`OTC5#\$EK+_)>,#[9]*@!@IH4)_#TR0"F*AG"(`$&0CP?I_4!Q">,A#` M!"A#``%:(``X9Z+BDG[0(]D,8J!0"?JOI1)R3&8EI_**5I:E7]!_QDJ#2[\7 MN9GD6PCTPLUP<`;`12K+4JRL%$-HAYY6N``.SKC`@%&WF2&O5Y;SI3F$)%W` M4'@$TL`YCS07E23G@LX"P'F/S!NL0TA08"J2#0'@2(%`B.A)&G][%(.D$9A& M@Z0AF$+@QN`6^P1E@ALA)6$`/%)Z15$G]+@1HT4W$`BR,B2)!DU6BJ089.7( M@@I-5HHD$&1E2,J$K!1),S MIV3F"%RPN1292B,X$V_;QK53Y24(G9]@DHE/6EEPP@Y5?#(O=BQZYL?0W#S9 M.YB*)CM3N_5%!E9@*O3#JK>JU%'>N'\NP"+`=(4C*BUGD_K*A?F#R.`7MRLC MI!($+N[(QH"^3C$T'@(-=1'LN3\G-\&`696(:F62RC@A'+70-1K55C<+H&]_ M3EPW/6JTRS7M@+BQSP\)"FY\XBIIF\U!P,[X]_=EP78>,TN2(RX_G M"HAYNNI9.5Q0#[T%85EJ.`8H'Q(X@_=9:Y#*>83*E\=D0"+"NBU)YJTA+./Q M*,Z$2M.DVY])PWD6:*-`I3'.[AOB,]+)--!"E?066$A35>%TW/4DQ51IU!\% M%0^P-,3JI,YK!#35WT`$PZLR#CK_F[J[:$A+BYWC(N!DEQ/"]\O,EV^@4(/@ M^3^>$-#D5S\^RCIWRSU*8)`X3L:GY_-M]?Q2SX$M?"'2%J)?4"!_OXUB9[T7 M*"]$E8?OOXS;;UJ^H;011O\%8V`2H* MU^P,'?FSP8NM*L,Z,KDKE[\G-U]U5O"]0_`NL.YOE1OEO85"\Z&_A[L06\>% MI^1P.1EW!"P(H\";)R?3-=QSLO(Q48-.3&7!EEM=67D:T'"7B.""-9*ZLD!] M$L!]L);(@AN6:\N"G;M4%N[A%;AT6"NIBPN:I+)XWP\$?:^?XI'M=A>XT&01 M7%16P2/NE1)98')=606/N--&9(')=645/`)"(DL')75E%3P""U06A%M=63F/ M.A!'9`T$?7]WDD<^5G%K2@07E57PR,=J7S!6J:R"1SY6T>2ZN`H>02KQEPX_ MU)55\,CG"5TP3U`;"QYYWP\$?7^84?F(UP0C/I%2<`??B(_@Y3I"/DJD%*SQ M4=X7C/)$2L$7']^Z8'PG4@JF0!ZQ2(G9NK+.OR`8/C MC`@,>&NDM77A;9X!O@N4;;UBM4\,PAMMA"2]V-:KLH`G:7)!?'_`851$T.-N MXYJ^&0?A7L'MUEP<3_I`4-P?@R#W$2]!@T,10'^"-Z?"2UD5\$OB(3Z&<3VF MCIB\+_#NP2*MCAAHG:#AXP_ODJLC!EHG8OBDBO63B)@/_F:;,\3G4ARZ141\ M=/Q7>\5'#N]A#4"*2/ID;^/0S../[U*:H&,^X?-7N0P^1;#'J0YKQD_PN%7F M1-R*)GT'JW\1X'_9QL2-V(H(P9FTHOGP^`HU;VVMRZ\5/^ MXU0MOO^9/:(.P91>]:WS)8B9B*E:?/^(S_Y#+X89"*2;CQ$\3PY_E6WH3-7_ M/,Z'XX='0[L9=>>C&[UO#V[&@_G#S4!?S!\>C'%7ZR[^"R[#%S'?PYM\+WC1 M,7LA,]Q2TM/O(Q=>AQRFQJ;@/Q?GIBHY2."S!WX!-FR^949THOQ%T;/_`0`` M__\#`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H M96UE,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B M0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$ M(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S: MWIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53& M`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4& M.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y& MK9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#% M-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\ M]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V M">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!# M\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G M^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U M."O3>H<],9&R;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X M+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXG MW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@= M/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5G MY*8TO;>$#6C\S21 M0*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09 MHW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3] M$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76 M&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA M_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005W MU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X M,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"? M[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4 MX9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F M!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q M\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q M)4TPP:&PO=V]R:W-H965TSZJFNS!6*F;C"913`DT0N>R*3/ZX_OZX8D2ZWB3\UHWD-%7L/1Y_O[= M[*#-UE8`CB!#8S-:.==.&;.B`L5MI%MH\$NAC>(.EZ9DMC7`\VZ3JED:QX], M<=G0P#`U]W#HHI`"5EKL%#0ND!BHN4/_MI*M/;,I<0^=XF:[:Q^$5BU2;&0M MW6M'2HD2TY>RT89O:JS[F`RY.'-WBQMZ)8715A4S6==?WY*.-BK9V(K??AH9/Y9-H#-QC'Y`6RTWGKH2^Y? MX69VLWO=#>"K(3D4?%>[;_KP"619.9SV"`OR=4WSUQ58@0U%FB@=>2:A:S2` M5Z*D3P8VA!^[^T'FKLIH^A2-DW@R&"/+!JQ;2T])B=A9I]6O`$I.5($D/9'@ M_40R>(Q&XWB0H.8_2%@PU-6WXH[/9T8?"&8&)6W+?0*3*1+_N2"LQ&,7'IS1 M,27HU>(0]O-TDLS8'CLG3IAEP."UQUP0#$5[952[7]F#O;)OK;>R#"^N9=+> MR!N9P?_(>'!&\=J;3P>#GC7P4.(^9@F.+S^;7^"%FEW"/H/F."6 ME_"%FU(VEM10X-8X\I$UX0R$A=-M%Z2-=IC=[K'"7Q7@G.((P876[KSPIZS_ M^-15FC/M1&JSG`2Q1CQ MFJED@Q,I;6.:U4S3/\P@U^G'_\,#LHO34EYQ8!0VTR7%K;3`DQ MK.22FD@UO(8_A=*26MCJ#3&-YC3W0;(BO3@>$4E%C0/#5-_#H8I",+Y4;"=Y M;0.)YA6UH-^4HC%G-LGNH9-4;W?-`U.R`8JUJ(1]\:08239]WM1*TW4%OH_) M@+(SM]_Y``>N[$CS(L-/R70QPF0^\_7Y M)?C!7+PC4ZK#)RWR+Z+F4&QHDVO`6JFM@S[G[A,$DYOHE6_`-XUR7M!=9;^K MPV]$`NN))$FB06\X3N]@(4&1-[BD MELYG6AT0#`WD-`UU(YA,@=DY&T%]7G<&EES,DPORH8`VT(W]O)>.9V0/)60G MS.(53(L@D+Q5`%F["OKO*G!!&8;GA8*TY?GU).HGC]O]5_OYU_K>= M.W`W[Z3E#7D#9G"A;=@BKC(#Y/^=NZ"N@J[S@!EYYVGR+^,P>I?IWS;NP)VT MD[\%#<8#Y@[CH^O,;NC>;[D+ZBA(N\8#YM3R.+UQ'DYX.``-W?"O5&]$;5#% M"]`01V.PH,/Y#ANK&C_H:V7A7/K7$JYA#J<@C@!<*&7/&W>#M!?[_`\```#_ M_P,`4$L#!!0`!@`(````(0"):TG-W0,``#@.```8````>&PO=V]R:W-H965T M&ULE)=1;Z,X$,??3[KO@/R^`9.2-%'(JE#U;J4[:;5WN_OL M@).@`N:PT[3?_F8P`6R:+7E)`OSYS\\S'MO9?'XM%US(394CHS",.+Q.1 M9N4A)-__??IT3QRI6)FR7)0\)&][$5=,`67]<&550NW8%E)M,.ZGN(A]OLLX8\B M.16\5-JDYCE3P"^/624O;D4RQ:Y@]?.I^I2(H@*+799GZJTQ)4Z1K+\<2E&S M70[C?J5W++EX-Q:#K MF"Z)N]TT"?J1\;,<_';D49S_J+/TKZSDD&VHDV*[?WC.$\53J!QQL"([(9[Q MU2]PRX,@LA%@$/G?)J;./_)L\-10:0` MTH#96*=OCUPF4`:(-?,#=$U$#A;PZ109SB=((WO5=%FJCB&9+V;!TIM3D#L[ M+M53AI;$24Y2B>*G%M'62IOXK0E\G_5S_W:3>6L"WZT)]6?^?4"#Q<GH*8BOBBP@,#0@4!NIH.@&$&P7D@6Z1O#N+X5=ZR8=PH#!+(P'03% M,"4&X[WK7#695MP-%(&IB'^E,,C`9#H9BD,"H^XJL3#C1EHQ)%N:BGBLZ-D- M,FB%Z60H-LGNS;B15@S)5J8B'BNND"UN(4.Q24;M":XE03/Y[RATGP6FGP_1 MKX!!%TU/&8HM,"MPI"7#P-1N@;'D"AONF),7!11;;'UGZ1[0$H/-:I-X++G" MMKJ%#<466V^KV;3$8+,:)1Y+>A.C#2CL:TU.7(0G%YCJ)7NXE%"[8UO-D(_:/?N.IA^# MR8>+]70^O;0/^?Q^X+K*5&N&?+[50?$[FFM\N&1/Y],+O,%GM69$QYN`;W51 M_([F&A^,\P8^5)OSS[?:,Z):8^1OQ#?67..[:;_`XYK-UQNW]1UO"+[=QJW/ M<`R]C3G_;MHUZ'C;\$?].]X7?*N'XM9G"I^U>4Q<9\:[B&_U:`3G=\RUWM_F M*R\807Z\B>ASN3YE%KP^\)CGN702<<)S-H7UJ;O;_7%H3_3=`SB"5^S`_V;U M(2NED_,]O.K-EE#F6A_B]84257.&W0D%A^_FYQ'^H7$X$WHS$.^%4)<+/'%V M__FV_P,``/__`P!02P,$%``&``@````A`"!F20*(`@``@P8``!D```!X;"]W M;W)K&ULG%7);MLP$+T7Z#\0O$=K;,>&Y2"IX39` M`Q1%ES--C20BHBB0])*_[U!L6"]IX/9"B.2;]][,D-3\=B];L@5MA.H*FD8) M)=!Q58JN+NCW;ZNK&TJ,95W)6M5!09_!T-O%^W?SG=)/I@&P!!DZ4]#&VGX6 MQX8W()F)5`\=[E1*2V9QJNO8]!I8.03)-LZ29!Q+)CKJ&6;Z$@Y558+#4O&- MA,YZ$@TML^C?-*(W+VR27T(GF7[:]%=:] M3Z\9?^$>)F?T4G"MC*ILA'2Q-WJ>\S2>QLBTF)<",W!E)QJJ@MZEL_L)C1?S MH3X_!.S,P3#0WXHDD)%=NT M]JO:?0)1-Q:[/<*$7%ZS\GD)AF-!D2;*1HZ)JQ8-X$BD<"<#"\+V!.7!!)Y2@C,'Z;1=9EL_C+2;-?V/N/0;'@$D#(D;1H(QJERL[ ML%-V57%6[OW"H4SVNDQ^+..*GF/KWD[4!0V%#DEDTT#O#7C(:*A"/DU&-V'_ M*,OK8_FW91WX1#:[#KQ>UV-P#-9&`7&DC&?BL+Z7)>Z"3AW\X?<./.;009:- M7_P\><^SA+QW`X_KO=7!!IQY.3X#'''G(D^#3]\(_!O[& M2=`U?("V-82KC;OH*9Z>L!K>H+MLN+%A`]^`GM7PR'0M.D-:J#`TB2;8!^U? M$3^QJA_N\UI9O/W#9X.//>!U22($5TK9EXE[I\+O8_$+``#__P,`4$L#!!0` M!@`(````(0!S\U"_B`0``+T/```9````>&PO=V]R:W-H965T\ MX&"E:CFF@IL"'LCFMS;_^C+\M M3(-T>7/(*]R@M?F!B/E]\^LOJQMN7\D9H32HOS`!M65[3G.S*[SLC$Y0]!^A@,?CV6!]KBXUJCI.$F+ MJKR#^9-S>2$]6UU\AJ[.V]?KY5N!ZPM0O)15V7TP4M.HBR`[-;C-7RK0_>[Z M>=%SLQ>-OBZ+%A-\["R@L_E$=VD#TV9U*$$!M=UHT7%M;MT@>G9FKS7+'4[_,NWZQ:?#-@/4$VR"6GJ],-EJ9!HMD+$A'J,JT;L^@A:6I1V/P:B M,1"/@60,I&,@&P`VF""=@(H;.T&K_XM.4!;J1*\A[(&!-2/9?40_9#\&HC$0 MCX%D#*1C(!L`BNS)3Y%-6:!RE`*8JSI#'@,=[&[%5`W9R1#IA89$&A)K2*(A MJ89D0T1Q!-K&3R@$R@*+"JKMOB8\1]4;BJ!GEL@0:8F&1!H2:TBB(:F&9$-$ ML036P="2QSM"WPQH,%/>SS@4"-M^V,K>:0R(-B34DT9!40[(AHJB";CU4 MQ?<[B[;Z[EP6KR'FN]4#M1/H<;SS40Y5+$>\F6P!.Q'#]TS6V$0,=&]9'.[" M5XLCDD&]C[&&)!J2:DC&$>AEP*/HAW[]O_53#E4_1X;Z1BVI?*[SU')CAT(^@)=K`)/D@XG#[ZC--@53%'0/$] MFPM/G3H-282><*:*JS3V6@?SOCG M!P4#!X2A3_T!\8M;)&51#>2(8J"[F(T<%,,&#G*$'E?N#LX7ZK!(!O46Q>+7 M/+E`$QGSA"B503U1QI$'/M$];FC4\X)BT:HA/707N].AO0Y%.A3K4*)#J0[1 MNP9+U&"]\+L#/T#6J#VA':HJ8A3X2N\%K@=E*F%^:0G]`+85L&R,3P-HS#J^ MGP70PA[@\R!BIZH13S(/8*4_B%\&D'H=3Y8!9%+'X7*U914QX@_II>M!?.@% M<*32><))`"<+'=_ZP18,A0^V_`6X/%WR$_HM;T]E0XP*'<%$AVU`+;]^\9<. M7\!^!B`(``(8&```9````>&PO=V]R:W-H965T>ZVNSO#O*&NVY-D(U&8Z"$"/>,)6+ILSP[U^;FP5&QM(F MI[5J>(9/W."[U>=/RX/2SZ;BW")@:$R&*VO;E!##*BZI"53+&_A2*"VIA:DN MB6DUIWFW2-8D#L,9D50TV#.D>@R'*@K!^(-B.\D;ZTDTKZF%_$TE6O/")MD8 M.DGU\ZZ]84JV0+$5M;"GCA0CR=+'LE&:;FOP?8RFE+UP=Y,K>BF85D85-@`Z MXA.]]GQ+;@DPK9:Y``>N[$CS(L/K*+V?8[):=O7Y(_C!#-Z1J=3AJQ;Y=]%P M*#9LD]N`K5+/#OJ8NQ`L)E>K-]T&_-`HYP7=U?:G.GSCHJPL['8"AIRO-#\] M<,.@H$`3Q(EC8JJ&!&!$4KC.@(+08_<\B-Q6\#8/IG$R7T2`1UMN[$8X3HS8 MSE@E_YY19R[/$I]9X'EFF8I$=<&`3(>(,.#'LP-'1= M6P\:(0U--5[:@3OIOKCGR$4=DMOW7\CPY)%L_"-$W_N_;&07)?\"Z]K@YC:N3,=0Z/WT?ZZ6<I3T'^`::&G)GZ@N16-0S0N@#`-G1?N+Q$^L:B%QN`N4A?/?O59PWW/H M]3``<*&4?9F`,.G_(*M_````__\#`%!+`P04``8`"````"$`E5SL8/@"```1 M"0``&0```'AL+W=O1#:2%7'U/:EJ$=,G8>C5^O.GU5[I M>U,(80DPU":FA;7-DC&3%*+BQE.-J.%+IG3%+;SJG)E&"YZV@ZJ2!9/)C%5< MUM0Q+/48#I5E,A$W*ME5HK:.1(N26YB_*61CGMFJ9`Q=Q?7]KKE(5-4`Q5:6 MTCZUI)14R?(NKY7FVQ)\/_HA3YZYVY<3^DHF6AF560_HF)OHJ><%6S!@6J]2 M"0XP[42++*8;?WGM3RE;K]H$_95B;WK/Q!1J_U7+]+NL!60;ZH05V"IUC]"[ M%$,PF)V,OFTK\%.35&1\5]I?:O]-R+RP4.X('*&Q9?IT(TP"&04:+XB0*5$E M3`"NI)+8&I`1_MC>]S*U!3P%7AA$\TL?\&0KC+V5R$E)LC-65?\Z5,?E6(*. M!>X=RW3F1?/)=`0)4 MP%P-E.%A[4?^BCU`ZI(.<^TP<'W!'!`,1`_*H#9>&<&HC+G%J5R[0%\F."\S M_8@,@F,*UY?)!\<&'2;L8:+SR@`9;Q#!4(.^H=/<.M`(:6BJ\=((;J4/R>TB M@SQ$K^1W]A$I!`^E7"1LEU^_.Z#)^@YPQ863A0[M%<=Q0P47Z2?.CZ?F* MX7X]>C$@>*CD(J=>%D-:]!)$[SK!44-^%QDZ"<\[\6&/&V^E10^UNM"I&6S1 M/C.ZF8;ONFF''4D@$Y2UMY+\Z)6UY!_M%J/[H1UXI.OVCJ'N[)4\XFKOM03J MSB"W;SM"0]'YD:@[@-S^7`F=BR^B+`U)U`X/EP!VW$/T$D:A\+ M^/40L.M. M4P,``"L+```8````>&PO=V]R:W-H965T&ULE%;;;J,P$'U? M:?\!\5[`A%R5I$JWZFZE76FUVLNS`R98!8QLIVG_?F? M/ZU/0CZIA#%M`4*N-G:B=;%R714F+*/*$07+X9]8R(QJ^)0'5Q62T:A7LI!KOEDK$Z:ODT7>>,X@VG!.> MP%Z()W1]C-`$B]W>ZH?R!'Y**V(Q/:;ZESA]8_R0:#CN*2A"8:OH]9ZI$"(* M,(X_1:10I+`!>%H9Q]2`B-"7\O?$(YW`V\+Q%U,RG8&_M6=*/W#$M*WPJ+3( M_E5>%99!\2L4^*U0)C-G.O0C-.B\L>'YMGF_*]#X!`V?Z65F_L(U3HW*8REJ`LOV9V0)(U%6#%!=[2@9V]GZ*X MKLU@+,V@D6!R^<2P7X\N!G1N,QE+7\NR#8M:YH-"<%$;WEC:0H++0@BTN/%* M2N\VU]G4%X,IVH0VO1#XWC^7-#$CJ-P]R[AYPD*W; M"\:-5K#*,I@,5G6YK%,&Y[;1N'2F7D>/&4W,S9TQ>6!?6)HJ*Q1''#M\N(MK M:ST2[7Q,OZX]6.W,J.36_\"H4M`#^T'E@>?*2ED,F)Z#&2?-L&,^M"A@ZS"O M"`TS2OF:P%#*X#[VL#/'0NCS!\:K'G.W_P$``/__`P!02P,$%``&``@````A M`.;KHQG:`P``0P\``!@```!X;"]W;W)K(X0%Z` M7*[/N>?:/K$7GU[*(GAF4G%1+4,RB<.`59G(>;59AG]^/WSX&`9*IU6>%J)B MR_"5J?#3ZOV[Q5[()[5E3`>`4*EEN-6ZGD>1RK:L3-5$U*R"?]9"EJF&1[F) M5"U9FIM!91'1.+Z.RI17H468RTLPQ'K-,W8OLEW)*FU!)"M2#?6K+:_5$:W, M+H$K4_FTJS]DHJP!XI$77+\:T#`HL_FW325D^EB`[A1;,(D%:+G(,";'L@V7H9WI+Y'9V%T6IA&O27L[UJ_0[45NR_ M2)Y_YQ6#;L,\X0P\"O&$J=]R#,'@J#?ZP:ZWRS"YGES=Q`F! M]."1*?W`$3(,LIW2HOQGDX@IRF*9TNY3G:X64NP#F&_(5G6*JX?,`?A8DT5H MJAPJ$JI#D%M$688W80#\"CK[O"+T9A$]0S>R0\Z=S8'/MYPF(X)JFI*@C'9) M_O89,6SE7349'(*1<+A"3 M87+:@OJ]M4D74,-":5/C=">PD$_W&`>9$IHF'R+=?GSTJ[WN4IZFPN0NE8U, MS2)NKQ)8;..5X*`N_"'253+S*T$C;NV5TTHPN4ME(WTELRXLS@DE9R<%1W7Q M;:2]"$@2^Y4@_.523':7ZQ#JB\&%VD9&-=-X-H$5<[I?9J!#@E@PO+6C2/*V MZSI[BHQR#9/MD%GC\"C"?=V:=F.1R7D]U@Y`5K-KB`UU]0RX$X&L-NN9YF&V MH\>&/'IP\SIZ*+Y!SE#@,(?"AKIZDH$5-\H&2-\'#B&/'L<)SLCH6P#Q>4`R M'=`QR@1(WP4.(8\.CP]0.*S*\T, M4`)MMA M&W(`W.P]!SC_QC'#'`J?`PR<`^@H!S#9#MG048`Z#G#9J<:,2&?69%H8),[/`Z0N%` MWT2;J](MQ1>;&Y_.;^T5*FK^@2M,G6[8CU1N>*6"@JT!,Y[3:)0ZPF<62;TO[]SM@T M38"VZ4L@P_$Y/C-C#\NKQ[KR'KC20C8I"?V`>+S)9"Z:;4K^_+Z]F!-/&];D MK)(-3\D3U^1J]?G39K%N@V(A*F"=+2KPZ2^ZVC51L4X'OQW#"LF=N^W)"7XM,22T+ MXP,==1L]];R@"PI,JV4NP`&FW5.\2,DZ3*[#F-#5TB;HK^![W?ONZ5+NORJ1 M?Q<-AVQ#G;`"&RGO$7J78P@6TY/5M[8"/Y67\X+M*O-+[K]QL2T-E'L*CM!8 MDC_=<)U!1H'&CZ;(E,D*-@!/KQ;8&I`1]F@_]R(W94JBT)]/IY/9_!)H-ER; M6X&P^Z M!B1UR[`'PP2(SSL"*XA=(S@EE\2#O6HHP\,JC((E?8#490?,M0ZAH9_947WD1PI7;1;K*M(SPW3.D(UCWU_V]A_MVQNG3HK2[N<5?G[=>7RT/1U!=P\5R=JO['X-2VZF+S MY7!NVOSY!+J_,S\OT/?P9>2^KHJVZ9I]/P-W;U?#T'3T^/NPH4\&6W MVG*_M3^S3>8R>_[T."S0WU7YVFF?K>[8O&9MM?NU.I>PVA`G'H'GIOG*H5]V MW`3D^8B=#A'XO;5VY3Y_.?5_-*^_E-7AV$.X%Z"("]OL?L1E5\"*@IN9N^"> MBN8$$X#?5EWQU(`5R;\/S]=JUQ^WMK><+0+'8P"WGLNN3RONTK:*EZYOZG\$ M:%"DG+C2"3RE$\8^[,233N`IG;@?]N%+'_#$B<"*WJD"]`Y+`<__/(&E]`%/ MG("FXL82!I((3TGTKNK'O+D(XY`5<=[G3X]M\VI!J4&@NDO."Y=MP!>F@_"@ M$F0J/R`QN)//W,O6!CZ$OH.D_O;$'/=Q_@T2L9"8\`V,B8@0P;..NXVI(:&& M%`WZP)[I-D,,+PM0K:1#]OT/TKD7+ATG':+A.B6R$A$BD!*CX4H)%J:(!"'( M2=%PY9!A,D10W5`P5+<'6?_V#H`1YB2H=2/"OCG'4&"@EE06$!41(E!%C(9) M2H((I*1HF*1DB*#"86:Z\-N".7AKPQHJ,2NJ5T!60[X_,'>Y8CX5+""^RH[8 MX`0KWU^LS%5,*"5%PW4F9)0,$50P[$RZ8%[KE*-A4D."""4;#9.4#!%4-FS`NNS;<>9@*C<@<@5&R/5\?S72*P":7C1, M3CY!A-*+ADE*A@BJES>EVN%U6R\'FWK7:R)70&1T'?@QWT?BO:86#9-33Q"A MU*)ADI(A@JI=?T0M!YMJF4-VFE!@_"&9@X#$/L*W./-8&,3J,!:0W3"A^!0- MTTH1094R.([TP/*-Z_WZ'5A4,PVQ!`D5#TO?HQ4L`5J034K@T\XF&5%299G6 MKB`C\;Q?T;+Z3O&BR]'/*\9(_H9,@&0]L^4HB)%$Z.IUCNOX`:V*9,1)E>6& M?.%V&,CHRAAO6S3YMXMZ0).8,V:6;2A!,N:^NW26!!))B*Y;M$^2M%@MUBMR M&"0C4JHL-X0+OV\(YVV+)OS.N(MF!WZKHY@QT@F&##NB*XB>UPJBREU9)DF) M@B`I599)4J8@H\3G;0Q9`!;P/T/?Z5B8Z'_,W"=U'4J0B*?KKQUQL.G&#)6WXDCN\I!*CMT_43W;;CUDQO`O2UNV=BA$]D[E81&?(;P3@ M^!"+!>7B,7)V1!*A%XS@Z*I(DB4C4JHLUT4GI$Q!1OG"VR!-]YT%(YHG4S\9 M,V0")/7#W08][2*)T/7K'/?-W!"(*R=57F[(UTAFV'E7I,E_)^RBAS)EDQ(( MF0#)&G$6+B-5%$G$54)L::C$BILMS0/=7T,=X?:;KO#+OHJDS] MI.4)!]>8]LQ;N60CC21`ER_\BB5;>.O`)4Z3$2=5EAOJIYI`QGNFCZL7G9:I MGI1T.+C>VN+O69>M'8^41201NGSA6'#8"M:,Y%0RXJ3OCI/I'"/G7=(8WL[Y M`0T76\.-Z'"C%(Y-T=@4CTW)V)2.39EA,F?.^QT2-[ZS??"BS15MDQY(>DB% M$L.;,'62,48:X>B*PL,['IN2L2D=F_B%-3\N8$2U1XL+:''56)?MH8S*TZFS MBN:%7R[S?%%6>?'M.G#S/82*O`%!>"=.WL!E^6>7CTGL(=O`5>'8GH*CM^RA MNX%+N3$^=C=P\3:VIRY,B-OG:F"X([_DA_*WO#U4Y\XZE7N0ZNSTT/M^/#QR/\-Z2$ZTYG!N!]T_3XA0^@_K_R]"\```#__P,`4$L# M!!0`!@`(````(0!6.PV&T0,``'4.```8````>&PO=V]R:W-H965T&ULG)==C[(X%,?O-]GO0+A7*/)JU">/PNP^R6ZRV>S+-4)5,D`)[8PS MWWY/._<_IR6'S[J$KCG;:\8/72)%/;-&B=L;RH]TOS[[]> M)J%I<)'6>5JRFB[-3\K-;ZN??UH<6?O*#Y0*`QQJOC0/0C1SR^+9@58IG[*& MUM"S8VV5"GAL]Q9O6IKFW:"JM!S;]JTJ+6H3'>;M(QYLMRLR&K/LK:*U0).6 MEJF`^?-#T?"36Y4]8E>E[>M;,\E8U8#%MB@+\=F9FD:5S7_L:]:FVQ*X/XB; M9B?O[N'"OBJREG&V$U.PLW"BE\R1%5G@M%KD!1#(L!LMW2W-[V2>$,>T5HLN M0/\4],C/OAO\P(Z_M$7^6U%3B#;D269@R]BKE/[(Y4\PV+H8_=)EX(_6R.DN M?2O%G^SX*RWV!P'I]H!(@LWSSYCR#"(*-E/'DTX9*V$"\&E4A5P:$)'THVN/ M12X.2W/F3[W`GA&0&UO*Q4LA+4TC>^."5?^BB/16:.+T)M#V)L2=.J%'//\) MEUGO`NW)Q7YZ*FYO`NW_YP'R+BC0GF9"'IV)A0'N\A6G(ETM6G8T8!-`"'F3 MRBU%YF`L$^5">SU1D"$YYKLW/> M[3IAX(0ZW;EBX@8>"6>:)%$EON.2K[]1X&!Y/@XGQ1K<3)W]&B7^`&>'OA;Y M#4I@20\A^II;%Z'XKB(94RA\\#>/\TFQQN=J?"AQ.SZ-?8-]/;L;>5I_?!I[ M$SS1'?SAWQ4HV&B/0TFQ!J7%>XV2?N*>;>L9PWZ8W,V,W54D8PH%SG\&3HHU MN*^8X79#R-HZM0H7ZF=DKQFCNR^)>PE& M8$(Y-/L#A,P"[_)& M[S4C"8_O2^2+A=PWUUTPE_CB@(5HD^[I[VF[+VINE'0'>;*G`=PR+;XVX(-@ M35=P;IF`H#7.PK5*%3CIK%C3)P>Y(O)\,*X^@\``/__`P!02P,$%``& M``@````A`#*":A?&`P``W0L``!D```!X;"]W;W)K&ULK%;9CILP%'VOU']`O)/U6E\8@9)[3>FJ[EF`:N,YJ3^K0U?WR_?[2883FITK7`M-PG")!/C/"]+P MCJW*_H>N0NSAW+S+:-4`Q8&41#PK4M.HLO#3J:8,'4K0_>0N4-9QJY<9?44R M1CD]"@OH;.WH7/.=?6<#TVZ3$U`@PVXP?-R:>S=,7<>T=QL5H)\$7_C@?X,7 M]/*!D?PSJ3%$&_(D,W"@]$&:?LHE!(?MV>E[E8&OS,CQ$9U+\8U>/F)R*@2D M.P!%4EB8/R>89Q!1H+&\0#)EM`0'X*]1$5D:$!'TI)X7DHMB:_I+*U@YO@OF MQ@%S<4\DI6ED9RYH]4L;N2V5)O%:$GBV)$O+6P=NL'P!"5RG/(%G2^*YUCH( M%LOUZI^NV%J6BE*"!-IM&+T84'K@.&^0+&0W!!89'A^"K,7T`?M3O"!0DF0O M6;;FRC3@.(`#0)Z%1#8J0J9 MY!>JD"Q217=_U`$#66-1<6?1'4FF0#H`1B[[K^*R9(&,#0/OKL8^1MH&FNPJ M(QB;Q+U)KV.&I$-DI&3Q*DHD"Q0A9'A00][8SZ@U^IN4WJ27,D/2(3*2`C4S MK*/;0Z(K>FFL/.YNBEI$3215P?$,269(.D1&WBS'WNC19AR_3\_(;Y@#PRAV(_>% MW2A9QIYKQ%OJ`>.XB_YZ'>SVQ%59HA$?2G?@]>18VAM!'DQG,HF4-R1U%< MZJ"N$KUSZ*]IA=D)Q[@LN9'1L]PG8)+M-CVLEYTH"*';0>P$CY&PO=V]R:W-H965T#I-HH+R,K0,:SF$0^SW/&4/(CT5K-261+*<:EB_.O)*?;`5Z1"Z@LJ7 M4W63BJ("BF>><_UN2,.@2-=/AU)(^IR#[C\BE81,.TV&0<%N.V!9/MM>$?6]_$BC'8;LT&_.#NKQO=`'<7Y+\FS;[QD ML-M0)ZS`LQ`O"'W*,`0O1[VW'TT%?L@@8WMZRO4_XOPWXX>CAG(O0!$*6V?O M#TREL*-`,['+2$4."X!K4'`\&K`C],U\GGFFC_!M-8EO%V21`#YX9DH_W_C)ADQ[L``2W,]E(7\"J38LM8Y9`Y_F]P_"M-K^--&M.DIE?"0'ZX5(, MNIW+A?IB\%R.8$9TA]F%F@4AR?R"CE&M@;A60#Z;@PMY=*!Y&\4VC7P%Q_WW M52'X6D>0#;7K?K"ZSU^K)A;J,\CKIF]V% M/#HZ=C=NF5UU"^D;WX7:=5E>T#/*^J3O?1?RZ/&X?WG]F/7=3WSVO]#(XE'V M-^CV,7.AOIQXE/T-NL/LM?_*7Y9XE/T-NI/-=@2/#H_]Y]/5Y&IEXGX#<*'6 M05M.+RA"_PYN`+%U._3<^@?9A3R*T+\-9F.MH/9G?Q:BC&Y^O[R`C/(CJ)S`Q5_3`OE-Y MX*4*3!P'`4``&T3```9````>&PO=V]R M:W-H965TCS'8^()L'\4V-ZF5 MJJJ79X+7-HIA+2!QSK?O[`TO.]3-.VO0:.T^1G4F;-B%Y)!7>.M"ZS%G[6)Z>YUB0[<*?RXGCC\H+\*]+DD%&0 M&7D^4\KI!08`?ZVR8*4!&^?56'-KSVI[,1OY\/''!W'HF31L53-*V\M>F MI>7?PLB54D+$DR)PE2*N/_(6ONO/F,H#SXGTA*OT7(X6OC^=+>:/':?2$:[2 MT1M-/7^^X.-^\$20Y0'#53I./_;$F72$JPK2';G3\7^%.)=^-="D=X2H='R?5$37!2VR?M=EF5=.;!>L69KVY9JP+N`&(J=H2V>VJ[=^* M#:J,B3PQE;4-X4,=-;!"WC;NPETY;U#5N;39#MCT+7;*@I4PD]V;(#1!9(+8 M!(D)4@TXD(0N$U#9GY`)IL(RH6+8*G!/C6>$K2R4R]X$H0DB$\0F2$R0:J`7 M-BS+3PB;J4!?T0O`,PM`V+C0_[HJ\8U4="9=+A`)$8D0B1%)$$EUTLL(])M/ MR`A3@44%U=9%B]>$-'J4DLZD2PDB(2(1(C$B"2*I3GHI@4[Z"2EA*CPE*I2M M(&P#T9)DKH_.2+GM$0D1B1")$4D02772RP!L"7H&AO=>U0Z9<3]02?A&SWO; M#I$](B$B$2(Q(@DBJ4YZ44''UJ/ZP>[/5/KA2J+7M;N8&(N],^KF%9$0D0B1 M&)$$D50GO0RP0[*V_SV>5V;<#U02;5X1V2,2(A(A$B.2()+JI!<5[.1Z5&)> M1^R\U9Z+_&5+8;E!9QJ(=@*[M]C3F48_6$&\6;>Y[:2-.'7R+5O:P,BT%3WM MSWS8&:F9CQ")$4D0206!LS#H].)GF\S_3@`7Z6=`(CT%RDK+@;):\I.0-W;- M^.\&70*4S#VY\=V*':A`QEA`R=U`R:1*9B`E[-SSX4IG^Y8Q^Q)![/>I79B] M6OGIV1!2'AQ`M)(P=OY0J<]YSJ83XWZD[GM=\<5W]$`X459"V)\9IY)4WA\J M(G9DTC+V@]W1%2(Z:I:U$O52ZBUE_E>R4HYY+H37I-=;YHN\82D>P4D^, MU!/U]'U$*\%::6]<_67'SE1:Q@;Z"^SUJL'`.S.J,8GN(>^4U1WM,0HQBC"* M,4HP8N_R?%S\B2(^\6XN7IQ*4I_(CEPNC9735_;>#;6S6758?!383@,X3D'^ M3>X'<,@8X+,`MND!/@]@\QK@BP#:/^;[90"-0IR&^91])!NRW7@"O)EAG.PG@A([YTS1X@@F"&TXW M)OC8<L/A558UW($29ES+>[6GPN$3]:>N7;WC-MX3,'__<,G[4(O&J. M1[`W'BEMU0_V@.Y#V>8?````__\#`%!+`P04``8`"````"$`/+U"Q;8%``!7 M%P``&0```'AL+W=O4S!2=!#3@"VG3^_1YC0VR?M$V[K4;3YLDY!][7 MQL=X^?VE/%K/M&X*5JUL,G)MBU89RXMJO[+__BOZ=F=;39M6>7ID%5W9/VEC M?U__^LORS.K'YD!I:T&%JEG9A[8]^8[39`=:ILV(G6@%W^Q87:8M?*SW3G.J M:9IW2>71\5QWYI1I4=FB@E_?4H/M=D5&`Y8]E;1J19&:'M,6[K\Y%*>FKU9F MMY0KT_KQZ?0M8^4)2CP4QZ+]V16UK3+S?^PK5JFZ4OZWF MP,YQ7>2_%14%MV&<^`@\,/;(0W_D'$&R@[*C;@3^J*V<[M*G8_LG.R>TV!]: M&.XI*.+"_/QG0)L,'(4R(V_**V7L"#<`_UMEP:<&.)*^=+_/1=X>5O9X-IK. MW3&!<.N!-FU4\)*VE3TU+2O_%4%$EA)%/%D$?LLBY.[#12:RR.Q2A(SFQ%V, MYW`G^.J.4-(9$Z1MNE[6[&S!;(-[;4XIG[O$AVG.'9D,%0:/7K,(O.%%[GF5 ME3VW+4AO8%R?UQZ9+9UG&(M,QFQP#-$CMGT$-YZ7#4P0FB`R06R"1`$.:!Z$ M@_VF<#X5A'4W"^=5N/#^EC<]4)PP5/81?4I@@M`$D0EB$R0*T%2.OT0EKP)S M71O>N2YK(V((/)/#')CJ(=LA9)".2(A(A$B,2*(233\\)U\PRKP*/"`PE09M M'KG3U6UDT%L&#"&#`8B$B$2(Q(@D*M$,@"FM&G!]I>L?8Q[SO;R-)MZQV MS^06D0"1$)$(D1B11"6:!ECD5`UBU1[QA:X]%-GCAL&HP-AC* M8$*/[4>3!^OZ!/%$J^U&4\9<%`+"N01#0 MH,RVF3';MC)-D273^%Q_7L_&TSOXIX]#B)(B+6DZ\;P[,RE&28E*-.%\V;]] M]+IH7;I$NO:YT6.V?:(BOD\4ZLG$Y3^&>IP6]6G0-Y4GV[`MQHF)AG0/^$[C MYAG,FXDQ_!(9'BQT,=L^4?5`U/*$!_,9_!C.A3@KZB\GYPU.BG%2HB%=/M^" MW"Y?;%B@7+]H;HA$2J_!*,`HQ"C"*,8HT9`NAF\H%#%*RSD4>4[%N\#MW8?( M#8HJ5Z#)8,"V#U)69(G>:4"7J-[,"*,8ET\TI!O`-Q1?:8#[TI]SN4ZB89T)_BV1'7B,OYO]RC^-F$^X0*I74I&75P( M)/&4-H6"(AP4HZ!$);HFOOGXE":Y:U&'42!]U4)=BX@H5:;,>ZMMH:Q($KG4 M7>];*"M1B6X$WXY\R@BYCU&-$$@W`K[&!F5D1DUCL-S,Q+9%YW M?=T*OJOYE!5R.Z1:(9!A!>ID(DJU0N:]U:7RPC+A=*5**[P+L]W=+CL;$R]L1/ZJ"'KY<#%L>(&[+PN2W0 M#7/I*G%]'R=LICZ\0U_A!*X,/L$WSE`*CC5/Z9[^GM;[HFJL M(]V!F6[W4EV+@U'QH64G,!D.-UD+!YK=GP&PO=V]R M:W-H965T[CDL:1C?1%Q3?')]S[O%UF-_M54V>P5BIFXS&T8@2 M:(3.95-F].>/]=4-)=;Q)N>U;B"C![#T;O'QPWRGS9.M`!Q!AL9FM'*N31FS MH@+%;:1;:/!-H8WB#I>F9+8UP/-NDZI9,AI=,\5E0P-#:B[AT$4A!:RTV"IH M7"`Q4'.'_FTE6WMD4^(2.L7-T[:]$EJU2+&1M72'CI02)=*'LM&&;VKL>Q]/ MN#AR=XLS>B6%T587+D(Z%HR>]WS+;ADR+>:YQ`Y\[,1`D=%EG-[/*%O,NWQ^ M2=C9P3.QE=Y]-C+_*AO`L/&8_`%LM'[RT(?I?_,HGN/,G2LV1T1@ENMQCL\R*)IW/VC&F(%\Q]P.!OCXE[!$,W MO26T,;3T=CQ'90_VRCXN;^4^%(8RR=LRX_?(>#`F,S"?Q*^\03E@)@/,:P0G M#2+D\@8]&`]GV%`\GO4M!>D`ND`:!^5R:0_NI/MP7RK#'(9F3KJ\?H^4!Y]* MA.;/M;02;C*X;XH,"5\@KJV M1.BMOZ8)#GI?[;\@R\1;_KL^29?=C++^!=[LEI?PR$TI&TMJ*)!R%,TP8A.^ M#6'A=(O&\7YKAW>Z>ZSP$PXXZZ,(P876[KA`8=;_*2S^````__\#`%!+`P04 M``8`"````"$`^`?8(-8&```^'@``&0```'AL+W=O4T(2U!`BH.WN MM[\QML'C8;/I7JO5MOTQ,_9_QK&G>/WY:W&V7K.JSLO+QG9'8]O*+FFYSR_' MC?WW7^S3@VW537+9)^?RDFWL;UEM?][^^LOZK:R>ZU.6-19$N-0;^]0TUY7C MU.DI*Y)Z5%ZS"SPYE%61-/!K=73J:Y4E^]:I.#O>>#QWBB2_V"+"JKHG1GDX MY&D6E.E+D5T:$:3*SDD#\Z]/^;56T8KTGG!%4CV_7#^E97&%$$_Y.6^^M4%M MJTA77XZ7LDJ>SJ#[JSM-4A6[_86$+_*T*NORT(P@G",F2C4OG:4#D;;K?0X* M>-JM*CML[$=W%7L+V]FNVP3]DV=OM?:S59_*MZC*][_EEPRR#77B%7@JRV=N M^F7/$3@[Q)NU%?BCLO;9(7DY-W^6;W&6'T\-E'L&BKBPU?Y;D-4I9!3"C+P9 MCY269Y@`_&\5.5\:D)'D:_O]+=\WIXWM36SK*:L;EO-0MI6^U$U9_"L>NC*$ MJ-%NYX.5D,.CIBUFT2@J1)MNNJ M?+-@9<'\ZFO"UZF[@F!*O9ASEX_OI0/RP(,\\B@;>V%;H+B&&KYNW86W=EXA M[ZFTV0W88`M?6?`D\["!"4(3,!-$)H@UX(#F3CBD_`.$\RA M?&6A7`(3A"9@)HA,$&L`J81U\@$J>92-#?_WY?5<7+R=L''A\]<9S;")WYET MT@D)"6&$1(3$.D'ZIQ^BGT>!#P@LI4X;7=_2Z%8".I,N`82$A#!"(D)BG:`$ MP&[P`0N`1VD3H":^$X3O4EI*)D;!.R/E%A`2$L((B0B)=8+TSK'>X5U<;5O< M&,N2I#TRVCW()R0@)"2$$1(1$NL$:8!]U*Q9OZO?O2?S*%B<)/H*=1=3HV:= M452FEGT.V:<6,L2Q*M9H0$A(2$,$(B0F*=(`U+K.$G MSU$>!8N3!-?,W%@[HZYFA(2$,$(B0F*=(+U\H[^_:*TU%J:05C:*`HI"BAA% M$44Q0E@,;Q*T%2BJ-^(?NN:4I\^[$C8YL!E8F1/H=F0/)#H-."54%7;\Q.#U M%'TC;VE\A>:=52"1!WNXMI?.\>$911,/'"&'9O&OXW[)%ZP&CJ'GM M7(ETV1+ILB5:M/VB-W:-G2A4899=9":1-U8^QHD3*9]^G!@AK)^W#9K^@?+" M`=?55S89NE"!O![YKK3JM0<2>5ZG(Z16C%I%U"I&"(OA+<#]8F3#T,]\YPH$ M8K1E.#>6H2^MM"4=*$?^47C=SB>S!_AGKEXY7I\6AMUF4\][,-TB.EJ,$,X` M;PKNSX!H(="ZE5T%RL!B@:7X_(]#_*$.)((__-H_?:9C_H7=0NK&E!M\$+0/ MOI&ZB#K&".$<\*;B_AS(%D1?!0+A5;!88C&^*QW[<@82R1PLYO!E9"ZD7@Q[ M#3A%U"E&",OG/<;]\F5'HLO7FQ31`+H$!12%%#&*(HIBA+`8WFQH8K13Z93O M]YEX^?".`THV+[I<@:;=SN2[TJC?0`.)?G0^"4>P4N<`ZQT5BFCX&"&<`-Y] M?&0"9#>C)T"@?M*^*XWT!$CT_9-*&N@GE4`W3BHR3HR&1IF`,#@3??UO'UJM M(VZ\)-(/+8GZ+`3*2#NSB!&C1A$QBG6"-?'F2*_NW9ID5Z65D6]7L"?C78N< M7=)*ERG];AU=Q(NIT837\,E%O&*=X$3P1NBG$B$[*#T1`O&QM"/%V(A]:$5X MNO1$2+];)QCQ8I+P;]IHY@%&_&*=X%08'9FVS_U@G=/F#$XBNB;(22:M]%1( M/Y&*P8.,.#$UF%Q(]/"+B$^L$YR%=[5R?%_F_8B^"B32_K925CT**`HI8A1% M%,4(83'OZLKX"R53C$3]S'UEU:.`HI`B1E%$48P0%O.N]LJC[95"_0["[B<(27K6B9M7W@P.F)?.?:Y""@**6(4113Q2Z-V M7FUX(5Q<`HG[CR*KCIF?G<^UE98O_(('CM_MNL/B]FGGS>#ZJ6USR9,Y/&F[ M!/)DH:ZLS"?PH+TK,/G#"MXL09-D\N4*WL`,<'>\XJ\SAI[`$-!2#CSQIC"K M=I\S1H$7$"O^+H'Z0.L'3X9F!K=RCVUO8,3:P6W=4*2=!X,/C+";K.#E/1WY M<0KQ!V6`BB$1.ZC38)F@2FV1G&ZF<'MW38[9[TEUS"^U=FO,*B@+N\LH'[N_;'$]S39O`:9SR"3>E0EHWZ!10XW&PO=V]R:W-H965T6J=,F],DBBF1K3"%:JN<_OIY M??:)$N=Y6_#&M#*GC]+1B]7'#\N=L7>NEM(38&A=3FOONXPQ)VJIN8M,)UMX M4QJKN8='6S'762.S>Z)ZXV MNR]6%=]4*Z'8T"9LP,:8.X3>%!B"P^SH]'7?@.^6%++DV\;_,+NO4E6UAV[/ M("',*RL>KZ034%"@B=(9,@G3@`&X$JUP,J`@_"&G*0BKPMFM7W//5TIH=@78#VG4K-)DNV3U40SQA+@,&K@,F&1`,W`R6P,;8TLOE MV2LC&)6Q7&CE,@3&,NG+,I/WR"`8*C,RGR;_>(-RP$Q'F-G+R@`Y/4$$0W/& M"263Y[4-H!.D85!.ET9P+ST4]RDRKL/8S$$;Y^^10O"A5(A,^^$=3P<,V3@# M'-AIO(C`V=N#@N<.%4)D7+1D\DK'<`./OI*WE1!\J!0BQ[DL#FG[A1#_-Q,\ M=<@?(H>9S)_-7EA+X=O7TE;RLVP:1X39XLI)X:,=HL,V7*=8_N?Q:;;NMR0; M7L"6ZG@E;[FM5.M((TN@C*-S2,6&/1<>O.G`..PJXV$_];&ULE%7;;J,P$'U?:?_!\GNYY8Y" MJG2K[E;:E5:KO3P[8,`JQLAVFO;O=P:G-"2HI2\$)L?GS)D9AO7UDZS((]=& MJ#JAH1=0PNM49:(N$OKG]]W5DA)C69VQ2M4\H<_PS^YTI)9>-2%;QK-6=8>DI4?!<'@R' MRG.1\EN5[B6OK2/1O&(6\C>E:,P+FTS'T$FF'_;-5:ID`Q0[40G[W))2(M/X MOJB59KL*?#^%4Y:^<+@3=F"GU`-"[S,,P6'_XO1= MVX&?FF0\9_O*_E*';UP4I85VS\`1&HNSYUMN4J@HT'C1#)E254$"<"52X&A` M1=A3^WL0F2WA;NF%TV`.:++CQMX)9*0DW1NKY+\CYLCD.*(C!_P>.29S;[8( M)N'[)+[+I[5WRRS;K+4Z$)@9D#0-PPD,8R`>]@-&$+M%<$(7E$"N!IKPN(F" M^=I_A,*E1\R-P\"UPX0=P@?13AG4QBLC&)6QLIC*C0N(,(AA[T#%W4UH%&2,-0C9=&<"O=%==%)K"\NCI$ MP6+8Y?PC4@CN2[D(2.';=SH>,&6G%MH7;@Z)O3VA>*HOX"*3_M`NA[W@MA[] M,B"X+^4B('7N9=7G;;TL80>][05/]05&PO=V]R:W-H965T@R*I^/ MQ5TLL@(HMCSE^LV0NDX6+[[N'LI"Z^.^H@3I\E3[[QG$&V MH4Y8@:T0SPC]FF`('O9:3S^9"OR03L)V])CJG^+TA?']04.Y)^`(C2V2MT>F M8L@HT(R""3+%(H4%P-7).&X-R`A]-9\GGNC#R@W&HQGQHW`&+%NF]!-'2M>) MCTJ+[*\%D9+*D@0E"7R6).%T-)GY(0'-&R2>79#Q]T@U72^E.#FP:4!2%12W M(%D`<;B%;*H-9? M&<&HC*G%I3S8P*5,T"T3#I%!\,J%Z_OB`U+Q6F6+&5]@)A6B9A`@_0TB&&IP M::B=6POJ(0W[H;\T@HUTE5P;":\MIN9R.D0*P74I&QF;[KO<';#)^CM`<)VV MC-0J.9]WUPF'=.\60'!=RD;:#J(Z+8Z,L1^-(+?_;S)\KJY@(Y=E)_.HVPN! MT=;?C$'7M_FJ(;B3-ACI\-+H=*Q-,;NXS?'\U M)6RH7I`*1C`D3C;C_!H`E@T/7LE:&VGZ!C`O3P8QYK2'3U_Y6W:#"H_PVZ(69' M0H>?1O]CWX3CF_6!J M:'6HW00X;9KQ\6)C#[M>]0L<-@NZ9]^IW/-<.2G;`:<_PM.EM,=5>Z-%`=F! MTZ+0<,PT7P_PMX+!D!0``!D```!X;"]W;W)K&UL MK%A;;^)&%'ZOU/]@^7WQ#4A`P"I@IUVIE:IJVSX[9@`KV(-L)V3_?;^Y,N/Q MDHORLEF^.>?X._>Q%U]?JJ/W3)JVI/72CT:A[Y&ZH-NRWB_]?[[??[GUO;;+ MZVU^I#59^C](ZW]=_?K+XDR;Q_9`2.?!0MTN_4/7G>9!T!8'4N7MB)Y(C9,= M;:J\P\]F'[2GAN1;KE0=@S@,IT&5E[4O+,R;M]B@NUU9D)063Q6I.V&D(<>\ M`__V4)Y:9:TJWF*NRIO'I].7@E8GF'@HCV7W@QOUO:J8?]O7M,D?CO#[)1KG MA;+-?SCFJ[)H:$MWW0CF`D'4]7D6S`)86BVV)3Q@8?<:LEOZ=]$\BR,_6"UX M@/XMR;DU_N^U!WK^K2FW?Y0U0;21)Y:!!TH?F>BW+8.@'#C:]SP#?S7>ENSR MIV/W-SW_3LK]H4.Z)_"(.3;?_DA)6R"B,#.*)\Q208\@@'^]JF2E@8CD+_SO MN=QVAZ6?`'H@;7=?,E.^5SRU':W^$X?<$ZT<2V7\E+AIX]U"0\:T\YJ_!H#F,J M;L);'AR9L$U0(D8<'21UD,Q$+#8SFPV+XQ3%_\[IS*S8-"5B]E$TF_7BJ(5T M'!TD,Q&+.1LW;P\DE[8I*L@(I0NE+I19D,V)K0\CN1\L2S:C>O&4D%68N`'V M`GJ1TA%UH1V,-4C3Y:T7E>&9)V?S9+C#XOQ)3N3E,FN8R$:,S M+C*D#I9$#919DUQ2%B\8>X)K@0LM) MW$5B;5@1E9!XJ6"WUHV42F+=>*D+997&8Z)%ALV<;PF'_[D40R45C MAEI`\93?VM%?8\U`!E[J7!Q,I9D$?690[REF%RFTH>T-VQJ.-^_-A5P]IB\" MNOC2O^9&4L?T14#)6+RUA+?]J9U))4CT_8A[.^Y#-<6-V*M/0O!##;"-DC*8 M2RAA%:S>NN*PYW)VD7+8#V[#2Q:^T]//.@)[3K5$["Y#!5VX;EPH=2'V@8#/ M':XH*D:\\(LWUHHT>[(AQV/K%?2)O?T3J`QJ0&%0_F:.F^H`J]LY[HP#^&R. M&]D`'H5@Q,=YCQ&&U9Q-)U<'70Z=H:>D$1Z#KAC0B?$<5)Q[@N\_=\.1AZD! M^352-2B/1`WEZ6X,^X.&D#_1N=IS?/*`=OOSP7CC@"Q_!C`]'Z+H=I9WZ`8\#_&PO=V]R:W-H965T(=&7<*BBD)FX5]FZ%HWU)%I4W$+^II2M MV;'5V25T-=>/Z_8J4W4+%$M92?OB2"FIL^3;JE&:+ROP_`Z\%.37!1\7=E?:O-5R%5IH=T3 M<(3&DOSE7I@,*@HTHVB"3)FJ(`%XDEKBUH"*\.>41B`L36["F`&< M+(6Q#Q(I*4&*OLTCQB;!4]0C6R+N?,8>':8/2*`;+J4((U^2J?+ MLU-&,"ICN3"5.Q_HRT1=(@.9^#TR"(9Z]Y*/V)[7*WO,N(>9G%8&R.4&$0S- M&1AB<4?LI3WH`FEH;5\:VQW#1CY?8USD4NB*O(WTZ\&B:9?4H,[70\GS4@@> M2OG(V&WB_BZ!S7;H)&)O6L%50WX?Z9>.Q>%I)SB(>V?EO!,$#Y5\Y-C)=$CK MCF`X'4&-SRO@NJ&"CPR]O'+(L%27FW'HH=8V=&P'MVJ?V8VY^$TW;MF!!#+! M/.J=*!;O3]U@E[%W30V'/A#S@^.$'SS7O;:CGP@G[OGNP$URV)YM:.AG?Y2] M'W]]^!E="[T2GT55&9*I-5X-$0S7+MI=6XL(C\=A?)PL_'46=+_`==+RE?C! M]4HVAE2B`,YP=`-NM+^0_(=5+50'+A5EX2)QKR7\<1`P8$/&UL(*($`2B@``$````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````E)%!3\,@&(;O)OZ'AGM+69$;QNQ4`)HMW\O M[;HZHQ>/Y'UY>+Z/2UXV! M"AW`HP6[O"B%I:)Q\.`:"RXH\$DD&4^%K=`N!$LQ]F('FOLL-DP,-XW3/,2C MVV++Q3O?`I[D^0QK"%SRP'$'3.U(1`-2BA%I/US=`Z3`4(,&$SPF&<'?W0!. M^S\O],E94ZMPL'&F0?><+<4Q'-M[K\9BV[996_0:T9_@E]7]8S]JJDRW*P&( M=?NIN0^KN,J-`GES8/LW5R?>[TK\.RNEZ.VH<,`#R"2^1X]VI^2YN+U;+Q&; MY&2:YM2WQJ#??9"-2#P+^(\S/B"8? M]YV_N_O.=G+ZM)*]-1HKM!I&!_O]J(>*ZURHQ3"ZF5WL?8]ZUH'*06J%PVB# M-CI-OWY)ID87:)Q`VR,7R@ZCI7/%21Q;OL05V'W:5K0SUV8%CJ9F$>OY7'`< M:UZN4+GXL-__%N.30Y5COE>\.(QJCR=K]UFGN>:>G[V=;0HBG"9G12$%!T=1 MIK\$-]KJN>M-GCC*)&YN)L0N0UX:X39I/XF;TR3C('%$CM,Y2(M)_+J07"+X MI$U!&)LF:W>R1NZTZ5GQC])V&/7NP:*G,XS68`0H1[2\63VIQK*PSJ1WVCS8 M):*S24P&]6(U;-HVQ^(H'1Q7%C1J6WH/-1/::'.<"2?17L^G8%R`\N"XR;EB M43.N"6VKR$@;;*(,F8!1%8IG4%/84#-A\I%-52 M?AVQH_N.;K'@`5EY;_&Q)`6QR=KK*&C57:VP2+LQAY\X9Q#$?%`!EM$MG9=! M2'C\"D-P7"?5@;XJ9'M-MM/T:M!>3ZM[+Z='<[K\N))?T*S#2.QDM@>ZC?&OS M?L-_9&[KWUIZ<+3?'_3IC])82^+7?UGZ'P``__\#`%!+`0(M`!0`!@`(```` M(0"I^C`/Y@$``,P7```3``````````````````````!;0V]N=&5N=%]4>7!E M&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L````````````` M````'P0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`/"@[F3T`0``R18` M`!H`````````````````10<``'AL+U]R96QS+W=O0H` M`'AL+W=O700``&(/```8 M`````````````````#0.``!X;"]W;W)K&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A``@?.;2!!```PA(``!D````````````````` M,!H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`"A"6R(8`P``7`D``!D`````````````````-"4``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&8A"7JD!@``&!L``!@````` M````````````-S@``'AL+W=O&POP``>&PO&UL4$L!`BT`%``&``@````A`('\ M:&];`@``004``!D`````````````````NXP``'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``[Q[X&(`@`` MA@8``!D`````````````````>IT``'AL+W=O&PO=V]R:W-H965T4P,``"L+```8`````````````````&BC``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`*'6/I3U`@``\@@``!@``````````````````:L``'AL+W=O&PO=V]R:W-H965T3!P M'`4``&T3```9`````````````````(3```!X;"]W;W)K&UL4$L!`BT`%``&``@````A`#R]0L6V!0``5Q<``!D````````````` M````U\4``'AL+W=O&PO=V]R:W-H965T M```9```` M`````````````(;.``!X;"]W;W)K&UL4$L!`BT` M%``&``@````A`-I\7I>J`@``)0<``!D`````````````````D]4``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&I@ M'!0``!D`````````````````--\``'AL+W=O&PO=V]R:W-H965T&UL4$L%!@`````N`"X`=`P``'ON```` !```` ` end XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transactions: Consulting Agreements (Details) (USD $)
9 Months Ended

Jul. 31, 2014

Oct. 31, 2013

Jul. 31, 2014

Synthetica, Ltd

Oct. 31, 2013

Synthetica, Ltd

Jul. 31, 2014

Entity controlled by Board chairman

Oct. 31, 2013

Entity controlled by Board chairman

Jul. 31, 2014

Entity controlled by Board chairman

September 2010

AccruedCompensation $ 67,600 $ 47,600

Related Party Transaction, Description of Transaction In September 2010, we entered into a business and financial consulting agreement with an entity controlled by our Board chairman for operational consulting services.

Related party payables $ 49,000 $ 39,000 $ 49,000 $ 39,000

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_AccruedCompensation

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6452652&loc=d3e36975-112693

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 2

-Article 4

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.10,11,23)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 10, 11, 23

-Article 5

+ Details

Name: us-gaap_RelatedPartyTransactionDescriptionOfTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 14 0001376474-14-000313-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001376474-14-000313-xbrl.zip M4$L#!!0````(`,UB*T7OD=.9!U4``*+<`@`1`!P`UDU9W('BOI]&"Q"$ID2:H.R>*P2#N>7[_O5?&4*.ITCAXT MT+$EUKOO*I9_^MMGSR7W+)1<^"_/S)9Q1IAO"X?[BY=G7(KF8-`=-LVSO_WU MO_[SI[\TF^0V%$YL,X?,'@ES%C1L2A;>_OJ]]]^_[\6>7AX:"DR%#9%0K.)M'Z> MA2X!YGQYX0O?C[V79\LH"B[.SW$)?ML2X>+DBPRFPW#;/9-M,E"-#AV8HB_-ZY M_C)]=,[=[#GY*0R02X38,?HY/(>M`)/,;BW$_3E\487>Y?ZG$H;:XJ$T'R790/9O8?/R&1%U)!NF-SHB1W@O64CN[N;EY?3ZXA8$PN->0J M&"L(+@%O2-VQ[[#/O[+'6@R&@>II]X=6$?P*A`S^91R&R!27-G7_P6BXB[B; M3=!@*NM-$%99$)XG_&DD[$_3)014>1-':(@8JHG#;.Z!K%^>C2>OSDJXQX!T M:$)EFN]\=](P2FS585@AZQ5T67@*A"Q'62W0*I,&SY(X%(HR0 M7DP!U'\L8BZ!6^5=BRA;/XUH%,M:G/]@LL17)805-+\)-_8C&FI:ZN%/1!'\ MRLH5N!^8Z_[JBP=_RJ@4/G/&4L8@C]WA;X"PYO&Y$;V"3^HY0)\O>_O*Z@W0 M=4S8#O_O[2KHA=4*?I(A+VY#%E#N7'\.F"]9HJYM=JWR7V;7[Z=7FBMPW%JP MQR)NF\8Z8G`F8[@/XO<^]=`8_\6<*S:+4*.85I(5![`^M(:]04Y!/?P2*2,I M620/%WJ[;9F=;HZZ!.]03)52MOI=C)O;$4&=&K`P>KQU(2.,?.?ZGS$/T`PG M[!`.A]:@J-O-L$]$1+6)]8WN`51H(1VDUC9\O"KMO6%7*W)HM7NUH*^A>A*/ MC-TQ%[*"\X;3&7=YQ-D1AFI91F]HY&BWXC@E195R&'2MP=X$04=P,;+M,&;. M'9,0K^UEXM;REC[2FBD)[,J MVQ:0E],GP$ENHB4+$S@GL:A.>V!TBCZR)\HGI+\(P>\-QE*&(H,Z`HO?&RI(^!P M%YDE'5J*[2H&4TO\\Y:&1YH/6'>!P4$6:[NR-9(\?A.).&7A4:N+%_20,>4?>0X#Z`UJ!O#8;[H;]C$>4^'!5"D#6@K78:'$[BMZ/$0VICGL6U8AC*V#/0KK M!MY[5L?L[HRT$%JA1#P)XZO=Y384)Z1GEXYT+W+*$1S*IIL0)XS,4>'EEH5J MF+JGD*23+CS[J]'"L71IO+0#PI/3N":X)Z513Z!'<;04(8ZQ]I-?.N9655ZI MT*O'=0I:CG&J?&=M"_CC2=@DBA.1L,[0^M($%?<-US9\S$YG^(4)LC1!E1)JFWVCW,GL2M"4N2Z8U6OFLY"Z M\/S(\;BO#BU$_'Z7C;]Z6VJ;UL`J&--N^$Y.8JUY=?K]X?#KDUAC<(-^KU,< M77TE$NM,L-/K#!`R_]!?I)LH19C?LMJV"P-9`'X.XSIBL@=$>FD^% MN,9$3##C87'3YZ28ZS3?'[0'Q7RQ(^*Q;PN/O1'R"#4W-^HYAWX<]CI=-SW*SQ4Z&OTWISH]HW8!\#9*AECB]/AL!VH5I:@7LXSEJW[@^>`F.= M/UL&_/<$2.N4VNV9NV%4^[%:T4=X[XHF"T`/0U;OK$45'H^JUC-7='LPXC',#XP/*#/G-$]1*$%6^N; M?J:2VU@..ZOO7C1)8;V,/P/PT%&^0X'J/^>U07.U`11D;G6[_&Z)X@Q/F M%%N#8;L[.)SBU,+3G9YT5G8*VRW-ZYI&JQB>MN`['6V;_'R5-O-KT+8AH*_2 MUOL*M&T*_ZNT=0ZC;8](O:4B['2Z@UURP\CY(Y:1.H`MPI$^$:S>N3H\Z0ZA M_RP>>=N$H=P4)Z)A#A[^ARKG2"+:G3;/?V0$9J#YDP/H5T_^.?7A42![ILWQ;S^ANJ;%ZG7:[6*MN1W9BZNI= MH5.NW8^F;OU(Y/IIR"/LUNR5E'H8_B=GH4[DEM'I&\9)68#X=4GE\C84]]QA MSL^/[\&1QW[6Z([LB-\?*?EFQ^H9Q0)^=Z1/0FM]IS'H#@>]HVF%YVW&'/DJ M%-Z4NNQFGK::8_]2A(&`U>P]H%XYD+;CJH]EB6\[G+5EU-\9=@L<[TS$%V:X MJ+;M#-?ZD=7O=;K?/,=&WQ@8_:**:PXDEI_>=BXRIT&%Y^D2BH=W+/3P_.WA MA@1>WC8'U7)=Q[.+;[_B/O7M$\4A(,[J=[:Z=@7.)R%U'PL]D%1<`SD`_\'# M4_=@;Y@R79+)R"J#\X?1KBOCJ_ MH]OQY=;3TG\27E?/-&\_!?T],W[`.>?CF3O@<-)6Y]M\9*GZG!(.0G4=AT4; M1!C3,"!UX"];8]E*$;]37$A>R:Q#^71T5?DO=@]?GJ@-/G(K:C7O5>?%KR*0_0459,H3HX=ZVW1JMGOE:=\>Y/RQ3AY(M)15?I-UHF( MV`>H&ZB_SS1OF]L8W4%J$>MH3D+!@2AO76HSG"J/%O"_DS/>[O93(JHQG8R0 MPS!G+1+S$)85H"N]C[P,,640S+1Z8W8SPY82>B9(_M[VJI;"V23*LW M,%?;-@9Y90NCK/V@N>?A->M[K#V/N?WS/@A M;V1^Z:9ASRIO[>6/^I<;)C2*0R@&D]T$X=??[/6C&[WX2[/)%I^;S1\7T0O\ M/2`R>G39RQ]I(.0+CX8+[E\8W$]^;,Y$%`GO0KV]%$3ZJ73M#']X9C[_D7K! MB_\V>\:+_"?R\_OI>'(]G9+1Y(K<_'9]]]OX^@.N.I^EZ\\#_(D<108B]&:"2<+"]9'[O@&F`S9)HR8A+'R01<_6S>DD,?[EB M\#&^D`:%KF(<23Z0_"L&I'%K[UAXK8(1W!Q/WB_4CVGX2$P3R3.M M8^&!L-4ECS+V/"5J2D*&-^DRXK%P@5*'8DY26W41SU#LN4+ODB??JB=SM3XG M#SQ:'LUK:B]D0GTHK>VE+URQ>*PPK,FX@/QXD1P+@8)$U0)!>8+R-`Q]1MHKF%HSX>F.OBOY0$H0A"SO!>3N()4&#LTA#RK`L: M@(\"ET9S$7J@01I!V`1KF&.BUCX8+04XJ$:"096(4(52`3\O^8Q'BI@Y]Y6. M(&\ZW,:H&L6>"!'U`D#AM=I%LRO*@&O389^ADI!H$RZWL;51^@6^L0135"G3 MBZFK^,$;_XBZ(1NB^8.O+^*^9`X-)9D",1QB"E+B$KRQ%@@N>#O>CU:,-0`? M6@DR`NMRF6R`H[$T0_BJ#$@?[KV0@)QY',0#YJ]?>"-X$3*/8ETOK`2X-YJ7 M`K:B&-1=<$N*W9%Z8TY%SSGU.$@2"`CU[5-`A"^:,RX"X3YZR86L?\0+^`[P M;73))1()L&]AE9BA/&B]PR4+.Y>65V M`O_+;!*PT."Q:)"M;]7Q#@B5'QARC:&WY)LH#1$KZW9B&RQ07_=.$]-5/X-` M;`%UMX2*$S]0;Z$Q3#Y@VI^4NPJB31.,&R(HSCP63/NW\CR/_H$>!.L]:C.P M+[1FG1=XZIWL,Y=*.2OZ0#U":%%,@8?)&!8H0KS%9"WTU;ZAS=ZNR+!U'Z,`HC(4`\@"T\#%6H[2`(H(6'`+S=`'9`[H` MQ03T"%#@:PY4JO.X"FQD'@HO$V,2`03>'@X!Y7:)V\SCL1+M&/Y=`==`U]3! M1Z5+=$09VS9$GWGL`HF1>ND!#)Y1\-H`P344L(5`1)K]!N'@$0%H]AX@,+/0H&J2BDPF\NA/(%'WB"1.&H MRCK)"RL0M1"T?2IC)A1G?2##)0=UV")V(8:S/+8AS>0>G$?$F"1#3Y:%RK6* MYS'V;-]'ZC\@`F&F5($`FNT&"D#%'8A)F/*R^//`(=>'#%IRM,;4>L&0M%&K M`.%"ML(@H9T,18?;'`!%=4&2O!+"4>YPA3F@^.KL>MW^ZFJT(:6]$\3!]`^> MH6P2ZFXH#EPT8N%]XW)^]PUE'(]6^NWJVU%0D5F/Y"P.0B%+G)@@ISQ[7I0/GV32JY MO)DG1SZ5R+_X[,!ZGMOLZYOQY#6YO)E<7M]-&N3M:#)Z??WV>O(NKV:FY/;- M:*)'"C^/IN,IN7E%;N^NI_#4Z-WX9O)UYPO-2`1%H*KTMTK/(Q!528D.!!D)5$/LEAN*HK4ZZ,KJCTJ@R`YN%Y$9=57`QR[S!PL`&NVN MHD5Q@I@?1/A)5X_IY8J:``#Z@]DPAX.&V1FVL%V3*C/K>Q.A**)<8G4UPS&J MJFD<$<^@%9Q!F:4(T,?;'W4%MUD#1]G4FK4_H=7JK6K=$X*NH(_VHZ6$`AY; M]Q4%/."?>X)JYH>^830`$)J4WN`EN,,+31O*6?6LD+<>GB8H1K5C`67@;;F,39]N1>5>M^D[J#YD=IH">7C`G)J1*#`D-H!02IIJ3)7 M?^V"/$+Q41X`8!&)GIO2J*>(VE"`#`<[V2*_Z23`+;RY@=T&X%`S(NR+L8:@ M+HA4%8R@!*CW$Q#JX1G64HZ"KUIO?(CJ%S+R=AY%XQ0JBER^.?WY#:(N5&4I M:9_8(RIOKN<=V.%`_[%$LW?90O5N,0!R=11)RG8G)]!)FW>::"`SA*QB*UF1 MTI]BM\AMJ-PQ`ZKG&&HO.H&>1`4M+8QEJ9"!`VB4W%)[L832+0$0Z$NP-?6I MJM2D`:-(7LVET==A,L"_?!:AJEUJ?T):$EP-U0@P["1\H>Q`EZ;PZ6K81EL0 MP%PC$PM&536W4`+W6\F40;;47HQZO?ZLI[N(S>/*?U9[CNEU:6BG?!>S M-=<&'\^@IL^C8C*_JR!>9IA;X$@%X[,!'$2(!73[?EI,@(&"$4`O78B6^4@! M*'"@Z0+F<.2A98>3VP+F[\<>QMK*L9R)\I`,`1]"Q$9#07TFC7C2?H+1<(_- M0^IA393([6`'#62&B3&?=!U$QH#.[I`BB*I-Y]OCJ.+I4DE;6 MGA"&4!9<;7G#@NQU7Y5;0C;'\8H.W!!Y\/K\9#B1L"E3/B'="WQ'/RF1U*C0 M!3OD\Z0W5M%-OP^:Q#+JJ?<(*YY5(:Z4%%%U'L79D8S==*:&GI(B+/O&DY9H M3SQ,45V5:KS5;`CCNQ_ID?V_3]/US5%_5(>7NE>4`(F3*J:T'XE;@`]+@3M. M>O,'6Q&($[C#-9J,B[X](?Y!,U=XJ.,0ND[G^D=MD2)4ZNTJ?UY>EC:1LFPP'I32+C7,A M(MSY)@Z4X5`/Q;BMY^,C*+I$U(KA2N(SDG&&#;H('=U/JB%:/N<*(./:/`"Z MD[X8@SS"IXI"436TD@I9$<8Q>DG#-<4:NA#) MG^'2I%O"%@8W,[3`,&Q#@Z]:+CR'R>3S='B=L"@"J$9T],ZKTH;:(?`9%@UH MGKCYHN,4F5,>`G@UQF(/*#2BHS8'LW5_W/2HR? M)WD$VC6F76A+%ZN>P;^76SI^DDTV4AI2N%M[8B4$R)ZI(+BR/[5=@WN^";DI MV"R'S9CJOVREQP07]I()DAL[$K/DX(AREQ3A+EGK*\7-/U.4CWT5Q+3'[>Q[ M`>02AS MB?7-V]"?M7+(:KKW>@OU&@*QIQ*&.H6$\R(UI/UWFJE_<]2_4Z,IK`RR9F5# M)8=^C04)-ATG*!JP"E1_.)T6=_C>MZ8M\GHTNBU.!Y)F5!;'0VJ/_Q,DE))1 MT=RH=-JANB?5Z0BWT7$BYV5U:-*7X=)BUZ6FAEF1I0:6JJ?"/>Z-:S06)SF$ M^O_M?6MSVT:RZ.?]%Z@ZSHV]1=$$29"4DTV5+,M9[;$EK2DG9S^E(&(HX00$ M&#PDZ_SZV]TS`PQ>%`F"(FAA:Y-0)#"/[IY^=T]:#\@PMK+EB/`#?XC%C743 M;W7\TI+*K%)*TPE/!Y!2%P6N9:,')?8X!@JX6GZX/WYX8GE+>=@NV(.F1)FO M?,^%S[Q^JN6+^UO]N0M*+ZC!7.&EQ(;X-"OXFF+E@>E;@?;>@_^HK.SCR?1] M*C&17WQQ,OU*@Q[IO4X:1#9/.$^"%5-*M#K#R]*1P[R^!IMDIAWKQIMWVIFP M<`4929LQ661R+_T7SCZ)_5!J+2_R0#<2<DOST-U#D*8\B+C.)I_XULLE: MS."45JQF7B=[4W8N#:O8*`\RW-&/EVJ1L<95QQL6/J!-J89O>.H9D\M"-NFA M;J@,$?](7"^6)UTM'>91EII=6,"E8>P$Y7P;5<\52P'XO=;?Q-9@'($&PCXB MF:!:\T(@*E*!,JTPI:V3V'VT/-48%.QWM=?^-YI@WS%DA<`*1 M]DM1EI(MX%"#-U+H,7HPF/EVS*=(MN7>56*'L">.9AXSQ#$Q(L3<6WC0X@&? MUT-E"IGR9?M`::30EPSA>IKCN5A\4+Y\F>Z,F@@@"H<+T&&-,3GR3(C9DT$U&6&1M;(G!#:(.-_#LR06G`V3A30./H M(^;^ZKVC?RN*@'(G<3;]*:X;%CG0)[<^XXK8\^=%#=XH@C'1?^('/IV?GEU, MS[237[^<\1RIAA96<>EC1J&'^8+LG>MA-924S24^._YE+QE>>)8"BBRL_=DK?`PA3HA)@>/-^QCA[@>YFB#P,# M7]6N*.TXT"Z\KC;N&$/X1]>5&-\)4$Y`,YZ+)%+.2F0>Z40[^[84]00XIGA* M^V<$>K[VJV-["S-(Y$A'3'0\,#JC\;BCS(1YI`L30X8G,]LZHIX#VF=0@^VY M<$3`R:5,R`\R&W[Z&`"#S(X^Z0P`R",XO^G!M=?O66AJG^,Y1/+A%8A/]&Q^ M8M&1^$>[!JZ)O-_B?",ICSE]!"7',8,%C)%:C+H*X!L*3?,U&:-^YW@$/`79 M()]8IM+^RP3>P##W^>RK,*MM`)Y,%%X*%)%MI*1K=N(GJ,Q$I`4G`HIR-HA3 MQIGD)(RP"N6.T)/*_25S*9O^''2$3YJGPCQDD]_C?%=X_2T`"JC_",F!2YU[ MEDW(IU@<[4RI+;$6^FGJ0V"M)"G/!'4MS7`.&/X.?DH,X M(?;>ZW#E<-"C/_6.2#*33BCXMW1+]2?R&\K&E>.(-P?=HJ50-DGA64P.8(#% M=I@6+-0?PF:'.[]X_NTC("URA=8I".$)&,2&MN\]F@Y(U3CS!`/CE$DPZ!H_ M2'W@UL>DC,!$LQ_D[HPI"EF(O)U&.91+.`A0:A)T)``07\B5?(*=]0 M0IS,K1+B.V9=6-=#[OX"(A$CJ43RQ+ZIDQ)[0?SRZ>3P2'[4;'I1T M$PL_3D]T,$U*%&!0(#A5GVKFIG@]XQ>3`T_I]P;]-S6G%*P6*;LI?TO!DK`F MCE`G(:B(B-:]2-4XJVYZ=JH[3_]>"#AJDID0^2*ZFSPL2WZ.9(*;Q2SKLOR"5.$5&*K&3U M$:B[OD4)88\4H$+M:([:L.*54S,ES"A(VP1H(\GD1V1.@KUH(I`83Q5@F8V: MK8*6$.7A/2I,7E1EMZ120BK4]\9*(/[*2')L^:D'_-\2O_4>T+V2->%X4>K" M4ZU4E$>4G2@EPXT9)$5DL7`0/%M6G?HEFI"H?:,\(IFXF5A%--BE/'=\<).LM:=`2 M;@GABE[!<>ZQ@C6#X^PU9EE(\GTC4^OBYTRL%.=^"N$>B-,T2W.7!3)+*)CB M"D4DW"*Q!(F75!1[PP!2+$?[PNDKA45P9\K,1UD-BR47Z:I5XB*\&I:'RURF M1,%3<@5=0V1E))7(6&FZ$USM6!M%!9RT8+F(D"8NE4T";K%!4"`R2!:C)`% M5;3XVH-)%OY=QM$O:JIX,0%YJO$1X?=,!5Q3`04T5NU@%@6()BF8`218WJ$= M)P5G:>]=.;U4D>IVPH8)BEI?W'7-HY%;O<'GG:V0%YB_JG,&L33WHBB-D]I4Q87UPE' MRP)&0?LSH/89[E]1UO+DA=&=U,%*:F@L4493Y`B0E31T]`1$8!+S4=;PY(L8 MQ+FVLB2=*ZM)46=1-:&L%713NY=I#(\J:E[UC4FG=ZP+U[#/1&@K2!(6'D0> M7\#\>S)^XH5B^Q:BJD-V;L2%F7::?ZG=;J@7!X'`P0HQWN&8O%[8R@XF]F9_ M=@J85N(9R16ZTJ")9ADSF9+1"0-(-/-"+Z0F M&>0O)$>>0B+)W.I2,3;DY.2PD0HI%06-"CKP[J,YWU!ISJ>]_W+^X=+R M^FS:U(#1=A6LIF*1T`E7*EIO>"TBS[;,>-35.L546'^K2E?LIY/S1Z=*(C'+ MV(JX@WC)[]PB18&,)CXP*8B."&Y3UK8[D2%"-MGHD4:\4+U!PBSO'L5F-36K! M:_N-9O3BD\=_QCEIS.(A`X[$V')'T>?8H`=8I65S>?\Y['(1GV(5V.1?>VW; M;]+,SL38L9CE_.J2)!WZU4+S3RR"P$;/(N(N"AY2<":!QI4S?)'<=P]VP%(= MLL2B0^PU!FL6T2:I_1?I&EG6ZDH[(0UN;K*!^%0@/>B!W'[4?O,<4!$T><>J M)BY9U:XRB(!%_Q5Y2@LB=/`?P0<>&6!^W&>(0R\/ON+=23#R6I4`&ZS:P9V0 MICG4EP-XK>V_TH%[))LJ;D(@;K(C:H_\^7*]^P^%RBE50LGH1T MRY\&`2C3!V.,%#@\%6H*I?)*`<7&!)N#2C=IJ8#P9!3OY5"`<90Q9-HJVN]D M"[JB-Q*^Y5"1'R^GPX.?/?1Y"1^_*QKX4*LIXE@/O`?Z"L:JB3;I)?'*,VQR M)4>),<@D#;:,@*%'MMJE6/"%,"/PWG%J"F`MLA%2LH_@2O0DX9(B8F] MHX7\.&4.SM/@$J`FOI*`&QZQ_?0:UCH(5"'%$Z;*$:'01;^;Z^F0T,7A%/S^ MCCS'="(>U$]C=^HWRL$86X4"1T<`D.>)AQOE_%FJ44K$1U:`88F5@47G>`, MVT?WR"WV'"6MR10KYK%HJEW#EEQ1-DA6)G?3,94%MD;$8^:&4I=!`2)E.-W& MVQP9?489(8 MWW8[0@?8=ABP*.W@3]`D&$NT3\K$WG9DO3LZ_F%KI)$I2+%8^_\`=/<>EBZ3 MWVS;H<>3[O;KHX@`F2W\NGI)`FFR0A-&Q!3FA2(MU1MUTTICWD65SP^_;:8NH)ESSZO0X^8)=+#CXR`"5%+T M5NW,L)L6JYM#0U(L=:#E@0#N0H^]H.0@D3=*\3:S02*`**F,=THML7IB4T=/ MW`!)UR#NHG<>Y5G)V3R%PC]CQUV=%#ZV(O>TY(TRVTKZH%2#K]2N+C'>R-CF M[[/21^.5I*DTHPNDU:.RO6RK(878/JQNA:?`S;2VXE.ZTSJTH('1&3=8":I7 M^VG5DY>HGJ3/5:SXKCQ9=(T!BL=4W&`3Z2=#N\!R6)A90X&R5+:2PU*;)IW^ M\=:7`=6C->F]SJ1O[$!K*L/4B]*?KE/IJ+Z2CII6`'BTC&=$\,P37MI7[N!` MY)>!&(`['':-'\K;K&>"NZG>ZA_@/'^(NRMP7E[\ M=O;E^OS]IX,)#%>@H=,DQ3G7@@F+G>*8HVBH0]5,,JC,2V[O*4=;[<66#39O MS4?&_5'',+;7D+!87@GE;]^*B[J2[(BX[E`_YG6'VSN5BDD5,4QF-#?D3%''[]C,E>;U M8RJ$++)&D?!"T[VEH421?/PG==;)Z&C2`L0>12+],[<8D1>ZD"%!BB!+H]=- MCA;E(E"Z=YPI3YWK9"`E!2QU'4JZ37GK,:S@P`PGBW>0M2+1L[;,1,_O`]Y[ MU05S.`G6:Z@_]7CD.O^\3%)4,[4*;A'(7#IITAU&@KF0AAS80%M=HI[&M:]' M:C;9]/KR]+__>?GIP]F7J=*VX^S?7\^O_W,86L1-93Y*8F5:*%::O^T-=WLI M+QC1^ISC#M;HT1"G/O!;W%`(RQ1:AR-DKR_$(^!UL2\]5 M2H;2":$R+BOGS#HGQ=`\:!Q$,K]'C[,%9VI/'+I_34G#%J/"'M"SFKYJ+1M' ME#/5$47L#W%U-;JFBJ*`1RD_6.R715_&KE\:_BK0Z;T;QMNO MYB&5]B"(]]=U),2NE:VA:HQJ`6H]CH31I([%%'@2^-'!4P.8XV=$8K'0F2!: M''+T%]8/Q06L:[@7TEV@E";`JP/`HHLS9>)+_2]IOR`O0HGKF:I[S';AZ&B2 MO*+TE`,35.NG?\>MGQ.3O6^(JF+X..(\/4(89"TV#IATPK=ZK`@LYSU?[DJP79?=Q$IQLY;KZS`XZQ4%O(`$,CA;% MOL>354IAN@M^GV1Z,DS^$*A4W5GC^=RA>>J5\H.32G26/7/6.P$EV9V[2US3 MQQV8I&Z-4UNE<9;N,A5->TB%S\@3(;MZD<10.7,,T#RQ;I&`5KS.ZR*JOO<< MT&'X'0*)^P1DRZTG"P1<0;GQO@JJZ^6R^3YX`H'G_2EJ5*RUY>7AZ#L;TMFJ M>M!19V!,\)\$Q*I+B0#$(ME3%$LPYU/O'[TGG.=@:Z:*F;^G7P""K"/X0$! MO:J22=X0[5+I=W\XRF8UK\@%&,"$:KB%I'5I=3L#PV?B.Y\YF)*)-HJ8HV[ M//JK71Z<3;G%M)5*@:>">Q2&D1/**A!>LDS6D&A*EECHN?(Y\6ZJ,Y6JM2*# M$[N0LFM<)KAN\9QQ[[HG.M;?4P5B())B@G>DY?+:7>E\$8]VZ%E1F(N.]=DL M`DB_':"=1QZ9I%#2=;'))%U7H[8K*MJ+JL$FVNMO8BI=T5P3#7N#]45+886B MNU;P=`GU=/"PO/$?KV*2@>Y^BG04A]0K6)"L_$GZ1L@*:Y>R2F3#EGABT3L_ MV^O)\^.K-U7J*8!0OT2W5]40.\XHKT,'`;8]K-_KM5('>3I[2^SOI>1N#<9; MYT9U5B1OU1`\KR5_*ZGY,8&G`E.]]3U@T-A6C(I<';J-3?8TDNPYY5V>I@ZK M$`:A1]*`+9:.]\B$9Q0]S&9`T46\\MCD'2ADEW@UO#>+%G2%F.I\"\0M8#RX ME10J*:,*]BN2P(H,T3BCSYS9Z)+N^2>O(Q8?;._?9Z9W&P=#N)^9S@8-,,_/.X,=N(=+J.' MJJ[A#3RQ9:[AP]&7-W>DQ$E&0U5C3(MY1474.T^HAUA2+'0,A<7P#HU"E`?K MZY!9CYU]6##+YI<1HWZEJ'8YC:YDMA5^$+D& M=,8,C#[6W]6K`RASJ]J`D.;ETECOCHP?GI"&),W6ET9Y,?0DTU=!%,?Q$L80 ML^>"6YBV9LD4W8O52_U13PGTQ.,#I6I$JDHOQ]1%2?2F:BYJ7TD4B%\Z ME)4UD][/L@7#28U";N!:MO!CE)3O\^N%Y#C"(LXYZ-R(?#:*$!52-7$'=:J93L1,1:ERLX.^#TDP(VZV@=\`&/3.I@ M0C&A3Y:+])4M6'CG60IQS45CSK2B1,FF:D9_>E!;-MG!Y90.R3,*U&3D!+-= M$GAT$8/HS2K:!*(AA)-Q,HZAR*BE9I#N2\'##XNXK45"6PG`8QRD(8^F'CQP M)'_^_J\U7*N%A8KR8L3%YU%IW"-IE-=6EN!+],62/LI=BQ5^F&^H#ZF0A#W^ M'U#K'4?8$06_+#$ZE?NE@!J2;LE\EJ,9;,UZO?ZJY:M#S2A?LA1'3S:?QJ'>B4&VVNDPWBH@'XA++G!0!8%&5Q_] M(*B*FI5*"A-[((4:IGI:R8TJ5 MS):D8/)*AQ]$3_,W^C;T6Z;X$BBX5XF$>]W>H;(_=,P\,U:PCI#5J!V@K4N@0J')OGD:8I>TKOT1%+W17$ MOVN@T'T^G:$V2;H>)1-KVY*0^1@MTK827BW2GAUI.Q`2.US]R^+\J6*0%T&- MV_#]O;&-."V\Q=,ZK'YO>#(ZPWZ_,WE)>&JY>W.Y>RK+\^60Y$&R>+TC&DJT M>&HTBQ=A>4-O-?B6QS>`QZO-G[`_Z]]?#ED>))\?CT:=T6C<8JG17/ZE(>EP M.?Q;RDO:W;Q-2'OZR;*#I6,^9N[9E1).'7/5DVW8_T#C;&TNU(IR_V**WSQM MZLE$_984=R0IFK'1C-G0,M7OG9)?7"[5!NPS3KO:$U=L<[#:'*S-239?_]X* M\E:0URG(F^L';(RP/P374IO#50_2UN?.F9V6=,QH<[]:9#?,'[G+7;]02;4^ M2%/I:9N349-.SXL)<&V`WG1:VV'C]U!$X2'013J-KJ6+5FJV4G,#D.;3_@[[ M"+6B,X_C=+I@B]_O301FT@Q?'H*;(\M:GV,-,JDX3?'ED?7W+I?4],;#QFYK MT-5HZ+=$T5IS^\_E_'X'_/L)MGQF@?;>MZU;?@UTX777V9M8`B8>'E*7R=PK M2BO"H/"VZ-*.P*F^P:=FI*Z+?KKU=6G ML\]G%]BSW>:0_*2O)L:'2' MAY5K&6Q/]$&<:+VDC*)?95=&]WARH'G`57LJ5K1(AFN[+IJ3'*G71RE] MO3MZ:6F[55LGMF*CX6+C7-P1]'*$1J7E#[JC?D.R#E]M@*I*#%[O=P?%%3%; M5VSL`!S#@=$@@7?86:9Z4S)K-Z'Q424:'W6'.ZI*J@P.\2V7_,"G^ZL[DXWT M5@Q_1V*8;EL*S6]L@[Y>ARZ*=V"_'50;J9&G@Z=DEOSTTF1)>\MF<^3[>3>W)&R"GCR[\)[1G9H(']9;E8W[=(<6@Q57*R8KQ;F/8-*P:ESDS METN\,#347NF4RH`75"\T-I^+6Z'_9;H1WLDM+G96U_M/[X'=,[]3",2%^0@P M^"O"2[!I>0C)U/)\?#G4;DQ^GSDNT@/Q;B-\^=WAL-1R""!6!SW-,A\#[<&W M@2Q"*\4YUO#+5U_`^Z07`XL9V'#P[ MYL*+8.*;B(-Z87ZCGVES,R]R@)X``7=`U!SK44`7[KJ/VBT`Q.5ST(2O=`/3 MS;O:AR1!8+.KM1]P[;@PO%N[QZ_5[E,.>_96[2@&P%/D1\=6S3+:\/!5V,P@ MOYG!H'/<$SO2]7%GM/&6MM[(29B&."WF#`'NECXMK.\&M'FMAV&%K?U M6H:UK"6+J,QU[>9LYD=TZ[K"!3:XH/W&=.CBZN".L1`YK)1J=-FKJ=U[#AQ0 M9%86,5\XZ\!!Y@R8GA4QA6QB1MWA'^FX@C!0R`FY-MX%J][1C%]B)=`"+S*V M0V2>P9TVAZ?*KH@_>($*(FG*EF$LDWIT8"E413A%,`%'#."4!_QBWCGP6'?& M;Y..U8X-A/%[S_0M9*.VOX#G4'QY()>(6-*#2HF6!_Z&FTQXH,(-TP+]@2X' M1ND(F[;I[F84(TA?>E_R-[DW,P+PPX)G\6]`JRY[,.5]TD"*#L(+AP!PB6O! MF4U74B])Z8R6<#">%F\YM<,%DH4W33[O4>@=\07@C=4!J2G\=NHZ9!YL]29F MW(G`2XD[>`A6C?XX"L"^5E.Y^#B#B>F0\Q5&;P<.\$+HQON$QU& M9F0^,M/?5KY*62X%K+Y2P*KK4E&TG5B,UP#279=R<6S@YW46HCW% M=7Q[D:F#6M:2;ZBYZ696RF1?F+J:-=\\ZY69D1T6<8!/#T4]!J2V.)S*C&MRP6_@W M('WI>_>VA>R5V7YBZ**X$$8M28.,V)S#,.@"CABW,[U`,9+O0-[?,(;G8X;> M,@MM>%1;!'NTUS\?B4*D,$H0Q_"3.&5@(ML+_FRR)EQ]$`'OEFOJ"/T"1O?Q M2,-L-"LH8G9(!\*"#UQ+(LL?U@B2T0Y-IUNX866[J-XDJT@M+F6))ZPD.:T! M5C>@9/9RO@)-I>1D,I1KKX9D`G-Y=EPH6*7G8FW)W6WJT4A.]O3S:?-/<@4A M<\I\5"(!9\3/N2E@V7!Z0L^/R4)1;)ZJ-]P\V M$K)J%'-`*C-Q;.(U!WQIDO!B@CL,(LDXL/L%SH*<8YZ.!?P21,NEYX-)1P"2\&S`?A!O9 M+>5FZZ;(+S#7MP;X9-P<0U8_-CJ32;Z'^0Z1GQ'%@*#,:=MZ4WUCTND=ZUM# MF(?Z'-@6-Q*$"5W=@E:W_KOG_UED(>/[XDQ86??2*OTXK=_$UEHL9A*-QI+A MRUA0%YY1>).2"9`'LV\A0RF-P4"TO,6VRD17DDFP05)`NA#:6RSLD%9WXEIH M:P`D&-A:K&'Y!%44ZF1O=(A3N\M#]-!2$CZ!9+\E?MO\17]$/Q:%_S%*#?^E M4X+Q[1M&J:/<=P8_.O&N%'UUYICV(I!Z)IP6VT6E90;G)"!+7(9/4@80-W3H M2(GX.>FW8C`<79W,MP-8U<)TS5LA.RD>+1TCPI)>:/:&%PTIQ4-9@P!OB;K@`[C"`OU(G\Q/D#V=%9[ MW+(#1W.;;>B#7M=("EEK;[=A#*M4=\":C%WT7ZB0#2\3AK?/A3]*' MQQ76K^MZ=YS0RF%4W?\'3'^-7S>HQ(Y7@&JKU/D&4/O&Q4QQ.X+U2*=2(<1. MFJE4*F$R:CO..M8PE1R')I;>OBIR.]?]J3!+)_DTP224]O"E#I^AM:=OB].W MM_,$ML6D)>:M::*EZ&)YLD6O&LN+T'907NMW^\K(&W>K.51II,@E?8(U`CL[ MK48!="I5`^Z[AB]'X)4K+Y^N!MS(%Y]RXT^CFP`+A=SP#-,ZGJV!:=[2*/3) MD^?^Z('1.;OQ'$M][W^C(+3GCP5Y$HX9F^W_7&6$-UKO9?ND_I^>O;O MKV<7U]K9;_#O:4G`I+*OHNXMUM16==4&Y'^Q=\3;EK(OZ&>03,OR<'D*DM>":"R"GAV8/PQP>9EM3%BKMT%@G\ MG`YP;39B*JU1N\7[UOBJ3`PJ07>VYCFAV_6H:2&")_=H?.2G37SM$+ M^=IX0[F+@690BAQO-"RR7Q8+&"R@^VG,D*<@,7]F!ZRT0W%'N$'EG-S1#QNU M-'L!_[;-D#F/VCT+8-EU^`A3V$WI&P,=/57/2U37:@H:9N5DZEA$G6P2P)FR M6>3S')13M68IJ4*\8>$#IHDJ:.](GS&F(-V1:QG^40B@@X@.(I-3%\>(2A]$ MT.ZM>9LC:%'$MY428UJ4^*2E,#^IKT>O1$.9LJ6]K`5-9,Y44O,Q0Q$WII, MM16)%2%F*\W\R`::TESV0)6BB1N9)_5)",FAQ-DI.6??'25=*0CD:-B8&`O6>*\E)3)DHF6%&*J^B MC"[8U2WP#EQ_WZC,J#H$E-A<]PL6KA M`D$=/RC#J2G:-8(_&710'?B)E$BEB3A4K4&Q9[FZ!QN^O(&5$0:XL.`!8679 M%&8F&!1VNB_5^5*:X2?[K\B&S3WN*IV#[#*%!7!C*L\3]#Z9:JH-C0]E(T&9 MM]8+(?52$209>?[50[($OC)C/F[UQDGR%.1,\-HW+Q#X),#PR'4JKL-28)V5L<,99$.GLP'CP@RSQ MM"CK>0:2_=6HT]./.\>387$"\T>>\=XI'C2;XL6;&O1AP-[`H+703G#F!\__ MDP#"*U'B!1#;Z>C'DXX^/.Z*A/^8ZP>:;R*+"H!-H.!#'*$C),3$^RBD!9@W MMF/SM))5&#B82+=2)[I.KC&0,5:"\HL+D:24VTH"[;5,;[]ACO?P!O4$9M_C M^"X+,8T'RW$)M:]&O5%GH$\T@2R`QDGQE9(BB##WP!;VU!R4R;+RKR70$RY;R?X.[WPONKU#Z841 M?GX`*=&0-S*9@VP`\LB7>*$=)VYRH34^L(108!F4X:CN5V:>.S8G+9K_B4R)'FBU,*T:/RXWD.V/2A-74[@JQ3,QD(=LSKDTOYD MCXB\.>@_]%N@R:H'!Q0P1V9RB30@-''P%,8+C),Z38&!F!"H5I-4))6*"'^\ MSE+9K4_',1Z4J_V!DC(JN`*'%L__>I39HJ@TI/+%[FR'B0%H:"98L$05*5/( M17C.DLI]+18`4V$$]7!-C*P%C&7[._"2]V1#GSB5/!MEFTC+8"9Y75BL"!7 MQ;%,`KB25L?M_XXFLGCDJ9%]I@HD,RH MN.J!B'LK`*HHSZ<6:^IY.-JU%[/Q^/Q+.?`$'TBV[6"Y+QQ=_(!PFMN\,0&` M^E:D:Y&"*P1X0B6*"89X/?L&"K-[2[,M;#H_V92WZ=FIFNF6Z?>PI$JBA"NF M:]K4Q0?QS%TX2`KQB8X)O#^"4":`0($(L/(EX9;2P$$Z`VX"9@+Y903LL+Q9 MF?EPZ.%QSFM#TPVB"@E%*7X1Q11692$._=-S,2U!=PJ'S!'VAB==.L2 MSGZ)=/)G$!$#.)NE$*&19E*2SYM520MU3V!#"`N1H@A[0,=#+%M$F0%GW,!Y M>!EC%$:^W&9<_X(9@[!_J2+A)F8.T"$8F[/8TP!_,[X5RG"D3A]!P;/$XE)" M$5''^WNA12P*_?&DR`DS]9YKJVB)@;C*]$O9B.\%M#]0T1PIV">N]1[;G5S. MKY`?N]POL\="`%H-`D5=SPLRVAJW^JTL1'D\95YP)+2@$]_WT&KCKCWX[N'. M0P^)]X`:+9HR0-"8^G]R<9[UL=CHB9[)XZ+4P"CV*"C.V[@Z"I8$F!B%OT"6S%9*:"0#DY0T3+`V`8ODMUC+;(J M"5Z3RYA;6V@"N51D@0!#MA_YW&3#O@L,2YU%XKL(22Q!F^''.$=>!?)E M[!F1:YBOEW$O@`#25P+")OJS2`C>QRTSY+"Q#+SAM0(4?I1SH2TJ)A%YJLEQ MV:19Q9[XYO?$Y2.7F!@_<6N?O>!.]O/TF2G9[?]&+@]\90U159V4LQ4.JS*\ M@!NH:`>54DU<8(Q6#X^$G``K<[1^CH82S6ESA2BE3WT-V.7\3/2"";YS+_M7 M7H&7;!N0V(9+S+LB',_&*[LMNWG,Q#W7"_6W>G=S)6N6!GVN^-] M7;11STU>O?[!7=$Y++D,:%`%@497+[["KK%E9;$Z9O=+L+TEJFV%C$YJXIJD3"O6[O4-E?U;NLMZ")791;?@<4-&DON6[9 M42M0JPM4.#;/(TV?I:YR)U3^?#I#;9+TH&[>?+%(:\I-UB\1:3L0$CM<_![.21YD"Q>[PQYW4R+IT:S>!%#-O16@V]Y?`-X_*GGXI75E'AOL9OP M[R^'+`^2SX]'H\YH-&ZQU&@N_]*0=+@<7NG\M9-YFY#V])-E!TO'?,PT1),2 M3AUSU9-MV/]`XVQM+E1R>4WNSIIBBM\\;2K5W*X-^3ZCI&C&1C-F0\M4OW=* M?G&Y5!NPSSCM:D]7#]@8X3](;B6VARN>I"V M/G?.[+2DDWB;^]4BNV'^R%WN^H5*JO5!FDI/VYR,FG1Z7DR`:P/TIM/:#AN_ MAR(*#X$NTFET+5VT4K.5FAN`-)_V=]A'J!6=>1RGTP5;_'YO(C"39OCR$-P< M6=;Z'&N02<5IBB^/K+]WN:2F-QXV=EN#KD9#OR6*UIK;?RYGG0,J]X;5WNRO MI)?@J1G]/DKIZ]W12TO%K-H.KQ4;#1<;YW3C?!"^'*%1:?F#[JC?D$RR5QN@ MJA*#U_O=07&5P]99^#L`QW!@-$C@'7;FH-Z4;,E-:'Q4B<9'W>&.*DTJ@T-\ MRR4_\.G^ZFY3([T5P]^1&)[A7<:A^8UMT*OIT$7Q#NRW@VH-]%+$4?W65Z-8 M<174ORB.W!^."_:D"-^TQ;D";.-^30/UBV(&508:U;4U?5#7UB8U#30YK@M& M5<.S.&550U6).QBV!*!=$F3__V@LT@*=.$/>G#XPKKUW6].TYHY3!<[DH.-H#:-[9,XMC">J132:O9262TDCUBU':<=31(2HY#$_UHKY+[ M,7?W25O]\Z2CKVR!^Q(/GZ&UIV^+T[>_ELZ]SJ0EYJUIHJ7H8GFR1>#9\B*T M'937^MV^,O+&H>=#E4:*7-(GG>,=GE:C`#J53/M]&^0Y`J_L1GG*M%_#+"VR(#B9_179@8V_G]&=ZO8]X^\JOZQ8S!\PD*L\>G3B^Q[>%7]ANE[(9G>N MYWBWN+8??_F7Z4:F_ZCI>D<#9:&?P&^CU3RUCPMS(5_PF<5A4],.Y$]:^K>. M!K]VU?ON3R[.E9ON5VZT:+E/;?$#"V:^O>3)V3O9J0GC+$`(/&IS;Q8%8'(" M&7A`3OC$ROVL6!MM:VX[[[ZP>^9&;&J[,P;3,7I:L]C,7IA.\(\?SR\^_KCJ M!&B1:_,?ODX__/A+[^>WI:/&S6;2('"`JZT/D@[SX`&\YWA(/ MZS0T;]FJ99P7SS_JZ&KZ_B.\ M_)OI1%56UM>/>P,CP==:\\0@>^_;UBV[`-H(3FYO?78+NYEZCE4=4^,>_H\# MJFSTHNDO6'CE>S/&K*#ZY*/>:*!/:/NOB`4K6<+J=?[R MWC%G?QY-9W>>`P/Q2GUMZ=OHL-46GL6<9-7KKJ=X$[#G:,$[`9Q]6P+O9Q:* MU&T6?V7\IV!U)1,]N:HO=O#G1Y\QF87V!>AU?6)OE% M*UH;N+]YP)QL!]CRKCDU%C.`#NPGQ.'B1&YXL/#^T_X\]P8^& M/:.4)0R/C:&>XPB%D]2TFM4,JC_.,\?RU=3.J:[,IWG5P!COGU45+C3#K)K( MI8K7W5@^]00]'!*G6G,K6_.JHGEJ9EJ3_G&?:NXF-Z;](TJZY-0 ME]H8+T.-NS'@BQL@_]I>,/@>R`U,@2,1,`.SLW=]YT>UR"^35E MLZ/,5'G=M3\R#(4X5BPSM1W\XMP-0C]"5J,\B:%F#=+VB`<\V+?#0.%Z`(!M2_ MR0RU5]U!3ULRGS^FO0YACL0:3G:H70%39HIIW$W@N3&<8 M[7Y3GF_?VBX1^M)\I.P4P)0,JNO'Y)_2RS:E+C1FK)E)+J,P"$T7'=+K*&'K M]:U%YI.+#$WX-33\-2A3G!'IW1DZ'/> ME=$?]E3%IBW8`^+L%DZM3;+>$DLUOOX0-^4F.<8"1/\I-FO9T;C9;V4XYFQJ/ MAL:*Z0Z;+M6F>U&\O@3C+:]?Q6R*85:!V:PW4,OK4^`O.:N;@W_-@?;! MZZ69>&7:6\1BAVKRGSIDQ;E6>;Z,D;YB+O2'G.V[ MP?M'_OEH^NB&=RRT9^:GT,JET8Q'TLM8,&/UU0ST7H75#)]>C00:#(?&WY7I MXP0F/#++9=0JWZ\?))NR9<@6(DQ6M`.>GPMT'_J>XS#K_>-[S_2MTSO3]A>F M^^,OYZX6#X+!L5Y'>V`:%:@RBT>(3>U&9`-KIFMI<]LUW9EM.KC,(')"#(69 MMSXC[Y3V8(=W\!P.(;.6^=3:S2.%3VD!VDRL0)M[ON8M&4]E3P\:,/_>GK%` MB25O",ET5#)BUYXR`!SDT\CWV6I!NH)8GP)N+BL-5#RJM M^@L+F.G/,"=9R8_>W$U4L/[3Z>?3W"(GH[ZA4LF*V>M:9^I8KKE.?=CO3<;/ MO5#5\%ESH9-Q"NO/LLZ4T%X7H,?&!!/T-U\H\&R4S<$5SQ.HDR\4+;1O3'K' MBAQ=9_ITAQ!F!@RV]86ZBFQ\DK+K.1X.%+`5#K[M]"K=Y;,=CM64J]W,OT)_ M&NB3R:[G7Z53#7J#X_XZ\_-\$%EU%GQU+>9?>.XIB&`@&:"<2RX[W5L:8V4< M^[Q0A_B/?T:Y)2)+9J!CLX49/CRLN+0X?1 M3<#^BI#AW<._%*5H9=7A![^K?0'-SG.6=TR;/@#M>6Y'^Q=\_6`&&G,H.*1A MKB`H9$R#[TQMP35&;ZYA2B#7Z>"/#[8/3WM^H`0T2U=%BQO[? M/_Z"=;W#WF",!RQYC8_Y5AGTYR4%0N4$+B99A;]@`>.1WCL:`+.6W_%7D\=_ M?BM67;`#KG=-P[._T!P(U!C[[O;UMY\#=HL4\\O/WVY\Q[+?L6]+!\O5/G,\ M67!@7$Q,C(WV=U,P6DEEYX%C7*WG4M78-QL,X;BR+%D_'^OGMX53_/+S6[F& M]2$]J!/2)U?GIP<%8C(=8=$-A^L7%II@_EG2N7%0,$X4P_0FF@CS??.]&JCF M22=*HVBGQ)O`UQ[_DAS6U%::2$&57$"'C)$G-M]_N8(WM#K;9;LK%L/?M]M=@*-MLMS<&&W[<%&*& M??0FU*IG5_QS?VA-";PMN$\F<[*UB9L@F$O1\M(-Z$8@H;6VFX&@\Y9K;6(7 M;:&DYB']TAG1KN#:\I;=&UQ5&_,U"1,%W?\4.B_;PP$S^:<:CC4!.=G6>C%" M\@MN])%H0=U`HB_N7]5H7!0M^5`(OP5W0^RN&GK.-`5KJ:TD>$OOR8MN[^)M M/8&^]6:5D,'4>"4PDX73`9+*&CU\FH/\YT7#3AAD2:^91L`X9Z.<.F80`,1Q MC2JXDX4?(,6OU[6H1MNZ-)IZ+%1I-D=8N-O4CN)[LY-1X-.]6<=IV!NW9CG<:CX3E.PXZQL78; MG48@HZ$U5_6%+^KNS-,$I*V(*Z8VN&TDL=GE7_L(.AXJQ30;D[NHJBKM`'/0 M^,`='*:^ODY;IA8U^S!LUVI$U:)F[W95BYJ#4/);G.RL9&*=#EF-@/P*!?T_ MS"Q:]X'"VSA0>!M[AS?V&2-@\PMAZ.$%OR+YER7\Z^>W\B]Z-9*7=<7O47^R MU&MVX`W[^O@=_/+DV[*Q&/X/8ZCWWG\\'<->Y,]8!H+E2UD':\G\WQ8.#.G>`O;=HZ_3'W_YA#V6+7&' M,K;3>Z4/C8XQZ/W\-K7(>G#..P:MB7/^\.YPGEO,,^!\,]A=^.?Y>&UY1W,]EVEV$$3,ZM9U^HI1]-0Q7/76,U#0>@>S7@K:#*Q* M#O&ZI[+TE5H!NL[""J$Y;,YY'-9T'D^52]/SA_$G.(TKCN-/6E_O#,9&9S** M?^5GDVXD\)(+LFL[JP6X>^J@EKZR:Z):[X@:S2$JHSE$9?2>D:BN?&_&F!7@ MO3'\#F%YG^KY2P\,$H;7"F>O(EHE'2H.6;/HV'YCA40[:@[1CFHBVI,0 MU'H@50T,=@UAL@_J2OE[ZZ&NU)![HZZRC3T#=>T,6ZF^=_5@*SWDOK!5NK'& M8>NY+Q,M1_(^KC6MC3;V",8"DOK8.VZ*>%&6LJUXP7N]097AWA4-VS7@[0\` M%_1@:TO?GC'N6I(RB'0?+6#BX2%=R95[968ZL\@AQ`2U*43/?4GL[H_5)M?5 M-NY850#C,QRK/9'4FE>!/@-);7`I:?-(:G,P?K[UIKLGJ4TN6FT<254` MXRY)*B,+/\$?\#4/^,*'_P]02P,$%`````@`S6(K17DK(H$6!@``[$(``!4` M'`!S:W)P+3(P,30P-S,Q7V-A;"YX;6Q55`D``T+,$51"S!%4=7@+``$$)0X` M``0Y`0``Y5QM;QHY$/[<2OT/>^D'[J0N"Z&Y)E%S%2%)194F")I>I-.I,KL# M6-VUM[87POWZ&R^06\B^T2;%<%]"UCMCSS//>#PV3MZ^NPM\:PQ"4LY.*O5J MK6(!<[E'V?"D0B6W#P\/CNQZY=T?+YZ__<6VK8[@7N2"9_6G%GA#(FP)8DQ= MD%67!U8D4=,Z/WO?[,J(*K`D'Z@)$?#*:GICPK1FBP=AI$!8;<;XF"@<6K[" M![?Z"M^%4T&'(V7]VOK-VJ_5#NW]6OVU]5>G#>B^?/GL7"QW>2+BE,&@OQNG/[\;+GCB`@-F52:50S14F/9=Q^R=T8 M5XDAK4P)_60OQ&S=9-?W[4:]>B>]A*$#ZM\/([^*4#O!T4ZKO6G4$W*ZIS5= M\$!E[H3ZT=&1$[]-2F-WGKH73_9^X,Q>KDC3''/N'8MD/INQ*;@/71A8^O.F MV\X&[6@)AWKB2XLS#Y@$#W^1W*<>4>"=$E_WW!L!*/F!L(B(::.NE6\8B3R, M(V_/BM$=JVD()WN2!J$/B[:1@`&VX:#V8D#-R,L?&L_Y#Z9+?#?RX_"YQ.\S\2/(L+R<;A)8(A::8ADC$>YB&/PU#H1*YFR:2S@R"H*X M-QO9#1;Z`\&#!_Y=#,;7M1_7`#2%AWH8XEX83I MD"GI^X`SZ5J-0&"SB,`K#6CM;C8=@-G(DE&XOG?,+G'/<;O*IX";95_O\TK3 M6ZRW'7R6P/]4=>_#8X$!];_,(ZD+$A#M:)[N%O'VB;=Z'ULKG)16,YN2\NC- MSOFG@GI#N.2$99W(4MH.G/,3I7/UN"%<)?,5%JTEL;*QN,Q#WT]0W!@%] MTJK!()R/M!8;B.@15S(#T>U$_L=TV5/<_3KB/IHH];&:FA8O"NEJ!A&6B^O_ MMGR4=L9.KBF%Z'=E>]KT/#HSK4.HUV8M$E*E[4P_QLN0WB;F"I%OWSI:&G-Q MN6#*UK#%@X"S&%7NQ8A5L6UDY2'6[R@%M@?L.O7=&T/"L8-]`5KJ%49DFN0V M\I2*.)VDPUV(R_4K\R-#8K,+BE`&WCD1C+*AQ+(D"J(8R!D,J$NS3M-**&XC MDV7\D5&/UU(I?>NLXK_$Y\>Y7MI3:)>^'2*O!_J.PH7/)_+Q;I,6=/^S+H\6 MF+&9>7,%2MO2$7Q,$=SI]`8M;;,VKD]28>`T747'>0>>:W2PN5M7+H`G+W!2 MG='8+!4)N!ZEE->[)<21QOV!IG-P']!&6'N M#^2XM`X,R'&XX"A!^U'\ET&Z8:U\EJ=M:"#G$)F5NW)]9'B>2L"(3UQ[(R[4 M)Q"!WDJ68#A%:7>(3?.(Z;?TE\(R>2Y0;KHN:>P.DP]\8?895WQW)U`K_97^!W(9QO9W3@W9]S3G.XRU79;@KSO5'B MRXA-[NJ2QA?-OW39W2&O:@[?Z%_Z/]J@"W_`E!+`P04````"`#- M8BM%/L#.G0@/``!L]@``%0`<`'-K`L``00E#@``!#D!``#M75EOXS@2?IX!YC]X>QZR"[3CN#/9 M/C#9@>,D@PS2B9&CIQ>+18.1:)MH67235!+OK]^B;,>R3>JP*(GJT4MBRT7R MJZ]X%(N'?OWM>>*U'C'CA/K'>]W]@[T6]AWJ$G]TO$GO_=N>$`$;G$Z M%$^(X=>MGON(?)FR3R?30NO!]^H@$%,U?PQ=G_S7\-ITQ,AJ+UM_[_VB] M.3AXUWYST/VE]9_!X//5[W_L3_^D'^>4`A(T@[>'G8C]:H5@/XC9%!^_XF0R]?#RV9CAH1;'$KAD_TCR_K/,K9,; MTQB`,"=XP&UXBGW9^@QB5.6>'_-+7FT7#U'@"8.(M_,VBI=.$#%)\%;6!M"& M&;4G>/*`F4FH:_E&<"Y!;B+X(\V=/=CC$6_(_`FQUV9OA-0Q?<[?0G`62\B^)YPPP M3-7T:)&W@CI?Q]1SP>,_^P8N\^P4E'6(**:J9RRZ@KJ>$:$$N$#H42<*:\^3 M+C]E>U&N]J*C_A#QAW"<#GA[A-!40CSL8$_PY1/)ZF'[H+OP\7]>//[R`O(. M/7AX68*''K!WO*<1ZE0,=4Z@G.I17]+;>R8\";DR35215:WHL765P(U:YK[P MJ-8U2NF$+_,8,CK14KLLF*95`6;%`(=.)7#D[;4H@RJVF&W/_;4/#O4%5.PS M+\SE>(_CD?Q0E1DWU#@-G4B-^=2RQ9EMT_E.L%E<18R:4*.RWG1U-9C."_3F$\I6J#MHE-%M=UB*U_47FHM#3:F M;2]D2+POO<%%7TGIQH]VD[BIB9JV-]7U03=8`&3LGB'F$W_$8VNQ1MAN$R1I MJC;)874F`5TFU$_N4[;EZF$(A7YJ&_Q2G0U>1C68L^`+^)CH\:X$*X.\.>>Y M\!TOD.L_`\K"BB`$(P^!D*[O';VBOAQ/P;P`970!(RO#7&C5-))YI154;]-U M_]\,C=9YF[=C!,BN`R%78Z0Z.E-OR=7!:MO*&1QJU1[*+?+P]?`>V.`]T3TX M&&`FOWQ"7K`YLT\4MYCB9%4-CJ"9F)X;/3W5"_EZJ$$7>$KZC` M?R+&$,S6%:U((60QWSJUU%S^TQR7`P\Y(:S>"/[$\*D1M)Q3G7IJ7M]6UP]) M1PSQ<5\Z8](]`V!GS[)1Z<+L,0DLMDD:==6V>5>A;;``+YI.\"7ENIG4NDP= M++"NE)KT]QNDF]4%>5Z^L6E]-62!^6#_:!5R]2@,3\=[@H5.;7P<=H.#^2)@ M9T-O0/35_$)S']K"N4>?"EIG5F1?P3)S/(I=M@$1+@T<@!_TH MMX'BIYWW_\1F6O#&G[1EYR+K=PI^'%C(PX:8V4 MI"<(\_MP7I^?*V6N9;&55'B^FA5,IW/G$7FKIRL'Q\0NY)T**ZTN[H8I%^DW MV)/[Y`:(B=D=S.(YF&MH%]AY@9 M.?29ES>(I,*0L]4_\[H9'[" M.L0-H!>9+3,*P[8&JD`9(*N M$8&T$KH'1M@5]?OR6)\GL2R.GOFC2XRX.?,7!%JR]+",W!NP2H+]PYWP+"YVO%^B-W.NE:'+;3JEJ[LT`J3>1'AG'LN:[D M=%4?OTNHCDGFW"#!NFW1A1G.AL-Y)FU7\A$]S:DPQB@,X_@*^51@9^Q3CX[D M#GW]4;&$%)5N-$I=^5[.DB7I;UW[JNPD#/1E>3&, M0]F4SF]Q.`4DU\.U1QN@,R2T>"=;%O6MJUB*MG,V'&)'3NWG&D1^2=^)Q^1A ML25W),6ZXZ@*_%=HLH3-\.(:I_3F5*:NIR'51%AW?%6!_!1SAY'I/*:VJR7C M,JFG06-I27?.I]E.+(,7MJZ]&HOH%(;,WE6:[`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`U/N0(YU2R12 MAQ7.A0[87:DE'=@8HR:GK8DA4Y!@W8K)>@6,+@R$-3!56]Q.51.#Q2INW;+( M.N(!FH75*K65UA+4SD#KZA:^S+$QK.K?K9P@;#'/26HV*Q>EKUQLO\?&V-J% M/NOJ7M+S%UB_,`RU[R$.7F%(9VA415B;YU4"%9]/VAB MM8L:3:6H=7/1'-:PX=+/G`:Q(@PH;^:F?HAJ$#!GC'CRQN?D-)7Z6?I:M?*S M$I4N/.(=EGX]WSZDC[BJI"PG5ZF8P2A)8CV.6TK<$K*<3)5:U@4M:ABD#E\R M<@+MWI6O(8'.'LW-#GW`_/*SD]E*9#'9[3TAYLY=Y=5$F%^+,69W8^0OJOPG MS,-`TP`S0MT[*I#WLF-01TLU8"R>#%=M)NL\I9X79HY=-2-R_ZG/M6=,TB6N M07U(2T/AP\TMDJ\UN0>*>`A%M<]B6\9BAC5*&1QK$HD<,.)@:(_R2SR=:Y+U M(75=08,![41J5:./4J0^9,;VU#N%GIL32A6=4-H,8C-VO._50?J6_._33G M?IIS/\VY'R6KR^4K/9V;$E;SN*5.\0&]>BW'I24RPV)3% M!+IXO9&\:S!1-41BNMZUF<,:G,/>!M/I'`/R5D^OAWW$Q^<>?;KPAY1-0KM% MW@*_^%&=V-S%$$6"*VU[9CDZY*H$-]B3:W$#Q,3L#L9KCIQPH`$OB(/;"DVU M-V)X?KV8,>/N4FA91ML%VW<<-3`#54?JR2SZ2\SVVPP96!V9V(60VFW0C:H0 MNR54(5CU!MWL-55G5FMW[.8PCPT[=DU;R(J(RNW,%V,LB(,NA:N?NBJD*ITB MZ*O2R^15I5CAH92S\+W`,&0+T,3#[LGLA"+F]L>(@,/E:PE.E\YRRE,J7W@X MIKG'IKG'IKG'IKG')L7HAZN%Q9%MBQDU\N(D/-_'A M)C[;^'"^*5+_]F-?O\MN]:/EHO>D[X!AL^0#,YW&>9CJ5*6@.3I:,@W?2YF:(9G*+) MNTF("#>S0'.2:T;$'V'?(4;?\9-81GFO^\D"I2AF(YN]5D+WH!F[HGX?^0XT M#ZA-US";0#+5)4:\''OD0V:!%?,I\!W/TYLEVJJ/?C5+M,T2;7V7:/\-+O=9 M>(WQXA4%Z9G8KF?%$%YXL>./X6R-C,H]'C([J,RSO7HR]_0:C\\P`U#Y[\ M'U!+`P04````"`#-8BM%+(LL]#PG``!*X`$`%0`<`'-K`L``00E#@``!#D!``#M7?]OXS:6_WD7 MV/^!UUWLS`#)9-)I[SK==A>.[;2^9F)O[.D7'`Z%(M&.;F3)%>7,Y!;[OQ\? M*=FR)7Z12$N7S_[VUS_\_IM_.S]'LS0)MCX.T/T3PL'*2\\)3A]# M'Y.7?K)&6T)KHO'HN\$=V8891B199A^\%)^A0?#HQ5!SF*PWVPRG:!+'R:.7 M4=+DC/[BOSRC?]L\I>'J(4//AR_0YZ]>?77^^:O++]!_S68_WW[WGW=?S2Z' M/WUQ^^7L^N-]&KU,TM4%I?'ZHBCXV1]^_[O?L<)??R3A084/KXOBEQ<_O[V9 M^P]X[9V',+GU M+R_X'X]*AQ)V=H*E@_F[;](DPG=XB1C-K[.G#?[V,Q*N-Q'^+/_VD.)E?7-1 MFEY`_8L8K[P,!R#)-R#)RW\'2?XQ_WSCW>/H,P0EW]U-A)R].6B+5[KHBL<9 M3L,D&,?MF#VJW3'7\\Q+,P.^2_4[XWQ!%T;ZX33(O:L?MOB;GEJ^> M\.&&_G3`-/Z8X3C`0<$VM".9QXP,6RF@X:+EQ"^W^2R"Y3))GY4E\0S6LO-B M'6/]I"O=K\,DIMM5%MY'>(3OL\NW>'V/=S49R]\^DQ2\*+,!I0\823%)MJF/ MC]JC__RJ)LXD\4PA"6CP&>Q'M&W88W%\_F[^[*^EEA$TC?YQ^<]O+O8\],MU MMD.S!NLRM@>ICY(TP&E^UBCWPDO]X@/]4<%67N+"3^@>L85 MS=.C7Q38PK`-_H/$WZYQG+&364T_%@\8>3ONO76RC3.4+%&Y?ZQ3*-BF<,S- M:(4P#D(?UE"T8=O42Y?@KY):>0+HX4YG"I0/@$N/W#.VM^1\Y7D;.)B^OL!1 M1HHO,%E>G[^ZS`^V?\P__PH'[&`;X>ER$&=A$$;;+'S$<^Q3V6/!=VQKBBC[X^@=4)"K:?JZ3MO,M$+ MKF!2E/E">\90P1D"%*(2;U"IX`Y1]A#CSY79W.YQY88R#8B+47@$4A8V1)F?"!&8CO`S],$,# MGQY7MA$[6X0Q/5H_XBC9,*C1N_#*N:53+I%C5.F,2X>'#1S1-E??X1BG7C2( M@T&P#N.09*D'J_+XXP;'Y!@.#2N;'PH:,6D"P9P$6\R\`R*N@:Z93"I[<(N1 MZPZ4=-=?)_$\HUO[CUZT%<&O4LP8:"+"9@H.:!,1:-0U$(GZ>PP7N:2;`H-@ M_^4J>;P(<,@Q07\XA@+]].N8'@^SIY\H5'^(DP_Q''LDH0OGA)!M9==3EV\- M#FU63%#""2"@2*""!N)$7(&.MC0*##4#;JR%_P5XZCN%Q=^IG"3UOO;ZD M9;X4ZM#EY8T4DEJLF*`"""#,**"8:`BBO(T!9$65'78%#:(V7N@6;B M71QFI.[L45O$"`\B@D;Z*H_KJEBK9XBUZ]+0B_I<'FVYE*V]HTVW&;RW`ZK4 M;VGEPC;?TVJ8L/JF5FK?)1BHI2!YJ!*.17?WE&LO3!DV!_0@L]XP>YZ[D+R_ M3C&>Q!FF(,CNO$QT?]&N;GRO:G%6KQ64%K7TP%K/@*4'5E2T;M-`P`;O4A.!N@ZXQ+S6 MR_#N/?A`O8]2S%6T68)F`W3/>QI#3S_D_!"H"UIS_"F^'-=+M?[E6#:ANMN/ M;L+?MF%`;U$C.D910K;J-V!I%>-]1XI?[L M;1+R%X)FM(9TSO6QR^@(YGAGT1^J#C6U'GFXCI(/\^UF$S&Q>]&>/:)"GW9U M<\UN0T:-;E\E&FA/!%908`,!'_00M$S2-5MW70-G4UE5M,6M1K6/9WNR2.XP M2"2,\"W.)K&?K/%-0NAWZ,0L31[#``=73^\(#B;QE.Y7=,3BU<#/PD=FK#"X MAS<3/U.^^%LD9=%8P+X`C.P,]GS!J2(M.$.4-<1Y0\^!NQ?PYYA^]&$^;0E_ M*$X*[I"W8^]KUR;7*64O-F`X%?JZF[1CNOEE3V`/E,2T0Z-D[84B.YOZLL;3 M1LJ"D1Z?-8QV+;N&66G'CT&G(?SVM]T%K3!=YK9B3X./(:FYY]84,KKABHF: M##JT"D>"HEU7!EW>X_+U1R7G[A8'NJ35+6/78>S1):^\C`E6C`8-&"\CS9DU M@=EML4MNC76(E)"IH]F$F)&UW<6,LH9$TC>C]#>>.N8$;=_8,7-`WA=VF\ M2C#MXL,@#DH6G7(#0WD="Z:L&BR9`*H@D!M'[TBX@J=&@J@:LFH/3I2$]B`R]34B' M2J@BJR]M0-GX&NTS5DZ8CB&%[Z@].A M!TSF9>R18KK,;TP4_`EATT"AW=>J:N[]TH!!(ZNQZ>UH?#L?CQ#]:3Z]F8P& M"_K+U>!F<#L/A.99P^RLTP0*-VA(3*GXU,T>L( M&;GLY>TA:-`5;(@Z6K8V%XOTM`X(=WC%O*SHDN>MZ\:ZMI@%]X-ZPA:\#_8- M(VC9)1#(>EYU/9#)O,/#L\^LJ\C,>_+N(7(2,[*:>2D<\X?;-*6@%9VD=:J: M'ZL;,&ATQL[IH)S0&O#AHU8\>]MSK2I]V].D=WI#FC:,F4^??<4<=`D?71EMIG)J,XANBUP M.U6?^!@'!"+IC,)'3.@QA_(U75Y!M%I,"%,<%EX)9!(/EG2E">F.(WHG-VG1 MAO+%M#M&4QE>ESW_MVV8H"`G!3C=I!C>EU`1 M:3ZW(V`'K)+W#P=:'K7L2..<]HB>(X^6UR?!TZ-&QWD3)$RYTG"5K%KF:6UW/ MW--#ES5#!7<*=J9T6&!`G'0%U!9$Q0NDV2"=^F'U.B2^%_%\&M?TV_%.+B]K MY.N+-(]:^*UC2$D+=VZQB(+I;J0K%QF"OYQEAXJ?AA@>F'N1* M(?Z.*%BV&C9BO(:U8]HH6D>A#RN1/$,EHBQ\>J%`XW1=`:F9U(Y7/Y.Q[D<] M#"KL-+S?LG@U\*&1*EA6VZK:5X--,[M.EJF-\!C^18"3#7]]=0VJ#>4B4^-J MCU^'X/2>D+FMFKPW,\A9A.*T'3,-N50UKIQ,U M2>$L]*67V:0KC\H\:@:X7@Q;J[X!^I:MDKHV35O5+!H9A"P&B_';\>UBCJ;7 M:+Z8#G_X?GHS&M_-C\?5D.%DXYR/22%(20U?=T>PEV/O, M2ZK0 MYE)VH+!U:K!W-.".;QYKS^:1H#F'&OYY:C9[,=&4;NDV]NUF9N'78833(9T0 MJR051Z4_+&7!*+R6K`6;<-8N*AIV9?`5_:Y:A$ODW<,Q;AC1N93OX#61;]3E M[1W71*P8[8#0)@N(XV*F%&77A68,E\;#DM4RBP8DIBL MT9Y&FT6[=FW&^#5D6&KY>LBU*YA5]/H@A),*'NWQF6=S*R5S&[$0P*58$2R; M6PUHM:L:(;DI@T;O-'EJ.Z^4VBZ/B%P*"X*(2^GMVLBHC*UVH]C=QKHSSU;H M0JKEC#=2(6DSC&5>&#EWU!;V]7C'5,BYPQ@R2;Q:X'0]HZ/XX!&\-_971M/6 MJ&D>24:?/2.562GG<=G#8QM3_*"8&7_1P8_`3:UD4!N!_9YS(&P@LTJ4E:9C MVOV[=.EM<1`'5QX)Z8%S1J%41/97X;9%0];>IYLS;_1&#>T#I,L47$-K>]&( M'J+;#FR'6.8\Y?ZOU6Q,XG+F2!21-@':06J",U%>`F;0_6E@4B2D"N3D`]2A MTX_'W9)R?X=[_&+ MAOD>OSA=OL?C2^K+F%P`9 M"T9&\+M3/",!2=M`*Y%3<`5+6F*HG.+50]'A>V/$&L_6D&R8.AB4C<#FH M-"N;OU"NO+&6V!4M(FR,D;1@1:1F'1M"LP4?:]O-MIR+W+8-V[N$-/BY1> M5#SFM]8@M$N3%BP$\F[,KAGL]H&HGE"9H"O(,Q!,-@_3A@0)H&T*=/EW:QO07(;=B(57<,?:9-T%M0Y%X9 M)(_M-J=#B0D:H!U!-RU'VLE+YJW1=)1[L>7ER4=J4KH?+[RR*C:M=X4,V3/; MS?/'E&BX!D8=>4@,=Q4CU.7*688[,R(6+H_5DA;60"%YLX6N6,F(FRN9L-?5 MY4HA]>Z@\B[>)2$?X?NL6#SE2A9%)6,`Z3%E9@UR#SG;Z2B`/L]/B'M&V'I" M.(96DZ$YE=%V'L.`.ZCG:NH1O24=C;BTJ)'YMHH!HSV-MUV$%&#/"[1Y!.V[ M`B$=&93MN?5&H;URC=N+,S?:)(H@UMI5XJ7!\,$+T[47"]^=].H9*=\:L6;! M]M_?48(,C(P61(ABQ%R!3V.YE!5U+<;,($;W4YP]X"STO9LL$,*HKI19;&XQ M62.;LEVS9X@V[!(<)#T^B,*MDG3_.MJKI_)?))XB#1HXF896S.QI%+1GL"@= M_-D5$+:7E*[&5C6NG<;]3-9XX7W$!/*,B;-YU12T$=-30-P$X[S4A.:62[Q(L/)(TL"&$2:F(!8!4"9I!@[?'8.$>(JJ=K6)!)-X. M;2;HJ2L(HRW$U8C#_ZT3;``0]BL]YLN?'D=#GVTIA>?$GA6CY8@S6B MR*3"2MOF%A5<5I?VAQQRO/!PJH=(?N M:WI!9ZKH`2';-;.O(:`V].F1&#Q\!%A75C-&OBYC)O,`:/"8,JA$Y0P5=!`0 M<@UENH(YQERS(6NOG;E*PV#%XW77W+/K2AAI903DC#P*6),\%+M-KWL#5J6K M8IE?!W@-\E"U7F[55PD0\("1Q[9T6,D#>),)0L(\8W;A);,$S0;HGG/-ZXBA4CO7QQ,'\>)82\V)_/78&-MA0J0<;U1J0[2-781"J""\AJ&,-* M@QTCJT*7\G@@XQ^/#@KHJB5FF4XV@<[5U[`6> MD[%DA+2"`+T0,Q)H3\,5?#42AC`/.6U:,%J^6K)K@K."),IIUI@,G[%X$#Y/]<XE$YI@U2N7L)GCS`;26',H?Y5^CKEUI#2L>4<,2V,&-^>ZCQ6XIN>2E&M= MQA'^,8FV<>:E/'1M79:K^G(68@D+2%NP*-RUS.,*.[,A*_M>C2@LE7O[C;<4 MG^T=A&=CB2>+X&R[J`X\J$/-KMNHNM&6VX914_^<3S)P75MAE??9]L-J<#>E M_6%6D?0OK\3VJC6ES&ZB8K)&UX*B60BF\\HE;$@Z?'"_5`G:X+"?/U)<"D?Y MN(398;V>G-%A/&_2I7$5=//@^"P3:Z])$47$77:`,![0\F-Z$/6H/!*L6,9,W)I%+$Z&@B(FB"J+Q- MM&O4%<9B%%G>9[ZG$-V\ELZ]@Q>I+'&=K4ADLI$7/_ M?54@&44*6_%(]9)TLUC\B'ZNS6H5FRDVA0P9;7T'F36'@_GWZ/IF^M/<-7CI MR$&2-U,Q,J?2ZHYR^\*]X_HU_5*GUQ65--+L*L@;Q:?(FSX(,\!:=P4Y&@(H M*WBU!N"TVO\\RL$=WH#5:+P"_-:"15K)FD:V:^+-BFM*N9)>-JP)B590>>UW,PE4A][0J` MFLKD(/%6X]'J)VB!U,.LIJ#5(`3V/,P^F6@"XB@`&=W2%TT=8M99EF`G9 MLHJU7?@)(/,I($XH%CGL%,/5?O^:>7N/M>+Q%4B/&D5[.OZ=4,^:?9.$@HXK.&PL$HV'=]EP=7LPT<^B(BIMY2!RHNPHSK\T M*?I>=\IP*-E)<,5;,DW!MSV&RJ<`MJI,=``G&JDN$R@=6#'EC\$" ML`D*6TB:)&/"UM4@=O%J(.]Z-3.2>@`ZC)#K,PT+F7E/8%<[B`/FA$H_IW09 MO0F]^S!BP4CEJ&KP.,44>YW[!PZVPJJ$J/6:(A/ M:\,$/M/I)DF9/I:[2!Q\.L)1@XH6[)ITF;-@X730[MG.8>;@LROX;"Z@JMU3 ML^'K/ M;?='3&C_)S%/N+N`F!^[H+R".=(3,^86]KT*T^4)EW5&(>\N64 MRQ66*ZP'NVA9I4X@'L,EH]U`TR+*-.\)Y)OF?3E#^WC4KBT!_8YGQ0?!@5EA M%I@DSQT[H]/H@3)9O`H+PP:HZQB'(-%BR33N2)$7&!5DD(L!![3%<1Q9I,$0 MM, M21:NZ?%*9,5W5,@\66\M41,XT!99RIRB3:9]*.4J<`4@<@E4,O-*Y-ZE@<4F MQ7Y8IRRH+6+!E*)*T,R`<]]>H8IR#1!U?:[:38BDW/<%I]$%Y%07!-L'^$U^ M,'<4,7(AZ)UZ7M:($\2KO4G(04(W9T/3-I2)*I.$(R%HV0G[ M(8FH#$EQGX-$C*<+%XX9]US&BE6 M(R2<#CO=3;/2BY=@CI1+&`.\AIS1W1(T-RC:-VK3GK(EK](@SXT8[F/NU'3Z M&/A"0%C1E8EC:M84LJ4-LQA9\T#]93&KG!FW\G2;)99=P:.\RP*%7.NPH/6H MG/I9DL>/73RDR7;U,-BD841_%X-47<<(L]HL&1GP"K5ED*O+0E M43$QTAL5*ZE7:_WVZLO82K]JT1_O(`'KYZ=(P&HY,?6)4[`VY_9?+KS'.X)0 MG((TK/VZ1);#./+H),7%D?`/N0Z MC+W8I^O>`,*6LRNO0J/8HB'CF=F>>:.+[B[>*;J^F[Y%UY/;P>T0W/X&P\7D MQ\EBXJ#C7WM1'4/:=*`_-4WZ237HKFC.K9QJO0@R#1&-%*WN=Y(?\.:9EV;" M,_'_O_Z.8Z$K?(/>?KI/'Z=]\G#&_UZPI%7+V?>WMZ*FV^5O&VLX;77*LCS1 M92.^G0@/()H0"JATZ#Q+CR*#.(!_8&(^TC,V)#BF1Y0T?:+\R9P/].J:N]8V M8='H8`I9:,!.PXEAO3<:.ZVP8Y`?'A0S]W@5QF#,`3=)WN`GT&?) M;JOL,:9_T^IK+Q[53>15<;!N/BM/Y9TZ6%,QL_C^D;,:-/, MI=@E+$@[7Y=I0R)X`RN,^=NAV/IB_T85#*"EL/0*OO2$6A-P]963=YLS_ZQWN>":HY:J*G6MWII2?_#0#6"NK6'M2 M/U6XZO)[]#3.WN8M]@#8QCFEPT?V!`O ML/\0A[]MA4HY[>K&>HJFC)K,SY(!5)D:5RYS+[@]05>0V590QS?<=D-J90>0 M+_;6UG7;2_@)5FK;B_)R&T5L*>8F;\A/'C%;;,O]<'615:RGCADG3.)'3#(+ MQ@FRADYEG*#!O$WCA,GMC^/YXM,T3M`0E:9Q@O9`]X[MW<.**;9E#9T*VQK, MV\3V/M[VIX=M#5%I8EM[H`V4+9'GLU/*8$7_5UQ3ZQ0M]07-E"Q2XD8*EJ)E MQ)K>:1VL:5B,.5<=/-XF,P$+!/CJ<^%;H9O9'K)0".0L-45])F0!R; M.J*;R>!J:QYFV>[ MU@QKQ$S2Y[J_(!&JW#-B>/2$8\6*5U_6+JZM:L8/,.+P8]9Z$".B:/T$AA\M>=>Q`8DKT2T. M(OV0))*:X)TA;YGA=!?5.5G2_Y;D7VU)&&-" M!OYOVY"$,)RWWAI/E^P#O:WQW&2"]5RWMO%BWI!-H^F7DT(E6G0:4FH`P8(> MX@1=@6!+.1VOX:W</-41*%_M,"?\RN*)7WBF.KJ+2Y;DC.AI$R")IV,!ZL MHLL578^.Z+O,8)AO(F2Z9#F@P"1:@)KZLA:R$4I8,$',OF%8GNAVL@X)2=(G M>Z:BYEUXP[L0XQ7L[Z(+?ON>]#$CI-*H)D-4@JHO_7NMFYBTJ&7=ND47L4-- MNFN(D75;KBSO-QPM/:5"'MHUAE08`J`3D4ED(`Q-TS]P.`?LS6^M M5CJ+2AL#2,&&D>)Y>CL:W\['(S1?#!;CM^/;Q1Q-KPO3[.GMW#4D*81QC":M M0>DSI*$`3#4%3Q!JT-[;'"FUG:?;P3S-\/,`+^D-,9-N8-UV1>/5SK`_;H30 M$TT*%;BZO.=F7ACCH,CE-?#][7K+W*!'7,S"2Z^RHH4;L"YS9M=A3@7E;;H& M*WTI5.^0S<:H0QTRTVC?))XHK62I@+DFN$+,PEM+[**&H=K3BKI6(-=.=0D; M+PSRN(=RLYCZLC:T"6(6#-4)T'#A.<13%`>8[E[N+2M2(=0H%U0#T>$9;GM/ MZ%F`*GX4:6HU9J3MX@A*R_?\%Q<1'O;``7D!8_,_^]4S]^MNM/P%;Q=K_I^ M"A=)1O8B+H=>IP\4*?8('F'^[R0>^"QJ'IEY3["!#.*`?DFW=/24^;);-F;C M><.@$X9/:(PBZ'3Y3R]0&*,$[!W`BI,=+=@EVN/T=S=KUP!M)L.:1Q-C)'3X MVD_%XY&'(21L@10N]/J6*PI$3__B"N9V`$IFS#Q^\V8I%`E.'T,'UU:U!"I& M`IKCT?$S'?JG>4-VGOE:,6]T7F9Y MXQ.F/4%^J?%BS70-I^W%5/N<9C#(!NJEV40<^+[T1S.E486(D7Z(MN8*%.I[ M=Z#Q$I!NM_-%"4L%X:5$S8W8]*M\=BO.7*V#1E\'Q^J`[ M(KW$#M!SJ)54L!E)X(2NM=&>BG/^M6H)2.(+&'O:"K86?KZ7G'%$IH#)G@X3T)?&N[:8T8#+"!N]"]!V M02%5M(S^!JH:)KWZBPX^AB(EF*CT*?Q! MRVS8]O]T!36:W==PZZP.0Y]FN^#A-=IE"U`^@FG7/X&1KX)5XTO_H94LI^D: M_!I+16TRJS6"/88['&RSAR2MR1"E4\-^V,,J.V:*T)K0AWL2KL%/0QK*$(BB MT>GSUJA]6SS%+='**?$@1%?ICFCS'=:,]08AQC3Y=^.*JW^U=0#O@SBH[@`- MPBY*JUN-Q:C#J,F,*05H1(-;\!N;#G_X?GHS&M_-BR/`W]]-%K^@YZ/Q]60X M63CG*--47++@COH#VW6D/*T0>;9CX]E$VF`^'R^<\S^L[V=]$#S;.CD&M2D/ M5'8I?/>I*V66NT!,UM:+H3/[E:*_!]D(5'+N\)$(WV?#)'ZD2Q#EAO^407(A MBC\6]0P4,J+W(JVZYD]'35@T@15+%KNG=(9VM-">V!D"Q M6X#N.\6OL95MA,/7F[5@!;BO6C4%"'JR*7JCJ@_6KUGI*S)G2D`88,&.LRN:@N<8&(("&7TT/T3 M>KZE)%$8@\UO3A5Y.[(V%4"GZ:Q4,62YQST%F&HHM?;99/M[6,H#T]R$,9[0 M'T5SLZ:@A:JJT7=SOL2M_<=TV[-@?$?:X^4,D!TLM+E#148[6< MS5WJ*\EN3:_@0=ECRG-2OJF*'4^;@JEKM>"%[*]T!42NKG&N(J.^J<+6H M$;"QS>`=)IAR_)`[<11.0XMD.'\[K%%8:E6S856HQ9@%,T.4YH3VD5AR:V:4 M)0B(N8*:IL*IL49L,&Q-5QF"_9>KY/$BP"%?8.@/Q^L*_?0KC_%>>3$7YV35 MK-0:<\V8,D$3&:2J9G;DB5[2KN.I;*=F=FZNDK1)"3A0A$*`"K6_OH#2%'B M"P""$E\`A5\2FVZ`W?V@F^A&`_CE[\]+_VP-,($H^/7%Y78]^&]R3$%)P1M",?G$P^.YLX*V=@+<?__J\H>S_YE._[S[[1_W;Z>7PS]^ MN'LSO?GS]S__]^79ER]?7D9L1&^+6#@_Y[SZ,/CT,__GR2'@C$D9D%^_75"Z M^OGB@C=Z?L+^2X3G%^P=KR\2PF__^I=OOHF(?WXF,-/@R^N$_/+BS_>W#^X" M+)US&!#*I8H;$O@SB9[?(C>22^.59U(*_MMY0G;.'YU??G_^^O+E,_%2C,Z@ MOWL-^8177`D77&FO?GI]F:+C/5540:')5@F7[]Z]NXC^FJ9FW7ET1Y[N_ M_14&A)%%SV_9@\QKP3,%@0>\Y,5<@MH$Y#QLF?"1FW[O"Y\/5(1?I.5]4927 MC;&/JE<,G@C%CDN3?GSG"?B_OM!N=E&5Q?0@(\!].4?K"P]`KJ'7_`?._NOS M5Y=;<_D;>_0Q?OT]F$/^UH#>.4N08UA*EF8P#>0`9YEUL)MTR7Z,4'PA'>-; MBHL5\X\!/7<7T/>2UC.,EA44F#"!%#(PY\RX02O>T/%?G"'L`1P[_5;TGPCR MR+H5Z#WS9\OTG15-K.?OV];S%&"(F`S>R*$JA6?I+-5\3E@Q!*_;@F#`6/(X M6S>^,Q>H/OMWRU2>$TZLZA_:4G7,]I"Q@QU_S+ZAS_\$&ZE;S]-9IGJ)L&(( MWK0%P3#$7-`;2%S'_Q=PL-SG2$DM`T(NLAB+'ULV![1K!"F;$P\,#V&1&X@8G(KX9")+L;E7;NX_([\D"D1QX-&#DB>SDHD"L)* MPK17[6+P!_#]?P;H2_``'(("X(T)"0&68B&CMQ(3J?`2;%J/H?<3CQOV1&0A M,DK+\)`*+$&B]2@[9BP./_6P2--:C49&:`D>K87:1 MU'V5-K0,*5UU2&#;A>^_7!0DOF4/CLK*#Q&+7`,"//8#03[T&&/>E>/S?/_# M`@!*_A'ZF]>7O.6'P`D]2/>9\:II^L->UG3>_C"NCK&CF4.>HH$7DO.YXZQB M8P(^)*`\F^8=^R[<$FI)&MF!4)GM# M*W4U?8MTOD'60)&33+YP=\:DF`%&YMW&W-&[25X]Q%I=F71]$0_"J.BQEF)D;9:6X MU(MZ%0T,`DL/%_.#X.OERD<;`.Z!SQ-S1=XE*)6W,P?Y+C9"$V"IT9`(W5!A;YQQ< M>^YM%R+ZWY"?+$]BE`-H$'*:D*GF==9A58SEQX'KA[P@>\I7"1@.E&+X%-)X M8GN'`A<%E''/6)F/`PH89&6QX[(MJ6T:RNJ"/-G)PU=4C'$&./`\&',S=:`W#H;."E+.FCB2 MEU"?/))2-1D7R]\#ZL``>-<.#IAP9."ZX3*,8JT1F$$7RKZZ&@U/'F8=Y1F7 M1RBJ17M>=?J(BI0CSS%8-Q\OFUP>N/#;];BH:P%1K)+&"@"Z*;:?1NI<``I= MQV^U\K[TS=V7X9>RV-?D-Q;.,=U/<,2N%TU_IP!'V[BU(CQIX\X_68?5HNBJ MQKCH+LMXO`]_$-(%PKPF5`O+0J.3P+"H"N.B.Q'#T5;8*KAM&YP09HD*C`O> M4@F#BLY3IZ6E"&HIQ;BHK'!V2:G/5+6P'SI=;]GI4F^.6Z6KE%&?"E1J)]GA MNF^%PY&TFIP*8%4.1VHT4MU)1":SR0K$6]5)??%H6?^M19UEC'1C'_R$@"78 M\5823LJH.S+NK1J#>5(C6<*^G+YCLRY!(6W)"IF-BP:3$M9!X(W`&O@HVK6D MW@FI;M,Q3J4#+KL^H)3>.+0>0)0H_PT$3$B?<3WPEC"(#A6F<%VR@56SL4WX MZ>K#N$"^(*6N.[0*'H&4)[19;R==_&FX1:04Q12EA9^SM)SF610OTH\YY/MO M-6<;ZD86850BO7&9L62M5_W)RE-U[?RTQE@:EX*8\BF%KO][%_N_`,RC/6"= M>L"]/LH-S#[P,N*=4-'O':"EGZPLC3V.,"=;C6ED\7;(/P"_'0EX@S7[2,Y! M(7-SY1#H\O`"^B$MY!X/Z<%\+`[2BW'9XZ1F+%F34".IV\I\]+3E+TDDMU8\ MD\[:%FT[*^;<,O?(*Q[+)(B)S%G` MJ+J[)2NK>>FSA,%8%G[Q(0JX90R>H6PBI&YC"E29T27$1"RR<1!ERSO>@^53 MX8Q[):DI@*A&F+R<)9'7.%A2BY-*3(ITM@$BD+3&7)?D3)7I>"A4:^Z/MN@R M+Y-QV:?\OA#EF)80VP)&F-;%FX):6V#1B*Q<2'Q3C`6L8`Q M^[%TTK0G-`63\IE22KCZDGYL`@U.8*>_%.]:.C=EC!2&=_U[^.M8"=B.K55T M[0MC'M-N1YAF\9ZY%7MJW'6+\@YP#\=#*)Y8/C@^F,P^!)"?DW_YZM448/Z+ M:%=_*;G1()4+6^,VX!GH48NZL(YN+1D>2 MW^:)TR5?%Q3=375$1T:#>8R":IRABHTJ/O#O#E'PAX.Q$Q0.+9<0&:UQF6`U M5N:+M3GU'3=>]YFS?Q0:E1`:KU69@`U=+7S$$CR;%#ID,>030SY59(RI*V$4 M#8Q&14?@ANX>_HH*)#0QT*F-./IJX9,.43]>V@%U;=*J;C\^*,BY#KJM63LX M2K4&>@'CJGN2:T"QM=UG_.ZW&Q]]:6CSF:#[3O:>"?CHO"QCQY-^-4:Q27?? M<\[+%*,U9!A=;3XPA8^#76'[P*5PK7,WRP$=F>(S%`CFY@B5567<:K5U\[?# M!VCE^5V7M\IZ_Q<2&ODX?EX\FW"XT`<9KA]1/8;:R*M.8I`T`T+C)1)L@LJ9 M&K+)S1S<('P/O-#EKQL'\0'WA/T\Q=`%S-'M3[SG"191@N.H[KJ^&:]!,TH2 M*<>IVV#/PV09Q/>?JG*\OJX$O;V6S;(BGDQ!>&)0Z12D7&% M5M565HQNVL*V>_>ZPRFL$&!(N5%EJAN0KP3"K%N-. MT6+28L"\QPC$_X\#QC`_=BJ^O4YUX;-6TZ\$93TU&K>>6&2[>(UA\09#[?&@ MU=E7.T+T5&WB*J>F.H[.AGXM8Z.*2N7+KS8>*"`2>QRL`:DCOZ[JZ#3RZTI5 M&7?6#N/>!<`C-TP5(QAQ3D,,)K.KD,``$!)=U9"L(A/F(64& MG1.DK[6COPNG,4"J*.R$3M23B+T]1OGX>82JH].81RA595QV./W1B_<3)!\X MOLR$5XC-F@'?5:`Q:U"W-],K:`QLV1RA1%VU;2Y;`_R$.MZZF)8[2L,\+!"F MCP`O^87F&F-#T.CD!H1(,48'#A'#50`\8=Q4<'5Z3,)J.U.=S,K@$M.>!%P2 M-<@7YBR'9*J@0],^\RU.`G:E2HQ;M4MSRPL#^)6)D]D]\`!8\JQT]J`A M#4PU.CDYF'449]S*7VZ<[E:8HP>5,F^JUB>'M5)5QBWPI;]!]R"ZP7KJ8'Y^ MH]87N=#D).!4*T6^X&;A]UE?84>G1$YC;%11V`DMQ7&9!X''_^/[_M:.S\TC MWLJ?7[F6C)1*75B6-JNF'N-*[\3L#]A(QWC#!K7H8)=J;3O&\Y#A6XYO04$G M=_92XP.C^]VOK0P-^5[9@T]U:GZK[`@2UTAD6=+L#!>R=PYM'$Y6'J.P$?W?Q^!1;'3%,O/]YV#WAG M>Z9]`'.]Y1\LQ%:=VV)5^<$713J[[%X@9Z=FO]V<-9AC$(WOXXVZT&-[)EMX M]5=ID.)]BWG=Y#@1DMAA6F+I.K6J_?EYI(89;JJS%F>VJ;?V9B0X\E%]UJ,M M\]&"3)W:37ZS_O'&4^BQ/0LJO/JK-*.Z=GT^40%;,@$DU':89*G,G9IH\>R^ MXXU4T&=[9BIX>6^H-9Z2R7V?ONGJM[?+F"OHI5/S3N[?X9L.D[LUCS=P8:_M MF;CP];V1UW;Y;)E1R^GM,F*%W-U^D\,5,TD>]SK^_NE^T7DUI2TK?*R M%K_B%;CJ+?^HE5RN3K&Z29DCT&YNEU_0UTJG;B)=A/:(G8`XT:%Y-439TI[; ME\E1[LLOE*NNDXJ;9M1M8?$$!?#R)C$>B]S.0=T9(\C.D1+EKFG#P1,9M>$ MPB7?>\U/SR4D7$;L=SHYTN++9(>E)4#ON2HSG]6KA.<)R^=<<42#^X" M>"$__FP04#9)\T-^<.8#<$,<[>>^?N8WG0(O/N1AN0ICKIA0^<5E?KQ'#:ZE M#2:[+>6H6YIN[#9Z^Y(R"2D&E"W M+34M>]G+%N)KLUIO5KK"BXDQ=I4$M"?Z MP*P?1Q=ALIC+YY+L[O&XY8=,U.;LFF+,B.J`HR3HW5P=67P4S/F9P-,0NPNF MW#T.IK%S&W6VS&[K\ZA8"(_T]0UD:4$9MRKEYF=$C6G@H MB&D%(/&U.F"$E@Z476):WJYCD$I&6AE:.1W4B)MXX_X`8\0F?>#."1`%[B)` M/IIOQH'['BR?`,ZAH-/"?/UKR6W<-0P[ZV=?=C!F/\J\EX#0>,`^W*.UA<>@#%L[(<\6NS1QVL625$^EK;7NS`!1DP\?O-+ZE$.O0H- M34&S,!`YHE448,-7Z7HV`]$E;[$$J;_H?Z$4?1B-Y8%J,BC;!@*%*W=U'3=Z^O`N`CVY"]"T#X5X>#;#EZW M?E!G?4L8Q3X[.;;S*_\RI30QF,]Q=$O2`]J/:/&QG5E2D\U,+6/CGZC4J^\` M3:XN4RLW36B1:C/RE7QL6G-7^Q__8/[489ZU"0Q@RIJ5;UP!55,TY'Z%6-%H/ORU5"#M)^X8.D" MJI34!BSRTIU0KK]?8+47NP$A@)(;!^(H?-[/DB00RNE-0;(P"--H*L0U;DUU MQ^5[X'`6HUIB_F"[`]I=!/!S*-V2J=W<"N#TE6%<]F['>FI#\O7S"K@4>+PP MMPP_63.[<),*;]RJIXCE>T@^W6``Q@%SV8#0>R9[!=R$S:W%3ZP,XZX/5@V] MWY'/=.U#NJF(I*0#:[&4*42,YIM&`M[D8A)^@]U@B3"%_P8E:55Q$Z-1T!-: MK/&W)/EG';9[7).:@3^?UZ;PVTWF/K,%DMCU#2*B6-2E-T`G).LP)R0>`6)L69.I2OI5_U2ZE63H)H=%HR(0S(CTDL0RX MY',`-FT/7"!S,04:LSU,4:0:4P`::I3[%P%5EP-:AKU0DQ8XEXE+$3,X]OS5 MXP*C<+X8K##TV>]R/U/>QF2$-"0V+OW5KP[L$EK6K0XD^]#B8]PS7SL)B*H6 MIJ"I3)(H139NC8"S-0Y8$!-RP5+\\MPJX<<,\R>$\7L#'"I?UJG>CQ5@'J`> MX_PGEV'/YU8&X.W%XA-5!:SE;:V!4D,-QJTF9(=@.F4>C4$M>RRVL@8RI>C& M+1ED.9XZF_@<;%V<,@TLA"@K<.-+`+G/ZR2DA#J!!X-Y>8(@36RTILL$[32K M_T"1^VF!?/9.P@]-H9O:\OKRKEN\5QZ@)"4X"0C:C,65H".0U.!/([2U`0<:M:82@0 MV0")3#Z#%QE2[":WRI16:9>WL1`LF?0U!JEB!**W3^(*'[E%B*ALT;)00N/B MR3[W;6]E?'0]Z16S7H]?8`H"LM4^L^3X0-ZKS9YD&SD/OCC8BR.-?51-)G0! M\./"";;C]7=`HLS5%&"(O$=$'7]7FB<;']TP8\H85.8PN@+*N-GIP(\Z!YY8 M([S4,R#2C1UZC:T8$;J*:+Q.X,'A=SU^""`E$2NBM`/^05: MV\I=")@@KA]ZP(M+>I:K,.9J,DLZ2SJJ;?&K%2[;6T=K19Q^2:Y?DNNWV_3; M;0S:X&'==IMDH4&>\\]3&*W_@CC-)VQL6SC14V2%U9(:4S;]YJ],KL:^%9!^ M]'2>`>$H_:91I.+_V5C^FJ3_HMB M-T"%#DR9A4OCM"K*,!I)Y7X!`6''R%0?A#+4RO.F=27O-@%=``I=YY9Z\N2= M@,I*74M%;CQ+>LVB8KIAGUC*!/2!=[6Y0@[VA@L'LB@GD*I>KYVU8&BJI?&\ M:W_(4W_(T\D<\O0`5C0R''[HD=RI"ZA,1D$HE7%'C_0+`%T4$@,",@PQUXX$1T4#*R!3"5PR0>TFQ]EX/M.LL]3]GG* MT\Q3#A_>#^6UJK9[IG*FKL4@\$9@#7RTXK*J-[:K MVYB":$E\I13;N,\)"^AYW1N9.AL^4*O$55I-K0!-3PF=UI/PHXH@C6HCV-#B M"Q[U3ZCC:O>BIEI@^ZM!B^!0X!3(?W4=FBV@.+:6T(P212=EK. MJQC#J=K2/=$'9C+X#@5#)W"9#V*N:+("V.&M(O%:,?7C.#/"01PG0N]6^EQ. MJ[M;O^(:@*;4V-<`=+3V^2\6_5Q'YZ5O+T!Z?5EY`ROB$86\!YOH]B_\GR=F[>S) M_P-02P,$%`````@`S6(K1:L-O].-"P``A70``!$`'`!S:W)P+3(P,30P-S,Q M+GAS9%54"0`#0LP15$+,$51U>`L``00E#@``!#D!``#M'&MOVSCR\QYP_X'7 M#^<4B&,[CV[C2[IP'BVR2!,C3G9[.!P*6J)MHI+HDE02[Z^_(279E"71LX9(X#"7!L/3&A6L_O'CT7&] M5?OMT]__=O*/>AUU.7-#A[BH/T'$'6)>%X0_4H>(/8?Y*!0P$UU>?.G'H*@C8(Y9`6NS"@[.W"V/C":?#D40[Y^_1 M?K/YL;[?;!VB_W2[WVZ^_'[WL=LZ__/PYJC[^=L?W_Z[AYZ>GO8T&YJ:9J%> M5[P*9T1\C$"\0+0#%@2A?UH;23EN-QIJTG.?>WN,#QNNY`TY&9,&`-4!BG#J MU*)YJ0E/!QH<6&HUOGV][FG\,6`[%/4AQN/IA`$6?0T>#\"TUD&]V:H?M)(I M`^I-P<4//E:\*[##YJ\S()?0*9#F6!!G;\@>&S"0@_/9H\&//*Y;Q\?'#3TZ M!05LKDPCC^4[:D2#"6B)I4N636(^)/(&^T2,L4,6"YAAV&3DH*&&^U@0L$J/ M^"20GQGW+\@`AQ[P_C/$'AU0XII"40LZ&@BI;+"&L)2<]L$*4PC#8(82C.B7 M$PP6*K6%JD=X'H]I,&#ZX9<3Q5T[8?&.#)!>X;9:DM-W@OICC[R+WXTX&<`[ M6(9ZL@3?QYSL`=\)"&<>3"OD70TW8(J`5=`<7<\()R@P=S)8,A8`2-B8<$F) MF*[ON\;KB.22P;(BP10:T&T5R,/]906"*<3;1ED<["TK"TQQ0F_-YJ9PW(,, M2/WQ<'( MNJ?O7C`O8C/FWL[.,=B M]-EC3U?@=;FO65.1UPT]8S!_LDWYZR1GL9F#_8S-F,C,$39`BAY2!)'!3ALE M#*5`=HL05297PG$L\`\VE;::5C=0K?G:]]T][GOY*EPC-5M@V,@FC_BJ]KBR M@',6N"0`_#T03Z^6N!W<0A(2U9H/`0Y=J!;=F_-0Z7V*`/Z>8IV] M%4JA,\1H)TQ05ZI+;]X[`G2)V\5<3NXA>1+8T4L&BRJ@6*/!L#/D)%I42Z1_ M"1I;!#_(;.Z8`M(DD$FCC694T(Q,%9&+HH-DSH\1\US"Q>7/D,J)+84K!+:I M+QNM33S_Q&,F_H4B=)6:"M1TB7D`%BVNF1!=PGLC#-J8QL].(*E+O5#21](C M3LBI*OTNGQTO=(G[F3,_.O_3K-\.$F0)(HO&WX2NS7A:&>-)L*`=>"7>(\"& M-+IT!#=Y0S/F4,(=&@![R.!/39KBGB*M+++`(L'-/JHC!DB!"O/Y#(PMJ<]J MVIA>9?:Y*O!]*G5\ZP0NK)8*>B1P:)$VBL%MBOF0HY@I)H0#]77!P%4IR4QN M53;"/.JJ=.4,>^HDO#BBG847730VD7ZXU&58Q=LVFOJJ,6=IJ9Y.S4#8]/?<69[QM-G MZ6^E@M3R?F'@K,"V'<*#KSC`0[U(O2[8M_*,9UA0*$6[QE+D*>D%6&QJ_)A1 MHR:`8@J[:$8C2IDA25&DM`/6Q%0"8Y*KM&Y-1BQ9;Q&H[00JNPTSZ4N52[[: MAGP04'Y<"DE]B$T*IB-$Z(_U$4`70E91#K0F2C;#R):_JV[L-@*F=+F2L*5A M#<;03L):96ISGQA4MPP12I&WCZJ+ACSE?HG(`;-Y[YP/DS$&K9H$1Z6,MSM= M*/Y&\19D;1YA\V<:U9>+!5\GNYV7-C;89MJ,(IO_I5L;NIVJNV&].84Y`R#F M)[UN6E&6F.U@YO5+AG8:@P8L0E*E&,L?RUEKCH6S;.?D1\L=TE5NX]7<1LZK MUW45-@(V]Y"M2%=W#[FO*U?P`E=@=+_,@!X"E_`;%IRKDU9/)6EQWT(PO"98 MV!IOUD7*EK-D/\Q;GY57[:''_9]+76[K] M,V>";3=]*-O].6WGK;H_E^]46+$Y8=E^A/V7]2-4_0>KI2;+Y"36K#%[$E&< MC%2Z*3I&+G?87":>9=NWS(/E*HPM]H9FA,IK@1Y0A\JROG%)9#9/>5324Z9C MH;7Y6E-_#ZAV'BH'6K9COERKO-5IYOQ^J4A-E3K6>^[ULC/ZU6C9BOLEVV]7 M/F2KXL&J/Z-<\7>15D>1K4Z7_:%CI==R90L.0LQ7*GSR,:RE]HE(5>7/V[<% M6,+%VFC9TOUL^?6F30%5]"B('GU!?H8@Y^6C"L;Y(6(.QA8'L@V'L^DHFE^I MP+J\UJM*\D%M:5H)A?P_[HZ3AG$_%SRD+N\ZH?Z8<8FBB^&NF:-'+)>%J:=Z M4A@,:FG"[#D65\H5M.7Z;4!$N+M M%22!:IL!*^!())6ASA`X"\<)("1X?@U%?T,=1YE[K]&X873714WYMMJ`>M]M M'RP[,6N1AD]KY6#3XMG$\5D`;H]/5A`HVM4R&>I'Z>]IS>$$LMR9F!W'`?*N MZH"&K#E>@TBJW*$R0D076;9=YF,:O*I2.IPSJ-K)#0:G29Q1P#PVA-5VOA*_ M3_B4\T5@2T@AR;,\\YCSXU4%F?^]8L)Y]OV;6LV,T05FD1V$4UI6, M3<,I&-Q*^X\/<,'60S_4'UTN0N5++D`&CXUU)2$A<9]N]=+P6RFN\0N["]*7 MMZ%4\]1%NHF`-HC-;GYU,L<"?M%=)^;O6O"O)']TLS[U)S8Y8YB[YR-,(4<.TOR7!-[P^D-*HQF!"J8YM_YY0^53 M`:%:@\7K;D.B;JHG;@<,&1(3W7PLC+"N3C`=J%PNU,\DB3O=ILM.VXY$U25] M,]_1GQ+%",R'#]4MZG?$#74CS540;6T5+KI0\NO/D.D[#)*56`W'A@NF[M7Y M7&UDO-FH7?:P^O;[$%`I(N.:;J'LP%;:5L3T49;;D M?V`O)#FJB-]OUIS_33"_U.[GUI$,;#CZ5)BV\`5`FY4@9DE%A_L1H!B..F-. M/7B>RSQ*`):2!,08QS]=6=?VU;ZO2[AZR+&<]/"6EL7E.U#,*K/\G`TGN;VO M!'G-HCM MB$ASM4"6W6(E;*D(70\[FJ'.$/Z9%Z-H=.,?!8U=F;-1MV6MYQ,8T^<-AYP, ML20]YKEY/C$]OO7RW!#9YJV8J%8/@^XY+^1?)T5`"W MG?+E.5>KH$M,4!*?-**F%OCS?U!+`0(>`Q0````(`,UB*T7OD=.9!U4``*+< M`@`1`!@```````$```"D@0````!S:W)P+3(P,30P-S,Q+GAM;%54!0`#0LP1 M5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`,UB*T5Y*R*!%@8``.Q"```5 M`!@```````$```"D@5)5``!S:W)P+3(P,30P-S,Q7V-A;"YX;6Q55`4``T+, M$51U>`L``00E#@``!#D!``!02P$"'@,4````"`#-8BM%/L#.G0@/``!L]@`` M%0`8```````!````I(&W6P``&UL550%``-" MS!%4=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`S6(K12R++/0\)P``2N`! M`!4`&````````0```*2!#FL``'-K`Q0````(`,UB*T4M:S3)Y1D``,/3 M`0`5`!@```````$```"D@9F2``!S:W)P+3(P,30P-S,Q7W!R92YX;6Q55`4` M`T+,$51U>`L``00E#@``!#D!``!02P$"'@,4````"`#-8BM%JPV_TXT+``"% M=```$0`8```````!````I('-K````L``00E#@``!#D!``!02P4&``````8`!@`:`@``I;@````` ` end XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Going Concern, Management's Plans and Basis of Presentation: Going Concern and Management's Plans (Details) (USD $)
9 Months Ended

Jul. 31, 2014

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2012

Details

Revenue since inception $ 0

Deficit accumulated during development stage 6,019,984

Cash and cash equivalents $ 219,035 $ 13,822 $ 181,386 $ 539,727

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_DeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_RevenueSinceInception

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events (Details)
9 Months Ended

Jul. 31, 2014

Details

Subsequent Event, Description Dr. Randolphe Swenson, Jr. was elected to serve as a member of the Board of Directors

X

- Definition

Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 855

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662

+ Details

Name: us-gaap_SubsequentEventDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 17 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

License Agreement
9 Months Ended

Jul. 31, 2014

Notes

License Agreement
(3) LICENSE AGREEMENT

On December 23, 2009, we entered into an agreement for the right to an exclusive license agreement with CSMC which provides us with the world-wide rights to U.S Patents No. 7,547,511 “Antisense Inhibition of Laminin-8 Expression to Inhibit Human Gliomas”, No. 7,935,677, “Polymalic Acid-Based Multifunctional Drug Delivery System”, No. 8,309,614 “Poly (Beta Malic Acid) with Pendant Leu-Leu-Leu Tripeptide for Effective Cytoplasmic Drug Delivery”, and No. 8,562,964 along with various Japanese, EU and Asian related patents and applications, related technical information to develop, market and sell human therapeutic and diagnostic products, including new pharmaceutical products and/or non-prescriptive products using the patented technology (the “CSMC Agreement”). The CSMC Agreement has been amended five times; December 8, 2010, June 30, 2011, August 31, 2011, October 28, 2011, and December 30, 2013. The CSMC Agreement also provides us with the rights to several other related, filed, but yet unissued patents. The CSMC Agreement requires royalty payments equal to 3.5% of the gross sales price and other forms of consideration (such as milestone and sublicense payments), as defined in the agreement, on all products using the licensed technology. The CSMC Agreement expires on a country-by-country basis on the date that the last patent covered under the agreement expires (currently 2032).

The CSMC Agreement, as amended, requires us to achieve certain other milestones in order to maintain the agreement. These include the following:

· Begin development or enter into a joint venture, licensing or sub-licensing agreement, or other business arrangement with a third party not an affiliate of the Company to cause development of at least one product consistent with sound business practices by December 31, 2012;

· Expend at least $500,000 in the aggregate toward the development or promotion of the sale of products based on the licensed patent rights or technical information commencing from the effective date of the agreement and continuing through and including December 31, 2012, and at least $1,000,000 annually thereafter, for further development or promotion of the sale of products through and including December 31, 2013;

· Provide to CSMC at least $150,000 (in aggregate) within at least a four year period to fund research and development of the licensed patent rights and technical information;

· On or before December 31, 2014, the Company shall have commenced a clinical trial or trials in connection with at least one intended commercial use;

We believe that we have achieved the required milestones for the contractual periods ended December 31, 2013. It is management’s belief that administrative expenses incurred in support of the Company’s business activities meet the definition of “development and promotion” of the licensed technology. We can, however, provide no assurance that CSMC has concurred with our position and that we will be able to meet any or all of these milestones in the future. In the event that we fail to meet one or more of the milestones required by the CSMC Agreement, there is no assurance that CSMC will agree to amend or waive the requirements and we could lose the License. Additionally, as discussed further in Note 9, we have entered into a research and development agreement with CSMC that satisfies the milestone requirement described above regarding funded research at CSMC. However, in order to extend the Company’s cash on hand, we have been deferring payment to CSMC of our obligations under the agreement. During the second quarter of 2014 we resumed making payments to CSMC but our outstanding balance with them remains delinquent. To date, CSMC has continued to do work under the agreement despite our payment delays but no assurance can be provided that CSMC will continue to do so. As of July 31, 2014, we had an outstanding liability to CSMC of $258,091 which represents amounts owed for services provided by CSMC.

Further, in the event the Company issues or sells shares of common stock, the CSMC Agreement requires that the Company issue to CSMC additional shares of common stock for no additional consideration so as to assure CSMC will own 5% of the total issued and outstanding shares of the Company until December 31, 2015.

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_LicenseAgreement

Namespace Prefix: fil_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 18 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]D,V)D.3`V,U\U8C4R7S1A.#-?.&-C,U]D9C
'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D)U#I. M86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQI8V5N#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I7;W)K#I7;W)K#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT M:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D=O:6YG7T-O;F-E#I7;W)K#I7;W)K#I%>&-E M;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O5]$971A M:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-U<'!L96UE;G1A;%]$:7-C;&]S=7)E M7V]F7T-A#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S7T1E=&%I;',\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R M:W-H965T&-E;"!8 M4"!O3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]D,V)D.3`V,U\U8C4R7S1A.#-?.&-C,U]D9C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!);F9O2!);F9O'0^)SQS<&%N/CPO'0^)V9A;'-E/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO3QS<&%N/CPO2!# M=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^)TYO/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)S(P,30\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO2!A;F0@97%U:7!M96YT+"!N M970\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO6%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.2PP M,#`\'0^)SQS M<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS M<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2`H1&5F M:6-I="D@+2`H56YA=61I=&5D*2`H55-$("0I/&)R/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPOF%T:6]N M(&]F(&1E8G0@<&QA8V5M96YT(&-O'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&5S(&%N9"!A8V-R=65D(&5X<&5N'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'1087)T7V0S8F0Y,#8S7S5B-3)?-&$X,U\X8V,S7V1F-S!B8F1F,#8U M,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D,V)D.3`V,U\U8C4R M7S1A.#-?.&-C,U]D9C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SPA+2UE9W@M+3X\<"!S M='EL93TS1&UA6QE M/3-$;&5T=&5R+7-P86-I;F6QE/3-$;&5T=&5R+7-P86-I;F2`Q,2P@,C`Q,CPO9F]N=#X\9F]N="!S='EL93TS1&QE='1E6QE/3-$;&5T=&5R+7-P86-I;F3PO9F]N=#X\9F]N="!S M='EL93TS1&QE='1E2!W87,@9F]U M;F1E9"!T;R!C;VUM97)C:6%L:7IE(&)O=&@@;F5W(&-A;F-E2!M;VQE8W5L87(@9&5L:79E2!R:6=H=',@ M;W=N960@8GD@0V5D87)S(%-I;F%I($UE9&EC86P@0V5N=&5R("@F(S$T-SM# M4TU#)B,Q-#@[*2!I;B!,;W,@06YG96QE2!R969E'!A;G-I M;VX@;W(@8V]N=')A8W1I;VXN)B,Q-C`[)B,Q-C`[($ET(&ES(&]U'!L;W)I;F<@=7-E(&]F(%!O;'EC M969I;B!A2P@;V8@;W5R('!L86YN960@<')O9'5C=',@ M=VEL;"!R97%U:7)E(&%P<')O=F%L(&]R(&UA2!$979E;&]P;65N="!497-T("@F(S$T-SM,1%0F M(S$T.#LI('=I=&@@87!P;&EC86)L92!R96=U;&%T;W)S+CPO9F]N=#X\+W`^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,V)D M.3`V,U\U8C4R7S1A.#-?.&-C,U]D9C'0O:'1M;#L@8VAA"TM/CQP('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0^/&(^*#(I)FYB6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0^)FYB'0M:6YD96YT.BXU:6X[;6%R9VEN+6)O='1O;3HP:6X[;6%R M9VEN+6)O='1O;3HN,#`P,7!T.W1E>'0M:6YD96YT.C!I;CX\8CY';VEN9R!# M;VYC97)N(&%N9"!-86YA9V5M96YT)B,Q-#8[6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM8F]T=&]M.C$R+C!P=#MM87)G:6XM;&5F=#HP:6X[=&5X="UI;F1E;G0Z M+C5I;CMM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UI;F1E;G0Z,&EN/B9N8G-P.SPO<#X@/'`@6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^1'5R:6YG('1H92!N:6YE M(&UO;G1H65A6UE;G1S('1O(&)E(&UA9&4@=&\@0U--0R!F;W(@ M86-C2P@8V5R=&%I;B!K97D@<')O9F5S6UE;G0L('1H97)E(&ES(&YO(&%S2!M86YA9V5M96YT M(&UE;6)E28C,30V.W,@8G5S:6YE28C,30V.W,@8G5S:6YE28C,30V.W,@F4@=&AE M($-O;7!A;GDN/"]P/B`\<"!S='EL93TS1&UA2!O=70@;V8@8G5S M:6YE6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&(^ M0F%S:7,@;V8@4')E'0M:6YD96YT.BXU:6X[;6%R9VEN+6)O='1O;3HP:6X[;6%R9VEN M+6)O='1O;3HN,#`P,7!T.W1E>'0M:6YD96YT.C!I;CY4:&4@86-C;VUP86YY M:6YG(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N M=',@:6YC;'5D92!T:&4@86-C;W5N=',@;V8@07)R;V=E;F4@86YD(&ET2!!3DDN)B,Q-C`[($%L;"!I;G1E2!I;F-L=61E9"!I M;B!F:6YA;F-I86P@2!A8V-E<'1E M9"!I;B!T:&4@56YI=&5D(%-T871E2!T M;R!P2!T:&4@9FEN86YC:6%L('!O2`S,2P@,C`Q-"!A;F0@,C`Q,RXF(S$V M,#L@3W!E6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M8F]T=&]M.C$R+C!P=#MM87)G:6XM;&5F=#HP:6X[=&5X="UI;F1E;G0Z+C5I M;CMM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB M'0M:6YD96YT.BXU:6X[;6%R9VEN+6)O='1O;3HP:6X[;6%R9VEN+6)O='1O M;3HN,#`P,7!T.W1E>'0M:6YD96YT.C!I;CY4:&4@=6YA=61I=&5D(&-O;F1E M;G-E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@28C,30V M.W,@875D:71E9"!F:6YA;F-I86P@6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$R+C!P M=#MM87)G:6XM;&5F=#HP:6X[=&5X="UI;F1E;G0Z+C5I;CMM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z,&EN M/B9N8G-P.SPO<#X@/'`@'0M:6YD96YT.BXU:6X[;6%R9VEN+6)O M='1O;3HP:6X[;6%R9VEN+6)O='1O;3HN,#`P,7!T.W1E>'0M:6YD96YT.C!I M;CXF;F)S<#L\+W`^(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$R+C!P=#MM87)G:6XM;&5F=#HP M:6X[=&5X="UI;F1E;G0Z+C5I;CMM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z,&EN/E1H92!P2!A8V-E<'1E9"!I;B!T M:&4@56YI=&5D(%-T871E6QE/3-$ M;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M M.C$R+C!P=#MM87)G:6XM;&5F=#HP:6X[=&5X="UI;F1E;G0Z+C5I;CMM87)G M:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E M;G0Z,&EN/B9N8G-P.SPO<#X@/'`@6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM8F]T=&]M.C$R+C!P=#MM87)G:6XM;&5F=#HP:6X[=&5X="UI;F1E;G0Z M+C5I;CMM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UI;F1E;G0Z,&EN/B9N8G-P.SPO<#X@/'`@2P@05-5(#(P M,30M,3`@96QI;6EN871E2P@*#(I(&QA8F5L('1H92!F:6YA;F-I86P@2P@*#,I(&1I M2!I2!297!O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)SQS<&%N/CPO6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA=71O2`H=&AE("8C,30W.T-334,@06=R965M96YT)B,Q M-#@[*2XF(S$V,#L@5&AE($-334,@06=R965M96YT(&AA65T('5N:7-S=65D('!A=&5N=',N)B,Q-C`[(%1H M92!#4TU#($%G6UE;G1S(&5Q M=6%L('1O(#,N-24@;V8@=&AE(&=R;W-S('-A;&5S('!R:6-E(&%N9"!O=&AE M2!B87-I'0M875T;W-P86-E.FYO;F4^)FYB2!$96-E;6)E6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;6%R9VEN+6QE9G0Z+C5I M;CMT97AT+6EN9&5N=#HM+C(U:6X[=&5X="UA=71O2!T:&5R96%F=&5R+"!F;W(@9G5R=&AE'0M:6YD96YT.BTN,C5I;CMT97AT+6%U=&]S<&%C93IN;VYE M/CQF;VYT/B8C,3@S.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R`\+V9O;G0^4')O=FED92!T;R!#4TU#(&%T(&QE M87-T("0Q-3`L,#`P("AI;B!A9V=R96=A=&4I('=I=&AI;B!A="!L96%S="!A M(&9O=7(@>65A6QE/3-$;6%R9VEN.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[;6%R9VEN+6QE9G0Z+C5I;CMT97AT+6EN M9&5N=#HM+C(U:6X[=&5X="UA=71O6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;6%R9VEN+6QE9G0Z+C5I;CMT M97AT+6%U=&]S<&%C93IN;VYE/B9N8G-P.SPO<#X@/'`@28C,30V.W,@8G5S M:6YE2!T:&4@0U--0R!!9W)E M96UE;G0L('1H97)E(&ES(&YO(&%S28C,30V.W,@8V%S:"!O;B!H86YD+"!W92!H879E(&)E M96X@9&5F97)R:6YG('!A>6UE;G0@=&\@0U--0R!O9B!O=7(@;V)L:6=A=&EO M;G,@=6YD97(@=&AE(&%G6UE;G1S M('1O($-334,@8G5T(&]U7,@8G5T(&YO(&%S6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CMT97AT+6%U=&]S<&%C93IN;VYE M/B9N8G-P.SPO<#X@/'`@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1&UA2!$871E)B,Q-#@[*2P@8F5A28C,30V.W,@8V]M;6]N M('-T;V-K+"!T:&5N('1H92!C;VYV97)S:6]N('!R:6-E('-H86QL(&)E(#4P M)2!O9B!T:&4@,S`@9&%Y(%9O;'5M92!796EG:'1E9"!!=F5R86=E(%!R:6-E M('!E2!$871E+B!&=7)T:&5R M+"!F;W(@979E&5R8VES86)L92!T M;R!P=7)C:&%S92!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%T(&$@<')I8V4@ M97%U86P@=&\@=&AE(&-O;G9E2!$871E+"!T:&5N('1H92!N;W1E(&AO;&1E M6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CXF M;F)S<#L\+W`^(#QP('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0^5V4@979A;'5A=&5D('1H92!C;VYV97)S:6]N(&9E871U'0@;V8@05-# M(#@Q-2!A;F0@9&5T97)M:6YE9"!T:&%T(#QF;VYT('-T>6QE/3-$;&5T=&5R M+7-P86-I;F28C,30V.W,@ M8V]M;6]N('-T;V-K(&)A6QE/3-$;&5T=&5R+7-P86-I;F6QE/3-$;&5T=&5R+7-P86-I;F6QE/3-$;&5T M=&5R+7-P86-I;F6QE/3-$;&5T=&5R+7-P86-I;F2`\+V9O;G0^/&9O;G0@6QE/3-$;&5T=&5R+7-P86-I;F6QE/3-$;&5T=&5R+7-P86-I;F6EN9R!C M;VYD96YS960@8V]N6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`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`V,U\U8C4R7S1A.#-?.&-C,U]D9C'0O:'1M;#L@8VAA"TM/CQP('-T>6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&(^*#4I/"]B/B8C,38P.R`\8CY# M3TY615)424),12!.3U1%4SPO8CX\+W`^(#QP('-T>6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE M/3-$;&5T=&5R+7-P86-I;F6QE/3-$;&5T=&5R+7-P86-I;F2!C;VYV97)T:6)L92!I;G1O(#PO9F]N=#X\ M9F]N="!S='EL93TS1&QE='1E6QE/3-$;&5T=&5R+7-P M86-I;F6QE/3-$;&5T M=&5R+7-P86-I;F6%B;&4@;VX@3V-T;V)E M2!I;G1E2`S,2P@,C`Q-"XF(S$V M,#L@3VX@86X@87,@8V]N=F5R=&5D(&)A&-E961S('1H92!P2`D,C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&(^*#8I)B,Q-C`[(%-4 M3T-+2$],1$524R8C,30V.R!%455)5%D\+V(^/"]P/B`\<"!S='EL93TS1&UA M6QE/3-$;&5T=&5R+7-P86-I;F6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB2`S,2P@,C`Q-"!A;F0@,C`Q M,RP@=V4@2P@9F]R("0Q+C`P('!E&5R8VES M86)L92!A="`D,BXP,"!P97(@6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$;&5T=&5R+7-P86-I;F2`S,2P@,C`Q,RP@=&AE('!L86-E;65N="!A9V5N=',@96%R M;F5D('=A6QE/3-$;&5T=&5R+7-P86-I;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0^/&9O;G0@6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&(^/&9O M;G0@6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$;&5T=&5R M+7-P86-I;F2!S=&]C:R!O<'1I;VX@=&\@86-Q=6ER92!U<"!T M;R`R,#`L,#`P('-H87)E&5R M8VES92!P'!I65A6QE/3-$;&5T=&5R+7-P86-I;F6QE/3-$;&5T=&5R+7-P86-I;F2!O9B`\ M+V9O;G0^/&9O;G0@2!O=F5R(#,V(&UO;G1H2`S,2P@,C`Q-"P@=V4@'!E;G-E(&9O6QE/3-$;6%R9VEN.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&9O;G0@65A2!O9B`W."XY)2!B87-E9"!O;B!A('!E97(@9W)O=7`@;V8@<'5B;&EC M;'D@=')A9&5D('-T;V-K2P@;V8@97AP96YS92!F M;W(@=&AE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA"TM/CQP('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0^/&(^/&9O;G0@;&%N9STS1%@M3D].13XH-RD\+V9O;G0^/"]B/CQB M/B8C,38P.R`\+V(^/&(^/&9O;G0@;&%N9STS1%@M3D].13Y%05).24Y'4R`H M3$]34RD@4$52(%-(05)%/"]F;VYT/CPO8CX\+W`^(#QP('-T>6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT.BXU M:6X[;6%R9VEN+6)O='1O;3HP:6X[;6%R9VEN+6)O='1O;3HN,#`P,7!T.W1E M>'0M:6YD96YT.C!I;CY%87)N:6YG2!P;W1E;G1I86QL>2!D:6QU=&EV92!S M96-U6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$R+C!P M=#MM87)G:6XM;&5F=#HP:6X[=&5X="UI;F1E;G0Z+C5I;CMM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z,&EN M/B9N8G-P.SPO<#X@/'`@&-L=61E9"!F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^ M)FYB6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[=&5X="UA;&EG;CIC96YT97(^)FYB6QE/3-$ M)W=I9'1H.C0U+C$V)3MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED M('=I;F1O=W1E>'0@,2XP<'0[<&%D9&EN9SHP)SX@/'`@86QI9VX],T1C96YT M97(@'0M86QI M9VXZ8V5N=&5R/B9N8G-P.SPO<#X@/"]T9#X@/"]T6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97(^ M)FYB6QE/3-$)W=I9'1H.C(P+C`V)3MB;W)D97(Z;F]N93MB;W)D97(M M8F]T=&]M.G-O;&ED('=I;F1O=W1E>'0@,2XP<'0[<&%D9&EN9SHP)SX@/'`@ M86QI9VX],T1C96YT97(@6QE/3-$ M)W=I9'1H.C4N,#(E.V)O'0M M86QI9VXZ8V5N=&5R/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$,C`E M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HR,"XP."4[8F]R9&5R M+71O<#IS;VQI9"!W:6YD;W=T97AT(#$N,'!T.V)O6QE M/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG M;CIC96YT97(^/&(^,C`Q,SPO8CX\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#4E M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C4N,#(E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R/B9N8G-P.SPO<#X@/"]T9#X@/"]T6QE/3-$;6%R9VEN.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[;6%R9VEN+6QE9G0Z,3`N,'!T.W1E>'0M M:6YD96YT.BTQ,"XP<'0^)FYB6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0^)FYB6QE/3-$=VED=&@Z,C`N,#8E.V)O6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$=VED=&@Z,C`N M,#@E.V)O'0M M86QI9VXZ6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^ M)FYB6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$=VED=&@Z M,C`N,#8E.W!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$=VED=&@Z,C`N,#@E.W!A9&1I;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0^)FYB6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X M="UA;&EG;CIR:6=H=#XQ+#0P,"PP,#`\+W`^(#PO=&0^(#QT9"!W:61T:#TS M1#4E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C4N,#(E.W!A9&1I M;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#XF(S$U,3L\+W`^(#PO=&0^(#QT M9"!W:61T:#TS1#4E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C4N M,#(E.W!A9&1I;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[;6%R9VEN+6QE9G0Z,3`N,'!T.W1E>'0M:6YD96YT.BTQ M,"XP<'0^0V]N=F5R=&EB;&4@9&5B="H\+W`^(#PO=&0^(#QT9"!W:61T:#TS M1#4E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C4N,#(E.W!A9&1I M;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#XW-C8L-C8W/"]P/B`\+W1D/B`\ M=&0@=VED=&@],T0U)2!V86QI9VX],T1B;W1T;VT@6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$=VED=&@Z,C`N,#@E.W!A9&1I M;F6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB M6QE/3-$;6%R9VEN+6QE9G0Z+C5I;CMB;W)D97(M M8V]L;&%P3IN;VYE/B`\='(@6QE/3-$=VED M=&@Z-2XP,B4[<&%D9&EN9SHP/B`\<"!A;&EG;CTS1&-E;G1E'0M86QI9VXZ M8V5N=&5R/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$-#4E(&-O;'-P M86X],T0S('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HT-2XQ-B4[ M8F]R9&5R.FYO;F4[8F]R9&5R+6)O='1O;3IS;VQI9"!W:6YD;W=T97AT(#$N M,'!T.W!A9&1I;F6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT M97(^/&(^/&9O;G0@2`S,2P\+V9O;G0^/"]B/CPO<#X@ M/"]T9#X@/'1D('=I9'1H/3-$-24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M=VED=&@Z-2XP,B4[<&%D9&EN9SHP/B`\<"!A;&EG;CTS1&-E;G1E'0M86QI M9VXZ8V5N=&5R/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$,B4@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,BXP)3MP861D:6YG.C`^(#QP M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97(^)FYB6QE/3-$=VED=&@Z-2XP,B4[<&%D9&EN9SHP/B`\<"!A M;&EG;CTS1&-E;G1E'0M86QI9VXZ8V5N=&5R/B9N8G-P.SPO<#X@/"]T9#X@ M/'1D('=I9'1H/3-$,C`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HR,"XP-B4[8F]R9&5R.FYO;F4[8F]R9&5R+6)O='1O;3IS;VQI9"!W:6YD M;W=T97AT(#$N,'!T.W!A9&1I;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA M;&EG;CIC96YT97(^/&(^/&9O;G0@6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97(^)FYB6QE/3-$)W=I M9'1H.C(P+C`X)3MB;W)D97(M=&]P.G-O;&ED('=I;F1O=W1E>'0@,2XP<'0[ M8F]R9&5R+6QE9G0Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED('=I;F1O=W1E M>'0@,2XP<'0[8F]R9&5R+7)I9VAT.FYO;F4[<&%D9&EN9SHP)SX@/'`@86QI M9VX],T1C96YT97(@'0M86QI9VXZ8V5N=&5R/B9N8G-P.SPO<#X@/"]T9#X@/"]T6QE/3-$9&ES<&QA>3IN;VYE/B`\=&0@=VED=&@],T0T,B4@=F%L:6=N/3-$ M=&]P('-T>6QE/3-$=VED=&@Z-#(N-S@E.W!A9&1I;F6QE/3-$ M;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR M:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#4E('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C4N,#(E.W!A9&1I;F6QE/3-$=VED=&@Z M,C`N,#@E.V)O6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0^/&9O;G0@6QE M/3-$=VED=&@Z,BXP)3MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&9O;G0@6QE M/3-$9&ES<&QA>3IN;VYE/B`\=&0@=VED=&@],T0T,B4@=F%L:6=N/3-$=&]P M('-T>6QE/3-$=VED=&@Z-#(N-S@E.W!A9&1I;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#X\9F]N="!S='EL93TS1&1I6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0^/&9O;G0@6QE/3-$9&ES<&QA>3IN;VYE/C4L M-#(R+#@U.#PO9F]N=#X\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#4E('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C4N,#(E.W!A9&1I;F6QE/3-$9&ES<&QA>3IN;VYE M/E-T;V-K(&]P=&EO;G,\+V9O;G0^/"]P/B`\+W1D/B`\=&0@=VED=&@],T0U M)2!V86QI9VX],T1B;W1T;VT@6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0^)FYB6QE/3-$=VED=&@Z,C`N,#8E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z-2XP,B4[<&%D9&EN M9SHP/B`\<"!S='EL93TS1&UA6QE/3-$9&ES<&QA M>3IN;VYE/B8C,34Q.SPO9F]N=#X\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#4E M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C4N,#(E.W!A9&1I;F6QE/3-$9&ES<&QA>3IN;VYE/B`\=&0@=VED M=&@],T0T,B4@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-#(N-S@E.W!A M9&1I;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA M;&EG;CIR:6=H=#X\9F]N="!S='EL93TS1&1I6QE/3-$=VED=&@Z-2XP,B4[<&%D9&EN9SHP/B`\<"!S='EL93TS M1&UA6QE M/3-$9&ES<&QA>3IN;VYE/B9N8G-P.SPO9F]N=#X\+W`^(#PO=&0^(#QT9"!W M:61T:#TS1#(P)2!V86QI9VX],T1B;W1T;VT@6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#X\ M9F]N="!S='EL93TS1&1I6QE/3-$;6%R9VEN.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&9O;G0@6QE/3-$=VED=&@Z,BXP)3MP861D:6YG.C`^(#QP M('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&9O M;G0@6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]D,V)D.3`V,U\U8C4R7S1A.#-?.&-C,U]D9C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;6%R M9VEN+6)O='1O;3HR-"XP<'0[=&5X="UI;F1E;G0Z+C5I;CY#87-H('!A:60@ M9'5R:6YG('1H92!P97)I;V0@9F]R.CPO<#X@/'`@6QE/3-$ M;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;6%R9VEN+6QE9G0Z M,3`N,'!T.W1E>'0M:6YD96YT.BTQ,"XP<'0^)FYB6QE/3-$=VED=&@Z M,3,N,R4[<&%D9&EN9SHP/B`\<"!S='EL93TS1&UA6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&(^3FEN92!-;VYT:',F;F)S<#M% M;F1E9"9N8G-P.TIU;'D@,S$L/"]B/CPO<#X@/"]T9#X@/'1D('=I9'1H/3-$ M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XQ."4[<&%D9&EN M9SHP/B`\<"!S='EL93TS1&UA6QE/3-$;6%R9VEN.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[;6%R9VEN+6QE9G0Z,3`N,'!T.W1E>'0M:6YD M96YT.BTQ,"XP<'0^)FYB6QE/3-$=VED=&@Z,3,N,R4[<&%D9&EN9SHP M/B`\<"!S='EL93TS1&UA6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97(^/&(^ M,C`Q-#PO8CX\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#(E('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C(N-#8E.W!A9&1I;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97(^/&(^,C`Q,SPO8CX\+W`^ M(#PO=&0^(#QT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C$N,3@E.W!A9&1I;F6QE/3-$ M=VED=&@Z,3,N,R4[<&%D9&EN9SHP/B`\<"!S='EL93TS1&UA6QE/3-$=VED=&@Z,RXV,B4[ M8F]R9&5R.FYO;F4[<&%D9&EN9SHP/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE M/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG M;CIR:6=H=#XD/"]P/B`\+W1D/B`\=&0@=VED=&@],T0Q,B4@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C,V)3MB;W)D97(Z;F]N93MB;W)D M97(M=&]P.G-O;&ED('=I;F1O=W1E>'0@,2XP<'0[<&%D9&EN9SHP)SX@/'`@ M86QI9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ6QE/3-$=VED=&@Z-2XQ."4[8F]R9&5R.FYO;F4[<&%D9&EN9SHP/B`\ M<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#XD/"]P/B`\+W1D/B`\=&0@ M=VED=&@],T0Q-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$V M+C0R)3MB;W)D97(Z;F]N93MB;W)D97(M=&]P.G-O;&ED('=I;F1O=W1E>'0@ M,2XP<'0[<&%D9&EN9SHP)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA M6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#XF M(S$U,3L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#(E('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C(N-#8E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED M=&@Z,C$N-B4[<&%D9&EN9SHP/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$ M;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;6%R9VEN+7)I9VAT M.C$P+C)P=#MT97AT+6%L:6=N.G)I9VAT/B8C,34Q.SPO<#X@/"]T9#X@/'1D M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XQ M."4[<&%D9&EN9SHP/B`\<"!S='EL93TS1&UA6QE/3-$8F]R9&5R.FYO;F4^ M/"]T9#X@/'1D('=I9'1H/3-$-S(@6QE/3-$8F]R9&5R.FYO;F4^/"]T9#X@/'1D('=I M9'1H/3-$,3,@6QE/3-$8F]R9&5R.FYO;F4^/"]T9#X@/'1D('=I9'1H/3-$-B!S='EL M93TS1&)O7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1&UA6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE M/3-$;&5T=&5R+7-P86-I;F2!O=7(@8VAI968@97AE8W5T M:79E(&]F9FEC97(@9F]R(&AI6YT:&5T:6-A($%G&5C M=71I=F4@;6%Y(')E<75E6YT:&5T:6-A($%G6QE M/3-$;&5T=&5R+7-P86-I;F2`S,2P@,C`Q,RP@=V4@=V5R92!B:6QL M960@)#,S+#DP,"!A;F0@)#$Q-RPV,#`L(')E2P@=6YD97(@ M=&AE(%-Y;G1H971I8V$@06=R965M96YT+B`\+V9O;G0^/&9O;G0@2P@:7,@:6YC M;'5D960@:6X@86-C6EN9R!C;VYD96YS960@8V]N2!3>6YT:&5T:6-A M('1O(&%L;&]W('1H92!#;VUP86YY('1O(&]P=&EM:7IE(&ET6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&9O;G0@2!R971A:6YE65A2`S M,2P@,C`Q-"P@=V4@=V5R92!C:&%R9V5D("0P(&%N9"`D,3`L,#`P+"!R97-P M96-T:79E;'DL('5N9&5R('1H:7,@86=R965M96YT+B8C,38P.R!$=7)I;F<@ M=&AE('1H6QE M/3-$;&5T=&5R+7-P86-I;F2P@:7,@:6YC M;'5D960@:6X@2!P87EA8FQEF4@ M:71S(&-A6QE/3-$;6%R9VEN.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB65A6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&9O;G0@65E2!A;F0@87)E('!R:6UA2!R97-P;VYS:6)L92!F;W(@:71S(&1E=F5L;W!M96YT+B8C,38P.R!!6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE M/3-$;&5T=&5R+7-P86-I;F2!P87EM96YT2XF(S$V,#LF(S$V,#L@5&AE M($QI8V5N6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^ M)FYB2!N96-E2`S,2P@,C`Q-"P@=V4@=V5R92!C:&%R9V5D(#PO9F]N=#X\9F]N M="!S='EL93TS1&QE='1E6QE/3-$;&5T=&5R+7-P86-I;F6QE/3-$;&5T=&5R+7-P86-I;F2!#4TU#('5N9&5R('1H M:7,@86=R965M96YT+B8C,38P.R!!2`S,2P@,C`Q-"XF(S$V,#L@07,@9&ES M8W5S7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1&UA6QE/3-$;&5T=&5R M+7-P86-I;F6QE/3-$;6%R9VEN.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0^)FYB2!T;R!L:71I9V%T:6]N(&%N9"!O=&AE2!L:71I9V%T:6]N+CPO<#X@/'`@ M6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0^/&(^3V9F:6-E($QE87-E/"]B/CPO<#X@/'`@6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^5V4@:&%V M92!A(&QE87-E(&%G2`H=&AE("8C,30W.T]F9FEC92!,96%S928C,30X.RD@=&AA M="!E>'!I2`S,2P@,C`Q-2XF(S$V,#L@1F]R('1H92!T:')E M92!M;VYT:"!P97)I;V1S(&5N9&5D($IU;'D@,S$L(#(P,30@86YD(#(P,3,L M('=E(')E8V]R9&5D("0Y+#0S-"!A;F0@)#$P+#DU,"P@'!E;G-E(&]N('1H92!A8V-O;7!A;GEI;F<@8V]N9&5N2`S,2P@,C`Q-"!A;F0@,C`Q,RP@=V4@ M6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X M="UI;F1E;G0Z+C5I;CXF;F)S<#L\+W`^(#QP('-T>6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^0V]M;6ET;65N=',@=6YD97(@;F]N M+6-A;F-E;&%B;&4@;W!E6QE/3-$=VED=&@Z-2XR<'0[ M<&%D9&EN9SHP/B`\<"!S='EL93TS1&UA'0@,2XP<'0[<&%D M9&EN9SHP)SX@/'`@86QI9VX],T1C96YT97(@6QE/3-$=VED=&@Z-#`N-35P=#MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;6%R9VEN+6QE9G0Z,3`N M,'!T.W1E>'0M:6YD96YT.BTQ,"XP<'0^)FYB'0M86QI9VXZ6QE/3-$8F]R9&5R.FYO;F4^/"]T9#X@/'1D('=I9'1H M/3-$,B!S='EL93TS1&)O'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPO'0M86QI9VXZ:G5S=&EF>3X\9F]N M="!L86YG/3-$6"U.3TY%/B@Q,"DF(S$V,#L@4U5"4T51545.5"!%5D5.5%,\ M+V9O;G0^/"]P/B`\<"!S='EL93TS1&UA'0M86QI9VXZ8V5N=&5R.VQE='1E2!G65A6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C,Q+C5P M=#XF;F)S<#L\+W`^(#QP('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIJ=7-T:69Y/E!U2`H:2D@9W)A;G1E9"!T;R!$&5R8VES92!P M2P@ M:6X@:71S('-O;&4@9&ES8W)E=&EO;BP@86=R965D('1O(&=R86YT('1O($UR M+B!3=V5N3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,V)D.3`V,U\U8C4R7S1A.#-? M.&-C,U]D9C'0O:'1M;#L@ M8VAA'0M:6YD96YT.BXU:6X[;6%R9VEN+6)O='1O;3HP:6X[;6%R9VEN+6)O='1O M;3HN,#`P,7!T.W1E>'0M:6YD96YT.C!I;CXF;F)S<#L\+W`^(#QP('-T>6QE M/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^5&AE(&%C8V]M M<&%N>6EN9R!C;VYD96YS960@8V]N2`S,2P@,C`Q-"P@:&%D(&$@2!T;R!C;VYT:6YU92!A'0M:6YD96YT.BXU:6X^)FYB2`S,2P@,C`Q-"P@=V4@28C,30V.W,@<&QA;FYE9"!A8W1I=FET:65S M('1H6UE;G0@;V8@8V5R=&%I;B!L:6%B:6QI=&EE6UE M;G1S(&]F('1H97-E(&1E9F5R2!D97-P:71E('1H:7,@ M;&%C:R!O9B!P87EM96YT+"!T:&5R92!I2!W M:6QL(&-O;G1I;G5E('1O(&1O('-O+"!A;F0@=&AE(&QO6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CXF;F)S<#L\+W`^(#QP('-T>6QE M/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^5&\@&-H86YG M92!#;VUM:7-S:6]N("AT:&4@)B,Q-#<[4T5#)B,Q-#@[*2!F;W(@86X@:6YI M=&EA;"!P=6)L:6,@;V9F97)I;F<@;V8@=&AE($-O;7!A;GDF(S$T-CMS('-E M8W5R:71I97,N($YO(&%S2!A;F0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,V)D.3`V M,U\U8C4R7S1A.#-?.&-C,U]D9C'0O:'1M;#L@8VAA'0M:6YD96YT.BXU M:6X[;6%R9VEN+6)O='1O;3HP:6X[;6%R9VEN+6)O='1O;3HN,#`P,7!T.W1E M>'0M:6YD96YT.C!I;CXF;F)S<#L\+W`^(#QP('-T>6QE/3-$;6%R9VEN+71O M<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$R+C!P=#MM M87)G:6XM;&5F=#HP:6X[=&5X="UI;F1E;G0Z+C5I;CMM87)G:6XM8F]T=&]M M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z,&EN/E1H M92!A8V-O;7!A;GEI;F<@8V]N9&5N2!O=VYE9"!S=6)S:61I87)Y($%.22XF(S$V,#L@ M06QL(&EN=&5R8V]M<&%N>2!T2!N;W)M86P@2`S,2P@,C`Q-"!A;F0@=&AE(')E2!F;W(@=&AE M('1H2!B92!E>'!E M8W1E9"!F;W(@=&AE('EE87(@96YD960@3V-T;V)E6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$R+C!P=#MM87)G:6XM M;&5F=#HP:6X[=&5X="UI;F1E;G0Z+C5I;CMM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z,&EN/E1H92!U;F%U M9&ET960@8V]N9&5N'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPO'0M:6YD96YT M.BXU:6X[;6%R9VEN+6)O='1O;3HP:6X[;6%R9VEN+6)O='1O;3HN,#`P,7!T M.W1E>'0M:6YD96YT.C!I;CXF;F)S<#L\+W`^(#QP('-T>6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$R+C!P M=#MM87)G:6XM;&5F=#HP:6X[=&5X="UI;F1E;G0Z+C5I;CMM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z,&EN M/E1H92!P2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D M,V)D.3`V,U\U8C4R7S1A.#-?.&-C,U]D9C'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$ M;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE M/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG M;CIC96YT97(^)FYB6QE/3-$)W=I9'1H.C0U+C$V M)3MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED('=I;F1O=W1E>'0@ M,2XP<'0[<&%D9&EN9SHP)SX@/'`@86QI9VX],T1C96YT97(@'0M86QI9VXZ8V5N=&5R/B9N M8G-P.SPO<#X@/"]T9#X@/"]T6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0^)FYB6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97(^)FYB6QE/3-$ M)W=I9'1H.C(P+C`V)3MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED M('=I;F1O=W1E>'0@,2XP<'0[<&%D9&EN9SHP)SX@/'`@86QI9VX],T1C96YT M97(@6QE/3-$)W=I9'1H.C4N,#(E M.V)O6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97(^/&(^ M,C`Q,SPO8CX\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#4E('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C4N,#(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R/B9N M8G-P.SPO<#X@/"]T9#X@/"]T6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[;6%R9VEN+6QE9G0Z,3`N,'!T.W1E>'0M:6YD96YT.BTQ,"XP M<'0^)FYB6QE M/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE M/3-$=VED=&@Z,C`N,#8E.V)O'0M86QI9VXZ6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0^)FYB6QE/3-$=VED=&@Z,C`N,#@E.V)O6QE/3-$ M;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$=VED=&@Z,C`N,#8E.W!A9&1I M;F6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$=VED=&@Z M,C`N,#@E.W!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H M=#XQ+#0P,"PP,#`\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#4E('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C4N,#(E.W!A9&1I;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X M="UA;&EG;CIR:6=H=#XF(S$U,3L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#4E M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C4N,#(E.W!A9&1I;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M;6%R9VEN+6QE9G0Z,3`N,'!T.W1E>'0M:6YD96YT.BTQ,"XP<'0^0V]N=F5R M=&EB;&4@9&5B="H\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#4E('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C4N,#(E.W!A9&1I;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X M="UA;&EG;CIR:6=H=#XW-C8L-C8W/"]P/B`\+W1D/B`\=&0@=VED=&@],T0U M)2!V86QI9VX],T1B;W1T;VT@6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0^)FYB6QE/3-$=VED=&@Z,C`N,#@E.W!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0^)FYB6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$;6%R9VEN+6QE9G0Z+C5I;CMB;W)D97(M8V]L;&%P3IN;VYE/B`\='(@6QE/3-$=VED=&@Z-2XP,B4[<&%D M9&EN9SHP/B`\<"!A;&EG;CTS1&-E;G1E6QE/3-$;6%R9VEN.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97(^/&(^/&9O;G0@ M2`S,2P\+V9O;G0^/"]B/CPO<#X@/"]T9#X@/'1D('=I M9'1H/3-$-24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-2XP,B4[ M<&%D9&EN9SHP/B`\<"!A;&EG;CTS1&-E;G1E6QE/3-$=VED=&@Z,BXP)3MP861D:6YG.C`^(#QP(&%L:6=N/3-$8V5N M=&5R('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UA;&EG;CIC96YT97(^)FYB6QE/3-$=VED=&@Z-2XP,B4[<&%D9&EN9SHP/B`\<"!A;&EG;CTS1&-E;G1E M'0M86QI9VXZ8V5N=&5R/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$ M,C`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HR,"XP-B4[8F]R M9&5R.FYO;F4[8F]R9&5R+6)O='1O;3IS;VQI9"!W:6YD;W=T97AT(#$N,'!T M.W!A9&1I;F6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97(^ M/&(^/&9O;G0@6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UA;&EG;CIC96YT97(^)FYB6QE/3-$)W=I9'1H.C(P+C`X)3MB M;W)D97(M=&]P.G-O;&ED('=I;F1O=W1E>'0@,2XP<'0[8F]R9&5R+6QE9G0Z M;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED('=I;F1O=W1E>'0@,2XP<'0[8F]R M9&5R+7)I9VAT.FYO;F4[<&%D9&EN9SHP)SX@/'`@86QI9VX],T1C96YT97(@ M'0M86QI9VXZ8V5N M=&5R/B9N8G-P.SPO<#X@/"]T9#X@/"]T6QE/3-$9&ES<&QA M>3IN;VYE/B`\=&0@=VED=&@],T0T,B4@=F%L:6=N/3-$=&]P('-T>6QE/3-$ M=VED=&@Z-#(N-S@E.W!A9&1I;F6QE/3-$;6%R9VEN.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\ M+W`^(#PO=&0^(#QT9"!W:61T:#TS1#4E('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C4N,#(E.W!A9&1I;F6QE/3-$=VED=&@Z,C`N,#@E.V)O'0M86QI9VXZ6QE M/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&9O;G0@6QE/3-$=VED=&@Z,BXP M)3MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0^/&9O;G0@6QE/3-$9&ES<&QA>3IN M;VYE/B`\=&0@=VED=&@],T0T,B4@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED M=&@Z-#(N-S@E.W!A9&1I;F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X M="UA;&EG;CIR:6=H=#X\9F]N="!S='EL93TS1&1I6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&9O;G0@ M6QE/3-$9&ES<&QA>3IN;VYE/C4L-#(R+#@U.#PO9F]N M=#X\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#4E('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C4N,#(E.W!A9&1I;F6QE/3-$9&ES<&QA>3IN;VYE/E-T;V-K(&]P=&EO M;G,\+V9O;G0^/"]P/B`\+W1D/B`\=&0@=VED=&@],T0U)2!V86QI9VX],T1B M;W1T;VT@6QE M/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB6QE M/3-$=VED=&@Z,C`N,#8E.W!A9&1I;F'0M M86QI9VXZ6QE/3-$=VED=&@Z-2XP,B4[<&%D9&EN9SHP/B`\<"!S='EL M93TS1&UA6QE/3-$9&ES<&QA>3IN;VYE/B8C,34Q M.SPO9F]N=#X\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#4E('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C4N,#(E.W!A9&1I;F6QE/3-$9&ES<&QA>3IN;VYE/B`\=&0@=VED=&@],T0T,B4@=F%L M:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-#(N-S@E.W!A9&1I;F6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#X\ M9F]N="!S='EL93TS1&1I6QE/3-$ M=VED=&@Z-2XP,B4[<&%D9&EN9SHP/B`\<"!S='EL93TS1&UA6QE/3-$9&ES<&QA>3IN M;VYE/B9N8G-P.SPO9F]N=#X\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#(P)2!V M86QI9VX],T1B;W1T;VT@6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#X\9F]N="!S='EL93TS M1&1I6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0^/&9O;G0@6QE/3-$=VED=&@Z,BXP)3MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&9O;G0@6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0^)FYB7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO M6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M;6%R9VEN+6QE9G0Z,3`N,'!T.W1E>'0M:6YD96YT.BTQ,"XP<'0^)FYB6QE/3-$=VED=&@Z,3,N,R4[<&%D9&EN9SHP/B`\<"!S='EL93TS1&UA6QE M/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&(^3FEN92!- M;VYT:',F;F)S<#M%;F1E9"9N8G-P.TIU;'D@,S$L/"]B/CPO<#X@/"]T9#X@ M/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z M,2XQ."4[<&%D9&EN9SHP/B`\<"!S='EL93TS1&UA6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;6%R9VEN+6QE9G0Z,3`N M,'!T.W1E>'0M:6YD96YT.BTQ,"XP<'0^)FYB6QE/3-$=VED=&@Z,3,N M,R4[<&%D9&EN9SHP/B`\<"!S='EL93TS1&UA6QE M/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG M;CIC96YT97(^/&(^,C`Q-#PO8CX\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#(E M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C(N-#8E.W!A9&1I;F6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97(^/&(^ M,C`Q,SPO8CX\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C$N,3@E.W!A9&1I;F6QE/3-$=VED=&@Z,3,N,R4[<&%D9&EN9SHP/B`\<"!S='EL93TS M1&UA6QE/3-$ M=VED=&@Z,RXV,B4[8F]R9&5R.FYO;F4[<&%D9&EN9SHP/B`\<"!A;&EG;CTS M1')I9VAT('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[=&5X="UA;&EG;CIR:6=H=#XD/"]P/B`\+W1D/B`\=&0@=VED=&@],T0Q M,B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C,V)3MB;W)D M97(Z;F]N93MB;W)D97(M=&]P.G-O;&ED('=I;F1O=W1E>'0@,2XP<'0[<&%D M9&EN9SHP)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA6QE/3-$=VED=&@Z-2XQ."4[8F]R9&5R.FYO;F4[ M<&%D9&EN9SHP/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#XD/"]P M/B`\+W1D/B`\=&0@=VED=&@],T0Q-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.C$V+C0R)3MB;W)D97(Z;F]N93MB;W)D97(M=&]P.G-O;&ED M('=I;F1O=W1E>'0@,2XP<'0[<&%D9&EN9SHP)SX@/'`@86QI9VX],T1R:6=H M="!S='EL93TS1&UA6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA M;&EG;CIR:6=H=#XF(S$U,3L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#(E('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C(N-#8E.W!A9&1I;F6QE/3-$=VED=&@Z,C$N-B4[<&%D9&EN9SHP/B`\<"!A;&EG;CTS1')I M9VAT('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M;6%R9VEN+7)I9VAT.C$P+C)P=#MT97AT+6%L:6=N.G)I9VAT/B8C,34Q.SPO M<#X@/"]T9#X@/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$=VED=&@Z,2XQ."4[<&%D9&EN9SHP/B`\<"!S='EL93TS1&UA6QE/3-$ M8F]R9&5R.FYO;F4^/"]T9#X@/'1D('=I9'1H/3-$-S(@6QE/3-$8F]R9&5R.FYO;F4^ M/"]T9#X@/'1D('=I9'1H/3-$,3,@6QE/3-$8F]R9&5R.FYO;F4^/"]T9#X@/'1D('=I M9'1H/3-$-B!S='EL93TS1&)O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D M,V)D.3`V,U\U8C4R7S1A.#-?.&-C,U]D9C'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1&UA6QE/3-$;6%R9VEN+6QE9G0Z,3,P+C5P=#MB;W)D M97(M8V]L;&%P6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0^)FYB6QE/3-$)W=I9'1H.C$Q,2XW-7!T.V)O'0M86QI9VXZ8V5N=&5R/EEE M87(@16YD960@3V-T;V)E6QE/3-$=VED=&@Z,2XP<'0[<&%D M9&EN9SHP/B`\<"!S='EL93TS1&UA'0@,2XP M<'0[<&%D9&EN9SHP)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA6QE/3-$=VED=&@Z-#`N-35P=#MP861D:6YG M.C`^(#QP('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[;6%R9VEN+6QE9G0Z,3`N,'!T.W1E>'0M:6YD96YT.BTQ,"XP<'0^,C`Q M-2`\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,2XP<'0[<&%D9&EN9SHP/B`\<"!S='EL93TS1&UA'0M86QI9VXZ6QE/3-$=VED=&@Z,2XP M<'0[<&%D9&EN9SHP/B`\<"!S='EL93TS1&UA'0@,2XP<'0[8F]R M9&5R+6QE9G0Z;F]N93MB;W)D97(M8F]T=&]M.F1O=6)L92!W:6YD;W=T97AT M(#(N,C5P=#MB;W)D97(M6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#XD)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[ M(#$X+#DP,#PO<#X@/"]T9#X@/"]T6QE/3-$8F]R9&5R.FYO;F4^/"]T9#X@/'1D('=I9'1H/3-$ M-B!S='EL93TS1&)O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,V)D.3`V,U\U M8C4R7S1A.#-?.&-C,U]D9C'0O:'1M;#L@8VAA'0^)TIA;G5A3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)T%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]D,V)D.3`V,U\U8C4R7S1A.#-?.&-C,U]D9C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E8W1E9"!6;VQA=&EL:71Y(%)A=&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)T)L86-K+5-C:&]L97,@<')I8VEN9R!M M;V1E;#QS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E8W1E9"!6;VQA=&EL:71Y(%)A=&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)W-H87)E2!P87EA8FQE(&]N M($]C=&]B97(@,3DL(#(P,3$\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H1&5T86EL'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E8W1E9"!497)M/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E8W1E9"!6;VQA=&EL:71Y(%)A=&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO&-L=61E9"!F'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&-L=61E M9"!F7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N M/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!" M;V%R9"!C:&%I2!C;VYT'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO2!O=7(@0F]A6%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#0Y+#`P,#QS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,V)D.3`V,U\U M8C4R7S1A.#-?.&-C,U]D9C'0O:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC M XML 19 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

Convertible Notes (Details) (Convertible Debt, USD $)
9 Months Ended

Jul. 31, 2014

Convertible Debt Outstanding $ 10,000

October 2010 through April 2011

Net proceeds from sale of Convertible Notes $ 726,550

Debt Instrument, Convertible, Terms of Conversion Feature The Convertible Notes were initially convertible into shares of our common stock at $.30 per share (the “Conversion Price”).

Debt Conversion, Converted Instrument, Type shares of our common stock

Debt Instrument, Interest Rate Terms Convertible Notes do not bear interest

Debt Instrument, Payment Terms originally payable on October 19, 2011

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_ConvertibleDebtOutstanding

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The type of the financial instrument that the original debt is being converted into (for example, new debt, common stock, preferred stock, etc.) in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentType

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentPaymentTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 20 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Bridge Notes: PA Bridge Note Warrants (Details) (USD $)
3 Months Ended 9 Months Ended

Jul. 31, 2014

Jul. 31, 2014

PA Bridge Note Warrants, Debt Discount Amortized $ 8,292 $ 10,825

PA Bridge Note Warrants

Assets, Fair Value Disclosure $ 35,700 $ 35,700

Fair Value Measurements, Valuation Techniques Black-Scholes pricing model

Fair Value Assumptions, Expected Term 5 years

Fair Value Assumptions, Risk Free Interest Rate 1.69%

Fair Value Assumptions, Expected Volatility Rate 78.90%

X

- Definition

The amount of debt discount related to PA bridge note warrantss amortized during the indicated period.

+ References

No definition available.

+ Details

Name: fil_PaBridgeNoteWarrantsDebtDiscountAmortized

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the inputs and valuation technique(s) used to measure fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementsValuationTechniques

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity (Details) (USD $)
9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2014

Common Stock

Jul. 31, 2014

Common Stock

Jul. 31, 2014

Common Stock Purchase Warrants

Jul. 31, 2014

Stock options

Jul. 31, 2014

Stock options

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value $ 224,000 $ 17,160 $ 58,400

Allocated Share-based Compensation Expense 56,000 168,000 2,433 7,300

Sale of Units, Shares 25,000 260,000

Sale of Units, price per unit $ 1.00 $ 1.00

Sale of Units, Value $ 24,956 $ 227,645

Fair Value Assumptions, Expected Term 5 years

Fair Value Assumptions, Risk Free Interest Rate 1.37%

Fair Value Assumptions, Expected Volatility Rate 78.90%

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_SaleOfUnitsPricePerUnit

Namespace Prefix: fil_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_SaleOfUnitsShares

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_SaleOfUnitsValue

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 22 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

Earnings (loss) Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)
3 Months Ended 9 Months Ended

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2014

Jul. 31, 2013

Warrants

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6,358,358 5,422,858 6,358,358 5,422,858

Stock options

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,400,000 1,400,000

Convertible Debt

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 766,667 ^[1] 66,667 ^[1] 766,667 ^[1] 66,667 ^[1]

[1] Assumes Bridge Note conversion price of $1.00 per share see Note 4 for conversion price calculations.

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 23 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Going Concern, Management's Plans and Basis of Presentation
9 Months Ended

Jul. 31, 2014

Notes

Going Concern, Management's Plans and Basis of Presentation
(2) GOING CONCERN, MANAGEMENT’S PLANS AND BASIS OF PRESENTATION

Going Concern and Management’s Plans

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since our inception in August 2007, we have not generated revenue, incurred operating losses, and as of July 31, 2014, had a retained deficit $6,019,984. Further, as of July 31, 2014, our cash balance was $219,035 and we had a working capital deficit of $1,198,149. These conditions raise substantial doubt about our ability to continue as a going concern.

During the nine months ended July 31, 2014, we sold $700,000 in Bridge Notes (defined below) receiving net proceeds of $606,318 after payment of offering expenses. Management believes that existing cash on hand will be sufficient to fund the Company’s planned activities through at least the end of our fiscal year. This assumes that we continue to defer payment of certain liabilities to our officers but allows for some payments to be made to CSMC for accrued research and development expenses. Additionally, certain key professionals such as legal counsel have also had payments deferred and the proceeds from the Bridge Notes will allow for some partial payments of these deferred balances but not payment in full. While these parties have continued to work with the Company despite this lack of payment, there is no assurance they will continue to do so, and the loss of a key management member, or the loss of CSMC as a research partner, could have a material adverse effect on the Company’s business prospects.

To raise sufficient capital to fund the Company’s business plan, we plan on filing a registration statement with the Securities and Exchange Commission (the “SEC”) for an initial public offering of the Company’s securities. No assurance can be given that this effort will be successful or adequately capitalize the Company.

In the event that we cannot raise sufficient capital within the required timeframe, it will have a material adverse effect on the Company’s liquidity, financial condition and business prospects or force the Company out of business. The accompanying financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from an inability of the Company to continue as a going concern.

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Arrogene and its wholly owned subsidiary ANI. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries), which in the opinion of management, are necessary to present fairly the financial position at July 31, 2014 and the results of operations and cash flows of the Company for the three and nine months ended July 31, 2014 and 2013. Operating results for the nine months ended July 31, 2014, are not necessarily indicative of the results that may be expected for the year ended October 31, 2014.

The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and footnotes thereto for the year ended October 31, 2013 filed on April 2, 2014.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods. Actual results may differ from these estimates.

Adoption of New Accounting Pronouncement

In June 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance (“ASU 2014-10”), which eliminates the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. Additionally, ASU 2014-10 eliminates the separate requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flow and shareholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective for fiscal years beginning after December 15, 2014 and interim periods therein, with early adoption permitted. The Company has adopted ASU 2014-10 effective with the filing of this Quarterly Report on Form 10-Q.

X

- Definition

The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

Supplemental Disclosure of Cash Flow Information: Schedule of Cash Flow, Supplemental Disclosures (Details) (USD $)
9 Months Ended

Jul. 31, 2014

Jul. 31, 2013

Details

Interest Paid $ 435 $ 561

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Balance Sheets (July 31, 2014 unaudited) (USD $)

Jul. 31, 2014

Oct. 31, 2013

Current assets:

Cash and cash equivalents $ 219,035 $ 13,822

Prepaid expenses and deposit 20,142 13,709

Debt offering costs 92,968

Total current assets 332,145 27,531

Property and equipment, net 928 1,705

Total assets 333,073 29,236

Current liabilities:

Accrued compensation 220,690 85,280

Accrued research expenses payable to CSMC 258,091 229,003

Accounts Payable and accrued expenses 438,043 128,368

Bridge notes 554,470 ^[1] ^[1]

Related party payables 49,000 39,000

Convertible notes 10,000 10,000

Total current liabilities 1,530,294 491,651

Total liabilities 1,530,294 491,651

STOCKHOLDERS' EQUITY (DEFICIT):

Preferred stock ^[2] ^[2]

Common stock 2,138 ^[3] 2,135 ^[4]

Additional paid-in capital 4,820,625 4,287,289

Retained Deficit (6,019,984) (4,751,839)

Total stockholders' equity (deficit) (1,197,221) (462,415)

Total liabilities and stockholders' equity (deficit) $ 333,073 $ 29,236

[1] Less discount of $145,530

[2] Preferred stock, $.0001 par value 10,000,000 shares authorized, none issued.

[3] Common stock, $.0001 par value; 100,000,000 shares authorized; 21,375,860 shares issued and outstanding.

[4] Common stock, $.0001 par value; 100,000,000 shares authorized; 21,350,860 shares issued and outstanding.

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_AccruedResearchExpensesPayableToCSMC

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, and other costs not separately disclosed in the balance sheet that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.

+ References

No definition available.

+ Details

Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 7

+ Details

Name: us-gaap_BridgeLoan

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_ConvertibleDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6386993&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_UnamortizedDebtIssuanceExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 26 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Statements of Cash Flows (unaudited) (USD $)
9 Months Ended 84 Months Ended

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2014

CASH FLOWS FROM OPERATING ACTIVITIES:

Net Income (Loss) $ (1,268,145) $ (784,458)

Adjustments to reconcile Net Income (Loss) to net cash used in operating activities:

Amortization of debt placement costs and debt discount 96,683

Share-based payment expense 344,883

Contributed services 90,000

Depreciation expense 777 1,174

(Increase) decrease in prepaid services and deposit (6,433) (7,402)

Increase (decrease) in other payables and accrued expenses 316,174 204,700

Net cash used in operating activities (426,061) (585,986)

CASH FLOWS FROM FINANCING ACTIVITIES:

Net proceeds from sale of Units 24,956 ^[1] 227,645 ^[1] ^[1]

Net proceeds from sale of Bridge Notes 606,318

Net cash provided by financing activities 631,274 227,645

Net increase (decrease) in cash 205,213 (358,341)

Cash and cash equivalents at the beginning of period 13,822 539,727

Cash and cash equivalents at the end of period $ 219,035 $ 181,386 $ 219,035

[1] At $1.00 per Unit

X

- Definition

The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDepositOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Noncash charitable contributions made by the entity during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_NoncashContributionExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a borrowing not otherwise defined in the taxonomy having initial term of repayment within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromOtherShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow resulting from the sale of an interest in a corporate unit during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfInterestInCorporateUnit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 27 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies (Details) (USD $)
3 Months Ended 9 Months Ended

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2014

Jul. 31, 2013

Details

Operating Leases, Rent Expense $ 9,434 $ 10,950 $ 31,880 $ 30,392

X

- Definition

Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

No definition available.

+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Supplemental Disclosure of Cash Flow Information: Schedule of Cash Flow, Supplemental Disclosures (Tables)
9 Months Ended

Jul. 31, 2014

Tables/Schedules

Schedule of Cash Flow, Supplemental Disclosures

Nine Months Ended July 31,

2014

2013

Interest

$

435

$

561

Income taxes

—

—

X

- Definition

Tabular disclosure of supplemental cash flow information for the periods presented.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies: Schedule of Commitments under non-cancelable operating leases (Details) (USD $)

Jul. 31, 2014

Commitments under non-cancelable operating leases $ 18,900

Year ending October 31, 2014

Commitments under non-cancelable operating leases 8,100

Year ending October 31, 2015

Commitments under non-cancelable operating leases $ 10,800

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_CommitmentsUnderNonCancelableOperatingLeases

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 30 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business and Overview (Details)
9 Months Ended

Jul. 31, 2014

Entity Incorporation, Date of Incorporation Dec. 07, 2006

Arrogene Nanotechnology, Inc.

Business Acquisition, Effective Date of Acquisition January 11, 2012

Business Acquisition, Name of Acquired Entity Arrogene Nanotechnology, Inc. (“ANI”)

Business Acquisition, Description of Acquired Entity a company focused on oncology

X

- Definition

Date when an entity was incorporated

+ References

No definition available.

+ Details

Name: dei_EntityIncorporationDateOfIncorporation

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Month, date and year in which the acquirer obtains control of the acquiree.

+ References

No definition available.

+ Details

Name: us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition

Namespace Prefix: us-gaap_

Data Type: us-types:dateStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Name of the acquired entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionNameOfAcquiredEntity

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 32 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business and Overview
9 Months Ended

Jul. 31, 2014

Notes

Business and Overview
(1) BUSINESS AND OVERVIEW

Arrogene, Inc. (“Arrogene” f/k/a SRKP 16, Inc.), was incorporated under the laws of the State of Delaware on December 7, 2006. On January 11, 2012, we consummated a reverse merger transaction (the “Reverse Merger”) with Arrogene Nanotechnology, Inc. (“ANI”), a company focused on oncology. Hereafter, SRKP 16, Inc., Arrogene and ANI are collectively referred to as the “Company.” Effective September 4, 2012, SRKP 16, Inc. officially changed its name to Arrogene, Inc.

The Company was founded to commercialize both new cancer treatments and imaging targeting technology as well as a proprietary molecular delivery platform that interferes with those targets in order to inhibit and finally eradicate tumor progression. The Company is the exclusive licensee to certain intellectual property rights owned by Cedars Sinai Medical Center (“CSMC”) in Los Angeles, one of the nation’s premiere research institutions (the “License”). CSMC has developed a family of related nano-biopolymers conjugates (collectively referred to here as Polycefin ), believed capable of acting as a drug delivery and targeting platform for cancer therapy and imaging.

We plan on commercializing our products using a licensing and cost sharing strategy, seeking to enter into arrangements with major pharmaceutical companies with existing cancer therapy drugs facing issues relating to patent expirations, market expansion or contraction. It is our goal to only commence later stage clinical trials with a commitment from a licensee to complete Phase II and III clinical trials, predicated on the successful outcome of each phase, and go to market, if approval is received. Further, we are also exploring use of Polycefin as a potential medical diagnostic product(s) for oncology related applications. We also have developed important related intellectual properties surrounding Laminin-411. Pre-clinical investigation is also on-going on methods of inhibiting Laminin-411 as a therapeutic agent, which could be conjugated in various forms of Polycefin in the future.

The majority, of our planned products will require approval or marketing clearance from the United States Food and Drug Administration (the “FDA”). To date we have not filed any applications with the FDA, but we have begun the process of validating our Laboratory Development Test (“LDT”) with applicable regulators.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Balance Sheets - Parenthetical (July 31, 2014 unaudited) (USD $)

Jul. 31, 2014

Oct. 31, 2013

CONDENSED CONSOLIDATED BALANCE SHEETS

Preferred Stock, Par Value $ 0.0001 $ 0.0001

Preferred Stock, Shares Authorized 10,000,000 10,000,000

Preferred Stock, Shares Issued 0 0

Common Stock, Par Value $ 0.0001 $ 0.0001

Common Stock, Shares Authorized 100,000,000 100,000,000

Common Stock, Shares Issued 21,375,860 21,375,860

Common Stock, Shares Outstanding 21,350,860 21,350,860

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events
9 Months Ended

Jul. 31, 2014

Notes

Subsequent Events
(10) SUBSEQUENT EVENTS

In August 2014, Dr. Randolphe Swenson, Jr. was elected to serve as a member of the Board of Directors. In consideration of his agreement to serve as a member of the Board of Directors, the Company granted to Dr. Swenson non-qualified options to purchase for five (5) years 50,000 shares of common stock at an exercise price of $1.00 per share, which options are deemed immediately vested.

The Company also entered into a Consultation and Securities Compensation Agreement between the Company, on the one hand and Dr. Swenson, pursuant to which Dr. Swenson was engaged to serve as a consultant to the Company for a term of six (6) months, to oversee and supervise an executive search to recruit a new CEO under the direction and supervision of the Board of Directors.

Pursuant to the Consultation and Securities Compensation Agreement and in consideration of his services as a consultant to conduct a CEO recruitment search, the Company (i) granted to Dr. Swenson non-qualified stock options exercisable for five (5) years to purchase an aggregate of 25,000 shares of common stock at an exercise price of $1.00, and (ii) conditioned on the Company successfully engaging a new CEO on terms acceptable to the Board of Directors during the term of Mr. Swenson’s consultancy, in its sole discretion, agreed to grant to Mr. Swenson additional non-qualified stock options exercisable for five (5) years to purchase an additional 35,000 shares of common stock at an exercise price of $1.00 per share. All of such options will be fully vested and exercisable upon grant.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
9 Months Ended

Jul. 31, 2014

Sep. 10, 2014

Document and Entity Information:

Entity Registrant Name ARROGENE, INC

Document Type 10-Q

Document Period End Date Jul. 31, 2014

Amendment Flag false

Entity Central Index Key 0001403792

Current Fiscal Year End Date --10-31

Entity Common Stock, Shares Outstanding 21,375,860

Entity Filer Category Smaller Reporting Company

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Well-known Seasoned Issuer No

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q3

Entity Incorporation, Date of Incorporation Dec. 07, 2006

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

Date when an entity was incorporated

+ References

No definition available.

+ Details

Name: dei_EntityIncorporationDateOfIncorporation

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_DocumentAndEntityInformationAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Going Concern, Management's Plans and Basis of Presentation: Going Concern and Management's Plans (Policies)
9 Months Ended

Jul. 31, 2014

Policies

Going Concern and Management's Plans
Going Concern and Management’s Plans

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since our inception in August 2007, we have not generated revenue, incurred operating losses, and as of July 31, 2014, had a retained deficit $6,019,984. Further, as of July 31, 2014, our cash balance was $219,035 and we had a working capital deficit of $1,198,149. These conditions raise substantial doubt about our ability to continue as a going concern.

During the nine months ended July 31, 2014, we sold $700,000 in Bridge Notes (defined below) receiving net proceeds of $606,318 after payment of offering expenses. Management believes that existing cash on hand will be sufficient to fund the Company’s planned activities through at least the end of our fiscal year. This assumes that we continue to defer payment of certain liabilities to our officers but allows for some payments to be made to CSMC for accrued research and development expenses. Additionally, certain key professionals such as legal counsel have also had payments deferred and the proceeds from the Bridge Notes will allow for some partial payments of these deferred balances but not payment in full. While these parties have continued to work with the Company despite this lack of payment, there is no assurance they will continue to do so, and the loss of a key management member, or the loss of CSMC as a research partner, could have a material adverse effect on the Company’s business prospects.

To raise sufficient capital to fund the Company’s business plan, we plan on filing a registration statement with the Securities and Exchange Commission (the “SEC”) for an initial public offering of the Company’s securities. No assurance can be given that this effort will be successful or adequately capitalize the Company.

In the event that we cannot raise sufficient capital within the required timeframe, it will have a material adverse effect on the Company’s liquidity, financial condition and business prospects or force the Company out of business. The accompanying financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from an inability of the Company to continue as a going concern.

X

- Definition

Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.

+ References

No definition available.

+ Details

Name: us-gaap_LiquidityDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Statements of Operations (unaudited) (USD $)
3 Months Ended 9 Months Ended

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2014

Jul. 31, 2013

OPERATING EXPENSES:

Research and development $ 82,497 $ 132,592 $ 271,449 $ 317,084

General and administrative 312,827 147,799 876,494 466,813

Operating Expenses 395,324 280,391 1,147,943 783,897

Income (Loss) from operations (395,324) (280,391) (1,147,943) (783,897)

OTHER INCOME (EXPENSE):

Interest (94,790) (278) (120,202) (561)

Other Income (expense) (94,790) (278) (120,202) (561)

Net Income (Loss) $ (490,114) $ (280,669) $ (1,268,145) $ (784,458)

Weighted Average Shares Outstanding, Basic and diluted 21,375,860 21,350,860 21,370,457 21,289,358

Loss Per Share, Basic and diluted $ (0.02) $ (0.01) $ (0.06) $ (0.04)

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_WeightedAverageSharesOutstandingBasicAndDiluted

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Reflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.4)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 4

-Article 7

+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6386349&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 38 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity
9 Months Ended

Jul. 31, 2014

Notes

Stockholders' Equity
(6) STOCKHOLDERS’ EQUITY

Common Stock

On August 29, 2013, we entered into an agreement for investor relation services that requires us to issue up to 400,000 shares of common stock as a component of the consideration for the services. The shares are issuable in 100,000 increments for each quarter of service rendered. We valued these shares at $224,000 using the Black-Scholes option-pricing model and are recognizing expense over the 12 months the services are being rendered. For the three months and nine months ended July 31, 2014, we recorded $56,000 and $168,000, respectively, of stock compensation expense which is included in general and administrative expense in the accompanying condensed consolidated statements of operations with a corresponding increase in accounts payable and other accrued expenses on the accompanying condensed consolidated balance sheet.

Units

During the nine months ended July 31, 2014 and 2013, we sold 25,000 and 260,000 units (the “Units”), respectively, for $1.00 per Unit, receiving net proceeds of $24,956 and $227,645, respectively. Each Unit consists of (i) one share of common stock, and (ii) two warrants with one warrant exercisable at $1.50 per share and one warrant exercisable at $2.00 per share. (the “Unit Warrants”). The Unit Warrants expire five years from the date of issuance.

Warrants

In connection with the sale of the Units during nine months ended July 31, 2013, the placement agents earned warrants to acquire 78,000 shares of common stock consisting of 26,000 warrants exercisable at $1.00 per share, 26,000 warrants exercisable at $1.50 per share and 26,000 warrants exercisable at $2.00 per share. Each warrant expires five years from the date of issuance. We valued these warrants at $17,160 using the Black Scholes option-pricing model. We recorded the warrants as a reduction to the net proceeds from the sale of the Units with a corresponding increase to additional paid in capital. The placement agents voluntarily agreed to forgo the earning of warrants in connection with the Unit sale that took place during the nine months ended July 31, 2014.

As of July 31, 2014, we had 6,358,358 warrants outstanding with weighted average remaining lives of 31 months and a weighted average exercise price of $1.44.

Stock Options

On November 1, 2013, we issued a non-statutory stock option to acquire up to 200,000 shares of common stock with an exercise price of $1.00 per share to a consultant for providing certain services as defined in the consulting agreement. The option expires 7 years from the date of grant. The options vest as follows: (i) as to 100,000 options, vesting shall occur 1/3 on each one year anniversary date of the consulting agreement (“Vesting 1”) and (ii) as to 100,000 options, vesting shall occur upon the closing of certain transactions as defined in the agreement at a rate of 2 stock options for each $100 received by the Company in a deal or transaction resulting from the efforts of the consultant (“Vesting 2”). We valued this option at $58,400 using the Black Scholes option-pricing model using the following assumptions: option life 5 years, risk free interest rate 1.37%, and annualized volatility of 78.9% based on a peer group of publicly traded common stocks. Stock options issued to non-employees are remeasured at each reporting date and the cumulative expense is adjusted based on the remeasured grant. We are recognizing expense for this option as the underlying services are provided, ratably over 36 months for Vesting 1, and upon the occurrence of a vesting event for Vesting 2. For the three and nine months ended July 31, 2014, we recognized $2,433 and $7,300, respectively, of expense for this option which is included in general and administrative expense on the accompanying condensed consolidated statements of operations.

In April 2014, we issued stock options to acquire 1,200,000 shares of common stock to certain employees and consultants with an exercise price of $1.00 per share. The options expire 7 years from the date of grant. The options vest under terms ranging from immediately to 1/3 on each anniversary date from the date of grant. We valued these options at $352,800 using the Black Scholes option-pricing model using the following assumptions: option life 5 years, risk free interest rate 1.65%, and annualized volatility of 78.9% based on a peer group of publicly traded stocks. We are recognizing expense for these options over the respective vesting periods. For the three and nine months ended July 31, 2014, we recognized $56,066 and $169,583, respectively, of expense for these options which is included in general and administrative expense on the accompanying condensed consolidated statements of operations.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Convertible Notes
9 Months Ended

Jul. 31, 2014

Notes

Convertible Notes
(5) CONVERTIBLE NOTES

Commencing October 2010 through April 2011, we sold in private transactions an aggregate of $726,550 of Convertible Notes. The Convertible Notes were initially convertible into shares of our common stock at $.30 per share (the “Conversion Price”). The Convertible Notes do not bear interest and were originally payable on October 19, 2011. The Convertible Notes are secured by a first lien security interest on all of our tangible and intangible assets. We did not repay the Convertible Notes by the maturity date and the notes were therefore technically in default. During the year ended October 31, 2012, agreed to reduce the conversion price of the Convertible Notes to $.15 per share. $10,000 of Convertible Notes remains outstanding as of July 31, 2014. On an as converted basis, as of July 31, 2014, the estimated value of the Convertible Notes exceeds the principal balance by $27,333.

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies: Schedule of Commitments under non-cancelable operating leases (Tables)
9 Months Ended

Jul. 31, 2014

Tables/Schedules

Schedule of Commitments under non-cancelable operating leases

Year Ended October 31,

2014

$ 8,100

2015

10,800

$ 18,900

X

- Definition

Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.

+ References

No definition available.

+ Details

Name: us-gaap_LongTermPurchaseCommitmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Going Concern, Management's Plans and Basis of Presentation: Basis of Presentation (Policies)
9 Months Ended

Jul. 31, 2014

Policies

Basis of Presentation
Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Arrogene and its wholly owned subsidiary ANI. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries), which in the opinion of management, are necessary to present fairly the financial position at July 31, 2014 and the results of operations and cash flows of the Company for the three and nine months ended July 31, 2014 and 2013. Operating results for the nine months ended July 31, 2014, are not necessarily indicative of the results that may be expected for the year ended October 31, 2014.

The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and footnotes thereto for the year ended October 31, 2013 filed on April 2, 2014.

X

- Definition

The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transactions
9 Months Ended

Jul. 31, 2014

Notes

Related Party Transactions
Related Party Transactions

Consulting Agreements

We have an agreement with an entity controlled by our chief executive officer for his part-time personal services as CEO. The agreement is referred to as the Synthetica Agreement. In December 2013, the Synthetica Agreement was amended so that the compensation paid for the services of our CEO is capped at $1 per annum effective January 1, 2014. However, our chief executive may request that his compensation revert back to the original terms of the Synthetica Agreement with 30 days written notice. Under the original terms, there was no monthly retainer or minimum billing amount but the maximum that could be charged to us in any given month was $15,000. During the three and nine months ended July 31, 2014, we were billed $0 and $20,000, respectively, under the Synthetica Agreement. During the three and nine months ended July 31, 2013, we were billed $33,900 and $117,600, respectively, under the Synthetica Agreement. At July 31, 2014 and October 31 2013, $67,600 and $47,600, respectively, is included in accrued compensation on the accompanying condensed consolidated balance sheets resulting from a voluntary deferral of fees due under the agreement, agreed to by Synthetica to allow the Company to optimize its cash flow.

In September 2010, we entered into a business and financial consulting agreement with an entity controlled by our Board chairman for operational consulting services. The agreement was for an initial term of 12 months with an automatic 12 month renewal period unless terminated by either party upon 30 days written notice. The agreement is now on a month-to-month basis. There is no monthly retainer or minimum billing amount but the maximum that can be billed to us in a given month cannot exceed $10,000. Effective January 2014, the fees for this agreement were capped at $1.00 per year. During the three and nine months ended July 31, 2014, we were charged $0 and $10,000, respectively, under this agreement. During the three and nine months ended July 31, 2013, we were charged $20,100 and $75,100, respectively, under this agreement which is included in general and administrative expense on the accompanying condensed consolidated statements of operations. At July 31, 2014 and October 31, 2013, $49,000 and $39,000, respectively, is included in related party payables on the accompanying condensed consolidated balance sheets resulting from a voluntary deferral of fees due under the agreement, agreed to by our Board chairman, to allow the Company to optimize its cash flow.

Contributed Services

As discussed above, effective January 1, 2014, the Company’s chief executive officer and Board chairman began to provide their services for $1 per year. The fair value of those services has been recorded as an expense in the accompanying condensed consolidated financial statements based on the estimated fair value for such services, with a corresponding credit to additional paid in capital. The fair value of the services was estimated based on the terms of the respective agreements prior to January 1, 2014. Contributed services were $45,000 and $90,000, respectively, for the three and nine months ended July 31, 2014.

CSMC

Certain founders and directors of the Company are employees of CSMC. These individuals are also the inventors of the Polycefin technology and are primarily responsible for its development. As described further in Note 3 above, we have an exclusive license agreement with CSMC for this technology.

The License requires royalty payments equal to 3.5% of the gross sales price and other forms of consideration (such as milestone and sublicense payments), as defined in the agreement, on all products using the licensed technology. The License also requires us to achieve certain milestones as described in Note 3.

In December 2012, we entered into an agreement with CSMC to support certain activities within the laboratory necessary to prepare compounds. For the three and nine months ended July 31, 2014, we were charged $38,625 and $142,087, respectively, by CSMC under this agreement which is included in research and development costs on the accompanying condensed consolidated statements of operations. For the three and nine months ended July 31, 2013, we were charged $87,000 and $195,884, respectively, by CSMC under this agreement. As of July 31, 2014, $258,091 is reflected as payable on the accompanying condensed consolidated balance sheets. Work under the agreement concluded during the three months ended July 31, 2014. As discussed in Note 3, we have deferred payments under this agreement in order to extend our cash balance.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Earnings (loss) Per Share
9 Months Ended

Jul. 31, 2014

Notes

Earnings (loss) Per Share
(7) EARNINGS (LOSS) PER SHARE

Earnings (loss) per share are calculated in accordance with the provisions of ASC 260 “Earnings Per Share” (“ASC 260”). Under ASC 260, basic earnings (loss) per share are computed by dividing the Company’s income (loss) by the weighted average number of common shares outstanding. The impact of any potentially dilutive securities is excluded. Diluted earnings per share are computed by dividing the Company’s income (loss) attributable to common shareholders by the weighted average number of common shares and dilutive potential common shares outstanding during the period. In calculating diluted earnings per share, we utilize the “treasury stock method” for all stock options and warrants and the “if converted method” for all other convertible securities. For all periods presented, the basic and diluted loss per share is the same as the impact of potential dilutive common shares is anti-dilutive.

Warrants and convertible securities excluded from the calculation of diluted loss per share are as follows:

Three and Nine Months Ended July 31,

2014

2013

Warrants

6,358,358

5,422,858

Stock options

1,400,000

—

Convertible debt*

766,667

66,667

Three and Nine Months Ended July 31,

2014

2013

Warrants

6,358,358

5,422,858

Stock options

1,400,000

—

Convertible debt*

766,667

66,667

*Assumes Bridge Note conversion price of $1.00 per share see Note 4 for conversion price calculations.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Supplemental Disclosure of Cash Flow Information
9 Months Ended

Jul. 31, 2014

Notes

Supplemental Disclosure of Cash Flow Information
(8) SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Cash paid during the period for:

Nine Months Ended July 31,

2014

2013

Interest

$

435

$

561

Income taxes

—

—

X

- Definition

The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_CashFlowSupplementalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
9 Months Ended

Jul. 31, 2014

Notes

Commitments and Contingencies
Commitments and Contingencies

Litigation

From time to time, we may become party to litigation and other claims in the ordinary course of business. To the extent that such claims and litigation arise, management would provide for them if upon the advice of counsel, losses are determined to be both probable and estimable. We are currently not party to any litigation.

Office Lease

We have a lease agreement for office space with a third party (the “Office Lease”) that expires on May 31, 2015. For the three month periods ended July 31, 2014 and 2013, we recorded $9,434 and $10,950, respectively, of rent expense under the Office Lease which is included in general and administrative expense on the accompanying condensed consolidated statements of operations. For the nine months ended July 31, 2014 and 2013, we recorded $31,880 and $30,392, respectively, of rent expense under the Office Lease.

Commitments under non-cancelable operating leases are as follows as of July 31, 2014:

Year Ended October 31,

2014

$ 8,100

2015

10,800

$ 18,900

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transactions (Details) (USD $)
3 Months Ended 9 Months Ended

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2014

Jul. 31, 2013

Research and development $ 82,497 $ 132,592 $ 271,449 $ 317,084

CSMC

Research and development 38,625 87,000 142,087 195,884

Accounts Payable, Related Parties, Current $ 258,091 $ 258,091

X

- Definition

Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 47 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Earnings (loss) Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Tables)
9 Months Ended

Jul. 31, 2014

Tables/Schedules

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Three and Nine Months Ended July 31,

2014

2013

Warrants

6,358,358

5,422,858

Stock options

1,400,000

—

Convertible debt*

766,667

66,667

Three and Nine Months Ended July 31,

2014

2013

Warrants

6,358,358

5,422,858

Stock options

1,400,000

—

Convertible debt*

766,667

66,667

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Bridge Notes (Details) (USD $)
9 Months Ended

Jul. 31, 2014

Details

Bridge Notes, Aggregate sold $ 700,000

Bridge Notes, Net Proceeds $ 606,318

X

- Definition

The aggregate amount of Bridge Notes sold during the indicated period.

+ References

No definition available.

+ Details

Name: fil_BridgeNotesAggregateSold

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net proceeds from Bridge Notes sold during the indicated period, after payment of offering costs.

+ References

No definition available.

+ Details

Name: fil_BridgeNotesNetProceeds

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Stockholders' Equity (Deficit) - (Unaudited) (USD $)

Common Stock

APIC

Deficit Accumulated in Development Stage

Total

Balances, Value at Oct. 31, 2013 $ 2,135 $ 4,287,289 $ (4,751,839) $ (462,415)

Balances, Shares at Oct. 31, 2013 21,350,860

Sale of Units at $1.00 per Unit, Value 3 24,953 24,956

Sale of Units at $1.00 per Unit, Shares 25,000

Stock option compensation expense 176,883 176,883

Bridge Note Warrants 205,800 205,800

Placement Agent warrants 35,700 35,700

Contributed services 90,000 90,000

Net Income (Loss) (1,268,145) (1,268,145)

Balances, Value at Jul. 31, 2014 $ 2,138 $ 4,820,625 $ (6,019,984) $ (1,197,221)

Balances, Shares at Jul. 31, 2014 21,375,860

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_BridgeNoteWarrants

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Monetary amount representing expense for Bridge Note Warrants, during the indicated time period.

+ References

No definition available.

+ Details

Name: fil_PlacementAgentWarrants

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_SaleOfUnitsAt100PerUnitShares

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_SaleOfUnitsAt100PerUnitValue

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Noncash charitable contributions made by the entity during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_NoncashContributionExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568447-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4590271-111686

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 50 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Bridge Notes
9 Months Ended

Jul. 31, 2014

Notes

Bridge Notes
(4) BRIDGE NOTES

During the nine months ended July 31, 2014, we sold an aggregate of $700,000 in bridge notes (the “Bridge Notes”), receiving net proceeds of $606,318 after payment of offering costs. The Bridge Notes are due and payable one year after the close of the offering (the “Maturity Date”), bear interest at 10% per annum, and are convertible into shares of our common stock at a conversion price of either (i) 50% of the price per share of our common stock as sold through a qualified initial public offering as defined in the terms of the Bridge Notes, or (ii) in the event a Qualified IPO has not taken place prior to the Maturity Date but there has otherwise developed a public trading market for the Company’s common stock, then the conversion price shall be 50% of the 30 day Volume Weighted Average Price per share as quoted on the over-the-counter market, or (iii) in the event a public trading market has not been established for our common stock prior to the Maturity Date, then the conversion price shall be $1.00 per share. Accrued and unpaid interest on the Bridge Notes will be payable in shares of common stock at the conversion price on the earlier of (i) the date of conversion of the Bridge Notes or (ii) the Maturity Date. Further, for every $1.00 of Bridge Note principal that an investor elects to convert into shares of common stock, the investor will receive one warrant (the “Bridge Note Warrant”). Each warrant shall be exercisable to purchase shares of common stock at a price equal to the conversion price of the Bridge Notes and shall have a life of 5 years from the close of the offering. If the investor elects not to convert their Bridge Notes prior to the Maturity Date, then the note holder will receive one warrant for every $2.00 in Bridge Note principal.

We evaluated the conversion feature of the Bridge Notes within the context of ASC 815 and determined that it did not meet the definition of an embedded derivative due to the Company having no active market for its common stock. We further evaluated the conversion feature of the Bridge Notes within the context of ASC 470-20 and determined that the Bridge Notes did not contain a beneficial conversion feature as the default conversion price of $1.00 per share is greater than the current fair value of the Company’s common stock based on the most recent price paid for the Units.

We evaluated the Bridge Note Warrants using the guidelines established by ASC 815 and determined that it did not meet the definition of a derivative due to the Company having no active market for its common stock. We valued these warrants at $205,800 using the Black-Scholes option pricing model which we recorded as debt discount with a corresponding increase to additional paid in capital using the following assumptions: expected life 5 years, risk free interest rate 1.69% and annualized volatility 78.9%. We are amortizing the debt discount over the life of the Bridge Notes. For the three and nine months ended July 31, 2014, we amortized $49,541 and $60,270, respectively, of debt discount which is included in interest expense on the accompanying condensed consolidated financial statements.

We are also obligated to issue to the placement agents warrants to acquire shares of common stock equal to 10% of the securities underlying the Bridge Notes and Bridge Note Warrants (the “PA Bridge Note Warrants”). The PA Bridge Note Warrants have a life of 5 years and are exercisable at the conversion price of the Bridge Notes and the exercise price of the Bridge Note Warrants, respectively. We evaluated the PA Bridge Note Warrants using the guidelines established by ASC 815 and determined that they did not meet the definition of a derivative due to the Company having no active trading market for its common stock. We valued the PA Bridge Note Warrants at $35,700 using the Black-Scholes pricing model using the following assumptions: expected life 5 years, risk free interest rate 1.69% and annualized volatility 78.9%. We recorded the PA Bridge Note Warrants as a debt offering cost on the accompanying condensed consolidated balance sheet. We are amortizing the PA Bridge Note Warrants over the life of the Bridge Notes. For the three and nine months ended July 31, 2014, we amortized $8,292 and $10,825, respectively, of PA Bridge Note Warrants which is included in interest expense on the accompanying condensed consolidated financial statements.

The effective rate of the Bridge Notes after taking into account the Bridge Note Warrants and PA Bridge Note Warrants is 44.5%.

X

- Definition

The full disclosure covering Bridge Notes.

+ References

No definition available.

+ Details

Name: fil_BridgeNotes

Namespace Prefix: fil_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Bridge Notes: Bridge Note Warrants (Details) (USD $)
3 Months Ended 9 Months Ended

Jul. 31, 2014

Jul. 31, 2014

Bridge Notes, Debt Discount Amortized $ 49,541 $ 60,270

Bridge Note Warrants

Assets, Fair Value Disclosure $ 205,800 $ 205,800

Fair Value Measurements, Valuation Techniques Black-Scholes option pricing model

Fair Value Assumptions, Expected Term 5 years

Fair Value Assumptions, Risk Free Interest Rate 1.69%

Fair Value Assumptions, Expected Volatility Rate 78.90%

X

- Definition

The amount of debt discount related to bridge notes amortized during the indicated period.

+ References

No definition available.

+ Details

Name: fil_BridgeNotesDebtDiscountAmortized

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the inputs and valuation technique(s) used to measure fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementsValuationTechniques

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 53 118 1 true 19 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://skrp.com/20140731/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000020 - Statement - Condensed Consolidated Balance Sheets (July 31, 2014 unaudited) Sheet http://skrp.com/20140731/role/idr_CondensedConsolidatedBalanceSheetsJuly312014Unaudited Condensed Consolidated Balance Sheets (July 31, 2014 unaudited) false false R3.htm 000030 - Statement - Condensed Consolidated Balance Sheets - Parenthetical (July 31, 2014 unaudited) Sheet http://skrp.com/20140731/role/idr_CondensedConsolidatedBalanceSheetsParentheticalJuly312014Unaudited Condensed Consolidated Balance Sheets - Parenthetical (July 31, 2014 unaudited) false false R4.htm 000040 - Statement - Condensed Statements of Operations (unaudited) Sheet http://skrp.com/20140731/role/idr_CondensedStatementsOfOperationsUnaudited Condensed Statements of Operations (unaudited) false false R5.htm 000050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) - (Unaudited) Sheet http://skrp.com/20140731/role/idr_CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit) - (Unaudited) false false R6.htm 000060 - Statement - Condensed Statements of Cash Flows (unaudited) Sheet http://skrp.com/20140731/role/idr_CondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (unaudited) false false R7.htm 000070 - Disclosure - Business and Overview Sheet http://skrp.com/20140731/role/idr_DisclosureBusinessAndOverview Business and Overview false false R8.htm 000080 - Disclosure - Going Concern, Management's Plans and Basis of Presentation Sheet http://skrp.com/20140731/role/idr_DisclosureGoingConcernManagementSPlansAndBasisOfPresentation Going Concern, Management's Plans and Basis of Presentation false false R9.htm 000090 - Disclosure - License Agreement Sheet http://skrp.com/20140731/role/idr_DisclosureLicenseAgreement License Agreement false false R10.htm 000100 - Disclosure - Bridge Notes Notes http://skrp.com/20140731/role/idr_DisclosureBridgeNotes Bridge Notes false false R11.htm 000110 - Disclosure - Convertible Notes Notes http://skrp.com/20140731/role/idr_DisclosureConvertibleNotes Convertible Notes false false R12.htm 000120 - Disclosure - Stockholders' Equity Sheet http://skrp.com/20140731/role/idr_DisclosureStockholdersEquity Stockholders' Equity false false R13.htm 000130 - Disclosure - Earnings (loss) Per Share Sheet http://skrp.com/20140731/role/idr_DisclosureEarningsLossPerShare Earnings (loss) Per Share false false R14.htm 000140 - Disclosure - Supplemental Disclosure of Cash Flow Information Sheet http://skrp.com/20140731/role/idr_DisclosureSupplementalDisclosureOfCashFlowInformation Supplemental Disclosure of Cash Flow Information false false R15.htm 000150 - Disclosure - Related Party Transactions Sheet http://skrp.com/20140731/role/idr_DisclosureRelatedPartyTransactions Related Party Transactions false false R16.htm 000160 - Disclosure - Commitments and Contingencies Sheet http://skrp.com/20140731/role/idr_DisclosureCommitmentsAndContingencies Commitments and Contingencies false false R17.htm 000170 - Disclosure - Subsequent Events Sheet http://skrp.com/20140731/role/idr_DisclosureSubsequentEvents Subsequent Events false false R18.htm 000180 - Disclosure - Going Concern, Management's Plans and Basis of Presentation: Going Concern and Management's Plans (Policies) Sheet http://skrp.com/20140731/role/idr_DisclosureGoingConcernManagementSPlansAndBasisOfPresentationGoingConcernAndManagementSPlansPolicies Going Concern, Management's Plans and Basis of Presentation: Going Concern and Management's Plans (Policies) false false R19.htm 000190 - Disclosure - Going Concern, Management's Plans and Basis of Presentation: Basis of Presentation (Policies) Sheet http://skrp.com/20140731/role/idr_DisclosureGoingConcernManagementSPlansAndBasisOfPresentationBasisOfPresentationPolicies Going Concern, Management's Plans and Basis of Presentation: Basis of Presentation (Policies) false false R20.htm 000200 - Disclosure - Going Concern, Management's Plans and Basis of Presentation: Use of Estimates and Assumptions (Policies) Sheet http://skrp.com/20140731/role/idr_DisclosureGoingConcernManagementSPlansAndBasisOfPresentationUseOfEstimatesAndAssumptionsPolicies Going Concern, Management's Plans and Basis of Presentation: Use of Estimates and Assumptions (Policies) false false R21.htm 000210 - Disclosure - Earnings (loss) Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Tables) Sheet http://skrp.com/20140731/role/idr_DisclosureEarningsLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTables Earnings (loss) Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Tables) false false R22.htm 000220 - Disclosure - Supplemental Disclosure of Cash Flow Information: Schedule of Cash Flow, Supplemental Disclosures (Tables) Sheet http://skrp.com/20140731/role/idr_DisclosureSupplementalDisclosureOfCashFlowInformationScheduleOfCashFlowSupplementalDisclosuresTables Supplemental Disclosure of Cash Flow Information: Schedule of Cash Flow, Supplemental Disclosures (Tables) false false R23.htm 000230 - Disclosure - Commitments and Contingencies: Schedule of Commitments under non-cancelable operating leases (Tables) Sheet http://skrp.com/20140731/role/idr_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsUnderNonCancelableOperatingLeasesTables Commitments and Contingencies: Schedule of Commitments under non-cancelable operating leases (Tables) false false R24.htm 000240 - Disclosure - Business and Overview (Details) Sheet http://skrp.com/20140731/role/idr_DisclosureBusinessAndOverviewDetails Business and Overview (Details) false false R25.htm 000250 - Disclosure - Going Concern, Management's Plans and Basis of Presentation: Going Concern and Management's Plans (Details) Sheet http://skrp.com/20140731/role/idr_DisclosureGoingConcernManagementSPlansAndBasisOfPresentationGoingConcernAndManagementSPlansDetails Going Concern, Management's Plans and Basis of Presentation: Going Concern and Management's Plans (Details) false false R26.htm 000260 - Disclosure - Bridge Notes (Details) Notes http://skrp.com/20140731/role/idr_DisclosureBridgeNotesDetails Bridge Notes (Details) false false R27.htm 000270 - Disclosure - Bridge Notes: Bridge Note Warrants (Details) Notes http://skrp.com/20140731/role/idr_DisclosureBridgeNotesBridgeNoteWarrantsDetails Bridge Notes: Bridge Note Warrants (Details) false false R28.htm 000280 - Disclosure - Bridge Notes: PA Bridge Note Warrants (Details) Notes http://skrp.com/20140731/role/idr_DisclosureBridgeNotesPABridgeNoteWarrantsDetails Bridge Notes: PA Bridge Note Warrants (Details) false false R29.htm 000290 - Disclosure - Convertible Notes (Details) Notes http://skrp.com/20140731/role/idr_DisclosureConvertibleNotesDetails Convertible Notes (Details) false false R30.htm 000300 - Disclosure - Stockholders' Equity (Details) Sheet http://skrp.com/20140731/role/idr_DisclosureStockholdersEquityDetails Stockholders' Equity (Details) false false R31.htm 000310 - Disclosure - Earnings (loss) Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://skrp.com/20140731/role/idr_DisclosureEarningsLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Earnings (loss) Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) false false R32.htm 000320 - Disclosure - Supplemental Disclosure of Cash Flow Information: Schedule of Cash Flow, Supplemental Disclosures (Details) Sheet http://skrp.com/20140731/role/idr_DisclosureSupplementalDisclosureOfCashFlowInformationScheduleOfCashFlowSupplementalDisclosuresDetails Supplemental Disclosure of Cash Flow Information: Schedule of Cash Flow, Supplemental Disclosures (Details) false false R33.htm 000330 - Disclosure - Related Party Transactions: Consulting Agreements (Details) Sheet http://skrp.com/20140731/role/idr_DisclosureRelatedPartyTransactionsConsultingAgreementsDetails Related Party Transactions: Consulting Agreements (Details) false false R34.htm 000340 - Disclosure - Related Party Transactions (Details) Sheet http://skrp.com/20140731/role/idr_DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) false false R35.htm 000350 - Disclosure - Commitments and Contingencies (Details) Sheet http://skrp.com/20140731/role/idr_DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false R36.htm 000360 - Disclosure - Commitments and Contingencies: Schedule of Commitments under non-cancelable operating leases (Details) Sheet http://skrp.com/20140731/role/idr_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsUnderNonCancelableOperatingLeasesDetails Commitments and Contingencies: Schedule of Commitments under non-cancelable operating leases (Details) false false R37.htm 000370 - Disclosure - Subsequent Events (Details) Sheet http://skrp.com/20140731/role/idr_DisclosureSubsequentEventsDetails Subsequent Events (Details) false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - Condensed Consolidated Balance Sheets (July 31, 2014 unaudited) Process Flow-Through: Removing column 'Jul. 31, 2013' Process Flow-Through: Removing column 'Oct. 31, 2012' Process Flow-Through: 000030 - Statement - Condensed Consolidated Balance Sheets - Parenthetical (July 31, 2014 unaudited) Process Flow-Through: 000040 - Statement - Condensed Statements of Operations (unaudited) Process Flow-Through: 000060 - Statement - Condensed Statements of Cash Flows (unaudited) skrp-20140731.xml skrp-20140731.xsd skrp-20140731_cal.xml skrp-20140731_def.xml skrp-20140731_lab.xml skrp-20140731_pre.xml true true XML 53 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Going Concern, Management's Plans and Basis of Presentation: Use of Estimates and Assumptions (Policies)
9 Months Ended

Jul. 31, 2014

Policies

Use of Estimates and Assumptions
Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods. Actual results may differ from these estimates.

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Related Party Transactions: Consulting Agreements (Details) (USD $)							9 Months Ended
	Jul. 31, 2014	Oct. 31, 2013	Jul. 31, 2014 Synthetica, Ltd	Oct. 31, 2013 Synthetica, Ltd	Jul. 31, 2014 Entity controlled by Board chairman	Oct. 31, 2013 Entity controlled by Board chairman	Jul. 31, 2014 Entity controlled by Board chairman September 2010
AccruedCompensation			$ 67,600	$ 47,600
Related Party Transaction, Description of Transaction							In September 2010, we entered into a business and financial consulting agreement with an entity controlled by our Board chairman for operational consulting services.
Related party payables	$ 49,000	$ 39,000			$ 49,000	$ 39,000

Going Concern, Management's Plans and Basis of Presentation: Going Concern and Management's Plans (Details) (USD $)	9 Months Ended
	Jul. 31, 2014	Oct. 31, 2013	Jul. 31, 2013	Oct. 31, 2012
Details
Revenue since inception	$ 0
Deficit accumulated during development stage	6,019,984
Cash and cash equivalents	$ 219,035	$ 13,822	$ 181,386	$ 539,727

Subsequent Events (Details)	9 Months Ended
Subsequent Events (Details)	Jul. 31, 2014
Details
Subsequent Event, Description	Dr. Randolphe Swenson, Jr. was elected to serve as a member of the Board of Directors

Convertible Notes (Details) (Convertible Debt, USD $)	9 Months Ended
Convertible Notes (Details) (Convertible Debt, USD $)	Jul. 31, 2014
Convertible Debt Outstanding	$ 10,000
October 2010 through April 2011
Net proceeds from sale of Convertible Notes	$ 726,550
Debt Instrument, Convertible, Terms of Conversion Feature	The Convertible Notes were initially convertible into shares of our common stock at $.30 per share (the “Conversion Price”).
Debt Conversion, Converted Instrument, Type	shares of our common stock
Debt Instrument, Interest Rate Terms	Convertible Notes do not bear interest
Debt Instrument, Payment Terms	originally payable on October 19, 2011

Bridge Notes: PA Bridge Note Warrants (Details) (USD $)	3 Months Ended	9 Months Ended
Bridge Notes: PA Bridge Note Warrants (Details) (USD $)	Jul. 31, 2014	Jul. 31, 2014
PA Bridge Note Warrants, Debt Discount Amortized	$ 8,292	$ 10,825
PA Bridge Note Warrants
Assets, Fair Value Disclosure	$ 35,700	$ 35,700
Fair Value Measurements, Valuation Techniques		Black-Scholes pricing model
Fair Value Assumptions, Expected Term		5 years
Fair Value Assumptions, Risk Free Interest Rate		1.69%
Fair Value Assumptions, Expected Volatility Rate		78.90%

Stockholders' Equity (Details) (USD $)	9 Months Ended		3 Months Ended	9 Months Ended		3 Months Ended	9 Months Ended
Stockholders' Equity (Details) (USD $)	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014 Common Stock	Jul. 31, 2014 Common Stock	Jul. 31, 2014 Common Stock Purchase Warrants	Jul. 31, 2014 Stock options	Jul. 31, 2014 Stock options
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value				$ 224,000	$ 17,160		$ 58,400
Allocated Share-based Compensation Expense			56,000	168,000		2,433	7,300
Sale of Units, Shares	25,000	260,000
Sale of Units, price per unit	$ 1.00	$ 1.00
Sale of Units, Value	$ 24,956	$ 227,645
Fair Value Assumptions, Expected Term							5 years
Fair Value Assumptions, Risk Free Interest Rate							1.37%
Fair Value Assumptions, Expected Volatility Rate							78.90%

Commitments and Contingencies (Details) (USD $)	3 Months Ended		9 Months Ended
Commitments and Contingencies (Details) (USD $)	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Details
Operating Leases, Rent Expense	$ 9,434	$ 10,950	$ 31,880	$ 30,392

Commitments and Contingencies: Schedule of Commitments under non-cancelable operating leases (Details) (USD $)	Jul. 31, 2014
Commitments under non-cancelable operating leases	$ 18,900
Year ending October 31, 2014
Commitments under non-cancelable operating leases	8,100
Year ending October 31, 2015
Commitments under non-cancelable operating leases	$ 10,800

Business and Overview (Details)	9 Months Ended
Business and Overview (Details)	Jul. 31, 2014
Entity Incorporation, Date of Incorporation	Dec. 07, 2006
Arrogene Nanotechnology, Inc.
Business Acquisition, Effective Date of Acquisition	January 11, 2012
Business Acquisition, Name of Acquired Entity	Arrogene Nanotechnology, Inc. (“ANI”)
Business Acquisition, Description of Acquired Entity	a company focused on oncology

Condensed Consolidated Balance Sheets - Parenthetical (July 31, 2014 unaudited) (USD $)	Jul. 31, 2014	Oct. 31, 2013
CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred Stock, Par Value	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares Issued	21,375,860	21,375,860
Common Stock, Shares Outstanding	21,350,860	21,350,860

Document and Entity Information	9 Months Ended
Document and Entity Information	Jul. 31, 2014	Sep. 10, 2014
Document and Entity Information:
Entity Registrant Name	ARROGENE, INC
Document Type	10-Q
Document Period End Date	Jul. 31, 2014
Amendment Flag	false
Entity Central Index Key	0001403792
Current Fiscal Year End Date	--10-31
Entity Common Stock, Shares Outstanding		21,375,860
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Entity Incorporation, Date of Incorporation	Dec. 07, 2006

Condensed Statements of Operations (unaudited) (USD $)	3 Months Ended		9 Months Ended
Condensed Statements of Operations (unaudited) (USD $)	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
OPERATING EXPENSES:
Research and development	$ 82,497	$ 132,592	$ 271,449	$ 317,084
General and administrative	312,827	147,799	876,494	466,813
Operating Expenses	395,324	280,391	1,147,943	783,897
Income (Loss) from operations	(395,324)	(280,391)	(1,147,943)	(783,897)
OTHER INCOME (EXPENSE):
Interest	(94,790)	(278)	(120,202)	(561)
Other Income (expense)	(94,790)	(278)	(120,202)	(561)
Net Income (Loss)	$ (490,114)	$ (280,669)	$ (1,268,145)	$ (784,458)
Weighted Average Shares Outstanding, Basic and diluted	21,375,860	21,350,860	21,370,457	21,289,358
Loss Per Share, Basic and diluted	$ (0.02)	$ (0.01)	$ (0.06)	$ (0.04)

Related Party Transactions (Details) (USD $)	3 Months Ended		9 Months Ended
Related Party Transactions (Details) (USD $)	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Research and development	$ 82,497	$ 132,592	$ 271,449	$ 317,084
CSMC
Research and development	38,625	87,000	142,087	195,884
Accounts Payable, Related Parties, Current	$ 258,091		$ 258,091

Bridge Notes (Details) (USD $)	9 Months Ended
Bridge Notes (Details) (USD $)	Jul. 31, 2014
Details
Bridge Notes, Aggregate sold	$ 700,000
Bridge Notes, Net Proceeds	$ 606,318

Condensed Consolidated Statements of Stockholders' Equity (Deficit) - (Unaudited) (USD $)	Common Stock	APIC	Deficit Accumulated in Development Stage	Total
Balances, Value at Oct. 31, 2013	$ 2,135	$ 4,287,289	$ (4,751,839)	$ (462,415)
Balances, Shares at Oct. 31, 2013	21,350,860
Sale of Units at $1.00 per Unit, Value	3	24,953		24,956
Sale of Units at $1.00 per Unit, Shares	25,000
Stock option compensation expense		176,883		176,883
Bridge Note Warrants		205,800		205,800
Placement Agent warrants		35,700		35,700
Contributed services		90,000		90,000
Net Income (Loss)			(1,268,145)	(1,268,145)
Balances, Value at Jul. 31, 2014	$ 2,138	$ 4,820,625	$ (6,019,984)	$ (1,197,221)
Balances, Shares at Jul. 31, 2014	21,375,860

Bridge Notes: Bridge Note Warrants (Details) (USD $)	3 Months Ended	9 Months Ended
Bridge Notes: Bridge Note Warrants (Details) (USD $)	Jul. 31, 2014	Jul. 31, 2014
Bridge Notes, Debt Discount Amortized	$ 49,541	$ 60,270
Bridge Note Warrants
Assets, Fair Value Disclosure	$ 205,800	$ 205,800
Fair Value Measurements, Valuation Techniques		Black-Scholes option pricing model
Fair Value Assumptions, Expected Term		5 years
Fair Value Assumptions, Risk Free Interest Rate		1.69%
Fair Value Assumptions, Expected Volatility Rate		78.90%